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RESUMO 
As amiloidoses relacionadas com a TTR são um grupo de doenças progressivas e 
fatais, com apresentação clínica variável. A TTR, uma proteína de transporte 
sintetizada no fígado, tem uma estrutura tetramérica instável com tendência para se 
dissociar, resultando na deposição extracelular de substância amilóide. Há duas 
formas principais de doença, uma hereditária e outra adquirida, sendo esta uma 
cardiomiopatia grave que surge, sobretudo, em doentes idosos do sexo masculino. A 
forma hereditária apresenta grande variabilidade genotípica e fenotípica. A 
apresentação clínica predominante pode ser uma polineuropatia sensitiva e motora 
axonal, associada a disfunção autonómica variável, ou uma miocardiopatia infiltrativa. 
Os dois fenótipos podem apresentar-se separados ou associados. 
Nesta tese descreve-se o desenvolvimento clínico dos três medicamentos 
modificadores da doença já aprovados na Europa, para o tratamento da neuropatia 
da amiloidose por TTR, e discute-se os dados de eficácia e segurança disponíveis. 
Apresenta-se também a validação das medidas de avaliação de eficácia utilizadas nos 
diferentes ensaios clínicos. A validação de escalas importadas de estudos com 
neuropatia diabética - a escala NIS-LL e o questionário de qualidade de vida Norfolk - 
foi realizada através de um estudo observacional transversal, com doentes em todos 
os estádios de doença e com voluntários saudáveis. Este estudo mostrou que estes 
instrumentos são reprodutíveis e têm sensibilidade para discriminar a progressão da 
doença. Mais tarde, foi construída uma escala composta denominada mNIS+7, com 
maior poder discriminativo.  
Tafamidis é uma pequena molécula que se liga ao tetrâmero da TTR, prevenindo a 
sua dissociação. É utilizado numa dose de 20mg por dia, de uso oral. O ensaio clínico 
para registo foi multicêntrico, internacional, de fase 3, randomizado 1:1 e controlado 
com placebo. Teve a duração de 18 meses e incluiu doentes em fase inicial da doença, 
com a mutação TTRVal30Met e demonstração de deposição de substância amilóide. 
A análise dos resultados mostrou que os doentes em medicamento apresentaram 
menos deterioração neurológica e melhoraram a sua qualidade de vida, quando 
comparados com os doentes sob placebo. No entanto, as medidas de eficácia pré-
especificadas (NIS-LL e Norfolk-QoL) não atingiram significância estatística. O uso 
comercial do medicamento, a longo termo, mostrou que a melhor resposta se encontra 
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no sexo feminino e nas fases iniciais da doença. O uso prolongado do medicamento 
revelou-se muito seguro, sem registo de efeitos adversos significativos. 
Patisiran é um ARN de interferência, envolvido numa cápsula lipídica, que se 
concentra no fígado, impedindo a síntese da TTR normal e variante. Uma dose de 300 
µg/Kg é utilizada em perfusão endovenosa cada 3 semanas, precedida de pré-
medicação com uma dose baixa de corticóides. O estudo de fase 3 (multicêntrico, 
randomizado 2:1 e controlado com placebo) incluiu doentes em fase inicial e 
intermédia da doença, com diversas mutações. Ao fim de 18 meses a escala mNIS+7 
mostrava melhoria, em média, sendo a comparação com a progressão da doença no 
ramo de placebo altamente significativa. Ocorreram algumas reações ligeiras à 
infusão, resolvidas com diminuição da velocidade de perfusão. Não foram detetados 
outros problemas de segurança significativos. 
Inotersen é um oligonucleotido antisense que impede a síntese da TTR normal e 
mutada no fígado. É utilizado por via subcutânea, com uma injeção semanal, numa 
dose de 300 mg. O ensaio clínico de fase 3 teve um desenho semelhante ao do 
Patisiran mas com uma duração de 15 meses. As medidas primárias de eficácia 
(mNIS+7 e Norfolk-QoL) mostraram diferenças significativas entre os dois braços do 
estudo. Três doentes desenvolveram trombocitopenias graves, tendo um deles 
falecido por hemorragia cerebral. Outros três doentes desenvolveram 
glomerulonefrites agudas, com progressão para insuficiência renal terminal num dos 
casos. Foram implementadas medidas adicionais de monitorização analítica, não se 
verificando novas ocorrências.  
O estudo final desta tese avalia a sobrevida dos doentes portugueses tratados, com 
transplante hepático, desde 1992, e com Tafamidis, desde 2007/2009, e mostra que 
a sua sobrevida comparada com a dos controlos históricos mais do que duplicou. 
No conjunto, este trabalho demonstra que para muitos doentes a amiloidose por TTR 
deixou de ser uma doença devastadora e fatal, tendo-se tornado uma doença crónica, 
com melhor qualidade de vida e sobrevida alargada. Há ainda muito trabalho a fazer 
para enfrentar os diversos problemas ainda não resolvidos e para fazer chegar as 
possibilidades de tratamento a todos os doentes, o mais cedo possível.  
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ABSTRACT 
ATTR amyloidoses are a group of severe, progressive and fatal systemic disorders 
with variable clinical presentation. TTR, a transport protein synthesized in the liver, is 
an unstable tetramer prone to dissociation and subsequent misfolding, resulting in 
amyloid deposition. There are two different forms of disease, one hereditary and one 
acquired, this one presenting as a severe cardiomyopathy in aged males. Hereditary 
ATTR amyloidosis shows a major genetic and phenotypic variability with more than 
120 pathogenic mutations so far identified. The two most common clinical 
presentations of the inherited disease are a length dependent axonal neuropathy with 
variable autonomic involvement and a severe infiltrative cardiomyopathy, presenting 
either isolated or in combination, from the onset or along the progression of the 
disease. 
In this thesis we describe the clinical development of the three new disease-modifying 
drugs currently approved in Europe, for the treatment of ATTR amyloidosis with 
polyneuropathy and we present the available data on efficacy and safety. In parallel 
we describe the study used for validation of the outcome measures used in the different 
clinical trials. Several scales designed for diabetic neuropathy studies were imported 
and adapted. The evaluation of NIS-LL and Norfolk-QoL in an observational single 
center study with patients in all disease stages and healthy volunteers showed that 
these tools are reliable and sensitive to discriminate disease progression. Several 
changes were later introduced to build up a compound score, mNIS+7, with a higher 
discriminative power. 
Tafamidis is a small molecule designed to bind to the TTR tetramer and prevent its 
dissociation and misfolding; it is presented as a 20mg capsule for daily oral intake. The 
registration clinical trial was a multicenter, international, double blind, randomized 1:1, 
placebo-controlled, phase 3 study. Patients had all the variant TTRVal30Met, proven 
amyloid deposition and an early stage of disease. The study lasted 18 months. 
Analysis of the results showed that patients on drug, as compared with those receiving 
placebo, had less neurologic deterioration and better quality of life. However, the pre-
specified primary outcome measures (NIS-LL and Norfolk-QoL), did not reach a 
statistically significant difference between treatment arms. Real-life use of the drug 
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concluded that patients with better results while receiving this drug are female patients 
with early disease. During long term use no safety issues were detected. 
Patisiran is an interference RNA, inserted in a lipid nanoparticle, that targets the liver 
where it prevents the synthesis of both, wild and variant TTR. A dose of 300 µg/Kg is 
infused every three weeks after pre-medication with a low dose steroid. The phase 3 
clinical trial included patients in early and intermediate stages of disease, with different 
mutations, for 18 months. The results of this multicenter, international, double-blind, 
randomized 2:1, placebo-controlled trial showed a highly significant difference between 
treatment arms, in the primary end-point, mNIS+7, with some degree of improvement 
in a large percentage of patients. Some mild infusion reactions occurred, but they were 
controlled by slowing the infusion rate. No other safety issues were detected.  
Inotersen is an antisense oligonucleotide that prevents TTR synthesis (wild and 
mutated). It is formulated for subcutaneous injection in a dose of 300mg every week. 
The registration study had a design similar to Patisiran trial but only 15 months 
duration. Results showed a highly statistically significant difference between treatment 
arms, in the primary end-points, mNIS+7 and Norfolk-QoL. During the study three 
patients developed a severe thrombocytopenia and one died from cerebral 
hemorrhage. Three other patients had a severe glomerulonephritis that progressed to 
end stage renal failure in one case. Monitoring rules with frequent blood and urine 
analysis were implemented and prevented similar events since then.  
The last study presented in this thesis compares the survival of treated patients (with 
liver transplant, after 1992 and with Tafamidis, since 2007-2009) with the data from the 
natural history of Portuguese patients, registered in Porto and Lisbon. Mean survival 
of treated patients more than doubled as compared with untreated patients (24.73 
years versus 11.61 years). 
There are several problems needing further investigation and these treatments are not 
available for all patients across the world. Anyway, the approval of these three new 
drugs and the increased survival of treated patients shows that we were able to change 
a devastating and life-threatening disease into a chronic condition with better quality 
of life and prolonged survival. 
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INTRODUCTION 
 
1. FOREWORD 
Portugal harbors the largest known focus of Familial Amyloid Polyneuropathy (FAP),1 
 a hereditary condition nowadays included in the larger group of transthyretin-related 
amyloidoses (ATTR amyloidoses).2 
Andrade developed the research that led to the definition of the condition, in 1952,3 at 
the Hospital de Santo António (HSA), recently integrated in Centro Hospitalar 
Universitário do Porto (CHUP). Since then the Hospital, and the Neuroscience 
Department in particular, have maintained a special interest in and dedication to this 
disease, as shown by the creation of a multidisciplinary team which included basic 
researchers and clinicians from different medical specialties, centered in Neurology. 
The Hospital has always been recognized as a reference center for the disease by 
patients, families and health services from all over the country, and we have 
participated actively in the international scientific meetings dedicated to this subject, 
particularly those organized by the International Society of Amyloidosis (ISA). 
I have worked with FAP patients for more than 30 years, first as a training neurologist, 
then as a neurologist and a neurophysiologist and, more recently, as the head of the 
multidisciplinary team of an officially recognized National Reference Center for the 
disease. 
I have witnessed extraordinary changes: at the beginning, there was no treatment 
available; then liver transplant changed the life of many patients who remained stable, 
without progression of the disease, for many years. More recently, I was invited to 
collaborate in the first clinical trials. It was a fantastic experience. I worked hard, I had 
to learn a lot about clinical trials and outcome measures but above all I had the great 
opportunity of being part of a major scientific achievement that I knew was extremely 
important for the patients I cared for. I feel unusually lucky and privileged.  
This work presents my contribution to the clinical development of the three drugs 
currently approved for ATTR amyloidosis treatment and it includes an evaluation of the 
impact of liver transplant in the natural history of the disease. However, we must 
remember that the approval of these drugs is just the first step of a long route: the real-
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life assessment of the effectiveness and safety of these treatments and their expansion 
to reach as many patients as possible. 
 
2. BACKGROUND 
2.1. ATTR amyloidoses: definition and subdivision 
ATTR amyloidoses are a group of severe, progressive and fatal systemic disorders 
with variable clinical presentation. Transthyretin (TTR), a plasma transport protein, is 
a tetramer with unstable quaternary structure prone to dissociation and subsequent 
misfolding, resulting in extracellular amyloid deposition and consequent organ 
dysfunction, presenting predominantly as a peripheral neuropathy, somatic and 
autonomic, and/or cardiomyopathy.4 
The condition includes two major subgroups: hereditary ATTR amyloidosis (hATTR 
amyloidosis), due to autosomal dominant mutations that cause unstable protein 
variants, and wild-type ATTR amyloidosis (wtATTRamyloidosis), a disease of aged 
people, caused by amyloid deposition derived from normal (wild) protein.5 
2.2. Historical background 
In 1939, Corino de Andrade, a Portuguese neurologist working at HSA, in Porto, 
observed a female patient, aged 37 years, with a sensory, motor and autonomic 
neuropathy he could not recognize, or even classify, from what he had previously 
observed and studied. The patient told him the condition was common in the small 
town where she lived and that it was known to run in successive generations of several 
affected families. 
This observation elicited a careful clinical and pathological study of a group of 74 
patients, which became the first description of a new clinical entity, FAP. The disease 
was presented as affecting young adults of both genders, around their thirties, and it 
was characterized by a severe progressive sensory and motor neuropathy along with 
a marked autonomic involvement, due to the early lesion of vegetative nerves. 
Extensive amyloid deposition in multiple tissues and organs and the concentration in 
different families were also established as important features of the condition.3 
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Several years later, two foci of a resembling neuropathy were ascertained in two 
prefectures of Japan, Kumamoto6 and Nagano7 and another one was identified in 
Northern Sweden.8 The latter showed a similar neuropathy but also two significant 
differences: the mean age-of-onset was later,9 in the patients’ fifties, and many patients 
presented vitreous opacities at the beginning or along the progression of the disease.10 
Distinct clinical presentations of amyloid neuropathies, in different populations and 
locations, were further described and this led to the first classification of FAP into four 
subtypes:11 type 1 includes the Portuguese, Japanese and Swedish description of a 
length-dependent neuropathy with extensive autonomic involvement; type 2 
corresponds to a neuropathy with early involvement of upper limbs due to a severe 
carpal tunnel syndrome and later and milder progression to the lower limbs;12,13 type 3 
presents as a length-dependent neuropathy, but patients also have severe renal 
disease and gastric ulcers;14 type 4 describes a cranial neuropathy with cutis laxa, 
corneal dystrophy and variable degree of sensory neuropathy and central nervous 
system (CNS) involvement.15 
Other presentations of familial amyloidosis with almost exclusive or predominant heart 
or CNS involvement (sometimes with simultaneous eye disease) were also 
ascertained. Consequently, several years before the identification of the genetic errors 
of all these diseases, three major clinical divisions were recognized, familial amyloid 
cardiomyopathy (FAC),16 familial (oculo)leptomeningeal amyloidosis,17 and the most 
frequent, FAP, with the four subtypes described above. 
Pre-albumin, later renamed TTR, was identified as the main component of the amyloid 
deposits in Portuguese patients.18 The presence of the same point mutation, (a 
substitution of a valine for a methionine residue in position 30, TTRVal30Met), in the 
protein extracted from the amyloid deposits and the plasma of Japanese19 and 
Portuguese20 patients confirmed the similarity of the condition in both countries. In the 
next decade, TTR, with the same or newly ascertained mutations, was identified as the 
amyloid precursor in many other foci and families with FAP type 121,22 and FAP 
type12,23,24 in FAC25 and in different families with leptomeningeal amyloidosis.26,27 
FAP1type13 and 4 were related to other proteins, apolipoprotein A-128 and gelsolin,29 
respectively. 
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Soon after the identification of multiple TTR variants related to different presentations 
of familial amyloidosis, a sporadic cardiac amyloidosis occurring in aged male patients, 
senile systemic amyloidosis (SSA),30 was found to be exclusively related to wild TTR.31  
The progressive ascertainment of innumerous TTR variants,32 pathogenic and non- 
pathogenic, was associated with an increasing recognition of a major phenotypic 
variability. Many patients present an extensive and variable overlap of neuropathy and 
cardiomyopathy, the so-called mixed phenotype.33 Predominant or even isolated 
involvement of other organs such as the eyes34,35 or the kidneys36 is a less common 
possible presentation. 
To emphasize the systemic nature of the disease the nomenclature committee of ISA 
recommends the use of the general designation of ATTR amyloidosis,2 instead of the 
outdated acronyms FAP and FAC. 
In less than seventy years, “a peculiar neuropathy”,3 described as a rare familial 
disorder concentrated in a small and poor region of Southern Europe, was found to be 
a worldwide condition, inherited or acquired, much more frequent, complex and 
variable than previously thought. 
2.3. TTR 
2.3.1. TTR metabolism 
TTR is a transport protein, present in plasma,37 cerebrospinal fluid (CSF),37 and the 
anterior and posterior chambers of the eye.38 Plasma fraction is almost exclusively 
synthesized in the liver.37 CSF and eye protein are produced in the choroid plexus37 
and retinal39 and ciliary40 pigmented epithelial cells, respectively. 
Metabolism of TTR is not fully understood. The protein half life is short (1-2 days) and 
a significant percentage of TTR is degraded in the liver, the muscles, the skin and the 
kidneys. A small percentage of TTR is excreted in the urine, unchanged.41 
TTR is a negative acute phase reactant protein, as its concentration in the plasma 
decreases with malnutrition and inflammation.42 Besides this physiological variation, 
TTR concentration is consistently lower in patients when compared to the general 
population.43 - 45 Recently, the concentration of TTR was found to be a prognostic factor 
for the survival of patients with cardiac disease.46 The mechanism leading to the 
lowering of TTR concentration is still a matter of debate.45 
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2.3.2. TTR functions 
TTR is a tetramer with four identical monomers with 127 amino acids, partially 
organized in a ß-sheet structure, with a central hydrophobic channel with two binding 
sites for thyroxine (T4).47 These binding sites exhibit negative cooperativity resulting in 
one single molecule binding.48 There are other major T4 carriers in plasma, either more 
abundant, as albumin, or with higher affinity, as thyroxine-binding globulin. Therefore, 
only a very small proportion of TTR molecules circulates in plasma with the central 
channel occupied by the hormone. In CSF, although TTR is the main transporter of T4, 
most TTR molecules circulate also unoccupied with the hormone.49 
TTR also binds the complex of vitamin A and retinol-binding protein (RBP), preventing 
its filtration by the kidney and promoting vitamin A transport from the liver to the 
tissues.50 No alternative carrier for vitamin A has been identified in the plasma. Null 
mice (knockout for the TTR gene) show a marked decrease in the plasma levels of 
vitamin A and RBP.51 
In recent years increasing evidence of additional TTR functions has been presented,52 
including proteolytic functions53 and a protective role in the CNS and the peripheral 
nervous system (PNS). Data derived from null mice and in vitro experiments suggests 
that TTR has an important role in the prevention of Aß aggregation,54,55 and in the 
response to ischemia56 and peripheral nerve injury.57 
2.4. Pathogenesis 
2.4.1. Protein misfolding  
Nowadays, the diseases characterized by the extracellular deposition of amyloid are 
included in the larger group of protein misfolding disorders, which are increasingly 
recognized as a common mechanism of disease for countless neurodegenerative and 
metabolic diseases.58 
Proteins are macromolecules that are essential for multiple biologic functions, intra and 
extracellularly. To accomplish their countless and diverse functions each one must fold 
appropriately into a specific three-dimensional structure and it must keep this structure 
until the end of its life, at the place of synthesis and/or elsewhere, whenever it exerts 
its role away from the synthesis location. Appropriate protein homeostasis, or 
proteostasis, is an error prone process, based on the intrinsic properties of the protein, 
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but it also needs the assistance of several other molecular chaperones, the 
proteostasis network (PN). This process is a dynamic one. Folding, misfolding, 
refolding and degradation are in constant equilibrium, intra and extracellularly.59 
Misfolded proteins may cause disease due to a loss-of-function mechanism (v. g. 
misfolding of fundamental enzymes leading to their early degradation, malfunction or 
inappropriate trafficking, which is what happens in Gaucher’s disease and α1-
antitripsin deficiency) or to a gain-of-function process (such as aggregation into toxic 
species in amyloid deposition). Both mechanisms are not exclusive and may work 
together for the development of a misfolding disorder.60 
2.4.2. Amyloidogenesis 
Mutations and aging are known risk factors for amyoid formation and deposition. 
Mutations induce changes in the intrinsic properties of the polypeptide chains, 
rendering them more prone to misfolding. However, the clinical heterogeneity, 
including complete non-penetrance of a gene, variable age-of-onset, and diverse 
organ involvement found among patients sharing the exact same genetic defect point 
to the contribution of additional factors, either genetic or environmental.61 
Aging is a risk factor for the most common neurodegenerative diseases. It is accepted 
as a cause for malfunctioning of the PN, but the exact mechanisms remain largely 
unknown.61 In fact, idiopathic neurodegenerative disorders, without an obvious genetic 
cause, may be influenced by genetic factors that increase susceptibility to protein 
misfolding. On the other hand, the inherited forms of these diseases probably also 
depend on some interaction with the same aging-related loss of protective 
mechanisms. This could explain why genetic errors present since fetal life produce 
their deleterious effects in adult life, very often at a very old age. 
ATTR amyloidogenesis is a multiple-step complex process.4,62 Several different 
mechanisms were hypothesized as possible pathways for TTR misfolding and 
deposition as amyloid. Multiple contributions from clinical and pathological findings in 
patients with ATTR amyloidoses, either untreated or after liver transplant, and in vitro 
experiments led to the identification of tetramer instability and dissociation, proteolysis 
and seeding (a self propagation prion-like mechanism, through the development of 
conformational changes in normal protein, induced by the presence of misfolded 
species63) as the most relevant mechanisms. 
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Nevertheless, multiple questions remain unanswered, either on the isolated 
mechanisms or on the interaction between them and their relative role in the whole 
process.64,65 
2.4.2.1. TTR tetramer instability and dissociation 
Tetramer dissociation into monomers that are prone to misfold and aggregate as 
amyloid fibrils is generally accepted as the first and rate-limiting step in the 
amyloidogenesis cascade.66,67 In vitro studies have shown that TTR tetramers, either 
wild or variant, dissociate spontaneously, but slowly, into monomers that subsequently 
misfold and aggregate. Acceleration of the process can be obtained with increased 
acidity, temperature or protein concentration.68 Experiments with different mutations 
showed that those causing the more aggressive clinical presentations are more 
unstable and wild-type tetramer is the more stable,69 remaining nevertheless prone to 
dissociation. 
An important observation came from the clinical description of a patient with a benign, 
non-progressive presentation of the disease, who was shown to be a compound 
heterozygous carrier of the TTRVal30Met mutation and a non-pathogenic mutation, 
TTRThy119Met.70 This mutation was later demonstrated to be resistant to dissociation 
and able to increase the stability of the pathogenic mutation, adding a strong argument 
to the dissociation theory.71,72 
Recently, a population-based study in Denmark showed that heterozygous carriers of 
the TTRThy119Met mutation have a decreased incidence of cerebrovascular disease 
and an increased life expectancy, when compared to carriers of wild protein.73 This 
suggests that a stable TTR is important for a healthy and long life, although we do not 
know the underlying mechanism(s). 
2.4.2.2. Proteolysis 
Amyloid fibrils extracted from vitreous body samples74 and from multiple tissues,75,76 
were found to have two different types of fibrils, some including the full-length peptide 
with 127 amino acid residues and some fragmented, containing only the C terminal 
portion of the chain, most commonly from residue 47-52 to residue 127. Detailed in 
vitro experiments confirmed that wild and several variant proteins are susceptible to 
trypsin cleavage,77 particularly after dissociation into monomers and when exposed to 
CHAPTER I | Introduction 
 
10 
shear forces.78,79 The fragments were shown to misfold and aggregate as amyloid 
fibrils more rapidly and efficiently than full-length peptides. All these laboratory results 
are in line with the pathological findings of an almost exclusive deposition of 
fragmented fibrils in the heart,80 an organ where circulating TTR is submitted to strong 
shear stress forces. 
2.4.2.3. Seeding  
Seeding is a mechanism well identified in several amyloidoses.63 The analysis of 
amyloid deposits in transplanted patients with continuing progressive disease,81,82 
many years after surgery, showed a higher proportion of wild versus mutant protein as 
compared with the findings in non-treated patients.83-85 A possible explanation is a 
seeding effect induced by the amyloid deposits already present in the tissues before 
transplantation. The first in vitro studies have shown this effect induced by amyloid 
fibrils extracted from explanted or post mortem patient’s hearts86 but further 
experiments are needed for confirmation. 
2.4.3. Tissue toxicity 
Amyloid deposits are nowadays regarded as stable and non toxic aggregates but they 
may nevertheless harm cells due to a volume effect that obstructs and distorts tissue 
components, occludes vessels or diminishes transparency.87 Multiple experiments in 
ATTR amyloidosis and other amyloidoses demonstrated that amyloid precursors, 
oligomers and protofibrils, induce calcium signaling abnormalities,88 oxidative stress, 
and neuroinflammation,89-92 resulting in cell death. All these mechanisms are self-
perpetuating as they may directely contribute to the malfunctioning of the PN.61 
2.5 Genetics 
2.5.1. TTR gene 
TTR gene locates in the long arm of the chromosome 18 and comprises 4 exons, 
coding for a polypeptide chain with 127 amino acid residues.62 The first exon includes 
an initial signal sequence with 20 amino acids and 3 other amino acids present in the 
mature protein. Recently, the Sequence Variant Description Working Group (SVDWG) 
convened by the Human Genome Variation Society93 recommended the inclusion of 
the whole DNA sequence in the numbering of variants and the new designation is 
frequently seen, v. g. (p. TTRVal50Met), instead of TTRVal30Met. However, the 
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nomenclature committee of ISA recommended keeping the former designation, taking 
into account the exclusive aggregation of mature protein into amyloid deposits.2  
2.5.2. Genetic epidemiology and heterogeneity 
More than 130 mutations have so far been identified and the vast majority is 
pathogenic.94 With one exception, a deletion,95 all others are point mutations. Most 
patients are heterozygous carriers of one mutated and one normal allele, as expected 
in an autosomal dominant disorder. Therefore, patients present both variant and 
normal polypeptide chains, in circulation, assembled in the tetramers in variable 
proportion, according to a random distribution.65 There are several descriptions of 
TTRVal30Met96,97 and TTRVal122Ile98 homozygous patients but they rarely present a 
more severe phenotype.99,100 Compound heterozygous carriers presenting either a 
combination of two pathogenic mutations or a pathogenic and a non-pathogenic 
mutation have also been identified, including the interesting case of the coexistence of 
TTRVal30Met and TTRThy119Met mutations in the same patient, as described above. 
TTRVal30Met is the most frequent pathogenic mutation, responsible for most of the 
largest foci of the disease (Portugal, Sweden, Japan, Majorca and Cyprus).101,102 This 
mutation is also frequently identified in smaller clusters and families scattered 
worldwide.94,103 
Another highly frequent mutation, TTRVal122Ile, has been described in the African-
American population, originating from the West coast of Africa. These patients present 
mainly a severe progressive late onset cardiomyopathy.104 
Smaller clusters of variable dimensions were identified in many regions, related to 
particular mutations. Examples of these concentrations are TTRThr60Ala, in Northern 
Ireland105 and populations with Irish ancestry;22 TTRGlu89Gln, in Bulgaria101 and 
several countries in the region, including Italy106 and Turkey;107 TTRSer50Arg, in 
Mexico;108 TTRPhe64Leu, in Sicily;109 TTRSer77Tyr and TTRSer77Phe, in France;110 
and TTRAla97Ser, in Taiwan.111 Conversely, many other mutations have only been 
described in single families.94,101 
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2.5.3. Variable penetrance and age-of-onset distribution 
2.5.3.1. Penetrance  
Hereditary ATTR amyloidosis is an autosomal dominant disease with a variable 
penetrance of the gene (the proportion of mutation carriers who will develop 
symptomatic disease). A full penetrance in adult age has been described in families 
with different mutations, most commonly in families with several affected generations, 
either isolated, as the Indiana/Swiss kindred with the TTRIle84Ser mutation62 or 
concentrated in some of the largest foci, v. g. in Japan,112 Brazil113 and Portugal,114 
where the mean age-of-onset is around the patients’ thirties. However, even in these 
countries there are families with incomplete penetrance.115,116 Outside these locations, 
and for most mutations, an incomplete penetrance is the rule. 
Several collaborative studies which have analysed extensively numerous families, with 
a variable number of affected members and with different mutations and origins, 
characterized penetrance as dependent on age,117,118 gender,118 mutation,118 genetic 
background,117 region of origin119 and gender of transmitting parent.120 In parallel, a 
few studies on the frequency of three different mutations in populations where the 
disease presents as a late onset disorder (Northern Sweden,121 Northern Ireland,122 
and African-Americans123) showed a frequency that varies between 1% and 4%, 
clearly above the values of disease incidence. These findings suggest there are many 
families in which the mutation remains completely silent. If this is the case, evaluation 
of penetrance of TTR mutations would be even lower if population-based studies were 
considered. 
2.5.3.2. Age-of-onset 
The age-of-onset of hereditary ATTR amyloidosis varies from the late teens until very 
old ages. The studies on the distribution of age-of-onset in the three largest foci related 
to the TTRVal30Met mutation (Portugal,114 Sweden,124 and Japan116) showed the 
same large range in all three, with a mean age-of-onset varying from the thirties, in 
Portugal and Japan, to the fifthies, in Sweden. Two distinct subgroups of age-of-onset 
distribution were identified, early onset (<50 years of age) and late onset (≥ 50 years). 
An interesting aspect of the variability of the age-of-onset inside families was presented 
in a study of hundreds of parent-child pairs of observed Portuguese patients, which 
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revealed a significant anticipation of the age-of-onset in the second generation.125 This 
effect is more relevant when the disease is inherited from the mother, with a stronger 
effect on male descendants. Conversely, female patients inheriting the disease from 
their father are protected from this variation. A similar occurrence was detected in 
Sweden126 and Japan.127 
These findings are in line with the observation of a variable penetrance according to 
the gender of transmitting parent120 and they could also explain the double distribution 
of the age-of-onset, with early onset cases appearing in more recent generations due 
to anticipation.127 
2.5.4. Genotype-phenotype relation 
CNS disease is related to a few extremely unstable mutations26,69 that are not found in 
plasma and rarely cause peripheral disease,128 probably because the hepatic PN 
degrades the misfolded protein before its secretion into circulation, while choroid 
plexus synthesis into CSF occurs throughout life causing a severe progressive CNS 
disease.69 
In addition to these particular cases there is also a clear correlation between the 
genotype and the phenotype in some other mutations: Val122Ile129 and Leu111Met130 
cause a cardiac phenotype,33 TTRSer50Arg108 and TTRVal28Met131 are related to a 
neurologic one,33 although not exclusively, because many of these patients also 
present a mild distal neuropathy or slowly progressive conduction disturbances, 
respectively. 
Nevertheless, the mixed phenotype33 with neuropathy and cardiomyopathy and the 
variable overlap of multiple organ involvement, including the eyes,132,133 the kidneys134 
and the CNS26,27 are the hallmark of this condition, particularly if we consider the whole 
course of the disease and not only the presentation at the onset. The finding of a much 
more frequent involvement of the eyes135,136 and the CNS137,138 in patients with a longer 
survival due to liver transplant stresses the need to observe patients in the long term, 
either those submitted to any therapeutical intervention or the untreated ones. 
An interesting case involves the most common mutation TTRVal30Met: early onset 
cases, with no gender disproportion, have a small fibre 
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 neuropathy at presentation, with extensive autonomic dysfunction and no 
cardiomyopathy while late onset patients, predominantly male, most commonly show 
a large fibre neuropathy, milder autonomic problems and a severe cardiomyopathy.139 
In conclusion, phenotype-genotype relation is driven by mutation, genetic background, 
gender and age-of-onset, but the exact causes and mechanisms of the full scenario of 
phenotype variability are far from understood. 
A partial explanation comes from studies76,80 showing that there are two types of 
amyloid fibrils, either type A (a mixture of full-length and fragmented peptides) or type 
B (exclusively full-length peptides). Type A fibrils were found in the majority of the 
cases, either patients with wtATTR amyloidosis or patients with hATTR amyloidosis. 
This last group included patients with 29 different mutations, a late onset of the disease 
and myocardial involvement. On the other hand, fibrils type B were rarer and 
exclusively present in patients with an early onset of symptoms, no myocardial 
involvement and almost exclusively the TTRVal30Met mutation. Further studies with 
different mutations and an early onset of the disease are needed to understand if these 
differences are present across the full spectrum of ATTR amyloidoses or just in the 
TTRVal30Met genotype.140 
2.6. Clinical presentation 
The involvement of the different target organs (PNS, heart, kidney, eye and CNS) in 
ATTR amyloidoses has some characteristics which are more or less typical, although 
not exclusive or pathognomonic. Their recognition could help clinicians to consider this 
diagnosis more frequently, avoiding mistakes and long periods of uncertainty.141 
Clinical picture may present many different combinations of the different aspects, 
causing additional difficulties to have a timely diagnosis.142 
2.6.1. Peripheral nervous disease  
The typical neuropathy related to ATTR amyloidosis is a length-dependent axonal 
neuropathy with early involvement of small nerve fibres from the somatic and 
autonomic nerves, progressing to an extensive damage of all nerve fibres.3 Young 
adult patients of both genders present with insidious and progressing symptoms of 
disautonomia and/or small nerve fibre sensory neuropathy. Sensory involvement 
causes severe neuralgic pain and loss of thermic and algic sensation, with an 
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ascending course. Extensive autonomic dysfunction is present with digestive, 
cardiovascular and genito-urinary symptoms. Digestive symptoms include early 
satiety, nausea, vomiting, constipation or alternating constipation and diarrhea;143 
genitourinary problems include impotence in male patients and anorgasmia in females, 
urinary retention with recurrent urinary tract infections that later evolves to permanent 
urinary incontinence; cardiovascular dysautonomia causes orthostatic hypotension, 
loss of pulse rate variability and loss of vasomotor control; other symptoms include 
loss of pupillary light reaction and accommodation and loss of sweating in the 
extremities, with compensatory increased sweating in the upper back and head.144 
The disease progresses with large nerve fibre involvement causing tactile and postural 
sensory loss and progressive ascending motor involvement. Sensory ataxia and loss 
of strength contribute together to the progressive walking disability that will ultimately 
render patient wheelchair bound.144 
Neuropathy in late onset patients is more variable: some patients have a neuropathy 
similar to the above description, but many others have a sensory and motor 
neuropathy, with early involvement of all nerve fibre types and less autonomic 
dysfunction.145-148 Early involvement of upper limbs, either due to carpal tunnel 
syndrome149 or to multiple nerve involvement is sometimes observed.150 
2.6.2. Heart disease 
A progressive infiltrative cardiomyopathy is the most common presentation of heart 
disease, leading to a concentric enlargement of the walls of the heart and cardiac 
failure associated with conduction and rhythm disturbances, particularly atrial 
fibrillation.151 
The clinical presentation of wild-type disease is not very different from the inherited 
cardiac phenotype, but mean age-of-onset is later.152 A previous diagnosis of carpal 
tunnel syndrome is common, sometimes many years before the onset of symptoms of 
cardiac failure.153 
Patients with early onset neuropathy also develop severe conduction disturbances, 
ultimately leading to the need of a pacemaker.154,155 They rarely present an infiltrative 
cardiomyopathy, but they have sub-endocardial amyloid deposition156 with extensive 
loss of conduction tissue and heart denervation.157 
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2.6.3. Renal disease 
Kidney involvement was described in the Portuguese patients with TTRVal30Met 
mutation.158 The most common presentation is a nephrotic syndrome progressing to 
end-tage renal failure. More rarely progressive renal failure occurs without significant 
proteinuria. Amyloid deposition in the kidneys is a common finding, even in patients 
without renal dysfunction, but those with evidence of kidney involvement have more 
glomerular deposition of amyloid159 than those without such signs. 
2.6.4. CNS and eye disease 
CNS involvement is due to a leptomeningeal amyloid angiopathy and may cause 
episodes of focal neurological deficits, hearing loss, ataxia, epilepsy, hydrocephalus, 
brain hemorrhage and dementia.26,27 
Eye disease manifests predominantly as vitreous opacities and severe progressing 
glaucoma. Another disabling aspect is the dryness of the eyes, which together with the 
sensory loss may cause serious injuries to the cornea and, ultimately, blindness.160 
2.6.5. Other aspects 
A hallmark of the disease is the marked loss of weight, partially but not totally related 
to the severity of digestive problems.161 Other aspects less common, and less studied, 
include anemia,162,163 susceptibility to osteoporosis164 and hypoglycemia episodes.165 
2.7. Disease-modifying treatments 
Disease-modifying therapies include any intervention which interferes with the natural 
course of a chronic, progressive, and degenerative disorder, stopping, or at least 
decreasing, the continuous process of tissue damage and all related clinical 
consequences.166 
Considering the complexity and the pathways identified so far in the pathogenic 
process of ATTR amyloidosis, we can conceive of five main approaches for the 
development of ATTR amyloidosis disease-modifying therapies:167,168 1) the partial or 
total removal of the amyloid protein precursor from the plasma, either with liver 
transplant (which completely removes the variant precursor) or gene-silencing drugs 
(which knockdown a large percentage of all TTR, variant and wild-type); 2) the 
stabilization of TTR tetramer, stopping the process at the first step, the dissociation of 
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the TTR tetramer; 3) the improvement of the proteostasis mechanisms; 4) the 
remodeling/reabsorption of amyloid deposits; and 5) the interference with the 
degeneration process induced by the presence of toxic species related to amyloid. All 
these different strategies aim at diminishing the amyloid burden and at stopping the 
degeneration process of the different affected tissues and a translation of these effects 
into the health status of the patients is expected.166 In fact, there are drugs under 
development in the laboratory or in the clinic which address all these different 
mechanisms of disease. 
The first disease-modifying treatment for ATTR amyloidosis that demonstrated efficacy 
was liver transplantation, which replaces the variant TTR present in plasma with wild-
type protein produced by the transplanted liver. Soon after the surgery the variant TTR 
was shown to disappear from the plasma.169 A high percentage of patients 
demonstrate stabilization of the disease, particularly neuropathy170,171 and data from 
tthe Familial Amyloid Polyneuropathy World Transplant Registry showed that patients 
with hATTR amyloidosis with the TTRVal30Met mutation had a 20-year survival rate 
of 55%.172 Unfortunately, not all patients are appropriate candidates for this 
intervention: carriers of mutations other than TTRVal30Met, with late age-of-onset, 
cardiac disease, longer duration of symptoms (each 1-year increase in disease 
duration is associated with an 11% increase in mortality172) and poor nutritional 
status173 have worse outcomes and were shown to have no significant benefit from the 
surgery.174 
Taken together, liver transplantion has shown success in the treamtent of hATTR 
amyloidosis but only for a subgroup of patients and remains an invasive option with 
long-term risks and morbidity.  
In consequence, other treatment options had to be looked for. The clinical development 
of these alternatives, the first three drugs approved for the treatment of ATTR 
amyloidosis, is the main subject of this thesis.  
 
3. OBJECTIVES 
To present and discuss the clinical development of the three new drugs currently 
approved in Europe for the treatment of TTR-related polyneuropathy: Tafamidis 
(Vyndaqel™),175 Patisiran (Onpattro®™)176 and Inotersen (Tegsedi™)177 and the 
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impact of disease-modifying treatments in the natural history of the disease, divided 
into three sections: 
1.Trial design options and development of outcome measures for Tafamidis and 
Patisiran registration trials. 
2.The positive evaluation of efficacy and safety of the three drugs, across their 
clinical development and the use of Tafamidis in clinical practice, determining 
a new landscape for the treatment of the disease. 
3.The demonstration of the major impact of the first disease-modifying treatment, 
liver transplant, in the survival of patients. 
 
Specific Issues to be addressed in the DISCUSSION  
1. Objectives and extent of disease-modifying therapies in ATTR amyloidosis 
2. Rules and needs for the approval of new drugs for rare diseases 
3. Strengths and limits of clinical trials 
4. Development of outcome measures and design of clinical trials 
5. Lessons learnt from the relative failure of Tafamidis pivotal trial 
6. Tools for evaluating new drugs in clinical practice 
7. Present landscape of neuropathy treatment 
7.1. Approved drugs 
7.1.1. Tafamidis 
7.1.2. Patisiran 
7.1.3. Inotersen 
7.2. Liver transplant indications 
7.3. A drug treatment algoritm 
7.4. Options for patients with predominant heart and renal disease 
7.5. The use of off-label drugs 
8. Questions brought by the increased survival of transplanted patients 
8.1. CNS and eye involvement as major unmet needs 
9. Future perspectives 
9.1. Combination therapies 
9.2. New drugs in clinical development 
9.3. The case for peri-symptomatic/ pre-clinical treatment 
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PATIENTS AND METHODS 
 
All studies presented here as separate articles include patients observed and regularly 
followed at Unidade Corino de Andrade (UCA), CHUP. 
Nine articles are reports of multicenter clinical trials and collaboration studies and 
include patients from countries worldwide. One article is the result of a collaboration 
with the reference center in Lisbon and three articles are based on studies conducted 
exclusively with patients from our center.  
UCA, integrated at the Neuroscience Department, is an outpatient multidisciplinary 
clinic that includes many different medical specialties (Neurology, Cardiology, 
Ophthalmology, Nephrology, Physical Rehabilitation, Urology, Nutrition and 
Psychiatry) as well as dedicated nurses.  
It was formally recognized by the Portuguese Ministry of Health as a National 
Reference Center for Familial Amyloidosis, in 2015. 
More than 1000 patients and asymptomatic confirmed carriers are observed every 
year, for treatment and regular follow-up. About 50 to 70 patients receive a diagnosis 
of disease onset every year, based on the clinical findings, molecular studies and 
confirmation of amyloid deposition in any appropriate tissue obtained with the least 
invasive available biopsy. 
UCA inherited and organized all the FAP patient files since Andrade’s first observations 
in 1939. This historical register includes more than 2500 observed patients from 600 
families 
Each and every study and clinical trial was authorized by the Administration Board of 
CHUP, after approval from the National (for clinical trials) or local Ethical Committee. 
All patients signed a written informed consent for each study.  
The specific methodologies applied in each study are described in the articles. 
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1. Trial design and outcome measures development 
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outcome measure in transthyretin familial amyloid
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Donna R. Grogan5, and Teresa Coelho6
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Abstract The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire is an
instrument to assess QOL in diabetic polyneuropathy. The objective of this observational,
cross-sectional study in 61 patients with V30M transthyretin familial amyloid polyneuropathy
(TTR-FAP) and 16 healthy volunteers was to validate the Norfolk QOL-DN for assessment of
QOL in TTR-FAP. Comparisons were conducted to identify the best items to discriminate
disease stages and assess which individual Norfolk domains (symptoms, large fiber,
small fiber, autonomic, and activities of daily living) would be most affected by disease
stage. Analysis of individual items revealed a significant pattern of discrimination among
disease stages (p< 0.001). Total QOL scores increased (indicating worsening) with duration
of symptoms, with a steeper increase observed earlier in the course of disease.
Significant correlationswere observed between each Norfolk domain and othermeasures of
neurological function. Limitations include cross-sectional study design, low patient numbers
in this rare disease, and the ordinal-based character of the metric used; future areas to
explore include item response theory approaches such as Rasch analysis. These results
suggest the Norfolk QOL-DN is a reliable indicator of the impact of disease severity on
QOL in patients with TTR-FAP.
Key words: nerve-fiber function, neurological function, Norfolk quality of life, outcome
measure, transthyretin amyloid polyneuropathy
Introduction
Systemic amyloidoses encompass both acquired
and inherited conditions in which various insoluble
Address correspondence to: Aaron Vinik, MD, PhD, FCP, MACP,
FACE, Murray Waitzer Endowed Chair of Diabetes Research, Direc-
tor of Neuroendocrine Unit, Eastern Virginia Medical School, Stre-
litz Diabetes Center, 855 W. Brambleton Avenue, Norfolk, VA
23510, USA. Tel: +(1)757-446-5912; Fax: +(1)757-446-5868; E-mail:
vinikai@evms.edu.
fibrillar proteins (amyloid) accumulate in tissues in
amounts sufficient to impair normal function. A num-
ber of different precursor proteins have been associ-
ated with familial amyloidosis, including transthyretin
(TTR; formerly known as pre-albumin), gelsolin, and
apolipoprotein. TTR is primarily synthesized in the liver
and circulates in the blood as a transport protein of
thyroxine and retinol-binding protein-retinol (vitamin A)
complex (Blake et al., 1978; Monaco et al., 1995). In its
native state, TTR exists as a homotetramer with two
C2 symmetric funnel-shaped thyroxine-binding sites
© 2014 Peripheral Nerve Society 104
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located at the central dimer–dimer interface (Nilsson
et al., 1975; Saraiva, 2001).
While TTR-familial amyloid polyneuropathy
(TTR-FAP) is a rare disease with variable penetrance
and onset in those carrying a causative mutation, it
represents the most common form of familial amyloi-
dosis and is an axonal degenerative disease affecting
sensory, motor, and autonomic function that is fatal
over an average time of 10 years from symptom onset
(Benson, 1989; Planté-Bordeneuve and Said, 2011;
Coelho et al., 2013). As this axonal degeneration begins
in the distal small unmyelinated fibers involved with
pain and temperature sensation, the initial symptoms
are hypoesthesia, paresthesia, and loss of sensation in
the lower limbs (LLs) (Thomas and King, 1974; Benson,
1989; Planté-Bordeneuve and Said, 2011), in a pattern
similar to that observed in diabetic polyneuropathy
(DPN) (Boulton et al., 2005; Vinik et al., 2013). As with
DPN, progression of TTR-FAP is accompanied by
greater involvement of the upper limbs and progres-
sion to more extensive motor involvement. The extent
to which a patient’s walking ability is impaired is a
particularly salient sign of disease progression. The
Coutinho classification system for TTR-FAP disease
progression utilizes three stages which are based on
limb involvement; the disruption of activities of daily
living (ADL); the severity of sensory, motor, and auto-
nomic neuropathic dysfunction; and ambulation status
(Coutinho et al., 1980). Autonomic neuropathy may
be the presenting symptom or it may be seen some-
what later, usually within 1–2 years of disease onset.
Symptoms such as nausea, vomiting, constipation
alternating with diarrhea, urinary retention or inconti-
nence, anhidrosis, orthostatic hypotension, and sexual
impotence may be present (Coutinho et al., 1980).
Health-related quality of life (QOL) can be mea-
sured by a variety of self-administered questions
regarding perceived aspects of physical and mental
health and function (McHorney, 1999; Centers for Dis-
ease Control and Prevention, 2000). Despite the sub-
stantial deleterious impact that TTR-FAP would be
expected to have on health-related QOL, there have
been very few reports of health-related QOL evalu-
ations in this patient population. Of the studies that
have addressed this important issue,most have sought
to characterize QOL specifically in patients who have
undergone liver transplantation. Nearly all these stud-
ies have utilized generic health-related QOL instru-
ments, such as the Medical Outcome Study 36-item
short-form survey, which have not been validated in
TTR-FAP (Jonsén et al., 1996; Jonsén et al., 2001;
Drent et al., 2009). The lack of a specific tool with
which to evaluate QOL in TTR-FAP stands in contrast
to DPN, for which several validated instruments are
available (Vickrey et al., 2000; Vileikyte, 2001; Vinik
et al., 2005).
One such instrument is the Norfolk Quality of
Life-Diabetic Neuropathy (QOL-DN) Questionnaire,
which was developed to address the need for a tool
to assess patients’ subjective perceptions of symp-
toms associated with specific nerve fiber damage
occurring in DN (Vinik et al., 2005; Vinik and Vinik,
2007; Vinik et al., 2008). This self-administered ques-
tionnaire captures patients’ perceptions of a wide
spectrum of neuropathy symptoms and is a nerve
fiber-specific tool comprising five domains: physical
functioning/large-fiber neuropathy, ADL, symptoms,
small-fiber neuropathy, and autonomic neuropathy
(Vinik and Vinik, 2007). Presence or absence of neu-
ropathic symptoms is recorded, and items assessing
ability to perform ADL, as well as generic health status,
are rated on a 5-point Likert-type scale, with higher
scores indicating poorer status. The Norfolk QOL-DN
has been validated in populations with mild-to-severe
DPN (Vinik and Vinik, 2007; Vinik and Ziegler, 2007;
Vinik et al., 2008) and discriminates DPN patients
from healthy controls, shows excellent reproducibil-
ity, and can discriminate across different levels of
disease severity (Vinik et al., 2005; Vinik and Vinik,
2007; Vinik et al., 2008). The authors have shown
previously (Vinik et al., 2005; 2008) that the primary
influences on QOL in DPN are physical functioning and
ADL, accounting for 59.7% of the variance. Effects
on ADL appear to be primarily determined by fine
motor functions, in contrast to the greater influence of
gross motor requirements for activities in the physical
functioning/large-fiber domain. The rapid loss of motor
function in the TTR-FAP patient population, resulting
in confinement to a wheelchair, clearly would be
expected to affect both ADL and physical functioning,
with a substantial impact on QOL.
The main objective of this study was to assess
the validity and reliability of the Norfolk QOL-DN as an
index of health-related QOL in patients with the rare
disease TTR-FAP. We have evaluated its ability to dis-
criminate between the different levels of TTR-FAP dis-
ease severity at early and later stages of disease. We
also examined the relationships, by TTR-FAP disease
stage, between the Norfolk QOL-DN and objective
measures of nerve-fiber function, autonomic function,
and impairment due to neuropathy.
Materials and Methods
Study protocol and participants
This was an observational, cross-sectional study
conducted in 61 TTR-FAP patients with the Val30Met
mutation and 16 healthy volunteerswhowere between
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18 and 50 years of age without neurological disease.
The TTR-FAP cohort comprised patients with stage
1 disease at baseline who were participants in a
phase II/III interventional study (n= 29), in addition
to stage 2 (n= 16) and stage 3 (n= 16) patients.
All patients were enrolled at a single study center
(Hospital Santo António, Porto, Portugal) and the study
protocol was approved by the institutional review
board. The Val30Met mutation is endemic in Portugal
with 90%penetrance. Disease staging of TTR-FAPwas
based on the criteria established by Coutinho et al.
(1980) and determined primarily by ambulatory status:
stage 1, fully ambulatory; stage 2, required assistance
with ambulation; and stage 3, wheelchair-bound.
Measures
QOL was measured using the 35-item Norfolk
QOL-DN questionnaire (Vinik et al., 2005; Boyd et al.,
2011), developed to reflect symptoms associated
with damage to various nerve fiber types (Vinik and
Vinik, 2007; Vinik et al., 2008). Following interviews
with >1,000 patients, specific items were selected
to address the symptoms, complications, and impair-
ment of ADL associated with small and large nerve
fibers and autonomic nerves. The original 68-item
pool was refined into a 47-item questionnaire, which
was then evaluated for its discriminatory ability and
found to have sensitivity >75% across all domains
and specificity between 71% and 90% (Vinik et al.,
2005; Vinik and Vinik, 2007). Following assessment of
test/retest reliability and psychometric factor analysis,
the Norfolk QOL-DN was further refined to 35 items
(Vinik and Vinik, 2007).
The questionnaire was translated into Portuguese
under the direction of the first two authors using
forward/backward translation and cognitive debriefing
with FAP patients and linguistically validated (Mapi
Research Institute, Lyon, France). Study participants
completed the Norfolk QOL-DN questionnaire at base-
line and 4weeks later (except for the stage 1 patients,
who were not assessed at week 4). List-wise deletion
was used to handlemissing data. The scoring approach
used in this study yielded a possible range for total qual-
ity of life (TQOL) scores of −2 to 138.
The validity of the Norfolk QOL-DN for assessing
the TTR-FAP population was further delineated by cor-
relating it with objectivemeasures of neurological func-
tion, evaluated using a modified form of the neuropa-
thy impairment score (NIS) (Dyck et al., 1995; Casellini
et al., 2007), the NIS-Lower Limbs (NIS-LL) (Dyck et al.,
1997; Bril, 1999), and quantitative sensory testing.
The NIS quantifies a neurological examination (total
score range, 0 [normal] to 244 [total impairment]), a
tool commonly used to assess clinical efficacy in the
treatment of neuropathy. The NIS-LL is restricted to the
LL (total score range, 0–88) and combines subscale
scores for muscle weakness (range, 0–64), reflexes
(range, 0–8), and sensation at the great toe (range,
0–16) (Dyck et al., 1997). The NIS-LL is particularly
appropriate for the assessment of early-stage disease
(Ziegler et al., 2011). To enhance reproducibility, the
average of two successive NIS-LL assessments per-
formed by the same neurologist at least 24 h apart (but
within 7 days) was used in the analysis.
Quantitative sensory testing was performed uti-
lizing the Computer Aided Sensory Evaluator IV (WR
Medical Electronics, Stillwater, MN, USA), a com-
puterized test of sensory threshold determination.
Cooling detection threshold (CDT), vibratory detection
threshold (VDT), and heat/pain detection threshold
(HPDT) of the upper and lower limbs (CDT and HPDT
assessed at the dorsum of the foot and hand; VDT
assessed at the dorsum of the great toe and index
finger) were determined. The heart rate response to
deep breathing (HRDB) was assessed only in those
patients without pacemakers.
Analytical methods
Prior to the primary analyses of the differences
between QOL in TTR-FAP disease stages, all items
were screened for floor or ceiling effects, invariance,
or other problems that might compromise their util-
ity in further analysis or in practice. Thereafter, several
analytical techniques were used. Due to the descrip-
tive nature of these analyses and the small sample size
inherent in this orphan disease population, no correc-
tions were made for multiple comparisons.
Exploratory factor analysis
As the Norfolk QOL-DN has 35 items scored in
five domains, a forced five-factor extraction was used
in the initial exploratory factor analysis for the QOL
instrument in the TTR-FAP population. Varimax rotation
was used to produce a more clearly interpretable
factor structure. Exploratory factor analysis was used
for the initial statistical approach because it allows
identification of the common factors underlying the
scale items. However, because the sample size was
relatively small compared with standard psychometric
studies, additional analyses were also conducted as
described in the following sections.
Test/retest reliability of the Norfolk QOL-DN
in TTR-FAP
The reliability of the Norfolk QOL-DN question-
naire has previously been tested in different DPN
study populations, including diabetic controls free of
evidence of neuropathy and patients with mild neu-
ropathy, as well as healthy controls. The questionnaire
was administered at study entry and again 4weeks
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after the date of entry (Vinik et al., 2005), and was
shown to have acceptable test/retest reliability in these
populations. The same methodology was used to
assess the test/retest reliability of both the Norfolk
QOL-DN and its individual domains. Paired t-tests were
used to compare the scores collected at study entry
and week 4. Patients enrolled in the current interven-
tional study were not retested.
Measurement of disease progression over time,
discriminatory validity, and item discrimination
by disease stage
Correlations between Norfolk QOL-DN domain
scores and time from symptom onset were examined,
with the hypothesis that there would be a significant
association between disease progression and wors-
ening scores on the Norfolk QOL-DN. Progressive and
hierarchical comparisons were conducted to identify
which items best discriminated between patients with
less severe or more severe disease and healthy volun-
teers, as well as on which Norfolk QOL-DN domains
(symptoms, large fiber, small fiber, autonomic, and
ADL) disease stage would have the greatest impact.
Eta squared (𝜂2) was calculated as a measure of
effect size.
Associations between QOL-DN and NIS-LL
subscales
Correlations (Pearson’s r) between subjective Nor-
folk QOL-DN domain scores and objective neuropathy
measures were assessed. Objective evaluations of
neuropathy were determined for strength, reflexes,
and somatosensory function, and the composite
NIS-LL was derived as a sum of the scores of the
individual components of the examination, as reported
by Casellini et al. (2006). Objective scores have been
shown to correlate with the individual domains of the
QOL-DN in DPN and form the basis of criterion validity
(Vinik et al., 2005; Vinik et al., 2008).
Associations between Norfolk QOL-DN
and symptom duration and NIS total score
The associations between Norfolk TQOL-DN score
and symptom duration and NIS total score were mod-
eled using ordinary least squares regression. Quadratic
terms were tested in these models to allow for curvi-
linearity in the associations.
Results
Patient demographics and clinical characteristics
The demographic and clinical characteristics of the
61 patients with TTR-FAP and 16 healthy volunteers
are summarized in Table 1. As expected, patients with
more advanced diseasewere older, had longer duration
of disease, and had a marked deterioration in both
NIS-LL and modified body mass index (a measure of
nutritional status).
Exploratory factor analysis
All items were screened for floor or ceiling effects
as previously mentioned. Two items, electric shocks
Table 1. Patient demographics and disease characteristics at baseline.
Characteristic
Healthy
volunteers
(n=16)
Stage 1
Independent
ambulation
(n=29)
Stage 2
Assistance
required to walk
(n=16)
Stage 3
Wheelchair-bound
or bedridden
(n= 16)
Overall
p-value*
Age, mean (SD) years 34.8 (10.0) 39.0 (11.6) 46.5 (12.8) 55.0 (10.0) <0.001
Men, n (%) 8.0 (50.0) 12.0 (41.4) 9.0 (56.3) 10.0 (62.5) 0.565
White race, n (%) 16.0 (100.0) 29.0 (100.0) 16.0 (100.0) 16.0 (100.0) NA
Height, mean (SD) cm 169.6 (7.6) 165.3 (11.2) 165.7 (9.4) 165.4 (10.1) 0.542
Weight, mean (SD) kg 73.8 (17.7) 65.5 (13.1) 62.8 (15.1) 54.7 (23.4) 0.021
mBMI, mean (SD) 1,199.0 (241.1) 1,031.9 (213.8) 886.4 (309.8) 759.7 (316.2) <0.0001
Symptom duration, years
Mean (SD) NA 2.6 (2.8) 7.7 (2.9) 14.2 (4.4) <0.001
Median NA 1.4 7.9 14.2
Range NA 0.2, 11.9 3.1, 13.1 6.0, 22.1
Age at symptom onset, years
Mean (SD) NA 36.9 (10.7) 39.3 (13.1) 41.7 (12.6) 0.421
Median NA 33.3 35.0 37.0
Range NA 24.0, 65.2 21.0, 61.0 27.0, 66.0
Total NIS, mean (SD) 0.0 (0.0) NA 84.8 (16.1) 128.7 (35.8) <0.001
NIS-LL, mean (SD) 0.0 (0.0) 6.9 (6.3) 55.3 (6.7) 69.0 (9.8) <0.001
TQOL, mean (SD) 2.6 (5.0) 21.0 (14.5) 73.1 (27.5) 95.4 (21.7) <0.001
Healthy volunteers did not have small- or large-nerve function tests performed, as they had normal neurological examinations. The total NIS
was not assessed in patients with stage 1 disease.
mBMI, modified body mass index; NA, not applicable; NIS, neuropathy impairment score; NIS-LL, neuropathy impairment score-lower limbs;
SD, standard deviation; TQOL, total quality of life score.
*On the basis of analysis of variance for continuous endpoints and Fisher’s exact test for categorical endpoints, unless otherwise indicated.
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and unusual sensations, demonstrated floor effects
and were excluded from the exploratory factor analysis
and analyses done at the item level. Two additional
general health-related items that had been adapted
from the validated SF-36 instrument with permission
(Vinik et al., 2005) were also excluded because they
had a restricted range of responses.
The forced five-factor extraction accounted for
77.5% of overall item variance. Varimax rotation of
these items showed that of the five factors, the
first factor (physical functioning/large-fiber neuropathy)
captured 48.5%, while the other four captured 9%
each. The results of the exploratory factor analysis are
presented in Table S1, Supporting information.
Test/retest reliability of the Norfolk TQOL
in TTR-FAP
There were no significant differences in Norfolk
TQOL scores between day 1 and week 4 in healthy vol-
unteers, stage 2 patients, or stage 3 patients (p> 0.05).
For the individual domains, there were no significant
differences in scores, except for small-fiber neuropathy
in stage 2 patients (−1.9± 2.9, p= 0.0237). Results are
not available for stage 1 patients because they were
not retested at week 4.
Norfolk QOL-DN scores by disease severity
Fig. 1 and Table 2 show the Norfolk TQOL and
the five domain scores for the healthy volunteers and
TTR-FAP patients by disease stage. Norfolk TQOL
scores discriminated between TTR-FAP disease stage
groups as well as healthy volunteers.
The groups could also be reliably differentiated on
the following individual QOL-DN domains:
• Healthy volunteers vs. stage 1: physical functioning/
large-fiber neuropathy (p= 0.0042), symptoms
(p<0.0001), and autonomic neuropathy (p= 0.0474)
• Stage 1 vs. stages 2 and 3: all domains (all p< 0.05)
• Stage 2 vs. stage 3: physical functioning/large-fiber
neuropathy (p= 0.0006), ADL (p= 0.0004), and
symptoms (p=0.0083).
Discrimination of stages by items
As noted earlier, two items, electric shocks and
unusual sensations, were excluded from further eval-
uation at the item level due to floor effects. Analysis of
the remaining items demonstrated the ability of spe-
cific items to distinguish among the different stages of
TTR-FAP as follows:
• Healthy volunteers vs. TTR-FAP patients at any dis-
ease stage: all items discriminated except “vomit-
ing, particularly after meals.”
• Healthy volunteers vs. stage 1: the majority of items
discriminated, with the exception of several items
reflecting fine motor control, extremity sensation,
and gross motor strength.
• Stage 1 vs. stages 2 and 3: the majority of items
discriminated, with the exception of items querying
pain, fainting/dizziness upon standing, and superfi-
cial sensation (e.g., touch of bed sheets).
• Stage 2 vs. stage 3: a majority of the items discrim-
inated.
Association of Norfolk TQOL and domain scores
with duration of disease
The association between duration of symptoms
in years and Norfolk TQOL scores is presented in
Fig. 2. A quadratic regression was modeled, with an
initial increase of 9.12 points in TQOL per year of
symptom duration. The slope of change diminished
over the course of disease, decreasing by 0.24 per year
squared. The TQOL scores level off at approximately
19 years estimated by the year at which the predicted
curve is maximized.
Significant correlations were also observed
between the individual Norfolk QOL-DN domains
and disease duration. The correlations for the domains
were as follows: physical functioning/large-fiber neu-
ropathy, r= 0.73 (p< 0.0001); ADL, r= 0.75 (p< 0.
0001); symptoms, r= 0.42 (p= 0.0009); small-fiber
neuropathy, r=0.68 (p< 0.0001); and autonomic neu-
ropathy, r=0.42 (p=0.0008). Thus, duration of disease
accounted for between 18% and 56% of the variance
in the Norfolk QOL-DN domain scores.
Associations between Norfolk QOL-DN and NIS
total score
Figure 3 illustrates the association between NIS
total scores and the Norfolk TQOL. A quadratic regres-
sion equation modeled an initial increase of 1.02 points
in TQOL per unit increase in the NIS total score. As
the NIS total scores increased, the slope of change
decreased by 0.003 per NIS total score unit squared.
Relationship between TQOL and NIS-LL as a
measure of peripheral nerve function of the LLs
Examination of linear associations between
QOL-DN domain scores and NIS-LL subscales (muscle
weakness, reflexes, and sensation) revealed consis-
tent positive correlations (Table 3). The QOL-DN
domain scores for physical functioning/large-fiber
neuropathy, ADL, and small-fiber neuropathy showed
particularly high correlations (the r range for these was
0.80–0.87).
Relationship between QOL and measures
of autonomic and small-fiber function
The relationships betweenmeasures of autonomic
function (i.e., HRDB) and small-fiber nerve function
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Figure 1. Mean change in Norfolk total quality of life (TQOL) score and individual domain scores for patients and healthy
volunteers. (A) TQOL (range, −2 to 138); (B) physical functioning/large-fiber neuropathy (range, −2 to 56); (C) activities of daily
living (range, 0–20); (D) symptoms (range, 0–32); (E) small-fiber neuropathy (range, 0–16); and (F) autonomic neuropathy
(range, 0–12). Error bars represent standard deviation. HV, healthy volunteer; NS, not significant.
(CDT and HPDT) and the Norfolk QOL-DN (both TQOL
and individual domains) were examined. The Norfolk
TQOL score correlated significantly with each mea-
sure of nerve-fiber function and HRDB (Table 4). There
were significant positive correlations between the indi-
vidual QOL-DN domains and most of the nerve-fiber
function measures and negative correlations with auto-
nomic measure (HRDB). The prevalence of pacemak-
ers among patients at stage 2 (31.3%) and stage 3
(68.8%) may have affected the results, because it
reduced the numbers of evaluable patients for HRDB.
Nevertheless, the results overall were consistent with
the early appearance of symptoms and autonomic neu-
ropathy (Figs. 1D and 1F).
Discussion
In this study, we hypothesized that the Norfolk
QOL-DN questionnaire was a valid tool with which to
evaluate the impact of TTR-FAP on health-related QOL,
that its five-domain construction could discriminate
healthy subjects from patients with TTR-FAP, and that it
would be able to distinguish between patients at differ-
ent stages of the disease. Furthermore, we explored
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Table 2. Norfolk TQOL and individual domain scores in healthy volunteers and patients with different disease stages.
Norfolk QOL-DN
Healthy
volunteers
(n= 16)
Stage 1
Independent
ambulation
(n=29)
Stage 2
Assistance
required to walk
(n= 16)
Stage 3
Wheelchair-bound
or bedridden
(n=16)
Overall
p-value*
TQOL (range, −2 to 138), mean (SD) 2.6 (5.0) 21.0 (14.5) 73.1 (27.5) 95.4 (2.7) <0.002
Physical functioning/large-fiber
neuropathy (range 0–58), mean (SD)
– 11.1 (9.6) 34.9 (14.5) 47.4 (8.2) <0.0001
ADL (range 0–20), mean (SD) 0.0 (0.0) 0.6 (1.4) 12.6 (5.6) 17.3 (5.0) <0.0001
Symptoms (range 0–32), mean (SD) 0.3 (0.8) 6.1 (3.9) 8.8 (5.2) 12.5 (4.4) <0.0001
Small-fiber neuropathy (range 0–16),
mean (SD)
0.1 (0.3) 1.1 (1.9) 12.1 (3.6) 12.4 (3.9) <0.0001
Autonomic neuropathy (range 0–12),
mean (SD)
0.1 (0.3) 2.0 (2.5) 4.7 (3.9) 5.8 (4.2) <0.0001
ADL, activities of daily living; QOL-DN, quality of life-diabetic neuropathy; SD, standard deviation; TQOL, total quality of life score.
*On the basis of analysis of variance with individual Norfolk QOL-DN measurement as the dependent variable.
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Figure 2. Association between the Norfolk total quality of
life (TQOL) score and disease duration. Note the early
manifestation of deterioration of quality of life. Regression
equation: Norfolk TQOL= 10.12+9.123× time from symp-
tom onset−0.239× time from symptom onset squared.
TTR-FAP, transthyretin familial amyloid polyneuropathy.
its utility as a measure of health-related QOL when
used in conjunction with objective measures of neuro-
logical impairment (NIS-LL muscle weakness, reflexes,
and sensation including warm and cold thermal thresh-
olds) at each disease stage. We conducted progressive
and hierarchical comparisons to identify which items
best discriminated between patients with less or more
severe disease and on which of the individual domains
the different stages of the disease would have the
greatest impact. These results have shown that the
Norfolk QOL-DN can discriminate between stages of
disease severity in TTR-FAP. The cross-sectional nature
of this study did not allow us to characterize its sensi-
tivity to change. Conducting such a longitudinal study
in a disease that progresses over several years would
be daunting and beyond the scope of this study.
Demonstrating that the Norfolk QOL-DN can
clearly distinguish between the stages is a necessary
first step, and suggests it may serve as an appropriate
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Figure 3. Association between Norfolk total quality of life
(TQOL) score and neuropathy impairment score (NIS) score.
Regression equation: Norfolk TQOL=9.78+ 1.02×NIS total
score− 0.003 NIS total score squared. The range for NIS is
0–244. For stage 1 patients, only NIS-lower limb (NIS-LL)
data were available.
endpoint for interventional trials designed to evaluate
the effects of investigational treatments (including
disease-modifying approaches) on disease progres-
sion. Support for its use comes from a longitudinal
18-month study by Coelho et al. (2012) in which it
was used as a co-primary endpoint (with NIS-LL)
and demonstrated changes from baseline in Norfolk
TQOL that were significantly different between the
placebo group and those treated with tafamidis for
18months. In the pre-specified analysis of co-primary
endpoints in the efficacy evaluable population (n= 87),
patients receiving tafamidis had significantly better
preserved TQOL than patients receiving placebo (least
squared mean change from baseline, 0.1 vs. 8.9;
p= 0.045). Of the domains comprising the Norfolk
QOL, tafamidis had the greatest impact on physical
functioning and ADL. This is not surprising in light of
the strong relationship between TQOL domains and
objective measures of neuropathy and responses to
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Table 3. Correlations between Norfolk QOL-DN domains
and NIS-LL subscales.
NIS-LL subscale
Norfolk
QOL-DN domain
Muscle
weakness Reflexes Sensation
Physical functioning/
large-fiber neuropathy 0.84 0.80 0.85
ADL 0.87 0.84 0.85
Symptoms 0.59 0.57 0.68
Small-fiber neuropathy 0.86 0.87 0.87
Autonomic neuropathy 0.51 0.52 0.60
n=77; all p<0.0001.
ADL, activities of daily living; NIS-LL, neuropathy impairment
score-lower limbs; QOL-DN; quality of life-diabetic neuropathy.
treatment based upon the mechanism of action of the
drug in question (Boyd et al., 2011; Coelho et al., 2011).
These results are encouraging and suggest that with
careful selection of patients, perhaps those earlier in
the course of TTR-FAP, the Norfolk TQOL could serve
as an appropriate endpoint in clinical trials.
In TTR-FAP, as in DPN, the Norfolk QOL-DN
total score differentiates between healthy volunteers
and TTR-FAP patients, as well as among patients
with different stages of the disease. TQOL scores
on the Norfolk QOL-DN significantly increased (i.e.,
worsened) as TTR-FAP disease severity increased.
Individual domains of the Norfolk QOL-DN differed
in their ability to discriminate between different
stages of the disease and between TTR-FAP patients
and healthy volunteers. The ADL and small-fiber
neuropathy domains were similar in patients with
stage 1 disease and healthy volunteers, but stage 1
patients had significantly worse scores on the physical
functioning/large-fiber neuropathy, symptoms, and
autonomic neuropathy domains. Patients with more
advanced TTR-FAP (stage 2 and stage 3) were signif-
icantly more impaired on all domains when compared
with stage 1 patients and healthy volunteers. Con-
sistent with the progressive nature of the disease,
physical functioning/large-fiber neuropathy, ADL, and
symptoms differed between patients with stage 2
and stage 3 disease, but small-fiber neuropathy and
autonomic neuropathy domains did not differ. The
Norfolk domain scores also had significant positive
correlations with symptom duration.
The forced five-factor extraction accounted for
77.5% of overall item variance (an objectively good
fit when reducing 31 items to five factors), while
varimax rotation of these items suggested a single
factor-dominated structure. These results are consis-
tent with previous exploratory factor analysis results
from a study conducted in a DPN population (Vinik
et al., 2008).
The curvilinear association between Norfolk TQOL
scores and disease duration (as measured from
patient-reported first symptoms) indicates that as the
disease progresses, health-related QOL worsens. The
statistical model demonstrates substantial worsening
of QOL that continues, albeit at a slower rate, at
advanced stages of the disease. Similarly, a positive
curvilinear trend for increased severity/impairment
with increasing duration of disease was observed for
the Norfolk QOL-DN and the NIS-LL. This indicates that
deterioration in neurological function is accompanied
by worsening health-related QOL. Furthermore, both
QOL and neurological impairment appear to worsen at
a faster rate early in the disease.
In addition to demonstrating the association
between worsening TQOL scores and TTR-FAP dis-
ease severity, we hypothesized that the Norfolk items
could discriminate between differing levels of neu-
ropathy. Progressive and hierarchical comparisons
between disease stage groups were conducted to
identify which items within each domain could best
discriminate between patients at different stages of
disease progression. All items but “vomiting, partic-
ularly after meals” discriminated between healthy
volunteers and all disease stages combined. When
examining contrasts between healthy volunteers
vs. stage 1 patients, several items that reflect fine
motor control, extremity sensation, and gross motor
strength were not different. However, the majority of
the items in the Norfolk QOL-DN could clearly distin-
guish between healthy volunteers and stage 1 patients
with TTR-FAP, suggesting that the Norfolk QOL-DN
can detect the earliest manifestations of the disease.
When contrasting stage 1 vs. stages 2 and 3, and
stage 2 vs. stage 3, pain worse at night or kept awake
due to pain was not discriminatory. This indicates that
from stage 1 to stage 3, all stages had similar levels
of pain and superficial sensation symptoms. Several
other items such as feeling unsteady when walking,
inability to distinguish hot from cold water on the feet,
bowel changes, and interference with social activities
also did not discriminate between stages 2 and 3.
An intriguing finding to emerge from this study
is the observation in some patients of a high Norfolk
TQOL score without a commensurate marked eleva-
tion in NIS total score (Fig. 3). This suggests that in the
population studied here, the Norfolk QOL-DN instru-
ment may have the capacity to detect TTR-FAP-related
symptoms earlier in the course of the disease than
commonly used objective tools such as the NIS.
Indeed, the deterioration in health-related QOL from
stage 1 to stage 2 was substantially greater than that
occurring between stages 2 and 3. As the deterio-
ration in physical functioning caused by large-fiber
neuropathy is the most substantial component of the
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Table 4. Correlations between Norfolk TQOL and domains, and measures of autonomic function (heart rate response
to deep breathing) and small-fiber function (cooling detection threshold, heat pain threshold) in the lower limbs.
Norfolk QOL-DN
Heart rate response
to deep breathing
(n=37)
Cooling detection
threshold
(n=60)
Heat pain
threshold
(n=60)
TQOL
r −0.38 0.42 0.65
p-Value 0.0197 0.0009 <0.0001
Physical functioning/large-fiber neuropathy
r −0.37 0.40 0.65
p-Value 0.0248 0.0014 <0.0001
ADL
r −0.40 0.38 0.62
p-Value 0.0143 0.0029 <0.0001
Symptoms
r −0.07 0.25 0.32
p-Value 0.6769 0.0541 0.0129
Small-fiber neuropathy
r −0.45 0.45 0.70
p-Value 0.005 0.0003 <0.0001
Autonomic neuropathy
r −0.32 0.32 0.37
p-Value 0.0521 0.0116 0.0037
ADL, activities of daily living; QOL-DN, quality of life-diabetic neuropathy, TQOL, total quality of life score.
neuropathy in this disease, a worsening in the physical
functioning/large-fiber neuropathy QOL domain in
stage 1 patients was unsurprising (Fig. 1B). In contrast
to other neuropathies, significant worsening in the
symptoms and autonomic neuropathy QOL domains
in stage 1 patients was also seen in this study (Figs. 1D
and 1F).
Together, these results raise the possibility that fur-
ther refinement of the disease staging approach used
in TTR-FAP may enable more accurate categorization
of disease severity than that afforded by the tradi-
tional three-stage scheme of Coutinho et al. (1980), in
which ambulation status is the main determinant of
the stages (stage 1, the patient is fully ambulatory;
stage 2, ambulation assistance is required; and stage
3, the patient is wheelchair-bound or bedridden). For
example, introducing another stage between stages
1 and 2 (e.g., a stage 1b) would further increase
the granularity in TTR-FAP staging. An example of
a more granular approach is the five-stage modified
polyneuropathy disability score which has five levels of
severity determined by mobility impairment (I, sensory
disturbances in extremities but without ambulatory
difficulties; II, difficulties in walking without the need
for a walking stick; IIIa, one stick or one crutch required
for walking; IIIb, two sticks or two crutches required
for walking; IV, wheelchair required or patient confined
to bed) (Steen and Ek, 1983; Suhr et al., 1995).
While this study reports on the first health-related
QOL instrument to be validated in the TTR-FAP patient
population, we acknowledge certain limitations. Simi-
lar to many studies in rare diseases, patient enrollment
was relatively low and the small number of partic-
ipants relative to the large number of questions in
the Norfolk QOL-DN questionnaire may have been a
limiting factor. The cross-sectional nature of this study
is also a limitation. However, our results are consis-
tent with the recent randomized, placebo-controlled,
multinational trial in V30M patients with TTR-FAP
(Coelho et al., 2012). Further, the Norfolk QOL-DN
instrument will also be used to evaluate QOL in the
much larger sample of TTR-FAP patients who are
enrolled in the Transthyretin Amyloidosis Outcomes
Survey (THAOS), a longitudinal, observational registry
that was established to improve understanding of
the disease (www.thaos.net). The THAOS registry
may help to support the observations reported here
and offers the opportunity to replicate these find-
ings in patients carrying other TTR mutations and/or
from non-endemic areas. Additionally, health-related
QOL measures such as the Norfolk QOL-DN are
generally developed using a composite classical test
theory-based approach, which makes certain assump-
tions in calculating subscale and total scores (e.g.,
they are treated as linear functions with items given
equal weighting). Future work could extend beyond
the classical test theory approaches used here in order
to explore the application of item response theory
(IRT) approaches such as Rasch analysis (sample size
permitting in this orphan disease population). In a
recent comparison of Rasch to classical test theory
approaches to shorten an existing questionnaire, both
methods produced very similar results, however, the
Rasch approach yielded interval scaling for responses
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(Prieto et al., 2003). In addition to potentially providing
interval or ratio scaling for a scale, the application of
IRT or Rasch methodologies yields standard errors that
vary across individuals, which can also be used to help
define the minimum clinically important difference
(Hobart and Cano, 2009; Vanhoutte et al., 2013).
These results support the use of the Norfolk
QOL-DN as an indicator of the impact of disease
severity and duration on health-related QOL in patients
with TTR-FAP. They also suggest its utility in clinical
trials designed to evaluate the effects of pharmacother-
apeutic agents on disease progression in the same
way as it has been acknowledged as an endpoint in
DPN studies (Casellini et al., 2007; Boyd et al., 2011).
The use of the Norfolk QOL-DN for registration trials
should take into consideration whether the TQOL
score or domain scores are best included as primary,
secondary, or exploratory endpoints, depending on
the scope and design of the trial.
Given the progressive and irreversible nature
of TTR-FAP, any treatment that modifies or slows
disease progression would be expected to maintain
health-related QOL, or at least slow the rate of wors-
ening of this important patient-reported outcome.
The finding of abnormalities in health-related QOL
that appear in early stages of the disease when the
condition may be more amenable to intervention is
an intriguing one, and if replicated, suggests that the
Norfolk QOL-DN may have a role in monitoring early
changes related to disease.
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Table S1 Exploratory factor analysis: rotated factor loadings for the five-factor solution 
Rotated component matrix 
Component 
1 2 3 4 5 
Have you had difficulty doing fine movements with your 
fingers, like buttoning your clothes, turning pages in a 
book, picking up coins from a table? 
0.926 0.113 0.193 – – 
How much difficulty have you had performing the 
following activities: bathing/showering? 
0.919 0.167 0.128 0.130 0.139 
Have you felt unsteady on your feet when you walk? 0.915 0.117 – – – 
Have you been unable to feel your feet when walking? 0.914 0.213 – 0.109 – 
Have you had any problems getting out of a chair without 
pushing with your hands? 
0.913 0.141 0.162 – 0.104 
How much difficulty have you had performing the 
following activities: dressing? 
0.904 0.172 0.134 0.138 0.157 
Have you had a problem walking down stairs? 0.902 – 0.112 0.142 0.142 
How much difficulty have you had performing the 
following activities: using eating utensils? 
0.876 0.137 – 0.159 0.157 
Were you limited in the kind of work or other activities 
you could perform as a result of your physical or 
emotional health? 
0.874 0.301 0.134 0.187 – 
Have you been unable to tell hot from cold water with your 
feet? 
0.868 – – – – 
Have you been unable to tell hot from cold water with your 
hands? 
0.867 – 0.274 0.107 – 
How much difficulty have you had performing the 
following activities: getting on or off the toilet? 
0.866 0.131 0.101 – 0.132 
How much difficulty have you had performing the 
following activities: walking? 
0.848 0.195 – 0.253 0.137 
Have you had difficulty performing the work/other 
activities (it took extra effort) as a result of your physical 
or emotional health? 
0.825 0.334 0.106 0.265 – 
Have any symptoms kept you from doing your usual 
activities during the day? 
0.800 0.296 0.217 0.247 –
Have you accomplished less than you would like as a 
result of your physical or emotional health? 
0.798 0.347 0.106 0.280  – 
Have you cut down on the amount of time you spent on 
work or other activities? 
0.782 0.384 0.133 0.212 0.104 
Norfolk Part I: Q7 Symptoms – weakness total score 0.725 0.263 0.243 0.168  – 
Have you had a problem with diarrhea and/or loss of 
bowel control? 
0.624 0.371  – –0.228 0.241 
Symptoms – numbness score 0.503  – 0.295 0.490 –0.122 
To what extent has your physical health interfered with 
your normal social activities with families, friends, 
neighbors, or groups? 
0.290 0.764  – – –0.200 
Have you had a problem with fainting or dizziness when 
you stand? 
0.150 0.652 0.238 0.210 0.288 
How much did weakness or shakiness interfere with your 
normal work (including work both outside the home and 
housework)? 
0.419 0.623  – 0.483 – 
Symptoms – tingling, pins, and needles score  – – 0.833 – – 
Symptoms – deep pain score 0.311 0.159 0.656 0.120 0.103 
Symptoms – superficial pain score 0.129 0.166 0.606  – 0.390 
Have you burned or injured yourself and been unable to 
feel it? 
0.516  – 0.516 -0.119  – 
How much did pain interfere with your normal work 
(including work both outside the home and housework)? 
0.418 0.387  – 0.693 0.179 
Has the touch of bed sheets, clothes, or wearing shoes 
bothered you?  
– – 0.183 – 0.720 
Has pain kept you awake or woken you at night? 0.249 –0.165  – 0.527 0.672 
Have you had a problem with vomiting, particularly after 
meals (but not due to flu or other illness)? 
0.264 0.452  – – 0.598 
 
Note: All questions were prefaced with “In the past 4 weeks…” 
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ABSTRACT: Introduction: This observational, cross-sectional,
single-center study aimed to identify instruments capable of
measuring disease progression in transthyretin familial amyloid
polyneuropathy (TTR-FAP). Methods: The relationship between
disease stage and Neuropathy Impairment Score–Lower Limbs
(NIS-LL) and Norfolk Quality of Life–Diabetic Neuropathy (Norfolk
QOL-DN) total score was assessed in 61 (stages 1–3) patients
with TTR-FAP (V30M variant) and 16 healthy controls. Compos-
ite measures of large- and small-nerve fiber function, and modi-
fied body mass index (mBMI) were also assessed. Results:
Ordinal-based NIS-LL and Norfolk QOL-DN scores discriminat-
ed between disease stages (P<0.0001 for NIS-LL and Norfolk
QOL-DN). Longer disease duration correlated with worse NIS-
LL and Norfolk QOL-DN. Karnofsky performance score declined
progressively by disease stage. Composite measures of nerve
fiber function differentiated stage 1 from stage 2 disease. The
mBMI declined with advancing disease. Conclusions: NIS-LL,
Norfolk QOL-DN score, composite endpoints of nerve fiber
function, and mBMI are valid, reliable measures of TTR-FAP
severity.
Muscle Nerve 55: 323–332, 2017
Transthyretin (TTR) is a 127-amino-acid, 55-kDa
tetrameric protein synthesized primarily in the liv-
er that serves as a transport protein for thyroxine
and the retinol-binding protein–retinol (vitamin
A) complex.1,2 A mutation in TTR or the aging
process can lead to destabilization and dissociation
of the protein’s tetrameric structure. This induces
aggregation and deposition of misfolded TTR
monomers as amyloid within tissues, with subse-
quent organ dysfunction.3–5 A major phenotypic
presentation of TTR amyloidosis is a relentlessly
progressive sensorimotor and autonomic polyneur-
opathy known as TTR familial amyloid polyneurop-
athy (FAP). The most common variant associated
with polyneuropathy is V30M, which causes
approximately 85% of cases of TTR amyloidosis
worldwide.6,7 The global population of patients
with TTR-FAP is estimated to be 5,000–10,000.
Patients often require assistance with walking
5–6 years after disease onset (between the second
and ninth decades of life), are wheelchair-bound
by approximately 7–9 years,8 and typically die 10
years from initial symptom onset from worsening
of the neuropathy, secondary infections, cachexia,
or sudden death.8 Coutinho et al. categorized TTR-
FAP clinically as having 3 stages, defined according
to ambulation status.8 In stage 1, the patient is ful-
ly ambulatory; in stage 2, ambulation assistance is
required; and in stage 3, the patient is wheelchair-
bound or bedridden.
As a length-dependent neuropathy, TTR-FAP is
characterized by progressive axonal degeneration
initially involving distal small unmyelinated fibers
associated with pain and temperature sensation,
which results in paresthesia, hypesthesia, and loss
of sensation in the lower extremities.9,10 As the dis-
ease progresses, larger myelinated fibers become
involved, with resulting abnormalities in touch,
vibration, and position sensation; diminished
reflexes; and muscle weakness. This results in
Abbreviations: ANOVA, analysis of variance; CDT, cooling detection
threshold; DML, distal motor latency; DN, diabetic neuropathy; DPN, dia-
betic polyneuropathy; FAP, familial amyloid polyneuropathy; HPDT, heat
pain detection threshold; HRDB, heart rate response to deep breathing;
HV, healthy volunteers; LL, lower limb; mBMI, modified body mass index;
NCS, nerve conduction studies; NIS, Neuropathy Impairment Score; QOL,
quality of life; QST, quantitative sensory testing; R3 NTSF nds, summated
normal deviate scores from 3 nerve tests of small-fiber function; R5 NCS
nds, summated normal deviate scores from 5 nerve conduction studies;
R7 NTs nds, summated normal deviate scores from 7 nerve tests (all but
1 of large-fiber function); TQOL, total quality of life; TTR, transthyretin;
VDT, vibration detection threshold
Key words: amyloidosis; modified body mass index; nerve fiber function;
Neuropathy Impairment Score; Norfolk Quality of Life
Disclosures: T.C.’s institution received support from FoldRx Pharmaceu-
ticals, Inc. She has served on the speaker’s bureau of Pfizer; received
funding from Pfizer for scientific meeting expenses (travel, accommoda-
tions, and registration); and currently serves on the scientific advisory
board of THAOS (natural history disease registry), but without financial
compensation. A.V. has received consultancy and speaker’s bureau fees
from Merck, Novartis Pharmaceuticals, Pfizer, the R.W. Johnson Pharma-
ceutical Research Institute, and Sanofi Aventis. He has received honoraria
and support for travel to meetings for the purpose of study from Pfizer,
and his institution has also received payment from Pfizer for participation
in review activities and use of QOL-DN. His institution has also received
fees related to patents from Eli Lilly & Company and grant support from
Abbott, GlaxoSmithKline, Merck, Pfizer, SUDOSCAN, and the American
Diabetes Association. E.J.V. has received consultancy fees from FoldRx
Pharmaceuticals, and her institution has also received fees related to
review activities such as data-monitoring boards, statistical analysis, and
endpoint committees. She has also received consultancy fees from the
Eisai Study and royalties from the Eastern Virginia Medical School through
a licensing agreement for QOL-DN. T.T.’s employer, DM-STAT, Inc., has
received funding for clinical data management and biostatistics of this
study from FoldRx Pharmaceuticals. J.P. was an employee of FoldRx
Pharmaceuticals during the conduct of this trial and preparation of the
manuscript. D.R.G. was an employee of FoldRx Pharmaceuticals during
the conduct of this trial and preparation of the manuscript.
This study was sponsored by FoldRx Pharmaceuticals, Inc., which was
acquired by Pfizer, Inc., in October 2010.
Correspondence to: T. Coelho; e-mail: tcoelho@netcabo.pt
VC 2016 Wiley Periodicals, Inc.
Published online 16 July 2016 in Wiley Online Library (wileyonlinelibrary.com).
DOI 10.1002/mus.25257
Clinical Measures in TTR-FAP MUSCLE & NERVE March 2017 323
postural instability, muscle atrophy, and motor
weakness, with difficulty ambulating.8 Upper
extremity involvement is also seen, with length-
dependent neuropathic progression similar to that
observed in the lower extremities. Gastrointestinal
complications (nausea/vomiting, constipation,
and/or diarrhea) can lead to severe malnutrition,
which is a poor prognostic factor.11
Previously, there were no validated endpoints
in TTR-FAP. To be useful, clinical measures must
be scientifically sound, valid, simple to apply,
reproducible, and sensitive to progression of the
various aspects of this complex, multifaceted, neu-
rodegenerative disease, both over the course of dis-
ease in the clinical setting and in therapeutic
clinical trials. The Norfolk Quality of Life–Diabetic
Neuropathy (Norfolk QOL-DN)12,13 questionnaire
has recently been validated as an endpoint for
TTR-FAP and has been shown to discriminate
among disease stages.14
The primary objective of this study was to evalu-
ate the relationship between V30M TTR-FAP dis-
ease stage and clinical aspects of the disease as
assessed by the Neuropathy Impairment Score–
Lower Limbs (NIS-LL)15,16 and the Norfolk QOL-
DN instruments.12–14 These ordinal-based outcome
measures were selected as suitable for study after a
review of the literature to explore what had been
used in diabetic peripheral neuropathy (DPN) and
consultation with experts in the field. We hypothe-
sized that these measures would discriminate TTR-
FAP disease stages, show a clear relationship with
symptom duration, and thus have utility in moni-
toring the progression of TTR-FAP. The influence
of TTR-FAP disease stage on composite measures
of large- and small-nerve fiber function and modi-
fied body mass index (mBMI) was also assessed.
METHODS
Participants. Sixty-one patients with genetically
determined V30M mutation stage 1, 2, or 3 TTR-
FAP, who were 18–75 years of age and provided
informed consent, were enrolled at a single site
(Porto, Portugal) between 2008 and 2009. The
stage 1 TTR-FAP patient data consisted of baseline
findings made by the lead author (T.C.), a neurol-
ogist, from patients with stage 1 disease. They were
previously enrolled in a randomized, placebo-
controlled trial of tafamidis, a small-molecule
kinetic stabilizer of the TTR tetramer that inhibits
the amyloid cascade. All patients had biopsy-
confirmed amyloid and symptoms of peripheral
and/or autonomic neuropathy. Patients with other
causes of sensorimotor neuropathy (vitamin B12
deficiency, diabetes mellitus, human immunodefi-
ciency virus treated with retroviral medications,
thyroid disorders, alcohol abuse, or chronic
inflammatory diseases) were excluded, as were
patients with immunoglobulin light-chain (AL)
amyloidosis or previous liver transplantation. Six-
teen healthy volunteers, 18–50 years of age, were
also enrolled. Chronic use (>3 or 4 times per
month) of most nonsteroidal anti-inflammatory
drugs, which can stabilize the TTR tetramer and
potentially alter TTR-FAP disease progression, was
not permitted for any participant, although ibupro-
fen and nimesulide use was allowed. The study
was approved by the institutional review board at
the site.
Study Design. This was an observational, cross-
sectional, single-center study. Primary measures
investigated were the NIS-LL and the Norfolk
QOL-DN total score (TQOL).
NIS and NIS-LL. The NIS is a composite score
derived from a neurological assessment of muscle
strength, reflexes, and sensation in the upper and
lower limbs. The NIS-LL quantifies the neurologi-
cal examination of the lower limbs by means of a
total score [range 0 (normal) to 88 (total impair-
ment)] that is the combination of subscale scores
for muscle weakness (range 0–64), reflexes (range
0–8), and sensation (range 0–16).17 Additional
measures included the muscle weakness subscale
of the NIS-LL assessed at the toe, ankle, knee, and
hip. To reduce variability, the NIS-LL assessments
were performed by the same neurologist, who had
training and extensive experience with these mea-
sures. The average of 2 successive NIS-LL assess-
ments, performed at least 24 hours apart but
within 7 days, was analyzed. Assessment of total
NIS was available in healthy volunteers and stage 2
and 3 patients.
Norfolk QOL-DN. The Norfolk QOL-DN scores
are derived from the results of a 35-item patient
questionnaire,12 and comprise the TQOL score
(range –2 to 138, as scored for this study) and the
subscale scores from the assessment of 5 domains:
physical functioning/large-fiber neuropathy; symp-
toms; activities of daily living; small-fiber neuropa-
thy; and autonomic neuropathy. The Norfolk
QOL-DN questionnaire was linguistically validated
in Portuguese. It was completed by study partici-
pants both at baseline and 4 weeks later (except
for the stage 1 patients, who completed it at base-
line only).
Large- and Small-Nerve Fiber Function. Secondary
assessments included summated scores of primarily
large-nerve fiber function [summated 7 nerve tests
normal deviate score (R7 NTs nds)] and small-
nerve fiber function of the lower limbs [summated
3 nerve tests (small fiber) lower limb normal devi-
ate score (R3 NTSF-LL nds)], which encompass a
variety of objective individual measures of nerve
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fiber function [nerve conduction studies (NCS),
quantitative sensory testing (QST), and heart rate
response to deep breathing (HRDB)]. These were
evaluated by a single neurologist in the patient
groups only. Results were recorded as measured
units (observed values), percentiles, and normal
deviates (z-scores), based on healthy subject cohort
data from the Mayo Clinic, Rochester, Minnesota.18
NCS were performed with the application of
surface electrodes using standardized techniques.19
Five attributes of nerve conduction were evaluated:
sural nerve sensory nerve action potential ampli-
tude; fibular nerve compound muscle action
potential amplitude; fibular nerve motor conduc-
tion velocity; fibular nerve distal motor latency
(DML); and tibial DML.
QST was performed using a computerized test
of sensory threshold determination (Computer-
Aided Sensory Evaluator V4; WR Medical Electron-
ics Co., Maplewood, Minnesota). Cooling detection
threshold (CDT), vibratory detection threshold
(VDT), and heat pain detection threshold (HPDT)
of the upper and lower limbs (CDT and HPDT
assessed on the dorsum of the foot and hand, and
VDT assessed on the dorsum of the great toe and
index finger) were determined.
HRDB assesses heart rate variability observed
with deep breathing at a rate of 6 cycles/min.
Results were recorded as measured units (observed
values), percentiles, and normal deviates.
Combining objective measures of nerve fiber
impairment into summated scores has been used
to detect disease progression in other neuropa-
thies.18 The R5 NCS nds, a measure of large-nerve-
fiber function, is the sum of the normal deviates
for each of the 5 NCS attributes described previ-
ously. The R7 NTs nds, an overall measure of pri-
marily large-nerve fiber function, with a possible
range of scores from –26 to 26, is the sum of the
normal deviates for the R5 NCS nds, average VDT
of the great toes, and HRDB. The R3 NTSF-LL
nds, a measure of small-nerve fiber function of the
lower limbs with a possible range of scores from –
11.2 to 11.2, is the sum of the normal deviates
from the CDT, HPDT, and HRDB.
mBMI. The mBMI [body mass index (BMI)
multiplied by the serum albumin concentration in
grams per liter] was an additional secondary out-
come that assessed nutritional status, an important
measure of wasting and autonomic gastrointestinal
dysfunction in patients with TTR-FAP.11 The
mBMI was recorded in all study participants.
Karnofsky Performance Status Score. The Karnof-
sky performance score20 is a general assessment of
a patient’s daily functional capacity based on the
clinician’s judgment. Scores range from 0 (death)
to 100 (normal, no evidence of disease).
Statistical Analysis. The primary analyses assessed
the relationship between TTR-FAP disease stage
(stages 1, 2, or 3, or no disease) and the NIS-LL
and Norfolk QOL-DN score. An analysis of vari-
ance (ANOVA) for each endpoint with effects for
TTR-FAP stage was modeled.21 P-values versus stage
1 were based on ANOVA with individual parameter
as the dependent variable. Pairwise comparisons
between the consecutive disease stages were per-
formed using the Fisher exact test for categorical
endpoints without adjustment for multiple testing.
Secondary analyses included comparisons of TTR-
FAP stages with respect to each of the 3 NIS-LL
subscales (muscle weakness, reflexes, and sensa-
tion), including the 4 individual muscle group
scores (toe, ankle, knee, and hip), comprising the
muscle weakness subscale. Additional secondary
analyses included comparisons of disease stages
with each of the 5 Norfolk QOL-DN domains
[physical functioning/large-fiber neuropathy, activ-
ities of daily living (ADL), symptoms, small-fiber
neuropathy, and autonomic neuropathy], R5 NCS
nds score, QST, HRDB, R7 NTs nds score, R3
NTSF-LL nds, Karnofsky score, and mBMI. These
secondary analyses used the same methods
described for the primary analyses.
The NIS total score was compared between
healthy volunteers and stage 2 and 3 patients, with
primary comparison between stage 2 and 3
patients.
In a post-hoc analysis, the association between
disease duration (as determined by time from
symptom onset) and several of the endpoints (NIS
total, NIS-LL, and TQOL scores, and mBMI) was
modeled using ordinary least-squares regression.
Quadratic terms were tested in these models to
allow for curvilinearity in the associations. In addi-
tion, correlations between Norfolk QOL-DN
domain scores and time from onset of disease
were examined with the hypothesis that disease
progression would have differential effects on the
individual domains of the Norfolk QOL-DN (symp-
toms, large fiber, small fiber, autonomic, and
ADL). Correlations (Pearson r) between individual
domain scores and objective neuropathy measures
(strength, reflexes, somatosensory function, and
the composite NIS-LL), derived as the sum of the
individual scores, were assessed.22 Objective scores
have been shown to correlate with the total and
individual domains of Norfolk QOL-DN in
DPN12,13 and in TTR-FAP.14
RESULTS
Patients. This study included 29 patients with
stage 1 disease, 16 with stage 2 disease, 16 with
stage 3 disease, and 16 healthy volunteers who
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served as controls. All patients enrolled were Cau-
casian. All participants completed the trial.
The age at symptom onset was similar among
the groups, and a similar gender distribution was
observed (Table 1). Patient characteristics demon-
strated significant differences between TTR-FAP
stages consistent with advancing disease progres-
sion (i.e., patients with more severe disease were
older and had the disease longer; Table 2).
Association of Disease and Clinical Assessments.
NIS-LL Scores. There were statistically significant
differences in NIS-LL total scores among TTR-FAP
disease stages, as well as between healthy volun-
teers and patients with stage 1 disease (Fig. 1).
Sensation and reflex deficits of the lower limbs
were similarly affected in patients with stage 2 and
3 disease and were significantly worse than in
patients with stage 1 disease. Sensory impairment
of the lower limbs was significantly different
between patients with stage 1 disease and healthy
volunteers, but reflexes were not. Mean subscale
scores for reflexes and sensation tended to
approach near-maximum values in stages 2 and 3.
There was minimal muscle weakness in patients
with stage 1 disease, and they were not statistically
distinguishable from healthy volunteers. Patients
with more advanced TTR-FAP (stages 2 and 3) had
significantly greater NIS-LL muscle weakness than
patients with stage 1 disease and healthy volun-
teers. Muscle weakness differed by disease stage.
The more severe the disease stage, the greater the
degree of proximal weakness (Fig. 2). In the most
distal muscle groups, differences between patients
with stage 1 and 2 disease were statistically signifi-
cant, but differences between patients with stage 2
vs. stage 3 disease were generally small, albeit statis-
tically significant at the ankle. Statistically signifi-
cant differences at the knee were evident between
patients in each successive disease stage, whereas
weakness in the hip was only observed in patients
with stage 3 disease.
Norfolk QOL-DN Scores. Increasing TQOL
scores (i.e., worsening QOL) on the Norfolk QOL-
DN were associated with more severe disease
(Table 2). In addition, there were statistically sig-
nificant differences between each TTR-FAP disease
stage, including a difference between healthy vol-
unteers and patients with stage 1 disease (P 0.002
for all comparisons). The Norfolk QOL-DN
domains of physical functioning/large-fiber neu-
ropathy, ADL, and symptoms differed significantly
Table 1. Demographics
HV (n5 16) Stage 1 (n5 29) Stage 2 (n516) Stage 3 (n516) Overall P-value
Age (years) [mean (SD)] 34.8 (10.0) 39.0 (11.6) 46.5 (12.8) 55.0 (10.0) <0.001
Men [n (%)] 8.0 (50.0) 12.0 (41.4) 9.0 (56.3) 10.0 (62.5) 0.565
Height (cm) [mean (SD)] 169.6 (7.6) 165.3 (11.2) 165.7 (9.4) 165.4 (10.1) 0.542
Weight (kg) [mean (SD)] 73.8 (17.7) 65.5 (13.1) 62.8 (15.1) 54.7 (23.4) 0.021
Symptom duration (years)
Mean (SD) NA 2.6 (2.8) 7.7 (2.9) 14.2 (4.4) <0.001
Median NA 1.4 7.9 14.2 NA
Range NA 0.2–11.9 3.1–13.1 6.0–22.1 NA
Age at symptom onset (years)
Mean (SD) NA 36.9 (10.7) 39.3 (13.1) 41.7 (12.6) 0.421
Median NA 33.3 35.0 37.0 NA
Range NA 24.0–65.2 21.0–61.0 27.0–66.0 NA
HV, healthy volunteers; NA, not applicable.
Table 2. Disease characteristics at baseline
HV (n5 16) Stage 1 (n5 29) Stage 2 (n5 16) Stage 3 (n5 16) Overall P-value
Total NIS 0.0 (0.0) ND 84.8 (16.1) 128.7 (35.8) <0.001
NIS-LL 0.0 (0.0) 6.9 (6.3) 55.3 (6.7) 69.0 (9.8) <0.001
TQOL 2.6 (5.0) 21.0 (14.5) 73.1 (27.5) 95.4 (21.7) <0.001
Small-nerve fiber function
(R3 NTSF-LL nds)
ND 4.7 (3.6) 10.7 (1.0) 10.5 (1.1) <0.001
Large-nerve fiber function
(R7 NTs nds)
ND 3.7 (8.4) 21.9 (2.3) 21.2 (3.0) <0.0001
R5 NCS nds ND 0.2 (7.0) 14.3 (2.0) 12.6 (2.3) <0.0001
mBMI 1,199.0 (241.1) 1,031.9 (213.8) 886.4 (309.8) 759.7 (316.2) <0.0001
Data expressed as mean (SD). HV, healthy volunteers; mBMI, modified body mass index; ND, not done; NIS, Neuropathy Impairment Score; NIS-LL, Neu-
ropathy Impairment Score–Lower Limbs; TQOL, total quality of life; R3 NTSF-LL nds, small-nerve fiber function of the lower limbs; R5 NCS nds, large-
nerve fiber function; R7 NTs nds, large-nerve fiber function.
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between each disease stage (P 0.035 for all compar-
isons). Small-fiber neuropathy and autonomic neu-
ropathy domains differed between patients with
stage 1 disease and those with stage 2 disease
(P 0.007 for all comparisons), but not between
patients with stage 2 vs. stage 3 disease (P> 0.05).
Whereas there was a staged progression in the
TQOL scores, the initial stages were significant for
symptoms, autonomic, and physical functioning
scores before observed impairment of ADL, and
small-fiber scores.14 The absence of an increase in
scores of objective measures of the NIS-LL was com-
patible with the rise in QOL domain scores and
increase in TQOL in stage 1. In contrast, stage 2
showed an increase in all domains but small-fiber
and autonomic, which had reached a maximum,
whereas physical functioning, ADL, and symptoms
continued to decline between stages 2 and 3.
Large- and Small-Nerve Fiber Function. Large-
and small-nerve fiber function in the lower limbs
(R7 NTs nds and R3 NTSF-LL nds, respectively)
was more severely impaired in patients with stage 2
disease than in patients with stage 1 disease. There
were no significant differences in large- or small-
nerve fiber function between patients with stage 2
vs. stage 3 disease, with near-maximum impairment
observed in both groups (Fig. 3).
mBMI. Table 2 presents the mBMI values for
healthy volunteers and patient groups. The differ-
ence between healthy volunteers and patients
with stage 1 disease was statistically significant
(P5 0.045), as was the difference between patients
with stage 1 vs. stage 3 disease (P5 0.002).
Karnofsky Performance Status Score. Karnofsky
scores were highest among healthy volunteers and
declined progressively by disease stage. The mean
FIGURE 1. NIS-LL and NIS-LL subscale scores in healthy volunteers and patients for the 3 stages of TTR-FAP. (A) NIS-LL total score.
(B) NIS-LL muscle weakness subscale score. (C) NIS-LL reflexes subscale score. (D) NIS-LL sensation subscale score. HV, healthy
volunteers; NIS-LL, Neuropathy Impairment Score–Lower Limbs; NS, not significant.3 symbols: mean; circles: median; bars: range of
scores. HV, n5 16; stage 1, n5 29; stage 2, n5 16; stage 3, n5 16.
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(6 SD) scores were 100.06 0.0 in healthy volun-
teers, 86.26 6.2 in stage 1, 60.06 5.2 in stage 2,
and 45.66 5.1 in stage 3 patients. The Karnofsky
score differentiated among all 4 groups
(P< 0.0001, for all).
Relationship between Disease Severity and Time from
Symptom Onset. Figure 4 displays the plots from
the post-hoc analysis, modeling the association
between duration of symptoms in years and NIS
total score, NIS-LL, TQOL, and mBMI.
Neurological function, QOL, and nutritional
status worsened with increasing duration of symp-
toms. The NIS total score, a comprehensive mea-
sure of neurological functioning, and mBMI were
linearly related to duration of symptoms. The earli-
est manifestations of expression of the gene defect
were reflected by development of an increase in
symptoms and selected autonomic scores of the
Norfolk QOL-DN before impairment in the
objective measures in the NIS-LL was observed.14
Thereafter, rapid worsening was seen relatively ear-
ly in the disease for the NIS-LL subscore, contrib-
uting to deterioration in all 5 domains of QOL
(TQOL). With advancement to stage 3, no further
increase in small-fiber and autonomic scores
occurred, but scores in the remaining domains
showed continued deterioration. With time, a
decrease in the rate of worsening of these relation-
ships required a quadratic component of duration
to fit the leveling off of scores. This pattern was
expected for the NIS-LL, as the disease reaches
near-maximum scores in stage 2, with little increase
in stage 3, and is not commensurate with increasing
disease duration.
DISCUSSION
In this study we have provided direct clinical
evidence of the use of the NIS-LL and Norfolk
TQOL to assess the severity of neuropathy and
FIGURE 2. Distal-to-proximal muscle weakness by disease stage, with a possible score range of 0–16. Muscle weakness in (A) toe,
(B) ankle, (C) knee, and (D) hip. HV, healthy volunteers; NS, not significant.3 symbols: mean; circles: median; bars: range of scores
observed. HV, n5 16; stage 1, n5 29; stage 2, n5 16; stage 3, n5 16.
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impact on quality of life in patients with TTR-FAP.
Both demonstrated relationships with disease dura-
tion and severity. These assessment tools have
been validated in mild and severe DPN.12,17
Recently, the NIS has been applied successfully in
clinical trials of a-lipoic acid23 and a protein kinase
C inhibitor22,24 in DPN. Assessment of the effect of
tafamidis therapy using the NIS-LL and Norfolk
FIGURE 4. Relationships between key efficacy variables and duration of symptoms. (A) NIS total score. (B) NIS-LL. (C) Norfolk Total
Quality of Life. (D) mBMI. Patients with stage 1 disease were not evaluated for NIS total score and are not included in the NIS plot in
(A). Regression equations are indicated below each curve. mBMI, modified body mass index; NIS, neuropathy impairment score; NIS-
LL, Neuropathy Impairment Score–Lower Limbs; TTR, transthyretin. Stage 1, n5 29; stage 2, n516; stage 3, n5 16. The year at
which symptom severity is predicted to level off corresponds to the estimated maximum of these functions. Decrease in symptoms
should not be assumed past the maximum estimated year.
FIGURE 3. (A) Large-nerve fiber (R7 NTs nds) and (B) small-nerve fiber (R3 NTSF-LL nds) function of the lower limbs by disease
stage. NS, not significant.3 symbols: mean; circles: median; bars: range of scores. Stage 1, n529; stage 2, n5 16; stage 3, n5 16.
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QOL-DN in patients with TTR-FAP has been
described in previous studies.25–27 Further support
for the utility of the NIS in the assessment of
patients with TTR-FAP was provided by Kim et al.,
who reported worsening scores in patients with
increasing disease severity, characterized by the
sequence and distribution of neurological involve-
ment.28 The Norfolk QOL-DN has been validated in
populations with mild to severe DPN, shows excel-
lent reproducibility, and can discriminate between
DPN patients and healthy controls, as well as across
different levels of disease severity.12,13 It has also
been shown to be sensitive to the effects of drugs
that affect large- and small-nerve fiber function.29
The NIS score is based on a full neurological
exam, including upper limb function, and captures
disease severity across the full disease course. Howev-
er, the NIS-LL subscore evaluates only lower limb
function and the distal toe level of all sensory modal-
ities. Consequently, it differentiates best stage 1 from
stages 2 and 3. The overall NIS-LL score and the sen-
sation subscore show differences between healthy vol-
unteers and patients in stage 1, although the
sensation and reflexes subscores do not differ
between stages 2 and 3. The sensation subscore has
a numerically smaller difference (from 4 to nearly
16) between stages 1 and 2 than the muscle weak-
ness subscore (from 0 to 32; Fig. 1), which may
reflect the fact that the NIS-LL assesses all sensory
modalities exclusively at 1 distal level, whereas motor
function is evaluated at all levels.
In contrast, the NIS-LL muscle weakness and
reflexes subscores do not distinguish healthy vol-
unteers from patients in stage 1, due to the later
involvement of large motor fibers. However, the
muscle weakness subscore does differentiate
between disease stages 1 and 2 and is also sensitive
to length-dependent impairment. Because the abil-
ity to walk is a key determinant of disease stage in
TTR-FAP, worsening NIS-LL and muscle weakness
scores are particularly relevant as patients progress
from full ambulation to inability to walk. A correla-
tion analysis between NIS-LL and disease duration
indicated that longer disease duration is associated
with greater neurological impairment. Further, the
sensory component and the symptom scores that
separate patients in stage 1 from healthy controls
may help to identify patients early in the disease
course who may be more responsive to intervention.
Composite measures of nerve fiber function
have been found to be more sensitive than individ-
ual nerve conduction tests in detecting abnormali-
ties in patients with generalized peripheral
neuropathy, particularly DPN and chronic inflam-
matory demyelinating polyneuropathy.19,30 In addi-
tion, the reproducibility of composite scores has
been shown to be greater than that of individual
nerve conduction scores,30 and composite scores
have correlated better with severity of neuropathy
(as assessed by the NIS-LL) than individual tests.30
The R7 NTs nds (primarily large-fiber function)
and R3 NTSF-LL nds (small-fiber function) dif-
fered between stage 1 patients and the more severe
stage 2 and 3 patients (Fig. 3). Although we do
not have results in healthy volunteers for direct
comparison, these lower limb nerve fiber assess-
ments appear to be appropriate for measuring the
progression of nerve fiber impairment in early-
stage disease (from stage 1 to stage 2) but not in
later stages (from stage 2 to stage 3), as maximum
impairment is usually observed by stage 2.
The Norfolk QOL-DN captures patient-
reported perceptions of neuropathy in individuals
with symptoms of both peripheral and autonomic
neuropathy; the constructs it assesses are ones that
would be expected to be relevant in the TTR-FAP
population. The Norfolk TQOL worsens as the dis-
ease progresses; in fact, it worsens more rapidly
during the early years of the disease, slowing in
the later stages. The mBMI served as a measure of
nutritional status among patients with TTR-FAP
and demonstrated a progressive linear decline with
duration of symptoms. As an endpoint, mBMI is
more reflective of nutritional status than BMI
because it corrects for the effect of edema due to
low serum albumin levels on BMI. The mBMI has
been found to correlate highly with neurological
function and duration of gastrointestinal symptoms
in patients with TTR-FAP.11 Diminished nutritional
status31 and early onset of gastrointestinal symp-
toms11 in patients with TTR-FAP are associated
with decreased survival after liver transplantation.
The mBMI is a prognostic pretransplant factor that
predicts survival (others are disease duration and
serum albumin levels).11,32–34 These findings have
led researchers to conclude that mBMI is well suit-
ed to monitor the progress of TTR-FAP.11 Our
data provide further evidence that mBMI is an
appropriate objective parameter for monitoring
TTR-FAP progression, particularly the wasting
aspect of the disease.
TTR-FAP is a particularly severe progressive
neuropathy that is fatal if left untreated. As
expected, stage 3 patients have reached an
advanced degree of neurological deterioration and
it can be expected that there would be a ceiling
effect in neurological assessments (neurological
exam or neurological tests). Because nerve regen-
eration is not expected with this degree of nerve
degeneration, evaluation of progression and possi-
ble impact of treatments must rely on other
aspects of the disease such as QOL, mBMI, and
even survival. The Kumamoto neurological score, a
clinical scale of motor, sensory, and autonomic
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function, combined with heart and kidney measures,
has also been used to follow disease progression in
TTR-FAP,35 but there is still a paucity of validated
measures of disease progression in TTR-FAP.
There were some limitations to this study. First,
not all potential clinical measures of neurological
impairment were evaluated, and no claim can be
made that the measures evaluated here were opti-
mal for assessment of disease progression. Second,
although it could be argued that a longitudinal
study would provide more precise estimates of dis-
ease progression than this cross-sectional investiga-
tion, such a study would have to be of sufficient
duration to demonstrate a significant degree of
disease progression. Patients, especially younger
patients with shorter disease duration and better
nutritional status, would likely not elect to partici-
pate in such a trial, given the option of liver trans-
plantation and small-molecule TTR-stabilizing
compounds. Such a study would require at least 10
years of follow-up.
Third, the analysis of the outcome endpoints as
mean scores postulates linearity in these ordinal-
based scales. The true difference between response
categories in such scales (especially when groups
that differ with respect to baseline status are com-
pared) is unknown, suggesting that any extrapola-
tion of mean score change per year should be
interpreted with caution.36,37 Fourth, the 3-stage
disease classification scheme used in this study may
be an oversimplification of this complex disease.
Finally, the study population in this trial was
limited to patients in Portugal with the V30M vari-
ant (present in approximately 85% of patients with
TTR-FAP worldwide) in order to facilitate enroll-
ment of a uniform, well-characterized patient pop-
ulation with this rare disease, and further global
studies are needed to generalize these observa-
tions. Neurological symptom presentation (at first
evaluation and diagnosis) and neurological disease
progression are similar across the TTR-FAP
genotypes.8,28,38–40
Future efforts should focus on designing new
outcome measures or modifying currently applied
measures to increase precision. These new outcome
assessments should be at the interval or ratio level,
because these scales provide a fixed unit across the
range of metric interest. Plans are underway for col-
laborative efforts to achieve these goals, as done
recently for other forms of polyneuropathy.41
In conclusion, in this study we have demon-
strated that the endpoints evaluated differentiated
among the TTR-FAP disease stages across the full
spectrum of disease severity. The NIS-LL, particularly
the muscle weakness component, and the composite
measures of large- and small-nerve fiber function of
the lower limbs (the R7 NTs nds and the R3 NTSF-
LL nds, respectively), are especially well suited to
assess the difference between patients in stage 1 and
2 disease, suggesting they may be useful to assess
therapy in early disease stages. The Norfolk QOL-DN
likewise differentiated between groups. We conclude
that these instruments are reliable measures of TTR-
FAP disease severity.
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Background: Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of
hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.
Methods: Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind,
placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with
polyneuropathy. Eligible patients are 18–85 years old with hATTR amyloidosis, investigator-estimated survival of
≥2 years, Neuropathy Impairment Score (NIS) of 5–130, and polyneuropathy disability score ≤IIIb. Patients are
randomized 2:1 to receive either intravenous patisiran 0.3 mg/kg or placebo once every 3 weeks. The primary objective
is to determine the efficacy of patisiran at 18 months based on the difference in the change in modified NIS+7 (a
composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the
patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic
Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor
function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the
Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function
and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed
throughout the study.
Discussion: APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with
endpoints that capture the multisystemic nature of this disease.
Trial registration: This trial is registered at clinicaltrials.gov (NCT01960348); October 9, 2013.
Keywords: Patisiran, APOLLO, RNA interference, hATTR amyloidosis, mNIS+7, Methods, PolyneuropathyBackground
Hereditary ATTR (hATTR) amyloidosis, formerly known
as familial amyloid polyneuropathy (FAP), is a progres-
sive, life-threatening disease caused by misfolded
transthyretin (TTR) protein that accumulates as amyloid
fibrils in multiple organs, including the nerves, heart,
and gastrointestinal tract [1, 2]. hATTR amyloidosis is a
multisystemic disease with a heterogeneous clinical* Correspondence: david.adams@aphp.fr; adams.david@neuf.fr
1CHU Hôpital Bicêtre, Le Kremlin-Bicêtre CEDEX, Paris, France
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zepresentation, including sensory, motor, autonomic, and
cardiac symptoms that are often concurrent [3–6]. The
unrelenting disease course begins with unimpaired
ambulation (FAP stage 1 [7]), then requirement for as-
sistance with ambulation (FAP stage 2), which proceeds
to wheelchair confinement (FAP stage 3), with patients
experiencing a range of life-impacting symptoms that in-
clude burning neuropathic pain, loss of sensation in
hands and feet, diarrhea/constipation, sexual impotence,
and dizziness/fainting [8–10]. The median survival forle is distributed under the terms of the Creative Commons Attribution 4.0
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is reported as 5–15 years from diagnosis [9, 11–13].
To date >120 TTR mutations have been reported [14];
some mutations are more strongly associated with poly-
neuropathy (e.g. V30M [8]), and others with cardiomyop-
athy (e.g. V122I [15]). However, this genotype–phenotype
association likely represents an over-simplification, with
wide variation in presentation reported between genotypes
and a mixed phenotype commonly observed [3, 16].
Effectively quantifying the disease burden in hATTR
amyloidosis remains challenging, as there is no single
test that captures the constellation of symptoms and the
multisystemic nature of the condition. Indeed, even as-
sessment of all signs and symptoms of polyneuropathy
requires numerous measures, which recent data suggest
are not adequately captured in current tests [17]. For ex-
ample, the Neuropathy Impairment Score (NIS)-Lower
Limb (NIS-LL) is based on examination of lower limbs
only, so dysfunction occurring in other areas as the dis-
ease progresses cannot be captured. The widely used
NIS overcomes this limitation through clinical examin-
ation of lower limbs, upper limbs, and cranial nerves, al-
though this tool does not include nerve conduction
scores, which are critical to assess the axonal neuropathy
which progresses during the disease course [6, 8, 12]. In
addition, the NIS does not adequately address sensory
loss over the body, which is a hallmark of the disease
[18]. Ultimately, scoring the full range of neuropathic
impairment likely requires a combined measure of the
type, severity, and distribution of neurologic signs and
symptoms [17]. There is also a limited set of tools that
have demonstrated utility in assessment of quality of life
(QoL) and physical functioning in hATTR amyloidosis,
primarily the Norfolk Quality of Life-Diabetic Neur-
opathy (QOL-DN), EuroQoL 5-Dimensions (EQ-5D™),
and Short-Form 36 (SF-36) Health Survey questionnaires
[19–24]. Consequently, the need remains for clinical
trials that include a comprehensive set of measures to
investigate disease progression and the effects of treat-
ment on patient well-being and function.
As TTR is produced predominantly in the liver [25, 26]
orthotopic liver transplantation (OLT) is a well-
recognized and effective treatment strategy for replacing
mutant TTR protein [27, 28]. However, OLT is only
recommended for patients with early-stage hATTR amyl-
oidosis, and survival varies according to modified body
mass index (mBMI), disease duration/severity, and TTR
mutation [8, 28, 29]. The procedure itself is also limited
by issues such as cost, donor availability, cardiac involve-
ment, and toxicities associated with immunosuppression
[2, 30]. Furthermore, disease progression can continue
after OLT as a result of amyloid fibril deposition from
wild-type TTR [31, 32]. More recently, the pharmacother-
apies tafamidis and diflunisal, which stabilize the TTRcomplex and prevent protein misfolding (TTR tetramer
stabilizers), have been utilized. Tafamidis was approved in
Europe for patients with hATTR amyloidosis with early-
stage neurologic disease (FAP stage 1), despite limited
data, with authorization under “exceptional circum-
stances” due to the clinical unmet need [33]. Subsequent
approvals for treatment of symptomatic polyneuropathy
have followed in regions of Latin America and Asia. Diflu-
nisal, a non-steroidal anti-inflammatory drug, has been
used off label for management of hATTR amyloidosis
[34]. In clinical studies, both compounds have slowed pro-
gression of neurologic impairment and were generally well
tolerated [19, 24, 35]. However, progression of neuropathy
symptoms or disability is still observed in some patients
[24, 35–37], and tafamidis may have reduced efficacy in
patients with more severe disease [38]. Thus, there re-
mains a need for novel treatment options for hATTR
amyloidosis.
Patisiran is an investigational RNA interference (RNAi)
therapeutic in clinical development for hATTR amyloid-
osis. Patisiran is a small interfering RNA (siRNA) that tar-
gets a sequence of mRNA conserved across wild-type and
all TTR variants and can thereby reduce serum levels of
both wild-type and pathogenic (mutated) protein [39]. It
is formulated as lipid nanoparticles which direct it to the
liver, the primary source of circulating TTR [39]. The
benefits of lowering mutant TTR levels in patients
with hATTR amyloidosis have been demonstrated by
OLT [40, 41], and data from other amyloidoses show
that clinical outcomes can be improved by reducing
amyloidogenic protein [42–44]. In a Phase 2 study
(NCT01617967) of 29 patients with hATTR amyloid-
osis, two doses of patisiran 0.3 mg/kg every 3 weeks
reduced mean serum TTR levels by approximately
80% [45]. This potent TTR knockdown was observed
for both wild-type and mutant (V30M) forms of TTR,
and in patients who were concurrently receiving TTR
tetramer stabilizers [45]. An ongoing open-label ex-
tension study (NCT01961921) has provided encour-
aging data, with stable measures of neuropathy
impairment and patisiran being generally well toler-
ated through 24 months of treatment [46].
Collectively, these data support the hypothesis that TTR
reduction has the potential to stabilize the progression of
– or even reverse – neuropathy in patients with hATTR
amyloidosis. To date, APOLLO is the largest Phase 3 clin-
ical study in patients with hATTR amyloidosis, designed
to assess the safety and efficacy of patisiran on neurologic
function and QoL.
Methods
Study oversight
This study is conducted according to the guidelines of
the International Conference on Harmonisation, the
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and the Health Insurance Portability and Accountability
Act of 1996. Written informed consent is obtained
from all patients who participate in the study, prior to
assessment of eligibility. The study protocol was ap-
proved by the local Institutional Review Boards and Ethics
Committees, and all subsequent protocol amendments
underwent the same approval procedure. A clinical moni-
tor, as a representative of Alnylam, will follow the study
through periodic site visits and frequent telephone/written
contact. A Data Monitoring Committee will be imple-
mented for the study and provide independent evaluation
to ensure patient safety. This trial is registered at www.cli-
nicaltrials.gov (NCT01960348).Study overview and setting
APOLLO is a randomized, multicenter, international,
double-blind, placebo-controlled, Phase 3 study designed
to evaluate the efficacy of patisiran and establish the
safety of chronic dosing in adult patients with symptom-
atic hATTR amyloidosis with polyneuropathy. A study
schematic is shown in Fig. 1. Patients are recruited from
46 sites across 19 countries (United States, France,
Taiwan, Spain, Japan, Germany, Mexico, Portugal, South
Korea, Sweden, Bulgaria, Italy, Canada, Turkey, Cyprus,
Brazil, Netherlands, United Kingdom, and Argentina).
All but two of the sites are academic hospitals.Informed consent and confirmation of eligibility 
(including tests for NIS and NCSa)
Day -42
to Day 0
Day 0
Day 0
to
Day 560
Randomization (2:1) to patisiran or placebo (double-blind)
9-month efficacy assessments
Rapid disease progression?
( 24-point increase in mNIS+7 and FAP stage progression relative to baseline)
Continue treatment
Decision: 
Continue treatment
Decision: 
Discontinue 
treatment
Continue on study Withdraw from
the study(modified schedule)
18-month efficacy assessments (end of study)b
Double-blind dosing every 3 weeks
NO YES
Screen for open-label extension
Double-blind dosing every 3 weeks
Fig. 1 APOLLO study schematic. aKarnofsky performance status, New
York Heart Association class, safety, and TTR genotyping also assessed
as part of eligibility criteria. b18-month efficacy assessments: mNIS+7,
NIS+7, FAP score, polyneuropathy disability stage, nerve fiber density,
dermal amyloid burden, modified body mass index, timed 10-m walk
test, grip strength test, Composite Autonomic Symptom Score-31
questionnaire, Norfolk Quality of Life-Diabetic Neuropathy questionnaire,
EuroQol 5-Dimensions questionnaire, Rasch-built Overall Disability Scale,
echocardiogram, and cardiac biomarkers. FAP familial amyloidotic
polyneuropathy; IV intravenous; mNIS+7 modified NIS+7; NCS nerve
conduction study; NIS Neuropathy Impairment ScoreEligibility
At screening, patients are 18–85 years old, with a diag-
nosis of hATTR amyloidosis, a documented TTR muta-
tion, and investigator-estimated survival of ≥2 years.
Eligible patients have an NIS of 5–130, polyneuropathy
disability (PND) score ≤IIIb, and adequate biochemical
liver function. The NIS range of 5–130 was selected to
include patients with disease sufficiently advanced to
show progression in the placebo group, but not so ad-
vanced as to preclude detection of a change in disease
status. Patients with previous OLT or sensorimotor/
autonomic neuropathy due to other known causes are
not included in the study. The key inclusion and exclu-
sion criteria are summarized in Table 1.Study design
Patients are randomized to receive either patisiran
0.3 mg/kg or placebo (normal saline 0.9%) once every
3 weeks for 18 months. Study drug is administered as an
intravenous infusion over 70 min (1 mL/min for the first
15 min, then 3 mL/min thereafter).
Patients have the option of discontinuing study drug if
they experience a protocol-defined rapid disease progres-
sion at 9 months, defined as ≥24-point increase in mNIS+7
from baseline (estimated 24-point increase in mNIS+7
score in the placebo group expected by 18 months based
on natural history study [47]), and FAP stage [7] progres-
sion relative to baseline, confirmed by an external adjudica-
tion committee. Such patients may receive alternative
therapy (local standard of care) and will be monitored
based on a modified visit schedule if they decide to stay on
study. All patients who complete the final 18-month assess-
ment are eligible to screen for an open-label extension
study of long-term patisiran treatment (NCT02510261).Premedication
To reduce the likelihood of infusion-related reactions,
patients are to receive the following premedications or
equivalent at least 60 min before each study drug
infusion: dexamethasone; oral acetaminophen/paraceta-
mol; an H2 blocker (e.g., ranitidine or famotidine); and
an H1 blocker (e.g., diphenhydramine).Concomitant medications
The use of tafamidis, diflunisal, doxycycline, taurourso-
deoxycholic acid, or any investigational agent other than
patisiran is prohibited during study participation. These
agents may have been used before screening, but a
wash-out period is mandated (14 days for tafamidis,
doxycycline, or tauroursodeoxycholic acid; 3 days for
diflunisal). Palliative and supportive-care medications
are permitted during the study.
Table 1 Key inclusion and exclusion criteria for the APOLLO study
Inclusion criteria Exclusion criteria
• Diagnosis of hATTR amyloidosis with documented mutation
• Anticipated survival ≥2 years
• Aged 18–85 years (inclusive)
• NIS of 5–130
• PND score ≤IIIb
• NCS sum of the sural SNAP, tibial CMAP, ulnar SNAP, ulnar
CMAP, and peroneal CMAP of ≥2 points
• Karnofsky performance status ≥60%
• Absolute neutrophil count ≥1500 cells/mm3
• Platelet count ≥50,000 cells/mm3
• Adequate biochemical liver functiona
• Serum creatinine ≤2 × ULN
• Previous liver transplantation, or liver transplantation planned during
study period
• Sensorimotor or autonomic neuropathy not related to hATTR amyloidosis
• Primary or leptomeningeal amyloidosis
• Type 1 diabetes
• Type 2 diabetes for ≥5 years
• Active hepatitis B or C, or HIV infection
• NYHA heart failure classification >2
• Acute coronary syndrome within past 3 months
• Uncontrolled cardiac arrhythmia or unstable angina
• Severe reaction to a liposomal product or hypersensitivity to oligonucleotides
• Unable to take premedications
• Received an investigational agent within 30 days/5 half-lives (whichever is
longer) of study drug administration
• Currently taking tafamidis, diflunisal, doxycycline, or tauroursodeoxycholic acid
CMAP compound muscle action potential; hATTR amyloidosis hereditary transthyretin-mediated amyloidosis; NCS nerve conduction study; NIS Neuropathy
Impairment Score; NYHA New York Heart Association; PND polyneuropathy disability; SNAP sensory nerve action potential; ULN upper limit of normal
aAspartate transaminase and alanine transaminase levels ≤2.5 × ULN; total bilirubin levels within normal limits; international normalized ratio ≤2.0
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Patients are randomized in a 2:1 (patisiran:placebo) ratio
using an interactive response system. Treatment arms are
balanced at study entry for: NIS (5–49 vs 50–130), early-
onset V30M disease (age < 50 years at onset) vs all other
mutations (including late-onset V30M), and previous use
of tafamidis or diflunisal. Patients and study personnel
who monitor patients during infusions and perform clin-
ical assessments are blinded to the study treatment. Un-
blinded personnel and pharmacists prepare the drug for
administration, but are not involved in patient manage-
ment or safety or efficacy assessments. Details of patients
who discontinue study drug at 9 months due to rapid dis-
ease progression remain blinded throughout the study.
Efficacy assessments
Primary outcome measure: mNIS+7
The primary objective is to determine the difference be-
tween the patisiran and placebo groups in change from
baseline in mNIS+7 at 18 months (Table 2). The mNIS+7
used in APOLLO has been modified from the original
NIS+7 to better characterize and quantify sensation all
over the body, autonomic function, and nerve conduction
changes associated with hATTR amyloidosis progression
[17]. A summary of the scoring components of the NIS+7
and mNIS+7 is provided in Table 3.
The mNIS+7 assessment tool [17] used in this study is
a 304-point composite measure of neurologic impair-
ment that includes: neurologic examination of lower
limbs, upper limbs, and cranial nerves (NIS-weakness
and reflexes); electrophysiologic measures of small and
large nerve fiber function (including nerve conduction
studies [NCS] Σ5 of ulnar, peroneal, and tibial com-
pound muscle action potential [CMAP] amplitudes and
sural and ulnar sensory nerve action potential [SNAP]
amplitudes; and smart somatotopic quantitative sensory
testing [S ST QSTing; including touch pressure and heatpain]) at defined body surface locations (Fig. 2); and
autonomic function (postural hypotension). Scoring for
NCS and postural hypotension is based on grading of
function: normal (<95th percentile) = 0 points; mildly
reduced (≥95th to <99th percentile) = 1 point; and very
reduced (≥99th percentile) = 2 points. The mNIS+7 is
measured in replicates during the pre-randomization
phase (at screening/baseline [21 days before the first
dose of study drug] and at baseline [≥24 h after screen-
ing/baseline measure]), and at 9 and 18 months. Two in-
dependent assessments are taken at each time point,
performed at least 24 h apart, but no greater than 7 days
apart. An increase in mNIS+7 score, or in any of its
components, indicates worsening impairment.
To standardize the efficacy assessment and minimize
variability across the multiple centers, neuromuscular
physicians were trained to perform the mNIS+7 evalu-
ation at a central center (Dyck Peripheral Nerve Re-
search Laboratory, Mayo Clinic, Rochester, MN, USA).
Secondary and exploratory clinical outcome measures
The secondary and exploratory objectives are to deter-
mine the effect of patisiran on a variety of clinical parame-
ters, based on their change from baseline to 18 months
(Table 2). Unless stated, parameters are assessed at screen-
ing/baseline, baseline, 9, and 18 months.
Neurologic and cardiac function
Neurologic function is measured using the NIS+7 tool [48]
based on two independent readings as described for mNIS
+7. For both mNIS+7 and NIS+7, the individual compo-
nents of the scores will be reported. Specific motor function
assessments include the timed 10-m walk test and hand
grip strength test (dynamometer), with measurements per-
formed on separate days. Cardiac function is assessed
through echocardiograms and cardiac biomarkers (troponin
I and N-terminal pro-brain-type natriuretic peptide).
Table 2 Study objectives
Objective
Primary • Determine the efficacy of patisiran by
evaluating the difference between the patisiran
and placebo groups in the change from
baseline of mNIS+7 at 18 months
Secondary
(hierarchical ordering)
• Norfolk Quality of Life-Diabetic Neuropathy
questionnaire
• NIS-weakness score
• Level of disability (Rasch-built Overall Disability
Scale)
• Timed 10-m walk test
• mBMIa
• Composite Autonomic Symptom Score
questionnaire
Exploratory • NIS + 7 score
• Grip strength
• EuroQol 5-Dimensions questionnaire
(EQ-5D-5L index, EQ VAS)
• Large versus small nerve fiber functionb
• Sensory and autonomic innervation and
analysis of nerve fiber density and sweat gland
nerve fiber density
• Dermal amyloid content on skin biopsy
• FAP stage and PND score
• Cardiac measures (echocardiogram, troponin I,
and NT-proBNP levels)
• Pharmacodynamic biomarkers
(TTR, RBP, and vitamin A)
• Proportion of patients with rapid disease
progression at 9 months
• Lower limb nerve injury via voluntary magnetic
resonance neurography
• Columbia-Suicide Severity Rating Scale (C-SSRS)
FAP familial amyloidotic polyneuropathy; mBMI modified body mass index;
mNIS modified Neuropathy Impairment Score; NIS Neuropathy Impairment
Score; NT-proBNP N-terminal pro-brain-type natriuretic peptide; PND
polyneuropathy disability; RBP retinol-binding protein; TTR transthyretin
amBMI calculated as kg/m2 × albumin (g/L)
bNerve fiber function assessed through nerve conduction studies of 5
attributes (Σ5): quantitative sensory testing by body surface area including
touch pressure and heat pain, vibration detection threshold, heart rate
response to deep breathing, and postural blood pressure
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QoL assessments include the Norfolk QOL-DN question-
naire [49], a 35-item measure sensitive to small fiber, large
fiber, and autonomic nerve function, which has been
shown to be a reliable indicator of disease severity in
patients with hATTR amyloidosis [20] (increase in
score = worsening QoL), and the EQ-5D™ questionnaire
[50] (decrease in score = worsening QoL). Autonomic
symptoms are evaluated using the 31-question Composite
Autonomic Symptom Score (COMPASS)-31 question-
naire, which covers six autonomic domains (orthostatic
intolerance, vasomotor, secretomotor, gastrointestinal,
bladder, and pupillomotor) [51] (increase in score = wors-
ening symptoms). Activity and social function are assessed
through the Rasch-built Overall Disability Scale (R-ODS),
a 24-item scale to capture limitations on everyday activ-
ities [52] (decrease in score = worsening disability). Nutri-
tional status is gauged using mBMI (kg/m2 × albumin [g/
L]), taken at baseline, and days 84, 189, 357, 462, and 546(18-month assessment). Changes in ambulation are
assessed according to FAP stage [7] and PND score [53]
(increase in stage/score = worsening impairment), and the
timed 10-m walk test (increase in duration = worsening
impairment). Lower limb nerve injury is serially evaluated
via voluntary magnetic resonance neurography approxi-
mately every 6 months in patients providing voluntary
consent.Pathologic nerve fiber and amyloid evaluation
Nerve fibers and amyloid deposits in the skin are quanti-
fied through measurement of intraepidermal nerve fiber
density, sweat gland nerve fiber density, and dermal
amyloid burden using tandem 3 mm skin punch biopsies
in patients providing voluntary consent. At each time
point, one set of biopsies is taken from the lower leg and
another from the distal thigh.Pharmacodynamic assessments
Levels of serum TTR protein, vitamin A, and retinol-
binding protein (RBP) are measured at baseline, pre-dose
on day 0, and on days 21, 126, 252, 253–272 (9 months),
273, 399, 546, and 553–560 (18 months). Serum TTR is
measured using an enzyme-linked immunosorbent assay
and a turbidimetric assay. Serum RBP is quantified using
nephelometry. Serum samples are evaluated by a high-
performance liquid chromatography assay to determine
vitamin A levels. Pharmacodynamic samples are not taken
at 18 months for patients who discontinue treatment at
9 months (modified schedule).Pharmacokinetic assessments
Plasma samples for pharmacokinetic analysis are taken pre-
dose and post-dose on days 0, 21, 126, 252, 399, and 546.
Pharmacokinetic parameters for plasma siRNA are evalu-
ated using a validated ATTO™-probe high-performance
liquid chromatography assay.Safety assessments
Adverse events (AEs) are assessed throughout the study,
and reported according to the Medical Dictionary of
Regulatory Activities (version 18.0 or later). AEs are
graded based on their severity (mild, moderate, or
severe) and the causal relationship to study drug or pre-
medication recorded. Clinical laboratory and chemistry
tests, thyroid function parameters, urinalysis, anti-drug
antibodies, electrocardiograms, physical and vital signs,
and ophthalmology examinations (including electroreti-
nography) are also monitored. The Columbia-Suicide
Severity Rating Scale (C-SSRS) is used to assess mental
status as it relates to suicidal ideation and behavior.
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Fig. 2 Schematic representation of smart QSTing of body sites. Smart testing uses defined and quantitated stimuli of touch pressure and heat as
pain using validated computer software, standard conditions, and previously obtained reference values from the assessment of healthy-subject
cohorts. Dots indicate testing site. HP5, heat as pain 5 (graded 1–10); mNIS+7 modified NIS+7; NIS Neuropathy Impairment Score; S ST QSTing
Smart Somatotopic Quantitative Sensory Testing; TP touch pressure [17, 62]
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A sample size of approximately 200 patients will provide
90% power to test a treatment difference of 8.95 points
(37.5%) in mNIS+7 change from baseline (primary end-
point) with a two-sided α = 0.05. The sample size of ap-
proximately 200 is based on an assumed premature
discontinuation rate of 25%.
The populations analyzed in the study are: the modi-
fied intent-to-treat (mITT) population (all patients who
were randomized and received at least one dose of study
drug); the per-protocol population (all patients who
completed all efficacy assessments and did not have any
major protocol violations); and the safety population
(all patients who received at least one dose of study
drug).
The analysis of efficacy endpoints will be conducted
for the mITT population. Formal statistical hypothesis
testing will be performed on the primary and secondary
efficacy endpoints with all tests conducted at the nom-
inal two-sided, 0.05 level of significance.
Discussion
The APOLLO study examines the efficacy and safety of
the investigational RNAi therapeutic patisiran in a broad
hATTR amyloidosis population, including patients with
any amyloidogenic TTR mutation and with a wide range
of neuropathy severity and age at baseline. The compos-
ite primary endpoint of APOLLO (mNIS+7) is well
suited for use in hATTR amyloidosis because it encom-
passes multiple aspects of the polyneuropathy and can
capture changes during disease progression. In addition,QoL, motor function, health status, autonomic symp-
toms, cardiac assessments, and everyday functioning
are included as secondary or exploratory endpoints to
assess the impact of patisiran on a range of disease
involvement.
The mNIS+7 used to assess neurologic impairment in
this study is more robust and comprehensive than the
tools used in the trials of tafamidis (NIS-LL) [19] or
diflunisal (NIS+7) [24], with the modifications outlined
in Table 3. One of the key attributes of the mNIS+7 ver-
sus NIS+7 is the measurement of sensation, with S ST
QSTing used in preference to NIS-sensation evaluation
and vibration detection threshold. Indeed, the NIS-
sensation score is not included in mNIS+7 in APOLLO,
as the study of Suanprasert et al. in 97 patients with
hATTR amyloidosis suggested that this score did not ad-
equately capture sensation loss [17]. Compared with
NIS-sensation, S ST QSTing provides an improved bal-
ance between large and small sensory nerve fibers and
measures sensation loss over the whole body rather than
at distal sites such as big toes and fingers. Whilst S ST
QSTing is time-consuming and requires specialist train-
ing and standardized protocols to avoid procedural vari-
ability [54, 55], these demands are necessary to assess
sensation loss somatopically and accurately [56]. Aside
from sensation, the other major alteration from the NIS+7
is in the measurement of nerve conduction. Here, the com-
bined NCSΣ5 in the mNIS+7 includes only action potential
amplitudes, which are more suited to capture changes in
disease course for hATTR amyloidosis as this disease has a
primarily axonal pathophysiology. A further change from
Adams et al. BMC Neurology  (2017) 17:181 Page 8 of 12the NIS+7 is the new autonomic measure: postural
hypotension was included because heart rate decrease
with deep breathing was considered an inconsistent
assessment of autonomic function as it is unevaluable
in patients with cardiac pacemakers and frequently
unevaluable in patients with arrhythmias [17, 56]. It
is recognized however, that pharmacologic interven-
tions (e.g., fludrocortisone and midodrine) can be
used to treat postural hypotension [57], and the use
of any such strategies should be considered when
gauging the effect of patisiran on this measure. With
the modifications to the NIS+7, the total score was
increased to 304 points for the mNIS+7 used in this
study. Measurement of muscle weakness and stretch re-
flexes were considered adequate with the original NIS+7,
so these elements have not been modified [17].
However, it should be noted that the mNIS+7 de-
scribed by Suanprasert et al., which is used in APOLLO,
is different from that currently being used in the study
investigating the anti-TTR antisense oligonucleotide
IONIS-TTRRx (mNIS+7Ionis). The critical difference be-
tween these two versions of the mNIS+7 is in the meas-
urement of sensation: mNIS+7Ionis includes the NIS-
sensation testing score from the original NIS+7, in
addition to S ST QSTing [56] (Table 3). As discussed,
NIS-sensation may not provide a true reflection of sen-
sation impairment, with inclusion of the original NIS+7-
sensation testing potentially being redundant. Indeed,
this may lead to double counting for assessments of sen-
sation. The other notable difference is that the mNIS+7Ionis
does not include postural hypotension, and instead retains
the heart rate decrease with deep breathing measure of the
NIS+7 for assessment of autonomic function, which has
the limitations discussed above for patients with pace-
makers or cardiac arrhythmias. Both mNIS+7 and
mNIS+7Ionis include only CMAPs and SNAPs as
nerve conduction measures (Table 3). Regarding as-
sessment of NCS, it is worth noting that these are
expressed as normal deviates in the mNIS+7Ionis,
whereas they are graded by defined categories in
mNIS+7 (Table 3).
The features of the mNIS+7 described above have
been introduced to create a tool suitable for use in
hATTR amyloidosis clinical studies. As assessment of
neuropathic measures is subject to variability between
investigators, extensive training is provided to support
the use of a standardized and validated methodology
and ensure that scoring is consistent and accurate. Spe-
cifically, specialized training is provided for neuromus-
cular physicians, with certification upon completion. For
clinical assessment of neuropathy signs and symptoms,
neuromuscular experts are trained to use only unequivo-
cal abnormalities (accounting for age, sex, physical fit-
ness, and anthropomorphic variables) rather than moretraditional clinical criteria, and not to grade for con-
comitant neuromuscular disease. Previous analyses have
shown that this strategy, when used by trained special-
ists, leads to increased reproducibility and a notable
improvement in proficiency when scoring clinical mea-
sures, such as weakness and reflexes, as used in
APOLLO [58, 59]. Variability between centers has
also been noted for NCS, which is countered in this
study through specialist training on techniques and
reference values, and evaluation of tracings at a cen-
tral reading center; these methodologies have been
shown to reduce inter-investigator variability [60, 61]. Of
the other mNIS+7 measures, the S ST QSTings used in
APOLLO are also standardized and referenced, to ensure
generation of accurate and comparable data across the
study [62].
The clinical relevance of NIS has been previously dem-
onstrated, with total NIS correlated with FAP stage,
PND score, and QoL (Norfolk QOL-DN and SF-36) in
patients with hATTR amyloidosis [47, 56]. In addition,
rapid worsening of NIS was observed in untreated pa-
tients in a natural history study of patients with hATTR
amyloidosis [47], fitting with the relentless progression
expected for this disease [8]. The estimated rate of NIS
progression for a patient with a baseline NIS of 32 was
14.3 points per year [47], and a separate analysis has in-
dicated a worsening in NIS-LL of up to 7.4 points over
12 months in patients with a baseline NIS-LL of 20–30
[63]. The rapid neurologic deterioration observed in pa-
tients with hATTR amyloidosis contrasts with lower
rates of NIS progression seen in other neuropathies
[64, 65]. For example, in patients with mild-to-moderate
diabetic distal symmetric sensorimotor polyneuropathy,
NIS and NIS-LL increased by only 0.61 and 0.43 points,
respectively, over 4 years of placebo treatment [64]. Fur-
thermore, a study of disease progression in Charcot–
Marie–Tooth disease type 1A reported an annual NIS
increase of 1.37 points [65].
Based on the described modifications to the NIS, it is
anticipated that the mNIS+7 will more accurately cap-
ture the degree of polyneuropathy and neurologic im-
pairment in patients with hATTR amyloidosis. Indeed,
rapid disease progression in untreated patients has also
been demonstrated using the mNIS+7, with an increase
of approximately 24 points anticipated after 18 months
[47]. The clinical value of the mNIS+7 was further dem-
onstrated in recent analyses of the baseline data from
APOLLO, which showed an association between mNIS+7
and FAP stage and PND score (Fig. 3). In addition, investi-
gation of the mNIS+7Ionis showed that clinical polyneur-
opathy signs and symptoms correlated strongly with
assessments of action potential amplitudes and soma-
totopic touch pressure [56], which are also included
in the mNIS+7. Of the other measures taken in
Fig. 3 Association between mNIS+7 and (A) FAP stage and (B) PND score using baseline data from the APOLLO study (n = 225). FAP familial
amyloidotic polyneuropathy; mNIS+7 modified Neuropathy Impairment Score +7; PND polyneuropathy disability
Adams et al. BMC Neurology  (2017) 17:181 Page 9 of 12APOLLO, a correlation between mNIS+7 and TTR
knockdown was demonstrated in the Phase 2 open-
label extension study of patisiran [66], supporting the
hypothesis that reducing levels of amyloidogenic pro-
tein leads to clinical benefit in hATTR amyloidosis
(e.g., via OLT [28]).
hATTR amyloidosis is associated with symptoms
across multiple systems [2, 67]. In addition to the neuro-
logic symptoms, patients often present with a mixed
phenotype including concurrent cardiac symptoms. Car-
diomyopathy associated with hATTR amyloidosis can
lead to heart failure and death, highlighting the need for
vigilance around cardiac amyloid fibril accumulation.
The APOLLO study therefore includes echocardio-
graphic and biochemical cardiac parameters to assess
the impact of patisiran on cardiac progression.
The impact of the diverse disease symptoms may not
be fully captured by clinical and laboratory examina-
tions, so QoL measures were included as key endpoints
in the studies of tafamidis and diflunisal [19, 24].
APOLLO uses the Norfolk QOL-DN and EQ-5D ques-
tionnaires to assess QoL. The Norfolk QOL-DN ques-
tionnaire evaluates small and large nerve fiber function
in addition to autonomic impairment and activities of
daily living. It has demonstrated utility in patients with
hATTR amyloidosis with polyneuropathy both as a
measure of disease severity and as a clinical endpoint to
assess response to treatment [20, 21]. The EQ-5D ques-
tionnaire has been used as part of the international
Transthyretin Amyloidosis Outcomes Survey (THAOS),
which demonstrated worsening QoL with disease pro-
gression [22]. Autonomic symptoms, particularly gastro-
intestinal events, are common in patients with hATTR
amyloidosis [23] underpinning the comprehensive
assessment of autonomic function using the COMPASS-
31 questionnaire [51]. Other measures in APOLLO
include the R-ODS survey [52] for assessment of the ef-
fects of patisiran on activities of daily living. The R-ODShas already been used to demonstrate that hATTR amyl-
oidosis can affect activities such as washing dishes or
fastening buttons [68], and has been validated in patients
with V30M hATTR amyloidosis [69].
The pharmacotherapies currently approved or avail-
able for hATTR amyloidosis can slow or sometimes
stabilize disease, but there is little evidence that
complete stabilization or reversal of nerve damage can
be achieved. Sensory and autonomic innervation in skin
punch biopsies are being evaluated in APOLLO to deter-
mine whether patisiran can increase nerve fiber density.
Increases in sweat gland fiber density were observed in
the Phase 2 open-label extension study of patisiran [46],
and APOLLO will provide an opportunity for these find-
ings to be validated in a placebo-controlled setting. Of
interest, sweat gland nerve fiber density has previously
been associated with ambulation in patients with hATTR
amyloidosis [70]. In addition to nerve fiber density, these
skin biopsies are also being evaluated in both the Phase
2 open-label extension study and APOLLO for changes
in dermal amyloid burden.
Aside from clinical endpoints related to efficacy, safety
and pharmacodynamics will also be assessed throughout
the APOLLO study and subsequent open-label exten-
sion. Longer-term data from the Phase 2 open-label
extension study suggest patisiran is well tolerated, but
APOLLO will allow comparison against a placebo-
controlled arm. In particular, the safety of prolonged
lowering of vitamin A levels, associated with TTR reduc-
tion, will be assessed. TTR reduction itself provides a
convenient biomarker to assess patisiran activity, and
reduction in the pathogenic protein may also relate to
clinical parameters.
Recruitment for APOLLO started in December 2013
and was completed in January 2016, with 225 patients en-
rolled. This trial represents the largest Phase 3 study of an
RNAi strategy for the treatment of hATTR amyloidosis,
with clinical endpoints that strive to assess the multiple
Adams et al. BMC Neurology  (2017) 17:181 Page 10 of 12ways in which this disease affects patient well-being and
function. The Patisiran Global open-label extension study
was initiated in July 2015, and will provide further data on
long-term safety and efficacy of patisiran in patients with
hATTR amyloidosis.
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ABSTRACT
Objectives: To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients
with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP).
Methods: In this randomized, double-blind trial, patients received tafamidis 20 mg QD or placebo.
Coprimary endpoints were the Neuropathy Impairment Score–Lower Limbs (NIS-LL) responder
analysis (2-point worsening) and treatment-group difference in the mean change from baseline
in Norfolk Quality of Life–Diabetic Neuropathy total score (TQOL) in the intent-to-treat (ITT) popu-
lation (n  125). These endpoints were also evaluated in the efficacy-evaluable (EE; n  87)
population. Secondary endpoints, including changes in neurologic function, nutritional status, and
TTR stabilization, were analyzed in the ITT population.
Results: There was a higher-than-anticipated liver transplantation dropout rate. No differences
were observed between the tafamidis and placebo groups for the coprimary endpoints, NIS-LL
responder analysis (45.3% vs 29.5% responders; p  0.068) and change in TQOL (2.0 vs 7.2;
p  0.116) in the ITT population. In the EE population, significantly more tafamidis patients than
placebo patients were NIS-LL responders (60.0% vs 38.1%; p 0.041), and tafamidis patients
had better-preserved TQOL (0.1 vs 8.9; p  0.045). Significant differences in most secondary
endpoints favored tafamidis. TTR was stabilized in 98% of tafamidis and 0% of placebo patients
(p 0.0001). Adverse events were similar between groups.
Conclusions: Although the coprimary endpoints were not met in the ITT population, tafamidis was
associated with no trend towardmore NIS-LL responders and a significant reduction in worsening
of most neurologic variables, supporting the hypothesis that preventing TTR dissociation can
delay peripheral neurologic impairment.
Classification of evidence: This study provides Class II evidence that 20 mg tafamidis QD was
associated with no difference in clinical progression in patients with TTR-FAP, as measured by
the NIS-LL and the Norfolk QOL-DN score. Secondary outcomes demonstrated a significant delay
in peripheral neurologic impairment with tafamidis, which was well tolerated over 18 months.
Neurology® 2012;79:785–792
GLOSSARY
AE  adverse event; ANCOVA  analysis of covariance; ARR  absolute risk reduction; CI  confidence interval; DPN  diabetic
polyneuropathy; EE efficacy-evaluable; ITT intent-to-treat; LS Mean least-squares mean; mBMImodified body mass index;
NIS-LL  Neuropathy Impairment Score–Lower Limbs; NNT  number needed to treat; QOL  quality of life; QOL-DN  Quality of
Life–DiabeticNeuropathyQuestionnaire;TQOL total quality of life;TTR-FAP transthyretin familial amyloidpolyneuropathy.
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare inherited amyloidosis that
presents as a progressive sensorimotor and autonomic polyneuropathy.1,2 Axonal degeneration
begins in small myelinated and unmyelinated fibers, resulting in sensory symptoms,3,4 progress-
ing to larger myelinated fibers, causing muscle weakness and motor impairment.4 Gastrointes-
tinal disturbances are a common autonomic manifestation, with malabsorption and cachexia
developing in late-stage disease.1,4 Death occurs within a decade of symptom onset.3,4
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TTR is a homotetrameric plasma protein
comprising 127–amino acid monomers pro-
duced primarily by the liver. TTR has 2
thyroxine-binding sites and orthogonal retinol-
binding protein/vitamin A complex sites.5,6
Mutations in TTR destabilize the tetramer, fa-
cilitating dissociation, the initial, rate-limiting
step in amyloidogenesis (figure 1).7 This enables
monomers to misfold andmisassemble into am-
yloid.7 More than 100 TTR mutations have
been linked to TTR-FAP,8 themost common of
which is Val30Met (V30M).1 Evidence suggests
that TTR amyloidogenesis leads to neurodegen-
eration and TTR-FAP.9,10
The current standard of care for patients
with TTR-FAP is liver transplantation, which
replaces the source of mutant TTRwith a genet-
ically normal organ.11 However, the high peri-
operative mortality12 and morbidity associated
with chronic immunosuppression13 highlight
the need for safe, effective alternatives.
Interallelic trans-suppressor mutations in-
hibit amyloid formation via kinetic stabilization
of tetrameric TTR and prevent TTR-FAP.9,14
Tafamidis, a small molecule that occupies the
thyroxine-binding sites with negative coopera-
tivity, kinetically stabilizes the tetramer.15 Thus,
it was hypothesized that tafamidis would halt or
slow neurodegeneration in TTR-FAP.
The primary objectives of this study were
to evaluate the effect of 18 months of tafami-
dis (20 mg QD) on disease progression and
assess its safety in patients with the V30M TTR
mutation. A secondary objective was to deter-
mine the pharmacodynamic stabilization effect
of tafamidis on human V30M TTR.
METHODS Patients. Men and women with TTR-FAP
were enrolled at 8 sites in 7 countries (Argentina, Brazil, France,
Germany, Portugal, Spain, Sweden). Key inclusion criteria were
age 18 to 75 years, documented V30M TTR mutation, biopsy-
confirmed amyloid deposits, and peripheral or autonomic neu-
ropathy with a Karnofsky performance status 50. Key
exclusion criteria were the presence of primary amyloidosis,
other causes of sensorimotor neuropathy, absence of a recordable
sensory threshold for vibration perception in both feet, liver
function test abnormalities, prior liver transplantation, renal in-
sufficiency (creatinine clearance30 mL/min), NY Heart Asso-
ciation classification 3, any comorbidity anticipated to limit
survival to 18 months, and chronic use of non–protocol-
approved nonsteroidal anti-inflammatory drugs.
Study protocol. Patients were randomized by a central
computerized telerandomization system, in a 1:1 ratio, to self-
administer once-daily tafamidis 20 mg [2-(3, 5-dichloro-
phenyl)-benzoxazole-6-carboxylic acid] as a 1:1 meglumine
[d-glucitol, 1-deoxy-1-(methylammonium)] salt or matching
placebo. Dose and interval were determined using a pharmacoki-
netic/pharmacodynamic model to achieve serum tafamidis:TTR
ratios of 1:1 to 2:1. The active drug was provided in soft-gelatin
capsules containing a suspension of tafamidis and excipients.
The packaging, appearance, and constitution of the placebo cap-
sules were identical to those of the active-drug capsules except for
the absence of tafamidis.
Study medication was initiated the day after the baseline
visit. Patients returned to the clinical sites during the double-
blind treatment period at weeks 2, 4, 8, and 12 and at months 6,
9, 12, and 18.
Outcome measures. As with many rare diseases, there were
no validated outcome measures for TTR-FAP. Therefore, mea-
sures of disease progression with demonstrated sensitivity and
specificity in another axonal degenerative neuropathy—diabetic
polyneuropathy (DPN)—were used.16,17 Detailed descriptions of
the outcome measures are provided in appendix e-1 on the
Neurology® Web site at www.neurology.org.
Figure 1 The TTR amyloidogenesis cascade is blocked by tafamidis-mediated kinetic stabilization of tetrameric TTR
Tafamidis, depicted as the black space-filling structure with a red carboxyl group, binds to tetrameric TTR (far left), slowing TTR tetramer dissociation,
which is the rate-limiting step for TTR amyloid fibril formation. Thus, the TTR-tafamidis complex is locked in a functional, nonamyloidogenic state, rendering
the neurodegenerative amyloidogenesis cascade inaccessible. TTR transthyretin.
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The Neuropathy Impairment Score–Lower Limbs (NIS-
LL)16 quantifies the motor, sensory, and reflex functions in the
lower limbs, which are most affected in early-stage TTR-FAP.
To reduce variability, the NIS-LL for each patient was assessed
by the same neurologist throughout the study. For each study
visit, the NIS-LL was assessed twice within a 7-day period with
an interval of at least 24 hours between tests. The 2 assessments
were averaged to provide the visit score.
The Norfolk Quality of Life–Diabetic Neuropathy Ques-
tionnaire (Norfolk QOL-DN)17 is a 35-item, patient-reported
questionnaire which provides a total quality of life (TQOL)
score ranging from 2 (best possible quality of life [QOL]) to
138 (worst possible QOL).
Summated scores, which are obtained by summing multiple
objective measures of nerve fiber impairment, have been used to
detect disease progression in other neuropathies.18,19 The sum-
mated 7 nerve tests normal deviates (7 NTs nds), which mea-
sures primarily large-fiber function, is scored from26 (extreme
normal function) to 26 (extreme abnormal function), and the
summated 3 nerve tests small-fiber normal deviates (3 NTSF
nds), which measures small-fiber function, is scored from11.2
(extreme normal function) to 11.2 (extreme abnormal function).
For statistical analyses, individual test data were expressed as nor-
mal deviates based on healthy subject cohort data from the Mayo
Clinic, Rochester, MN.
Modified body mass index (mBMI), a measure of wasting
and autonomic gastrointestinal function, was calculated as the
product of the BMI and serum albumin concentration (g/L).
TTR tetramer stabilizationwas assessed using a validated immuno-
turbidimetric assay performed on patients’ plasma samples.15,20
Statistical analysis. Primary endpoints. The coprimary effi-
cacy endpoints at month 18 were NIS-LL response to treatment
(“responders” were patients with an increase from baseline in
NIS-LL of2 points21,22) and the least-squares mean (LS Mean)
change from baseline in the Norfolk QOL-DN total (TQOL)
scores. The primary efficacy analyses were performed on the
intent-to-treat (ITT) population (all randomized patients who
received at least 1 dose of study medication and who had 1
postbaseline assessment for both coprimary endpoints or who
discontinued due to liver transplantation). For patients with
postbaseline assessments, the last-observation-carried-forward
method was used to impute missing data at month 18. Patients
who discontinued due to liver transplantation were categorized
as NIS-LL nonresponders. A 2 test for proportions assessed
treatment comparability for the NIS-LL responder outcome. An
analysis of covariance (ANCOVA) with baseline as covariate as-
sessed the treatment group difference in LS Mean change from
baseline TQOL scores. The assumptions of the ANCOVA were
assessed and met. Analyses of the coprimary endpoints were per-
formed in an efficacy-evaluable (EE) population consisting of
ITT patients who completed the study per protocol. This EE
population was prespecified as it was anticipated that the major-
ity of patients enrolled would be on the liver transplant list and
that many would undergo liver transplantation during the study
if a donor organ became available.
Absolute risk reduction (ARR) in the ITT population was
calculated as the treatment group difference in the percentage of
NIS-LL responders, and the number needed to treat (NNT) was
calculated as the reciprocal of the ARR.
Secondary endpoints. Multiple secondary endpoints were
used to assess the efficacy of tafamidis, including change from
baseline at months 6, 12, and 18 in NIS-LL, TQOL, 7 NTs
nds, 3 NTSF nds, and mBMI. Analyses of the secondary end-
points were conducted in the ITT population using a repeated-
measures analysis of variance model that included fixed effects
for treatment, month, their interaction, and patient as a random
effect. Only observed values were used. Within each treatment
group, a 1-sample t test was used to determine whether the change
from baseline in TQOL was significantly different from 0.
Post hoc models were used to investigate whether muscle
weakness (measured by the NIS-LL) progressed in a distal-to-
proximal fashion.
Sample size, based on the coprimary endpoints, assumed
2-sided tests,   0.05, 90% power, and a discontinuation
rate of 10%. Response rates of 20% for placebo and 50%
for tafamidis (a 30% difference) were anticipated, and a 2
test was assumed for the NIS-LL analysis. A true difference of 0.6
SD was assumed between the groups in TQOL, where SD was the
square root of the mean squared error of the ANCOVA model for
change from baseline scores. Each group required 58 patients.
Standard protocol approvals, registrations, and patient
consent. This study (ClinicalTrials.gov: NCT00409175) was
approved by the institutional review boards at each site. All pa-
tients provided written informed consent.
RESULTS Patient disposition. A total of 162 pa-
tients were screened and 128 were randomized to
tafamidis (n 65) or placebo (n 63). Eighty-eight
(69%) were on liver transplant waiting lists at enroll-
ment (see figure e-1). Thirteen patients in each group
(21%) discontinued treatment to undergo liver
transplantation; 19 (73%) discontinued prior to the
12-month assessment.
Baseline demographics and clinical characteristics. In
general, patients had early-stage neurologic disease,
greater involvement of small than large nerve fibers,
relatively well-preserved nutritional status, and some
impairment in QOL. Baseline characteristics of the
tafamidis and placebo groups were similar (table e-1).
Coprimary endpoints. In the ITT population at
month 18, there was a trend toward more NIS-LL
responders in the tafamidis group than in the placebo
group (45.3% vs 29.5%; p 0.068; figure 2A). The
ARRwas 15.8% (95% confidence interval [CI]0.9%
to 32.5), resulting in an NNT of 6.3 patients. Treat-
ment group differences (5.2-point difference; p 
0.116; 95% CI 11.8 to 1.3) in the LS Mean change
from baseline in TQOL score at month 18 in the ITT
population were not significant (figure 2B).
In the prespecified analyses of coprimary end-
points in the EE population, significantly more pa-
tients in the tafamidis group than in the placebo
group were NIS-LL responders (60.0% vs 38.1%;
p  0.041; figure 2A). The LS Mean change from
baseline in TQOL for tafamidis-treated patients was
0.1 point compared with 8.9 points for patients re-
ceiving placebo, a significant difference of 8.8 points
(p 0.045) (figure 2B). The within-treatment com-
parison (ITT population) demonstrated statistically
significant worsening in QOL in patients who re-
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ceived placebo (LS Mean change from baseline,
7.2  2.4; p  0.002), but no change in tafamidis-
treated patients (2.0  2.3; p  0.384).
Secondary endpoints. In the repeated-measures analy-
ses of secondary endpoints in the ITT population,
tafamidis-treated patients demonstrated 52% less
neurologic deterioration at month 18 than patients
who received placebo, with a difference of 3 NIS-LL
points (2.81 vs 5.83; p  0.027) (figure 3A). This
difference was due primarily to significantly more
muscle weakness in the placebo group (p  0.013).
Patients who received placebo had significantly
greater muscle weakness than tafamidis-treated pa-
tients at distal sites such as the hallux (p  0.009)
and ankle (p  0.016), but not at more proximal
joints, such as the knee (p  0.054) and hip (p 
0.835). Nerve function was preserved in tafamidis-
treated patients, but worsened in patients who
received placebo. The latter group experienced 5 times
greater mean deterioration in small-fiber function
(3 NTSF nds; p  0.005) (figure 3B), with no
trend toward more deterioration in large-fiber func-
tion (7 NTs nds; p  0.066) (figure 3C). Nutri-
tional status at 18 months significantly improved in
tafamidis-treated patients (mBMI increase from
baseline [LS Mean  SE] 39.3  11.5) compared
with a worsening mBMI in patients who received pla-
cebo (33.8 11.8; p 0.0001) (figure 3D). Figure
3E depicts no trend toward preserved TQOL in the
tafamidis group (p 0.209). TTR stabilization at 18
months was demonstrated in 98% of tafamidis-
treated patients and none of the patients who re-
ceived placebo (p  0.0001).
Adverse events. The overall incidence of nonserious
adverse events (AEs) was similar in both groups (ta-
ble e-2), with AEs leading to drug discontinuation in
4 tafamidis-treated patients (6.2%) and 3 receiving
placebo (4.8%). The incidence of serious AEs was
similar in the tafamidis group (9.2%) and placebo
group (7.9%). The only serious AE reported by 1
patient was urinary tract infection, which was re-
ported by 2 tafamidis-treated patients. Complica-
tions following liver transplantation led to the deaths
of 2 patients in the tafamidis group (cardiac tampon-
ade postpacemaker insertion; unknown cause) and 3
patients in the placebo group (sepsis; hepatic failure;
unknown cause). There were no clinically relevant
effects on laboratory measures, including thyroid
function.
DISCUSSION This randomized, placebo-controlled,
double-blind trial in patients with TTR-FAP assessed
the ability of tafamidis to stabilize the TTR tetramer
and evaluated its effect on clinical progression over
18 months. For the coprimary endpoints, the differ-
ences between treatments failed to achieve the pre-
specified statistical significance. Nevertheless, based
on analyses in the EE population and secondary end-
points that demonstrated a significant reduction in
neurologic deterioration, preservation of nerve fiber
function, improved nutritional status, maintenance
of QOL, and TTR stabilization, we contend that ta-
famidis had a beneficial effect on disease progression
in patients with V30M TTR-FAP.
Designing the trial of a novel investigational agent
in a rare and progressive disease for which no approved
Figure 2 Coprimary endpoints in the ITT population and secondary analysis in the EE population
(A) Percentage of patients in each treatment group classified as NIS-LL responders at month 18 based on an increase of
2 points in NIS-LL overall score in both the ITT (primary analysis) and EE (prespecified secondary analysis) populations.
EE  efficacy-evaluable; ITT  intent-to-treat; NIS-LL  Neuropathy Impairment Score–Lower Limbs. (B) LS Mean (SE)
change from baseline at month 18 in the TQOL score from the Norfolk QOL-DN in the same populations. LS Mean 
least-squares mean; QOL-DN  Quality of Life–Diabetic Neuropathy Questionnaire; TQOL  Norfolk Quality of Life–
Diabetic Neuropathy total score.
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pharmacotherapeutic agent exists is inherently diffi-
cult.23 Without previous studies or extensive literature
on the natural disease history to guide trial design, the
choice of outcome measures, study duration, and sta-
tistical analyses (including power calculations and
sample size determination) presents a substantial
challenge. Moreover, for a therapy designed to influ-
ence disease progression, it is also necessary to evalu-
ate the consistency of the treatment effect across
multiple endpoints, each of which measures different
aspects of the disease.
The NIS-LL is validated in DPN and measures
motor, sensory, and reflex function in the limbs most
affected in early-stage TTR-FAP.22 Like TTR-FAP,
DPN involves small- and large-fiber neuropathy re-
sulting in peripheral and autonomic symptoms.
Figure 3 Secondary endpoints in the ITT population
This figure shows the LS Mean (SE) changes from baseline at months 6, 12, and 18 for the NIS-LL (A), small- (3 NTSF nds) and large- (7 NTs nds) nerve
fiber function (B and C, respectively), mBMI (D), and TQOL (E). Analyses were performed using observed cases. ITT  intent-to-treat; LS Mean  least-
squares mean; mBMImodified body mass index; NIS-LL Neuropathy Impairment Score–Lower Limbs; TQOL Norfolk Quality of Life–Diabetic Neuro-
pathy total score; 7 NTs nds summated 7 nerve tests normal deviates; 3 NTSF nds summated 3 nerve tests small-fiber normal deviates.
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There are emerging data that suggest the NIS-LL is
useful in assessing disease severity and can differenti-
ate between disease stages in TTR-FAP.24,25 The
NIS-LL responder analysis was chosen as a coprimary
endpoint based on its use in a DPN registration
trial21 and an expert consensus report that deemed a
2-point change to be the smallest change that is rec-
ognizable by a physician.22 More patients receiving
tafamidis than placebo were NIS-LL responders in
the ITT and EE populations, with the difference
achieving statistical significance in the latter. The
treatment effect in the EE population (22%) was
nearer to the anticipated 30% than that observed in
the ITT population (15%). Although an evaluable
population analysis may overestimate treatment ef-
fects, the observed effect size is supported by the
change from baseline in NIS-LL at 18 months in the
ITT population. The 3-point difference between
the treatment groups represented approximately
50% less neurologic deterioration in the tafamidis-
treated patients, which was attributable to differences
in muscle strength. This suggests that tafamidis treat-
ment long-term may slow progression to ambulatory
difficulties.
In addition to the effect of tafamidis on NIS-LL,
the 55% and 84% preservation of large– and small–
nerve fiber function, respectively, suggests that ta-
famidis may directly slow neurodegeneration. A 50%
decrease in neurophysiologic deterioration is clinically
meaningful26 and should result in better long-term
outcomes in treated patients. Finally, one likely
consequence of the preserved neurologic function
by tafamidis was the trend to maintained QOL, as
compared with the decline in QOL seen in the
patients administered placebo over the 18 months.
In contrast, QOL assessed in post-transplant pa-
tients is inconsistent; in some studies patients re-
port satisfaction with the procedure while other
studies report lower health-related QOL, particu-
larly when compared with patients transplanted
due to underlying liver disease.27–30
The mBMI predicts survival after liver transplan-
tation and correlates highly with pretransplant neu-
rologic function and duration of gastrointestinal
symptoms.31 The patients in the present study had
relatively normal baseline mBMI, consistent with
early-stage disease. Tafamidis-treated patients experi-
enced improvements in mBMI, while the patients
who received placebo showed worsening. Continued
worsening of mBMI over time is indicative of ca-
chexia, a positive prognostic factor for mortality in
TTR-FAP.32
Eighteen months of tafamidis treatment was well
tolerated, with AE profile similar to placebo. The
safety profile of tafamidis contrasts with that of liver
transplantation, which has a reported 10% perioper-
ative mortality.12
While this trial demonstrates the promise of ta-
famidis as a treatment for individuals with TTR-
FAP, we acknowledge its limitations, most notably
the inability to achieve statistical significance in the
coprimary endpoints. The lower-than-expected
treatment effect size for NIS-LL responder analysis in
the ITT population was likely due to the higher-
than-anticipated discontinuation rate due to liver
transplantation (21% observed vs 10% estimated).
Current clinical practice is to perform liver trans-
plantation as early in the course of TTR-FAP as pos-
sible, and the timing in the current study suggests
that patients chose transplantation when a donor or-
gan became available and not as salvage therapy. For
this reason, and due to the a priori designation of
these patients as nonresponders in the ITT popula-
tion, it is likely that the study was underpowered to
demonstrate a statistical difference. The results in pa-
tients completing the 18-month treatment per proto-
col (EE population) provide an accurate measure of
the treatment effects of tafamidis over that period of
time.
Another potential limitation concerns the dura-
tion of the trial. While sufficient to observe effects on
neurologic outcomes, a period of 18 months did not
allow the assessment of longer-term outcomes, such
as the occurrence of AEs arising from long-term
TTR stabilization or the impact on survival, ambula-
tion, and non-neurologic manifestations of disease,
including cardiomyopathy. As such, patients were
followed in a 12-month open-label extension study
in which all received tafamidis 20 mg QD. In addi-
tion, the longer-term outcomes of tafamidis-treated
patients will be followed in the Transthyretin Amy-
loidosis Outcomes Survey (THAOS), an observa-
tional registry established to improve understanding
of the disease (www.thaos.net).
Eighteen months of treatment with tafamidis
20 mg QD was well-tolerated by patients, and al-
though the coprimary endpoints were not met, the
totality of the results demonstrate the potential of
tafamidis to slow neurologic deterioration and
maintain nutritional status compared with pla-
cebo. These findings support the hypothesis that pre-
venting TTR tetramer dissociation by tafamidis-
mediated kinetic stabilization results in slowing of the
neurodegenerative process and preservation of neuro-
physiologic function, which ultimately translates to
maintenance of QOL. Future studies will address the
effect of tafamidis on longer-term outcomes of TTR-
FAP patients, including survival, ambulation, and car-
diomyopathy.
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Supplementary Material  
 
Classification of Evidence 
Does 18 months of treatment with tafamidis 20 mg QD reduce clinical progression in 
patients with transthyretin familial amyloid polyneuropathy (TTR-FAP), as measured by 
2 primary outcomes, the neuropathy impairment score–lower limbs (NIS-LL) and the 
Norfolk quality of life–diabetic neuropathy (QOL-DN) score? This study provides Class II 
evidence that 20 mg tafamidis QD was associated with a nonsignificant decrease in 
clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the 
Norfolk QOL-DN score. Secondary outcomes demonstrated a significant delay in 
peripheral neurologic impairment with tafamidis, which was well tolerated over 18 
months. 
 
Methods 
This supplemental material provides a description of the outcome measures used for 
the coprimary endpoints—NIS-LL and the Norfolk QOL-DN score, and outcome 
measures used for the secondary endpoints in the study. 
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Neuropathy Impairment Score of the Lower Limb (NIS-LL)  
The NIS is a composite clinical scoring system that has been widely used to objectively 
assess the severity of peripheral neuropathy. The NIS-LL is a subset of the NIS that 
assesses function of the lower limbs, the extremities most affected early in TTR-FAP 
disease progression. The NIS-LL quantifies the findings of the neurologic examination 
by attributing a score (ranging from 0 [normal] to 88 [total impairment]) to the clinical 
abnormalities noted in the physical assessment of sensation, muscle power, and tendon 
reflexes. Each component of the NIS-LL measures a different attribute of peripheral 
nervous system function, all of which are believed to have merit in the assessment of 
the complex system that controls human movement. The components of the NIS-LL 
include the following: 
• Sensation (touch pressure, pinprick, vibration, joint position). The components of 
the sensory examination, except for joint position, are assessed on the dorsal 
surface at the base of the right and left great toenails. Joint position is assessed 
by moving the terminal phalanx of the right and left great toes. Sensory 
assessment is scored as 0 (normal), 1 (decreased), or 2 (absent). As 
assessments are performed on the right and left feet, the maximum total score 
possible for the sensory component is 16. 
• Reflexes (quadriceps femoris, triceps surae [Achilles]). Reflex assessment is 
scored as 0 (normal), 1 (decreased), or 2 (absent). Adjustment is made for the 
age of the patient (eg, absent reflexes in a patient older than 60 years of age is 
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assessed as 0, or normal). As assessments are performed on the right and left 
feet, the maximum total score possible for the reflex component is 8. 
• Muscle weakness (hip flexion, hip extension, knee flexion, knee extension, ankle 
dorsiflexors, ankle planter flexors, toe extensors, toe flexors). Muscle weakness 
is scored as 0 (normal), 1 (25% weak), 2 (50% weak), 3 (75% weak), 3.25 (move 
against gravity), 3.5 (movement, gravity eliminated), 3.75 (muscle flicker, no 
movement), or 4 (paralysis). As assessments are performed on the right and left 
lower extremities, the maximum total score possible for the muscle component is 
64. 
 
Norfolk QOL-DN 
The Norfolk QOL-DN is a self-administered questionnaire that quantifies the impact of 
neuropathy on patients’ QOL. The 35 scored questions are numbered items that 
comprise the entire (total) scale, or TQOL, to yield a score of –2 to 138. Each item is 
attributed to 1 of the following 5 domains: 
 Physical functioning/large-fiber neuropathy. Functions related to large-nerve 
fibers, including motor function, and those sensory functions related to large 
sensory fibers, especially tactile discrimination. 
 Activities of daily living (ADLs). Items associated with the impact of neuropathy 
on routine activities of daily life, related to large-fiber function. 
 Symptoms. An inventory of the common symptoms of neuropathy at each of 4 
body sites (feet, legs, hands, and arms). 
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 Small-fiber neuropathy. Sensory function related to pain and loss of thermal 
sensation. 
 Autonomic nerve function. Neuropathy-related items, including orthostasis, 
gastrointestinal, and genitourinary functions. 
 
The scores across the 5 domains are summed to provide the TQOL score. The Norfolk 
QOL-DN was shown to discriminate the presence of neuropathy and distinguish among 
5 neuropathic disease stages in a population of German patients with diabetic 
polyneuropathy.e1 The Norfolk QOL-DN underwent linguistic validation for each country 
and language. 
 
Summated 7-nerve tests–normal deviates (Σ7 NTs nds) 
The Σ7 NTs nds combines results from 5 nerve conduction studies (sural nerve sensory 
nerve action potential, peroneal nerve compound muscle action potential, peroneal 
nerve motor conduction velocity, peroneal nerve distal motor latency, and tibial distal 
motor latency) with vibration detection threshold (VDT) of the hallux, and heart rate 
response to deep breathing (HRDB) at 6 breaths/minute. The components of the Σ7 
NTs nds are primarily measures of large-fiber function. The score ranges from –26 
(extreme normal function) to 26 (extreme abnormal function). HRDB is a sensitive 
measure of parasympathetic cardiac control, and normative values by age have been 
determined.  
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Summated 3-nerve tests–small-fiber normal deviates (Σ3 NTSF nds)  
The Σ3 NTSF nds includes 3 assessments of small-fiber function: cooling detection 
threshold (CDT), heat/pain detection threshold (HPDT), and HRDB. All were assessed 
using the Computer Aided Sensory Evaluator V4, a computerized test of sensory 
threshold determination. The thermal sensations of cooling and heat pain assess small 
myelinated and unmyelinated sensory nerve function. The score ranges from –11.2 
(extreme normal function) to 11.2 (extreme abnormal function). 
 
Modified body mass index (mBMI) 
mBMI is obtained by multiplying the BMI (weight [kg]/height2 [m2]) by serum albumin 
concentration (g/L). As an endpoint, mBMI may be more reflective of nutritional status 
than BMI because it corrects for the effect of edema due to low serum albumin level on 
BMI.e2 
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Table e-1. Patient demographics and baseline data 
Characteristic 
 
Tafamidis 
(n = 64) 
Placebo 
(n = 61) 
Men, n (%) 32 (50) 26 (43) 
Age, yr   
Mean ± SD 39.8 ± 12.7 38.4 ± 12.9 
Race/ethnicity, n (%)   
Caucasian 56 (88) 54 (89) 
Latino 6 (9) 6 (10) 
Other 2 (3) 1 (2) 
mBMI (BMI × serum 
albumin) 
  
Mean ± SD 1004.6 ± 165.20 1011.5 ± 212.92 
Median 974.7 983.8 
25th, 75th percentile 867.2, 1155.1 896.4, 1094.7 
Disease duration, mo   
Mean ± SD 47.0 ± 48.40 34.7 ± 32.88 
Median 28.0 21.0 
25th, 75th percentile 13.8, 41.7 13.5, 72.2 
NIS-LL (range, 0–88)   
Mean ± SD 8.4 ± 11.40 11.4 ± 13.54 
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Median 4.0 6.0 
25th, 75th percentile 0.0, 13.0 2.0, 9.3 
Norfolk QOL-DN (TQOL) 
(range, –2 to 138) 
  
Mean ± SD 27.3 ± 24.17 30.8 ± 26.7 
Median 19.0 22.0 
25th, 75th percentile 11.0, 40.0 10.0, 43.5 
Σ7 NTs nds (large-fiber 
range, –26 to 26) 
  
Mean ± SD 7.8 ± 9.1 8.7 ± 8.5 
Median 7.4 9.7 
25th, 75th percentile 1.0, 15.0 1.0, 15.0 
Σ3 NTSF nds (small-fiber 
range, –11.2 to 11.2) 
  
Mean ± SD 5.5 ± 4.5 5.6 ± 4.1 
Median 4.8 5.0 
25th, 75th percentile 1.8, 11.2 2.0, 9.1 
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Table e-2. Most common AEs.* 
Event 
 
Tafamidis  
(n = 65) 
Placebo  
(n = 63) 
Subjects, n (%) 
Subjects with ≥1 AE 60 (92.3) 61 (96.8) 
Diarrhea 17 (26.2) 11 (17.5) 
Urinary tract infection 15 (23.1) 8 (12.7) 
Pain in extremity 11 (16.9) 6 (9.5) 
Influenza 10 (15.4) 9 (14.3) 
Headache 10 (15.4) 12 (19.0) 
Nasopharyngitis 9 (13.8) 8 (12.7) 
Upper abdominal pain  8 (12.3) 2 (3.2) 
Nausea 8 (12.3) 8 (12.7) 
Vomiting 7 (10.8) 8 (12.7) 
Lacrimation decreased 6 (9.2) 7 (11.1) 
Myalgia 5 (7.7) 2 (3.2) 
Punctate keratitis 5 (7.7) 3 (4.8) 
Back pain 5 (7.7) 4 (6.3) 
Vaginal infection 4 (6.2) 1 (1.6) 
Peripheral edema 4 (6.2) 8 (12.7) 
Constipation 4 (6.2) 7 (11.1) 
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Pharyngitis 4 (6.2) 5 (7.9) 
Upper respiratory tract infection 4 (6.2) 3 (4.8) 
Thermal burn 4 (6.2) 5 (7.9) 
Anxiety 4 (6.2) 3 (4.8) 
Depression 4 (6.2) 3 (4.8) 
Erectile dysfunction 4 (6.2) 4 (6.3) 
Paresthesia 3 (4.6) 10 (15.9) 
Abdominal pain 3 (4.6) 5 (7.9) 
Weight decreased 3 (4.6) 5 (7.9) 
Vertigo 3 (4.6) 4 (6.3) 
Neuralgia 2 (3.1) 12 (19.0) 
Pharyngolaryngeal pain 2 (3.1) 7 (11.1) 
Muscle spasms 2 (3.1) 7 (11.1) 
AV block, first degree 2 (3.1) 6 (9.5) 
Dizziness 2 (3.1) 4 (6.3) 
Hypoesthesia 1 (1.5) 4 (6.3) 
Fatigue 0 (0.0) 6 (9.5) 
Anemia 0 (0.0) 5 (7.9) 
 
*Reported by >5% of subjects in either treatment group. 
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Figure e-1. Patient disposition and analysis populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AE = adverse event; I/E = inclusion/exclusion criteria; ITT = intent-to-treat;                 
VDT = vibration detection threshold. 
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Abstract Tafamidis, a transthyretin (TTR) kinetic stabi-
lizer, delayed neuropathic progression in patients with
Val30Met TTR familial amyloid polyneuropathy (TTR-
FAP) in an 18-month randomized controlled trial (study
Fx-005). This 12-month, open-label extension study eval-
uated the long-term safety, tolerability, and efficacy of
tafamidis 20 mg once daily in 86 patients who earlier
received blinded treatment with tafamidis or placebo.
Efficacy measures included the Neuropathy Impairment
Score in the Lower Limbs (NIS-LL), Norfolk Quality of
Life-Diabetic Neuropathy total quality of life (TQOL)
score, and changes in neurologic function and nutritional
status. We quantified the monthly rates of change in effi-
cacy measures, and TTR stabilization, and monitored
adverse events (AEs). Patients who continued on tafamidis
had stable rates of change in NIS-LL (from 0.08 to 0.11/
month; p = 0.60) and TQOL (from -0.03 to 0.25;
p = 0.16). In patients switched from placebo, the monthly
rate of change in NIS-LL declined (from 0.34 to 0.16/
month; p = 0.01), as did TQOL score (from 0.61 to -0.16;
p \ 0.001). Patients treated with tafamidis for 30 months
had 55.9 % greater preservation of neurologic function as
measured by the NIS-LL than patients in whom tafamidis
was initiated later. Plasma TTR was stabilized in 94.1 % of
patients treated with tafamidis for 30 months. AEs were
similar between groups; no patients discontinued because
of an AE. Long-term tafamidis was well tolerated, with the
reduced rate of neurologic deterioration sustained over
30 months. Tafamidis also slowed neurologic impairment
in patients previously given placebo, but treatment benefits
were greater when tafamidis was begun earlier.
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Introduction
Transthyretin familial amyloid polyneuropathy (TTR-FAP)
is an autosomal dominant disorder caused by TTR gene
mutations that destabilize the tetrameric transthyretin
(TTR) protein, leading to tetramer dissociation, monomer
misfolding, and aggregation [1, 2]. TTR is a plasma protein
produced mainly by the liver that functions as a backup
transporter for thyroxine and as the primary transporter of
the retinol-binding protein/vitamin A complex [3, 4]. The
dissociation of the TTR tetramer into its monomeric sub-
units is believed to be the rate-limiting step in amyloido-
genesis [5]. Subsequent monomer misfolding and
misassembly leads to efficient TTR aggregation, including
amyloid fibril formation. Evidence suggests that TTR
amyloidogenesis causes axonal degeneration, leading to
progressive sensorimotor and autonomic neuropathy [2, 6].
The length-dependent axonal degeneration initially
involves the unmyelinated and small myelinated nerve
fibers that mediate pain and temperature sensation, causing
sensory disturbances that typically start in the lower
extremities. Concomitantly, autonomic dysfunction
affecting the gastrointestinal, urogenital, and cardiovascu-
lar systems, and subsequent degeneration of larger mye-
linated fibers results in further sensory deficits and muscle
weakness [7, 8]. The gastrointestinal complications ulti-
mately lead to malabsorption, extreme malnutrition, and
substantial weight loss, with death often occurring within a
decade of symptom onset [7–9].
Liver transplant is the current standard of care for
patients with TTR-FAP, replacing the mutated TTR gene
producing the majority of circulating transthyretin with a
wild-type gene found in a genetically normal donor organ
[10]. Although liver transplant has been shown to slow
disease progression [11, 12] and prolong survival [13–15],
it is associated with a first-year mortality of &10 % and
substantial morbidity due to chronic immunosuppression
[13, 15, 16]. Furthermore, due to continuing tetramer dis-
sociation, monomer misfolding and misassembly of wild-
type TTR into oligomers and amyloid, and the extrahepatic
production of mutated TTR, transplant does not prevent
clinical deterioration (in particular, heart and ocular com-
plications) in all recipients [17–21]. This underscores the
need for new treatment approaches.
TTR kinetic stabilizers offer a promising approach, in
which small-molecule binding to the unoccupied thyrox-
ine-binding sites on TTR stabilizes the protein in its native
tetrameric state, thereby markedly slowing tetramer
dissociation and, consequently, amyloidogenesis [10, 22].
Tafamidis is a small molecule that binds selectively to TTR
in human blood and slows TTR fibril formation in vitro
[23, 24]. The compound binds with negative cooperativity
to at least one of the two thyroxine-binding sites on TTR to
kinetically stabilize the tetramer.
The safety and efficacy of oral tafamidis, 20 mg once
daily, in patients with TTR-FAP was evaluated in an
18-month, multicenter, randomized, double-blind, pla-
cebo-controlled trial (study Fx-005) [25]. The co-primary
efficacy endpoints were the Neuropathy Impairment Score
in the Lower Limbs (NIS-LL) response (\2-point change
from baseline at month 18) and change from baseline to
month 18 in the Norfolk Quality of Life-Diabetic Neu-
ropathy Total Quality of Life (TQOL) score. Multiple
outcome measures were used to evaluate the efficacy of
tafamidis on neurologic progression, nutritional status,
and QOL. There was a higher than anticipated liver
transplant dropout rate, and statistically significant dif-
ferences between the tafamidis and placebo groups were
not observed in the primary analysis in the intent-to-treat
(ITT) population for both co-primary endpoints. However,
in a predefined secondary analysis, where the primary
analysis of the NIS-LL response rates was repeated using
the per-protocol (efficacy evaluable) population that
excluded liver transplant patients, significantly more ta-
famidis-treated patients were NIS-LL responders com-
pared with placebo recipients (60.0 vs. 38.1 %; p = 0.04).
Additionally, the tafamidis-treated patients had better
preserved QOL. As several secondary outcomes also
demonstrated a significant reduction in the worsening of
peripheral neurologic impairment with tafamidis, the
totality of the evidence supported the hypothesis that
preventing TTR dissociation can delay peripheral neuro-
logic impairment in TTR-FAP [25].
The main objectives of the extension study (study
Fx-006) were to evaluate the long-term safety and tolera-
bility of tafamidis and to assess the long-term effects on
disease progression with tafamidis.
Methods
Patients
Men and women who had TTR-FAP with the Val30Met
mutation and completed the month 18 visit of study Fx-005
were eligible. Key exclusion criteria were the presence of
liver function test abnormalities considered by the inves-
tigator to be due to reduced liver function or active liver
disease and the chronic use of non-protocol-approved non-
steroidal anti-inflammatory drugs. Female patients who
were pregnant or breastfeeding were also ineligible.
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Study protocol
This extension study was an open-label, multicenter,
international, single-arm trial, in which all patients
received oral tafamidis 20 mg once daily for 12 months.
This study, in combination with the previous double-blind
study, represents a delayed treatment type of design.
Patients randomized to placebo in study Fx-005 were
switched to tafamidis and constituted the ‘placebo–tafam-
idis’ group, whereas patients randomized to tafamidis ini-
tially continued to receive the active drug and constituted
the ‘tafamidis–tafamidis’ group. Although the patients and
investigators were aware that all patients were receiving
tafamidis during the extension study, they remained blin-
ded to the treatment assignment in study Fx-005. The
values obtained in the procedures and evaluations con-
ducted at the month 18 visit of study Fx-005 served as the
baseline for this extension study. It was intended that study
medication would not be interrupted between the two
studies. However, three sites experienced an extended
interval between the end of study Fx-005 and initiation of
the extension study because of delays in regulatory
approval. As a result, 14 patients (6 in the tafamidis–
tafamidis group and 8 in the placebo–tafamidis group) had
their treatment interrupted for more than 2 months. For
these patients, who were not included in the ITT popula-
tion, new baseline assessments were conducted at enroll-
ment into the extension study.
All patients self-administered a once-daily dose of
tafamidis 20 mg for 12 months. The active drug was sup-
plied in soft-gelatin capsules filled with a suspension
containing 20 mg of tafamidis meglumine.
Clinic visits were scheduled at week 6 and months 3, 6,
and 12. Efficacy measures were performed at months 6 and
12, and vital signs were assessed, electrocardiography was
performed, clinical laboratory evaluations were made, and
adverse events (AEs) were recorded at each visit. Tele-
phone calls to enquire about any change in each patient’s
health status, AEs, and concomitant medications were
made during the months in which no clinic visits were
scheduled and at 30 days after the last dose of the study
medication.
This study (ClinicalTrials.gov NCT00791492) was
approved by the Independent Ethics Committee at each
site. All patients provided written informed consent.
Efficacy measures
Efficacy measures and the rationale for their use in eval-
uating patients with TTR-FAP have been described previ-
ously [25]. In addition to the safety and tolerability
analyses performed to address the protocol-specified
objectives, statistical analyses were also performed on the
efficacy data from this extension study (Fx-006). The
details of these efficacy analyses were outlined in the sta-
tistical analysis plan for this protocol.
The NIS-LL, which quantifies the neurologic examina-
tion of the lower limbs [26], ranges from 0 (normal) to 88
(total impairment) and is obtained by adding subscale
scores in each lower limb for muscle weakness, reflexes,
and sensation. The NIS-LL was assessed twice at each
visit, separated by at least 24 h and within 1 week, with the
results reported as the average of the two tests. Clinical/
neurophysiologic composite endpoints (NIS-LL ? R3 and
NISLL ? R7) were calculated after data availability.
The Norfolk Quality of Life-Diabetic Neuropathy
questionnaire is a 35-item, patient-reported questionnaire
that comprises domains for physical functioning/large-fiber
neuropathy, symptoms, activities of daily life, small-fiber
neuropathy, and autonomic neuropathy [27]. The TQOL
score, representing the sum of the five domain subscores,
ranges from -2 (best possible QOL) to 138 (worst possible
QOL).
Large- and small-fiber function were assessed using
composite scores obtained by summing multiple measures
of nerve fiber impairment, including the results of five
nerve conduction studies [NCSs] (sural nerve sensory
nerve action potential, peroneal nerve compound muscle
action potential, peroneal nerve motor conduction velocity,
peroneal nerve distal motor latency, and tibial nerve distal
motor latency), three measures of sensory detection
thresholds (vibration detection threshold at the hallux and
cooling detection threshold, and heat/pain detection
threshold at the dorsum of the foot) obtained using quan-
titative sensory testing (QST) with the Computer Aided
Sensory Evaluator (version 4; CASE IV), and the heart rate
response to deep breathing (HRDB) at six breaths/min. The
summated seven nerve tests normal deviate score (R7 NTs
nds), which measures primarily large-fiber function, com-
bines the results of the five NCSs with the vibration
detection threshold of the hallux and HRDB, and is scored
from -26 to 26, with a higher score demonstrating more
impaired nerve function. The summated three nerve tests
(small fiber) normal deviate score (R3 NTSF nds), which
measures small-fiber function, comprises cooling detection
threshold, heat/pain detection threshold, and HRDB and is
scored from -11.2 to 11.2, with a higher score demon-
strating more impaired nerve function. For statistical
analyses, individual test data were expressed as normal
deviates based on healthy subject cohort data from the
Mayo Clinic, Rochester, MN, USA.
Modified body mass index (mBMI) is calculated by
multiplying BMI (kg/m2) by serum albumin concentration
(g/L) to compensate for the edema that may be caused by
malnutrition associated with gastrointestinal dysfunction.
The mBMI was found to correlate better with survival than
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the standard BMI measure in TTR-FAP patients who had
not undergone liver transplant [28].
The stability of the TTR tetramer was analyzed using a
validated immunoturbidimetric assay performed on
patients’ plasma samples [24, 29].
Safety and tolerability assessments
Safety and tolerability were assessed by monitoring treat-
ment-emergent AEs (AEs that started or worsened between
the start of study treatment and 30 days after the last dose).
In addition, physical examinations, 12-lead electrocardio-
gram, laboratory tests, and recording of vital signs were
performed at each clinic visit, and Holter monitoring,
echocardiography, and eye examinations with fundal pho-
tography were conducted at the 6- and 12-month visits.
Statistical analyses
Efficacy analyses were conducted in the ITT population,
which included all patients who received at least one dose
of study medication and had an interruption of B2 months
between study Fx-005 and the extension study. As enroll-
ment was constrained by the number of patients who
completed study Fx-005 and elected to continue their
participation, the sample size in the extension study was
not based on formal sample size calculations and the study
was not powered specifically for the evaluation of the
efficacy measures. To assess efficacy in the extension
study, three main hypotheses were proposed in the statis-
tical analysis plan; (i) to determine whether the treatment
effect of tafamidis in slowing disease progression over
18 months could be sustained for an additional 12 months
(comprising a total of 30 months), we compared the
monthly rate of change of the various outcome measures
during the extension study (i.e., the last 12 months of
treatment) with the monthly rate of change during the first
18 months (i.e., in study Fx-005) in the tafamidis–tafami-
dis group; (ii) to evaluate the efficacy of tafamidis in
slowing disease progression in patients previously given
placebo, we compared the monthly rates of change in the
outcome measures during the extension study (tafamidis
treatment) and study Fx-005 (placebo) in the placebo–ta-
famidis group; (iii) to assess whether earlier initiation of
treatment resulted in better outcomes, we compared the
changes in each efficacy measure from the baseline of the
double-blind study (Fx-005) with month 12 of the exten-
sion study in the tafamidis–tafamidis group and the pla-
cebo–tafamidis group.
A mixed-model analysis of variance was used to assess
the sustainability of the treatment effect, and the efficacy of
tafamidis in slowing disease progression in patients
previously given placebo, with the measurement at differ-
ent visits as the dependent variable, and the study-by-
treatment interaction and the time-by-study-by-treatment
interaction as independent variables. The intercept and
time variables were modeled as random effects. The test of
treatment effect was based on the time-by-study-by-treat-
ment interaction. If each patient underwent the same
number of observations, the model would be equivalent to
a 2-stage analysis, in which the slope of each patient’s
efficacy measure is determined by linear regression for Fx-
005 and Fx-006 separately and the slopes within treatment
groups are compared between the studies using a paired
t test. To evaluate the early-start treatment effects, the
changes from the pretreatment baseline of study Fx-005 to
the end of the extension study by treatment sequence were
compared using the Wilcoxon rank sum test. Muscle
weakness at the individual joint locations (toe, ankle, knee,
and hip) was also evaluated for early-start treatment effect.
Safety analyses were performed on all patients who
received at least one dose of the study medication (i.e., the
safety population).
Results
Patients
Ninety-one patients completed the month 18 visit in study
Fx-005, and 86 patients (94.5 %) enrolled in the extension
study, which ran between July 2008 and October 2010. Of
the five patients who decided not to participate in the
extension study, two cited liver transplantation, two preg-
nancy, and one refused regular clinic visits. All but one of
the enrolled patients received tafamidis; therefore, the
safety population consisted of 85 patients. Fourteen
patients (16.3 %) had treatment interrupted for [2 months
between studies and were excluded from the ITT popula-
tion (Fig. 1). Of the 71 patients in the ITT population, five
(5.8 %) discontinued treatment to undergo liver transplant,
and three (3.5 %) discontinued after withdrawing consent.
In total, 63 patients (88.7 %) in the ITT population and all
14 patients who had treatment interruption [2 months
between the two studies completed the extension.
The demographic characteristics of patients in the
tafamidis–tafamidis and placebo–tafamidis groups at the
baseline of the extension study were similar (Table 1). The
patients who had received placebo in study Fx-005 [25]
demonstrated greater disease severity at the start of the
open-label extension than the patients who had been treated
with tafamidis (Table 1). Of relevance to the use of mBMI
as an outcome measure, 6 of 85 patients (7.1 %) had a
medical history of peripheral edema.
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Sustainability of the treatment effect of tafamidis
on disease progression
In the tafamidis–tafamidis group (n = 38) there were no
statistically significant differences in the monthly rate of
change in measures of neurologic function (NIS-LL, large-
fiber function, and small-fiber function) or TQOL between
the last 12 months and first 18 months of tafamidis admin-
istration (Fig. 2a–d). Similarly, monthly rates of change in
clinical/neurophysiological endpoints NIS-LL ? R3
(p = 0.56) and NIS-LL ? R7 (p = 0.69) were stable over
the same period. Following an increase in mBMI during the
randomized trial, the monthly rate of change dropped in the
tafamidis–tafamidis population after entry into the extension
study (Fig. 2e). The reason for this observation is not known
but it is not expected or desirable for patients to continu-
ously increase their weight. Importantly, mBMI levels
remained higher than those observed prior to treatment.
Taken together, these results indicate that the treatment
effect of tafamidis was sustained over 30 months.
Efficacy of tafamidis in patients previously given
placebo
The efficacy of tafamidis in patients previously given
placebo was assessed by comparing the rate of disease
progression (as measured by the monthly rate of change or
slope) for each endpoint during the last 12 months of
treatment (study Fx-006) with the first 18 months of
treatment (study Fx-005) in the placebo–tafamidis group
(Fig. 3). To place these results into perspective, the rate of
disease progression in the 64 patients who received ta-
famidis in the ITT group in study Fx-005 is also displayed
for each endpoint in Fig. 3.
In the placebo-tafamidis group there was a significant
reduction in the rate of neurologic deterioration following
the initiation of tafamidis in the extension study, as quanti-
fied by the NIS-LL (monthly rate of change, study Fx-005:
Study Fx-005
Randomized: N=128
Tafamidis (n=65)
Completed: n=47
18-Month
Double-blind
Study (Fx-005)
12-Month
Extension Study
(Fx-006)
Placebo (n=63)
Completed: n=44
Tafamidis-tafamidis
Enrolled: n=45
Placebo-tafamidis
Enrolled: n=41
Did not receive treatment
(n=1)
Treatment interruption
excluded from ITT
population (n=6)
Treatment interruption
excluded from ITT
population (n=8)
Tafamidis-tafamidis
Enrolled: n=44
Placebo-tafamidis
Enrolled: n=41
Discontinued (n=5)
   Liver transplantation (n=4)
   Withdrew consent (n=1)
ITT population (n=38) ITT population (n=33)
Completed (n=33) Completed (n=30)
Safety population (n=85)
Discontinued (n=3)
   Liver transplantation (n=1)
   Withdrew consent (n=2)
Fig. 1 Patient disposition and analysis populations
Table 1 Baseline demographic and disease characteristics (intent-to-treat population)
Tafamidis–tafamidis (n = 38) Placebo–tafamidis (n = 33) p-Valuea
Age [year, median (range)] 37.5 (26, 76) 36.0 (24, 73) 0.537
Females [n (%)] 21 (55.3) 18 (54.5) 1.000
Race/ethnicity [n (%)]
Caucasian 37 (97) 33 (100)
Not available 1 (3) 0 (0) 1.000
Symptom duration [mo, median (range)] 35.6 (21, 287) 36.8 (20, 152) 0.917
NIS-LL [median (range)] 5.3 (0, 65) 10.0 (0, 75) 0.015
TQOL [median (range)] 11 (-1, 97) 28 (-1, 96) 0.020
R7 NTs nds [median (range)] 5.0 (-6.6, 25.3) 10.8 (-7.3, 25.1) 0.185
R3 NTSF nds [median (range)] 4.2 (-2.5, 11.2) 7.4 (-2.1, 11.2) 0.020
mBMIb [median (range)] 1,038.1 (780.1, 1,473.7) 945.7 (567.5, 1,583.8) 0.080
a p-Values comparing the tafamidis–tafamidis and placebo–tafamidis groups are based on Wilcoxon’s rank sum test
b Calculated as BMI (kg/m2) 9 serum albumin (g/L)
R7 NTs nds summated 7 nerve tests normal deviate score, R3 NTSF nds summated 3 nerve tests (small fiber) normal deviate score, mBMI
modified body mass index, NIS-LL Neuropathy Impairment Score in the Lower Limbs, TQOL total quality of life
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0.34; extension study: 0.16; p = 0.01; Fig. 3a). The deteri-
oration in TQOL seen in those patients (monthly rate of
change: 0.61) was arrested by tafamidis during the extension
study (monthly rate of change: -0.16; p \ 0.001; Fig. 3d).
Additionally, there was a positive rate of change in mBMI
with tafamidis treatment (monthly rate of change: 5.19), in
contrast to the decline observed in study Fx-005 (monthly
rate of change: -1.77; p \ 0.0001; Fig. 3e).
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Fig. 2 Sustainability of the treatment effect, as measured by the
mean rate of change per month for each efficacy measure in the
tafamidis–tafamidis ITT population. a NIS-LL. b R7 NTs nds score.
c R3 NTSF nds. d TQOL. e mBMI. For comparison, the 30-month
rate of change from Fx-005 baseline for the tafamidis–tafamidis
group (n = 38) is also displayed for each endpoint. R7 NTs nds
summated 7 nerve tests normal deviate score, R3 NTSF nds summated
3 nerve tests (small fiber) normal deviate score, mBMI modified body
mass index, NIS-LL Neuropathy Impairment Score in the Lower
Limbs, TQOL total quality of life
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Long-term effects of tafamidis on disease progression
To assess the effects of tafamidis on disease progression
over a period of 30 months, the changes from study Fx-005
baseline in efficacy measures at 6, 12, 18, 24, and
30 months in each treatment group were examined (Fig. 4).
Compared with patients originally given placebo, neuro-
logic function (NIS-LL, NIS-LL muscle weakness, large-
and small-fiber function) in the tafamidis–tafamidis
patients remained relatively stable, and pre-treatment
TQOL and mBMI were preserved.
Early-start treatment effect
Patients who received early treatment with tafamidis (i.e.,
the tafamidis–tafamidis group) had less neurologic
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Fig. 3 Efficacy of tafamidis in slowing disease progression in 33
patients from study Fx-006 previously given placebo in study Fx-005,
as measured by the mean rate of change per month for each efficacy
measure in the placebo-tafamidis ITT population. a NIS-LL. b R7
NTs nds score. c R3 NTSF nds. d Norfolk TQOL. e mBMI. For
comparison, rate of disease progression in 64 patients treated with
tafamidis in study Fx-005 is also displayed for each endpoint. R7 NTs
nds summated 7 nerve tests normal deviate score, R3 NTSF nds
summated 3 nerve tests (small fiber) normal deviate score, mBMI
modified body mass index, NIS-LL Neuropathy Impairment Score in
the Lower Limbs, TQOL total quality of life
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Fig. 4 Effect of tafamidis on disease progression over 30 months as
measured by the mean change from study Fx-005 baseline in efficacy
measures in the ITT population. a NIS-LL. b NIS-LL muscle
weakness subscale. c R7 NTs nds. d R3 NTSF nds. e TQOL. f mBMI.
R7 NTs nds summated 7 nerve tests normal deviate score, R3 NTSF
nds summated 3 nerve tests (small fiber) normal deviate score, mBMI
modified body mass index, NIS-LL Neuropathy Impairment Score in
the Lower Limbs, TQOL total quality of life
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deterioration than the patients who began tafamidis
18 months later (i.e., the placebo–tafamidis group) [Fig. 5],
suggesting that early initiation of tafamidis treatment has
long-term beneficial effects on neurological disease pro-
gression. Thus, there were significant treatment group dif-
ferences in the mean change from study Fx-005 baseline at
30 months for NIS-LL (3.0 vs. 6.8 points; Wilcoxon’s rank
sum test p = 0.04) and for R7 NTs nds (1.6 vs. 4.7; Wil-
coxon’s rank sum test p \ 0.01) [Fig. 5]. There was no
statistically significant difference between treatment groups
for the mean change from study Fx-005 baseline at
30 months for TQOL and mBMI. The lack of a significant
difference in the mBMI may be primarily due to the
worsening in the placebo group in study Fx-005 being
reversed following delayed initiation of tafamidis
treatment.
TTR stabilization
At month 12 of the extension study, TTR stabilization was
demonstrated in 94.1 % of patients in the tafamidis–
tafamidis group and 93.3 % of patients in the placebo–
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Fig. 5 Early-start treatment effect (tafamidis–tafamidis group) vs.
late-start treatment effect (placebo–tafamidis group) as measured by
the mean (±SEM) change from baseline at 30 months in efficacy
measures in the ITT population. a NIS-LL and muscle weakness
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tafamidis group. The results at month 12 were similar to
those at week 6 (94.6 and 96.8 %, respectively), which
suggests that tolerance did not develop to the TTR-stabi-
lizing effects of tafamidis.
Long-term safety and tolerability of tafamidis
No new safety or tolerability issues were identified
during the extension study, and the overall incidence of
AEs was similar in both groups (Table 2). The incidence
of serious AEs (SAEs) was also similar in both groups,
with five patients in the tafamidis–tafamidis group hav-
ing a total of nine SAEs and four patients in the pla-
cebo–tafamidis group having a total of 14 SAEs. No
patient reported deterioration in renal function that
required therapeutic measures. No SAEs were life
threatening. No patients died or discontinued treatment
due to an AE.
Discussion
The combination of the double-blind trial (study Fx-005)
and the present open-label extension study resembles the
design of a delayed-start trial. In such trials, patients are
assigned to either receive study drug for the entire length of
the study (early-start) or to receive placebo in phase I and
study drug in phase II of the trial (delayed-start). This
design has been developed to try to distinguish between
long-term effects on disease progression and symptomatic
effects [30]. With both cohorts receiving drug therapy for
an extended period of time, confounding short-term effects
on disease symptoms may be identified by a persistence of
benefit that may be consistent with disease modification for
the treatment group receiving a longer duration of active
therapy. The delayed start design has been used success-
fully in trials of other neurodegenerative diseases [31–34],
such as ADAGIO, which assessed neuroprotection by ra-
sagiline in Parkinson’s patients [32, 33]. The results of the
current extension study provide support for the efficacy and
safety of tafamidis in the treatment of patients with TTR-
FAP, and demonstrate that treatment benefits are sustained
over 30 months, corresponding to one-fourth of the aver-
age disease duration of 10 years [7, 8]. The sustainability
of the tafamidis treatment effect in delaying neurologic
deterioration was demonstrated using a variety of efficacy
measures, and may account for the observed preservation
of QOL.
The findings of the original double-blind trial and the
present open-label extension study demonstrate that the
tafamidis treatment benefits that were accrued over
18 months could be sustained for an additional 12 months.
The design of these studies (in which only the initial
18 months were placebo-controlled) precludes direct
assessment of the extent to which tafamidis preserved
neurologic function and QOL over 30 months, compared
with placebo.
In addition to deterioration in neurologic function,
weight loss is a characteristic complication of TTR-FAP,
and mBMI has been shown to be a useful indicator of
disease severity [28]. The finding that mBMI was main-
tained at pretreatment values for 30 months in the
Table 2 Adverse event (AE)
profile in the safety population
Event Tafamidis–tafamidis
(n = 44)
Placebo–tafamidis
(n = 41)
Summary of AEs [n (%)]
Patients with C1 AE 37 (84.1) 40 (97.6)
Patients with C1 treatment-emergent SAE 5 (11.4) 4 (9.8)
Patients who discontinued due to a TEAE 0 (0) 0 (0)
Most common (C5 % incidence overall) treatment-emergent AEs [n (%)]
Urinary tract infection 5 (11.4) 7 (17.1)
Influenza 3 (6.8) 7 (17.1)
Thermal burn 4 (9.1) 4 (9.8)
Headache 2 (4.5) 6 (14.6)
Nasopharyngitis 5 (11.4) 3 (7.3)
Vomiting 3 (6.8) 4 (9.8)
Diarrhea 4 (9.1) 3 (7.3)
Punctate keratitis 3 (6.8) 3 (7.3)
Anxiety 1 (2.3) 5 (12.2)
Upper respiratory tract infection 2 (4.5) 3 (7.3)
Dry eye 2 (4.5) 3 (7.3)
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tafamidis–tafamidis patients provides further support for
the long-term efficacy of tafamidis in delaying disease
progression.
The extension study also provided the opportunity to
evaluate tafamidis in the group of treatment-naı¨ve patients
who were randomized to receive placebo in study Fx-005.
During study Fx-005, this group had greater disease pro-
gression than the group randomized to tafamidis, and
demonstrated worse neurologic function at the time of
tafamidis initiation in the extension trial. Nevertheless,
even the delayed introduction of tafamidis significantly
slowed the rates of change in NIS-LL, Norfolk TQOL, and
mBMI compared with placebo [25]. Interestingly, while
TTR stabilization is evident at week 6, there was a delay in
the onset of the stabilizing effect of tafamidis on the rate of
deterioration in NIS-LL and large nerve fiber function in
the placebo–tafamidis cohort. The underlying reason for
this delay is unknown, but the more severe disease stage at
the start of the treatment of placebo-tafamidis patients is a
conceivable explanation.
The mechanism of action of tafamidis in kinetically
stabilizing TTR and thereby preventing tetramer dissocia-
tion leading to amyloidogenesis should be expected to slow
disease progression rather than just provide symptomatic
benefit. This is based on the observation of T119M inter-
allelic kinetic stabilization of the TTR tetramer, which
inhibits onset and progression of Val30Met TTR-FAP [10,
24, 35, 36]. Accordingly, it was hypothesized that starting
tafamidis earlier in the course of the disease would provide
long-lasting effects on neurologic function and QOL. This
hypothesis was tested by comparing the various efficacy
endpoints between the tafamidis–tafamidis and placebo–
tafamidis groups from the study Fx-005 baseline to the
extension study month-12 assessment. Patients who started
tafamidis treatment earlier had less neurologic impairment
and large-fiber dysfunction compared with patients who
started tafamidis 18 months later. Although the difference
was not statistically significant, patients who began ta-
famidis 18 months earlier had numerically lower TQOL
scores, indicating a relative preservation of QOL compared
with patients who started later. As improvements in
nutritional status have been demonstrated in patients with
TTR-FAP who undergo liver transplant [37], the finding
that the deterioration in mBMI in patients who received
placebo could be reversed following 12 months of treat-
ment with tafamidis is noteworthy.
Tafamidis was safe and well tolerated during long-term
treatment, with no apparent differences in AEs reported
between the tafamidis–tafamidis and placebo–tafamidis
groups. The type and incidence of AEs were consistent
with those expected in patients with TTR-FAP, with most
reported as mild or moderate in intensity and none resulting
in treatment discontinuation or death. These findings
confirm the safety of tafamidis that was demonstrated
during the 18 months of treatment in study Fx-005 [25].
It is important to acknowledge several limitations of the
present study. First, it was intended that patients who
completed study Fx-005 would continue treatment without
interruption at entry into the extension study. However,
delays in regulatory approval led to treatment interruption in
patients enrolled at three sites. Removal from the ITT
population of 14 patients who had treatment interruptions of
[2 months (due to the inability to assess a sustained treat-
ment effect) resulted in a reduced sample size for evaluating
the tafamidis treatment benefit. Treatment was interrupted in
six patients in the tafamidis–tafamidis group and eight
patients in the placebo–tafamidis group; all completed the
12-month extension study. Second, the open-label design of
the extension study introduced bias into the study assess-
ments, in that all patients received active drug and were
expected to show at least some benefit. This may have
influenced the assessments of the sustainability of the
tafamidis treatment effect and the efficacy of tafamidis in
slowing disease progression in patients previously given
placebo. However, as the treatment assignment of study
Fx-005 remained under double-blind conditions during the
conduct of study Fx-006, with investigators and patients
unable to distinguish between the tafamidis–tafamidis and
placebo–tafamidis groups, the open-label design would not
be expected to influence the evaluation of early-start versus
delayed-start treatment benefit. Longer-term data are
expected from an open-label extension study
(NCT00925002) that enrolled patients from the current trial
and patients who completed a separate 12-month, open-label
trial of tafamidis. In addition, patients will be followed in the
Transthyretin Amyloidosis Outcomes Survey (THAOS), an
observational registry established to improve understanding
of the disease (http://www.thaos.net).
In summary, several conclusions can be drawn from the
results of this extension study. First, tafamidis is safe and
well tolerated over 30 months. Second, the effect of ta-
famidis in slowing neurologic progression and preserving
QOL is sustained over this time. The finding that patients
who started tafamidis early had less neurologic impairment
at 30 months than those who started treatment after an
18-month delay supports the value of the early initiation of
this disease-modifying approach.
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ABSTRACT
Transthyretin (TTR) transports the
retinol-binding protein–vitamin A complex
and is a minor transporter of thyroxine in
blood. Its tetrameric structure undergoes
rate-limiting dissociation and monomer
misfolding, enabling TTR to aggregate or to
become amyloidogenic. Mutations in the TTR
gene generally destabilize the tetramer and/or
accelerate tetramer dissociation, promoting
amyloidogenesis. TTR-related amyloidoses are
rare, fatal, protein-misfolding disorders,
characterized by formation of soluble
aggregates of variable structure and tissue
deposition of amyloid. The TTR amyloidoses
present with a spectrum of manifestations,
encompassing progressive neuropathy and/or
cardiomyopathy. Until recently, the only
accepted treatment to halt progression of
hereditary TTR amyloidosis was liver
transplantation, which replaces the hepatic
source of mutant TTR with the less
amyloidogenic wild-type TTR. Tafamidis
Electronic supplementary material The online
version of this article (doi:10.1007/s40120-016-0040-x)
contains supplementary material, which is available to
authorized users.
T. Coelho (&)
Hospital de Santo Anto´nio, Centro Hospitalar do
Porto, Porto, Portugal
e-mail: tcoelho@netcabo.pt
G. Merlini
Foundation IRCCS Policlinico San Matteo,
University of Pavia, Pavia, Italy
C. E. Bulawa  J. A. Fleming
Pfizer Rare Disease Research Unit, Cambridge, MA,
USA
D. P. Judge
Johns Hopkins University School of Medicine,
Baltimore, MD, USA
J. W. Kelly
The Scripps Research Institute, La Jolla, CA, USA
M. S. Maurer
Columbia University College of Physicians and
Surgeons, New York, NY, USA
V. Plante´-Bordeneuve
CHU Henri Mondor, Cre´teil, France
R. Labaudinie`re
Labaudiniere Consulting LLC, Lewes, DE, USA
R. Mundayat  S. Riley
Pfizer Inc., New York, NY, USA
I. Lombardo
FORUM Pharmaceuticals, Watertown, MA, USA
P. Huertas
Massachusetts General and McLean Hospitals,
Harvard Medical School, Boston, MA, USA
Neurol Ther (2016) 5:1–25
DOI 10.1007/s40120-016-0040-x
meglumine is a rationally designed, non-NSAID
benzoxazole derivative that binds with high
affinity and selectivity to TTR and kinetically
stabilizes the tetramer, slowing monomer
formation, misfolding, and amyloidogenesis.
Tafamidis is the first pharmacotherapy
approved to slow the progression of peripheral
neurologic impairment in TTR familial amyloid
polyneuropathy. Here we describe the
mechanism of action of tafamidis and review
the clinical data, demonstrating that tafamidis
treatment slows neurologic deterioration and
preserves nutritional status, as well as quality of
life in patients with early-stage Val30Met
amyloidosis.
Keywords: Familial amyloid cardiomyopathy;
Familial amyloid polyneuropathy; Hereditary
TTR amyloid cardiomyopathy; Pharmacology;
Senile systemic amyloidosis; Therapeutic use;
Wild-type TTR amyloidosis
INTRODUCTION
The transthyretin (TTR)-related amyloidoses are
rare, fatal protein misfolding and aggregation
disorders. Historically, the TTR amyloidoses
were grouped into three categories: (1)
wild-type TTR amyloidosis (TTRwt), formerly
known as senile systemic amyloidosis,
presenting as a cardiomyopathy and involving
the aggregation of wild-type (WT) TTR; (2)
familial amyloid polyneuropathy (FAP); and
(3) hereditary TTR amyloid cardiomyopathy,
formerly known as familial amyloid
cardiomyopathy (FAC). Both hereditary forms
involve aggregation of primarily mutant TTR.
Current knowledge suggests that the TTR
amyloidoses do not fit neatly into these
categories, as patients often exhibit a spectrum
of phenotypes depending on mutation, genetic
background, and extent of progression.
Non-fibrillar aggregates and amyloid composed
of mutant and/or WT TTR of hepatic origin
accumulate in various tissues and organs,
particularly the peripheral and autonomic
nerves and heart, leading to tissue damage and
end-organ failure [1–3]. TTR gene expression by
the choroid plexus and retinal pigmented
epithelium leads to leptomeningeal and ocular
degeneration linked to TTR amyloidogenesis,
respectively [4].
Tafamidis (2-(3,5-dichloro-phenyl)-benzoxazole-
6-carboxylic acid) is a once-daily, orally
bioavailable, non-NSAID small molecule, and
specific kinetic stabilizer of TTR [5]. In clinical
studies, tafamidis slowed peripheral neurologic
impairment and additional clinical
manifestations in patients with Val30Met
amyloidosis and was associated with an
excellent safety profile [6–8]. Tafamidis is the
first pharmacotherapy approved to treat
TTR-FAP in the European Union and several
countries in Latin America and the Asia-Pacific
including Argentina and Japan.
The aim of this article is to focus on TTR as a
drug target, to provide the rationale used in the
development of tafamidis, and review
comprehensively the pharmacology of this
disease-modifying therapy for TTR
amyloidoses. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
STRUCTURE AND FUNCTIONS
OF TTR
Transthyretin, also known as prealbumin, is a
soluble, b-sheet rich, 127-amino acid,
non-glycosylated protein primarily synthesized
and secreted into the blood by the liver. TTR
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circulates in the blood predominantly as a
55 kDa tetramer, along with a very small
amount of dissociated monomer [6].
The monomeric subunits of TTR fold into a
b-sandwich tertiary structure that
spontaneously assembles into a tetramer
within the cellular endoplasmic reticulum. The
tetramer exhibits two distinct dimer–dimer
interfaces, the less stable of which makes up
two highly conserved thyroxine (T4) binding
sites [9–13]. The three-dimensional structures of
the TTR tetramer bound to T4 and its other
known ligand, the vitamin A–retinol-binding
protein complex, have been solved [14–16].
Transthyretin is expressed from embryonic
development through adult life and its blood
concentration over this time reflects those of
total body nitrogen and total body potassium
levels [17]. Serum TTR concentration so closely
mimics the body’s nitrogen balance that it has
been widely used as a marker of malnutrition
and inflammation in several conditions [17–19].
In fact, TTR is a negative acute phase reactant
[20]. In adult humans, plasma TTR
concentrations range from 3 to 6 lM; the TTR
concentration in cerebrospinal fluid is an order
of magnitude lower (approximately 0.36 lM)
[21–23]. The half-life of TTR in vivo blood is
24–48 h [22, 24, 25].
In blood, the TTR tetramer binds
retinol-binding protein bound to retinol
(holo-retinol-binding protein) and a small
amount of T4, and transports them to tissues on
the minute-to-hour timescale [9, 26, 27].
Although TTR is the only known transporter of
circulating holo-retinol-binding protein that
facilitates retinol transport, two other proteins,
namely, albumin and thyroid binding globulin
transport thyroid hormones. Of the three T4
binding proteins, albumin has by far the highest
plasma concentration and thyroid binding
globulin has the highest affinity for T4 [28, 29].
Thus, given the low level of circulating T4, less
than 10% of T4 in blood is bound to TTR and more
than 99% of the T4 binding sites in circulating
TTR are vacant [21]. Thus, TTR is thought to play
only a minor role in the physiological transport of
T4. In contrast, TTR is the primary T4 carrier in
cerebrospinal fluid [10].
In addition, transthyretin may be a natural
detoxifier, as its T4 binding sites bind small
molecules with substituted aromatic rings
connected by linkers of variable chemical
composition [30]. These structures include
stilbenes, flavones, benzoxazoles,
tetrahydroquinolines, dihydropyridines,
benzodiazepines, and phenoxazines [31, 32].
Emerging evidence suggests that WT TTR may
also have a protective effect in Alzheimer’s
disease through an interaction with the
amyloidogenic Ab-amyloid peptide [30]. TTR
has also been shown to influence nerve
physiology and to enhance nerve regeneration
in the mouse [33]. A role for TTR in nerve
biology and repair may explain the preferential
deposition of mutant TTR aggregates in the
peripheral nervous system of patients with
TTR-FAP [33].
MOLECULAR MECHANISM OF TTR
AMYLOIDOGENESIS
Experiments with cell lines and Drosophila
melanogaster model systems demonstrate the
proteotoxicity associated with various TTR
sequences linked to pathology [3, 34–39].
Biophysical in vitro studies suggest that
tetrameric TTR protein does not form amyloid
fibrils and that amyloidogenesis starts with TTR
tetramer dissociation into dimers, which then
rapidly dissociate to folded monomers (Fig. 1a)
[23, 40–45]. Amyloid fibrillogenesis appears to
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require partial denaturation of released
monomers, which exposes stretches of
hydrophobic residues that misassemble into
spherical aggregates which then undergo
conformational conversion into cross-b sheet
assemblies [46–49]. In vitro, amyloid formation
by TTR monomers proceeds in an energetically
downhill polymerization process that is fast
compared with the initial tetramer dissociation
[50]. Thus, tetramer dissociation is thought to
be rate limiting for TTR amyloid formation in
the case of the WT protein and most tetramers
produced by heterozygotes comprising mutant
and WT TTR subunits [45].
Most amyloidogenic TTR variants form
approximately 6% homotetramers and
approximately 87% variant/WT
heterotetramers with reduced kinetic or
thermodynamic stabilities relative to WT
homotetramers (approximately 6%), which
renders them more prone to tetramer
dissociation and amyloid formation [43, 45].
Oxidative modifications have also been found
to energetically destabilize the tetrameric
structure and to increase the amyloidogenic
potential of TTR protein in vitro [51, 52]. Given
the well-established increase in protein
oxidation with ageing, this may contribute to
senile forms of TTR amyloidosis [52].
Increasing evidence indicates that
proteolytic cleavage may also play a role in
TTR amyloid formation. Analyses of ex vivo TTR
amyloid fibrils have revealed that, in addition to
full-length protein, amyloid deposits in patients
with TTRwt amyloidosis contain a high
proportion of C-terminal TTR fragments
starting at amino acid residues 46, 49, 52, or
53 [53–55]. Similarly, in patients with
hereditary TTR amyloidosis, amyloid fibrils
with N-terminally truncated TTR were
observed more frequently than amyloid fibrils
containing predominantly full-length TTR
protein [55–57]. Based on the small N-terminal
cleavage products detected at very low amounts
in amyloid fibrils, it has been speculated that
proteolytic cleavage may occur prior to and play
a role in fibrillogenesis [53, 54]. A recent study
suggests that, at least for the Ser52Pro
(p.Ser72Pro) variant, proteolytic cleavage of
the Lys48–Thr49 peptide bond may indeed be
a prefibrillar event in vivo which produces a
C-terminal fragment that, once released from
the TTR tetramer, is highly fibrillogenic at
physiological pH in vitro [58].
CLINICAL OVERVIEW OF TTR
AMYLOIDOSES
The hereditary TTR amyloidoses are rare,
autosomal dominant diseases caused by point
mutations in the TTR gene [27, 59–62]. More
than 100 destabilizing mutations of TTR have
been identified [63]. The propensity for a
particular TTR mutant to undergo
amyloidogenesis in vitro depends on the
thermodynamic and kinetic destabilization of
the tetramer caused by the substitution [23, 27,
42–45]. However, the most amyloidogenic TTR
mutants (e.g., Asp18Gly [p.Asp38Gly] and
Ala25Thr [p.Ala45Thr]) do not cause the most
severe, early-onset systemic amyloid disease
because they are degraded by the quality
control system located in the endoplasmic
reticulum of liver cells [27, 45]. Thus, for these
two mutants, the concentration of destabilized
mutant TTR in blood is insufficient to result in
systemic amyloidogenesis; however, late-onset
central nervous system (CNS) pathology is
observed [64, 65].
Although the main pathologic manifestation
of hereditary TTR amyloidosis is a progressive
ascending polyneuropathy and/or
cardiomyopathy, mixed phenotypes, extreme
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phenotypic variability, and incomplete
penetrance often obscure a proper diagnosis
for physicians not considering TTR amyloidosis
[62, 66–69]. As a consequence, hereditary TTR
amyloidosis is under-recognized and often
misdiagnosed.
Most known cases of TTR-FAP result from the
Val30Met (p.Val50Met) mutation, which is
particularly frequent in regions of Portugal,
Japan, Sweden, and Brazil [68, 70].
Importantly, age at onset of symptoms and
disease penetrance of the Val30Met mutation is
very heterogeneous [70–72]. TTR-FAP is
characterized by a length-dependent sensory,
motor, and autonomic neuropathy [68].
Gastrointestinal symptoms are a common
complication of autonomic neuropathy.
Amyloid deposits, typically found in ganglia,
the endoneurium, and nerve blood vessels, lead
to the reduction of nerve fiber density and
eventual destruction of unmyelinated nerve
fibers, and then small and large myelinated
nerve fibers [68, 73]. Distal axonal degeneration
is the main pathogenic feature. Possible
underlying mechanisms that are not mutually
exclusive include: (1) a combination of toxic
and mechanical effects of fibrillar amyloid
deposits on nerve fibers [68, 74]; and/or (2)
the proteotoxicity of non-amyloid TTR
aggregates [2, 3]. Clinical manifestations of
cardiac involvement may follow later in the
course of disease; however, echocardiography in
patients with only neurologic symptoms may
reveal features of cardiac amyloidosis and
electrocardiography can reveal conduction
defects early in the course of the condition
[75, 76]. In some TTR mutants such as Thr60Ala
(p.Thr80Ala), cardiac involvement may be seen
early or as the first phenotypic manifestation
[77], early and frequent carpal tunnel
syndrome, predominant negative sensory
symptoms at onset, significant vibration
deficits, as well as a non-length-dependent
progression of motor deficit are also
characteristic [78]; while for patients with the
Ser77Tyr mutation, the distinguishable features
are late-onset ([50 years) of disease and
frequent ataxic phenotype [79]. Neurologic
and cardiac deterioration progress relentlessly
during active TTR amyloidogenesis, typically
leading to death within 5–15 years of symptom
onset [66]. It is worth noting that for patients
with the Val30Met mutation and whose disease
onset occurs at an older age ([50 years), studies
of the disease history revealed that the initial
manifestation of amyloidosis was somatic
neuropathy, and the mean duration of the
disease onset to death was 7.3 years [76].
However, for many late-onset cases, due to the
inconspicuous nature of the symptoms (i.e.,
autonomic dysfunctions and sensory
dissociation), they are often misdiagnosed as
other neuropathies [75]. In addition, distinctive
clinical presentation has been found in
late-onset cases with the Val30Met mutation
from non-endemic areas that differs from that
of conventional early-onset cases in endemic
foci [79, 80]. Consequently, late-onset cases are
still under-recognized and an appropriate
diagnosis may benefit from examinations for
subclinical cardiac amyloidosis.
In the exclusive or predominant cardiac
phenotype, known as hereditary TTR amyloid
cardiomyopathy, amyloid is found throughout
the cardiovascular system, including the valves,
ventricles, atria, and the conduction system,
leading to left ventricular wall thickening with a
non-dilated left ventricle and impaired
longitudinal contraction, and resulting in
congestive heart failure and arrhythmias [67,
73, 81]. Survival data for hereditary TTR
amyloid cardiomyopathy are not as well
documented as for TTR-FAP, but the prognosis
is known to be poor with median survival from
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diagnosis ranging from 25.6 to 36.4 months in
three small series [82–84], and with death
primarily from heart failure or sudden death
[85]. The most common mutation associated
with TTR amyloid cardiomyopathy is Val122Ile
(p.Val142Ile), which is found in up to 4% of
African Americans [86, 87]. The level of
penetrance of this mutation has yet to be fully
elucidated [87]; 10% of Afro-Caribbean patients
with acute decompensated heart failure carry
the Val122Ile mutation [88]. Other pathogenic
TTR mutations are less prevalent, and often lead
to a more ‘mixed’ phenotype of neurologic and
multi-organ system involvement [67].
In TTRwt amyloidosis, WT TTR tetramers
dissociate into monomers, misfold, and
undergo amyloidogenesis. Biopsies from
gastrointestinal tract and subcutaneous
tissue of TTRwt amyloidosis patients
confirmed amyloid deposits in 44% (4/9) of
the samples [89]. At autopsy, up to 22–25% of
individuals [80 years of age, and 32% of
adults over the age of 75 with heart failure
and a preserved ejection fraction, have
demonstrable TTR amyloid deposits in
cardiac tissue (mainly found inside the
ventricular wall in a patchy plaque-like
shape) albeit usually mild in extent [85, 89,
90]. The process is not well understood but
seems to be related to ageing and possibly to
destabilizing post-translational modifications.
Cardiac amyloidosis is the primary feature of
those exhibiting active TTRwt amyloidosis,
generally a late-onset sporadic condition
Table 1 Clinical PK parameters of tafamidis [100, 101]
PK parameters Values
AUC0-infinity, mean (SD), ng  h/mL 47,864.31 (11,380.38)
AUClast(female), lgh/mL 60.8
AUClast(male), lgh/mL 51.9
Apparent total clearance, mean (SD), L/h 0.44 (0.12)
Cmax, mean (SD), ng/mL 1430.93 (91.0)
Cmax(female), mean, lg/mL 1.12
Cmax(male), mean, lg/mL 1.23
Cmax(SS), lg/mL 2.7
Cmin(SS), lg/mL 1.6
t1/2(single dose), mean (SD), h 53.86 (16.04)
t1/2(SS), h 59
tmax(fasted), median (range), h 1.75 (0.50, 6.00)
tmax(fed), median (range), h 4 (1.50, 12.00)
Vc/F (95% CI), L 0.482 (0.366, 0.598)
Vp/F (95% CI), L 18.9 (17.6, 20.2)
AUC mean area under the concentration–time curve, CI confidence interval, Cmax maximum plasma concentration, Cmin
minimum plasma concentration, PK pharmacokinetic, SD standard deviation, SS steady state, Tmax time to reach Cmax, Vc/F
volume of distribution of the central compartment, Vp/F volume of distribution of the peripheral compartment
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Table 2 Stabilization of transthyretin tetramer mutants by tafamidis in an ex vivo study [105]
Mutation Measurable vehicle (DMSO) FOI values Stabilization demonstrateda
Cys10Arg Yes Yes
Asp18Glu Nob; Retest: Yes Yesc; Retest: Yes
Pro24Ser Yes Equivocald
Ala25Ser Yes Yes
Val30Gly Nob; Retest: Yes Yesc; Retest: Yes
Arg34Ser Yes Yes
Arg34Thr Yes Yes
Lys35Thr Yes Yes
Ala36Pro Yes Yes
Asp38Ala Yes Yes
Trp41Leu Yes Yes
Gly47Glu Yes Yes
Thr49Ala Yes Yes
Ser50Arg Yes Yes
Glu54Gln Yes Yes
Glu54Lys Yes Yes
Leu55Gln Yes Yes
Thr56Lys Yes Yes
Phe64Ser Nob Yesc
Tyr69His Yes Yes
Val71Ala Yes Yes
Tyr78Phe Nob Yesc
Ile84Ser Yes Yes
His88Arg Yes Yes
Glu89Gln (2 patients) Yes Yes
Ala97Ser Yes Yes
Tyr114Cys Yes Yes
DMSO dimethylsulfoxide, FOI fraction of initial
a Percent stabilization C 32%
b DMSO vehicle FOI was zero, therefore percent stabilization could not be determined
c FOI in tafamidis-spiked sample (but not DMSO-spiked sample) was quantifiable, suggesting the sample was indeed
stabilized by tafamidis
d Deemed stabilized but upon retesting, did not cross 32% stabilization threshold (26% stabilization)
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Table 3 Summary of completed clinical trials evaluating tafamidis
Fx-005 [7] Fx-006 [8] Fx1A-201 [106] Fx1B-201 [107]
Study design 18-month, randomized,
placebo-controlled,
double-blind
12-month, open-label
extension of Study Fx-005
12-month, open-label,
non-comparative
12-month, open-label,
non-comparative
Control Placebo None None None
ITT population Tafamidis (T): n = 64
Placebo (P): n = 63
T–T: n = 38
P–T: n = 33
T: n = 21 T: n = 35
TTR genotype Val30Met Val30Met Non-Val30Met, non-Val122Ile
mutant
Val122Ile or wild-type
Main eligibility criteria Documented Val30Met
mutation
Biopsy-confirmed
amyloidosis
Peripheral or autonomic
neuropathy with
Karnofsky
performance status
C50
Completion of the Month
18 visit of Study Fx-005
Biopsy-confirmed amyloidosis
Documented non-Val30Met,
non-Val122Ile TTR mutation
Peripheral and/or autonomic
neuropathy and/or
cardiomyopathy with
Karnofsky performance status
C50
Documented TTR
amyloid
cardiomyopathy
Val122Ile or wild-type
TTR confirmed by
DNA sequencing
NYHA classification
I–II
or
Completion of TRACS
Study [120]
Primary endpoint Treatment group
difference in:
NIS-LL response to
treatment, defined as
\2 point increase in
NIS-LL from baseline
to 18 months
Mean change from
baseline to 18 months
in Norfolk TQOL
score
Safety data on chronic use of
tafamidis
TTR stabilization at week 6 TTR stabilization at
Week 6
Location(s) Argentina, Brazil, France,
Germany, Portugal,
Spain, and Sweden
Argentina, Brazil, France,
Germany, Portugal, Spain,
and Sweden
France, Germany, Italy, and USA USA
Baseline characteristics (in ITT population)
Age, years Median (percentile
range)
T: 35.5 (31 to 44)
P: 34.0 (29 to 47)
Median (range)
T–T: 37.5 (26 to 76)
P–T: 36.0 (24 to 73)
Median (percentile range)
64.3 (56.9 to 70.8)
Median (percentile
range)
76.3 (72.1 to 79.3)
NIS-LL score (scale 0 [normal] to 88
points)
T: mean (SD), 8.4
(11.4); median (range),
4.0 (0 to 54)
P: mean (SD), 11.4
(13.5); median (range),
6.0 (0 to 57)
T–T: mean (SD), 8.4 (13.2);
median (range), 5.3 (0 to
65)
P–T: mean (SD), 17.5
(20.8); median (range),
10.0 (0 to 75)
Mean (SD), 27.6 (24.7)
Median (range), 18.0 (0 to 69.9)
N/A
Norfolk QOL-DN (TQOL, scale –2
[best] to 138 points)
T: mean (SD), 27.3
(24.2); median (range),
19.0 (–1 to 110)
P: mean (SD), 30.8
(26.7); median (range),
22.0 (0 to 107)
T–T: mean (SD), 21.1
(21.9); median (range),
11.0 (–1 to 97)
P–T: mean (SD), 38.1
(31.9); median (range),
28.0 (–1 to 96)
Mean (SD), 47.8 (35.1)
Median (range) 38.0 (5.0 to
104.0)
N/A
Outcomes of interest (in ITT population, if not otherwise indicated)
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primarily affecting men [62]. In two separate
observational studies, the prevalence of
sensory neuropathy among patients with
symptomatic TTRwt amyloidosis was around
28% and nearly half had a history of carpal
tunnel syndrome apparently owing to
amyloid deposition in the connective tissue
of the transverse carpal ligament [69, 84].
Table 3 continued
Fx-005 [7] Fx-006 [8] Fx1A-201 [106] Fx1B-201 [107]
Proportion of patients with TTR
tetramer stabilizationa, % (95% CI)
Week 8
T: 98.4% (95.3 to 100%)
P: 6.7% (0.4 to 13.0%)
T vs. P: p\ 0.0001
Month 18
T: 97.9% (93.9 to 100%)
P: 0.0% (0 to 0%)
T vs. P: p\ 0.0001
Week 6
T–T: 94.6% (81 to 99%)
P–T: 96.8% (83 to 99%)
Month 12
T–T: 94.1% (80 to 99%)
P–T: 93.3% (77 to 99%)
Week 6
94.7% (74.0 to 99.9%)
Month 12
100.0% (80.5 to 100.0%)
Week 6
97.1% (85.1 to 99.9%)
Month 12
87.5% (71.0 to 96.5%)
Effect on polyneuropathy
progression
Proportion of patients
with\2-point increase
from baseline at
Month 18, % (95%
CI)
ITT population
T: 45.3% (33.1 to
57.5%)
P: 29.5% (18.1 to 41.0%)
T vs. P: p = 0.068
Pre-specified EE
population
T: 60.0% (45.7 to
74.3%)
P: 38.1% (23.4 to 52.8%)
T vs. P: p = 0.041
T–T: Proportion of patients
with\2-point increase
from Fx-005 baseline at
Month 12 (30 months),
18/33 (54.5%)
P–T: Proportion of patients
with\2-point increase
from Fx-006 baseline at
Month 12 (12 months),
18/30 (60.0%)
Change from baseline to Month
12
NIS-LL
Mean (SD): 2.7 (6.2)
95% CI: –0.4 to 5.8
Median (range): 1.0 (–10.5 to
11.5)
NIS-UL
Mean (SD): 2.5 (7.4);
95% CI: –1.2 to 6.2
Median (range): 0.5 (–6.0 to
18.0)
N/A
Effect on deterioration in Norfolk
QOL-DN (TQOL)
LS mean change (95%
CI) from baseline at
18 months in TQOL,
points:
ITT population
T: 2.0 (–2.6 to 6.6)
P: 7.2 (2.6 to 11.9)
T vs P: p = 0.116
Pre-specified EE
population
T: 0.1 (–5.8 to 6.0)
P: 8.9 (2.8 to 15.0)
T vs. P: p = 0.045
Monthly rate of change in
TQOL, points/month
(SEM):
T–T (n = 38):
Fx-005, –0.03 (0.15);
Fx-006, 0.25 (0.20)
P–T (n = 33):
Fx-005, 0.61 (0.16);
Fx-006, –0.16 (0.21)
Change from baseline to Month
12 in TQOL, points
Mean (SD): 0.1 (18.0)
95% CI: –8.9 to 9.0
Median (range): 1.0 (–42.0 to
27.0)
N/A
CI confidence interval, EE population efficacy-evaluable population defined as all randomized patients who received C1 dose of study drug, had C1 post-baseline
assessment for both co-primary endpoints, and completed the study per protocol (tafamidis, n = 45; placebo, n = 42), ITT population intent-to-treat population, LS
mean least square mean, NIS-LL neuropathy impairment score-lower limb, NIS-UL neuropathy impairment score-upper limb, percentile range 25th to 75th
percentile, NYHA New York Heart Association, SD standard deviation, SEM standard error of the mean, TQOL self-reported quality of life score (from the Norfolk
Quality of Life-Diabetic Neuropathy questionnaire), TRACS Transthyretin Amyloidosis Cardiac Study, TTR transthyretin
a Percentage stabilization values (post-treatment relative to pre-treatment) falling above the upper 95% CI of mean percent stabilization in placebo-treated healthy
volunteers were considered to be ‘‘stabilized’’
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RATIONALE FOR DEVELOPMENT
OF TAFAMIDIS
Three separate but reinforcing clinical
observations suggested that molecules
stabilizing the TTR tetramer may be effective
in treating the TTR amyloidoses. First, in 1990,
Holmgren et al. [91] showed that it was possible
to halt the progression of polyneuropathy in
patients with TTR-FAP by orthotopic liver
transplantation using donors carrying two WT
TTR genes, which replaces mutant TTR with a
native allele, affording a more stable and less
amyloidogenic TTR tetramer. Second, a clinical
observation showed that a domino recipient of
a liver graft from a patient with Val30Met
amyloidosis developed amyloidosis [92]. Third,
in the 1990s, it was observed that some
Portuguese individuals with symptomatic
TTR-FAP had uncharacteristically mild
symptoms [93]. Gene sequencing studies
revealed that these individuals are compound
heterozygotes harboring a Val30Met mutation
on allele 1 and a Thr119Met (p.Thr139Met)
mutation on allele 2, conferring protection
against disease development [93].
Incorporation of Thr119Met subunits into
tetramers containing disease-associated
subunits increases the kinetic stability of the
tetramer, slowing tetramer dissociation and
suppressing disease [42, 44, 93, 94].
Binding of either T4 or holo-retinol-binding
protein stabilizes the TTR tetramer, preventing
its dissociation into amyloidogenic monomers
[95, 96]. Notably, approximately half of TTR
circulating in blood lacks a bound ligand. These
observations provided a strong rationale to
develop small molecule ligands that bind to
the largely unoccupied T4 binding pockets and
stabilize the native TTR tetramer as a potential
pharmacotherapy to prevent TTR
amyloidogenesis [13].
Numerous, structurally distinct, small
molecules that bind to the T4 binding sites
were found to inhibit amyloid fibril formation
in vitro, by kinetically stabilizing the
quaternary structure of the TTR tetramer [13,
23, 44]. These TTR kinetic stabilizers included
certain non-steroidal anti-inflammatory drugs
(NSAIDs) such as diflunisal [23, 97, 98].
However, since NSAIDs are associated with
gastrointestinal, renal, and cardiac side effects
[99], attention turned to the benzoxazole
carboxylic acids. Of these, tafamidis (Fig. 1b, c)
was selected for clinical development due to its
lack of NSAID-activity, good oral bioavailability,
and low toxicity profile.
CLINICAL PHARMACOKINETICS
OF TAFAMIDIS
Tafamidis is highly bound to plasma proteins
(binding rate[99.5%) with glucuronidation as
the major metabolic pathway, and the major
circulating form in plasma is parent compound.
In healthy volunteers, tafamidis was rapidly
absorbed after a single oral dose of 20 mg. The
median time (Tmax) to reach the maximum
concentration (Cmax) was approximately 2.0 h.
Administration of tafamidis with food reduces
the rate of absorption, but overall extent of
absorption is not affected. Pharmacokinetic
(PK) parameters were similar after single and
repeated dosing, indicating a lack of metabolic
induction or inhibition by tafamidis.
Elimination of tafamidis is slow, with a mean
half-life of approximately 59 h. Steady state (SS)
was achieved by day 14 after once-daily dosing
with 20 mg tafamidis for 14 days, with Cmax(ss)
and Cmin(ss) at 2.7 and 1.6 lg/mL, respectively
(Table 1) [100, 101].
Based on population PK analysis, SS
clearance of tafamidis was similar in subjects
with creatinine clearance\80 and[80 mL/min.
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However, compared with healthy volunteers,
patients with moderate hepatic impairment
(Child–Pugh Score of 7–9 inclusive) had
decreased systemic exposure (by approximately
40%) of tafamidis. In subjects [60 years old,
clearance following repeated tafamidis 20 mg
once daily was 19% slower and the Cmax(ss) was
21% higher compared with those\60 years old
[100].
TTR STABILIZATION BY TAFAMIDIS
Nonclinical in vitro and ex vivo experiments
have demonstrated that tafamidis binds with
selectivity, high affinity, and negative
cooperativity (KD1 * 2 nM, KD2 * 200 nM) to
recombinant WT TTR and to TTR in human
plasma [5, 102]. Tafamidis exhibits comparable
potency against dissociation of WT TTR and
heterotetramers of[35 TTR mutants, including
the two most common amyloidogenic mutants,
Val30Met and Val122Ile [5].
As stated in previous publications [5, 102],
an indirect means of detecting TTR monomer
formation under physiologic conditions is to
employ subunit exchange experiments [42, 103,
104], in which, two homotetramers composed
of WT TTR subunits with and without the
N-terminal negatively charged FLAG-tag were
mixed, and time-dependent subunit exchange
was then quantified using ion-exchange
chromatography at physiologic pH. Since TTR
tetramer dissociation should be slowed by
tafamidis, the subunit exchange between the
untagged WT TTR homotetramer and the
FLAG-tagged WT TTR homotetramer would be
slowed in the presence of tafamidis.
Experiments showed that subunit exchange
was complete in the vehicle control after 96 h
of incubation at 25C when the pH was 7.0;
while in the presence of tafamidis, the fraction
of subunit exchange was considerably lower.
For instance, at a tafamidis:TTR tetramer molar
ratio of 1, the subunit exchange was 15% after
24 h compared with 70% in the absence of
tafamidis; and when the molar ratio was 1.50,
the fraction of exchange was\10% after 11 days
[5]. Based on these findings, it has been
concluded that tafamidis decreases the rate of
tetramer dissociation at physiologic pH in a
dose-dependent manner.
By measuring TTR tetramers in plasma, an
immunoturbidimetric assay [98] (for details see
the supplementary material) was used in
nonclinical and clinical studies to measure a
key pharmacodynamic endpoint as it
demonstrated that tafamidis stabilized TTR
mutants ex vivo [5]. In this assay, 4.8 lM urea
was added to plasma samples for over 48 h,
which was followed by glutaraldehyde
crosslinking, and then the remaining
tetrameric TTR was quantified using a TTR
antibody [5, 98, 102]. In the absence of
tafamidis and the presence of urea, TTR
tetramers dissociate and irreversibly unfold
into monomers, which are extensively
modified by glutaraldehyde and thus are not
detected by TTR antibody precipitation. In the
presence of tafamidis, plasma samples are
resistant to TTR tetramer dissociation induced
by urea and epitope modification by
glutaraldehyde. The immunoturbidity signals
are preserved since the TTR tetramer structure is
preserved. Therefore, the percentage of TTR
stabilization can be calculated as:
Percent TTR stabilization
¼ FOI dosed FOI baseline
FOI baseline
 100;
where FOI (fraction of initial) is the percentage
decrease in TTR immunoturbidity of the plasma
samples after 48-h incubation with urea, FOI
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baseline shows tetramer dissociation at baseline
while FOI dosed shows tetramer dissociation
after tafamidis dosing. After assessment of
random variation in TTR stabilization in
placebo-treated healthy volunteers, a cut-off
value of 32% was chosen, above which TTR
tetramers are considered to have been stabilized
by tafamidis. Nonclinical studies suggested that
Fig. 1 TTR amyloidogenesis and TTR stabilization by
tafamidis (a). The TTR amyloidogenic cascade. TTR is a
tetrameric protein that can be destabilized by mutations in
TTR, resulting in its dissociation into monomers that
rapidly misfold and misassemble into aggregates, including
pathologic structures associated with TTR amyloidosis [23,
40–45]. Also shown are the molecular structure of
tafamidis (b) and the co-crystal structure of tafamidis
(black, ball-and-stick) bound to a TTR tetramer (ribbon)
(c). TTR transthyretin
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a 1–1.5:1 tafamidis:TTR stoichiometry should
be sufficient to stabilize TTR and inhibit
tetramer dissociation in human plasma (Pfizer,
data on file). In two clinical studies of healthy
volunteers with orally administered tafamidis,
mean percent TTR stabilization increased with
increasing plasma tafamidis:TTR stoichiometry
and appeared to reach a plateau (Fig. 2), but at
ratios higher than projected from nonclinical
data.
TTR TETRAMER STABILIZATION
IN PLASMA OF TTR AMYLOIDOSIS
PATIENTS
An ex vivo study on plasma samples from 28
patients with TTR amyloidosis showed that
tafamidis can increase the stability of the
native tetrameric structure of multiple
amyloidogenic TTR variants. Eligible subjects
had been diagnosed with TTR amyloidosis and
had a documented non-Val30Met,
non-Val122Ile TTR mutation, and study
protocol and informed consent
documentation were approved by the relevant
institutional review boards. The stability of
tetrameric TTR in the plasma samples [TTR
baseline concentration range 4.2–29.6 mg/dL
(0.76–5.38 lM)] was compared in the presence
or absence of 7.2 lM tafamidis, using the
immunoturbidimetric assay. Tafamidis
increased the stability of the TTR tetramer in
26 of 27 TTR mutants (Table 2) [105]. One
mutant (Pro24Ser) demonstrated equivocal
results in vitro. TTR stabilization was also
found in patients with TTRwt amyloidosis who
were treated with tafamidis (20 mg orally, once
daily). Compared with the untreated TTRwt
amyloidosis patients and untreated
age-matched controls, those treated with
tafamidis showed a [73% decrease in the
tetramer dissociation rate, and the rate of
Fig. 2 Percent change from baseline in TTR tetramer fold
stabilization relative to tafamidis:TTR molar ratio in the
plasma of healthy volunteers. The data presented originate
from two Phase 1, randomized, double-blind, ascending
dose tolerance studies. In study Fx-002, healthy adults aged
18–65 years with a body mass index of 19–29 kg/m2
administered single doses of up to 120 mg tafamidis. In
study B3461040 (ClinicalTrials.gov identifier,
NCT01655511), healthy adults aged 21–55 years with a
body mass index of 17.5–30.5 kg/m2 administered single
doses of up to 480 mg tafamidis. TTR transthyretin
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tetramer dissociation (as measured by subunit
exchange) correlated strongly with tafamidis
concentration in the plasma (R2 = 0.929) [102].
Evidence showed that tafamidis binds and
stabilizes the functional TTR protein (i.e., the
tetrameric form) and the stabilized tetramers are
less likely to dissociate into monomers;
however, the relationship between increased
TTR stabilization and the increase in
concentration of circulating functional TTR
requires further investigation [7, 8, 102].
THERAPEUTIC USE
Transthyretin stabilization, efficacy, and safety
of treatment with oral tafamidis 20 mg once
daily have to date been evaluated in four
completed clinical trials in polyneuropathy
and cardiomyopathy (Table 3) [7, 8, 106, 107]:
1. The pivotal Fx-005 study, a randomized,
placebo-controlled, 18-month trial in 128
patients with early-stage Val30Met-FAP,
showed that tafamidis successfully
increased TTR tetramer stability in 98% of
the tafamidis group throughout the
18-month treatment period and this
increase in TTR stability was associated
with a reduction in neurologic
deterioration, preservation of nerve
function (large and small fibers), improved
nutritional status, and maintained quality
of life after 18 months compared with
placebo group (Fig. 3) [7].
2. In Study Fx-006, a 12-month, open-label
extension study to Study Fx-005, where 86
of the 91 patients who had completed the
Month 18 visit of Fx-005 either continued
to receive tafamidis (tafamidis–tafamidis) or
were switched to tafamidis
(placebo–tafamidis) for 12 months,
tafamidis conferred increased TTR tetramer
stability in[93% of participants. Moreover,
the observed slowing of disease progression
among the tafamidis-treated patients of
Fx-005 was extended to 30 months in the
tafamidis–tafamidis cohort and the rate of
disease progression was reduced in the
placebo–tafamidis group over the
12-month active treatment period (Fig. 4)
[8].
Fig. 3 Least square mean (±standard error) change from
baseline to Month 18 in efficacy measures (Fx-005, ITT
population) [7]. Least square mean estimates and p values
are based on a repeated measures analysis of variance model
using observed values with change from baseline as the
dependent variable. R7 NTs nds summated 7 nerve tests
normal deviates, R3 NTSF nds summated 3 nerve tests
small-fiber normal deviates, ITT intention to treat, mBMI
modified body mass index,NIS-LL neuropathy impairment
score—lower limb, TQOL total quality of life
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3. Fx1A-201, a Phase 2, open-label study in 21
patients with TTR-FAP due to eight different
non-Val30Met TTR mutations,
demonstrated general tolerability and
efficacy of tafamidis on TTR tetramer
stability in [94% of the polyneuropathy
patients with other TTR genotypes. These
patients were older, had longer disease
duration, and more severe disease—
frequently including cardiac
abnormalities—at baseline than the Fx-005
population [106].
4. Fx1B-201, a Phase 2, open-label, 12-month
study (ClinicalTrials.gov identifier,
NCT00694161), found that tafamidis was
associated with an acceptable safety profile
and successfully increased the kinetic
stability of TTR tetramers in the vast
majority (96.8%) of 35 patients with
Val122Ile or TTRwt amyloidosis [107].
Fig. 4 Mean (±standard error) change from baseline to on-treatment visits in efficacy endpoints measured in the ITT
populations of Studies Fx-005/Fx-006 and Fx1A-201 [7, 8, 106]. ITT intention to treat
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Patients in these trials had variable
characteristics and severity of symptoms at
baseline. Therefore, the differences observed in
clinical efficacy and safety across these trials
may be confounded by the patients’ underlying
disease and comorbid conditions.
SAFETY
Adverse Events
The risk of adverse events (AEs) is difficult to
evaluate based on the small number of patients
who received tafamidis to date. The available
clinical trial data indicate that tafamidis was
generally well tolerated, with the type and
frequency of the most commonly reported AEs
partly dependent on the primary phenotype
and clinical status of the patient in addition to
any drug effects. Many of the AEs with an
overall incidence[5% are of a similar nature as
the symptoms of the underlying disease.
In the Fx-005 study of patients with
early-stage Val30Met-FAP, the overall
incidences of any AE, AE leading to drug
discontinuation, and serious AEs were similar
in the tafamidis and placebo treatment groups
[7]. Furthermore, the overall incidence rates of
AEs among the polyneuropathy patients in
studies Fx-005, Fx-006, and Fx1A-201 were
similar [7, 8, 106]. Differences in incidence
rates of individual AEs across these studies were
generally not clinically meaningful. One
exception was treatment-emergent urinary
tract infection (UTI): 15 of 65 tafamidis-treated
patients (23%) in Fx-005 reported a UTI
compared with 8 of 63 placebo-treated
patients (13%) [7]. UTIs were also reported by
12 of 85 tafamidis-treated patients (14%) in
Fx-006 [8], and by 3 of 35 patients (9%) in
Fx1B-201 [107]. In contrast, none of the 21
patients who received tafamidis in the
open-label Fx1A-201 study developed a UTI
[106]. Additionally, a higher incidence of
diarrhea was reported in the tafamidis group
than in the placebo group in the pivotal Fx-005
study (17 of 65 [26.2%] vs. 11 of 63 [17.5%]) [7].
Diarrhea events were also reported by 7 of 85
patients (8.2%) in Fx-006 [8], by 5 of 21 patients
(23.8%) in Fx1A-201 [106], and by 7 of 35
patients (20.0%) in Fx1B-201 [107]. Also of note
was the incidence of patients experiencing a fall
in Fx-005 (0 of 65 tafamidis-treated patients vs.
1 of 63 placebo-treated patients), Fx-006 (2 of 85
patients), Fx1A-201 (5 of 21 patients), and
Fx1B-201 (3 of 35 patients).
In the Fx1B-201 study of TTR amyloid
cardiomyopathy, 15 of 35 patients had a
serious AE, the most common being cardiac
disorders (12 patients) including heart failure
(9 patients) and atrial fibrillation (3 patients)
[107]. Four patients reported six SAEs that were
considered possibly related to tafamidis,
namely, syncope, ataxia, falls (reported by two
patients), hemorrhagic stroke, and cardiac heart
failure [107].
Deaths
In the Fx-005 study, five Val30Met-FAP patients
(two receiving tafamidis, three receiving
placebo) died, all after liver transplant [7].
These deaths were considered unrelated to the
study drug. No deaths were reported in Fx-006
or Fx1A-201 [8, 106].
Two TTRwt amyloidosis patients died during
the Fx1B-201 study (causes of death were
hemorrhagic stroke and amyloid light-chain
[AL] amyloidosis) [107]. These deaths were
considered unrelated to the study drug. The
patient with AL amyloidosis had been enrolled
in the study based on positive amyloid biopsy,
absence of evidence of a plasma cell dyscrasia,
and positive TTR staining by immunogold
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electron microscopy. After an unexplained,
rapid decline at 11 months, a re-biopsy
demonstrated amyloid positive for
immunoglobulin light chain and no evidence
of TTR deposition, after which the patient
withdrew from the study, and died from
complications due to pleurodesis treatment for
AL amyloidosis. Subsequent re-evaluation of the
biopsies using mass spectrometry demonstrated
that both had amyloid deposits derived from
light chains, without evidence of TTR.
DISCUSSION
The nonclinical and clinical studies described
here demonstrate that tafamidis kinetically
stabilizes TTR tetramers thereby slowing TTR
tetramer dissociation. TTR tetramer disassembly
is the rate-limiting step of amyloidogenesis and
its inhibition is expected to inhibit the
amyloidogenesis cascade and, in turn, to slow
disease progression. Strong evidence for this
concept was that tafamidis treatment slowed
neurologic disease progression in patients with
Val30Met amyloidosis compared with placebo
[7], and by the fact that modest deterioration in
neurologic function was observed in patients
with TTR-FAP caused by non-Val30Met
mutations and who were treated with
tafamidis [106].
Tafamidis increases the kinetic stability of a
large number of TTR variants, as well as for
TTRwt, suggesting that the tetramer
stabilization effect may extend to many of the
[100 TTR genotypes associated with
amyloidosis. Furthermore, tafamidis proved
effective in stabilizing TTR throughout the
treatment period in a number of study
populations, differing in severity of disease,
phenotype(s), and TTR genotype. While TTR
tetramer stabilization along with patient- and
disease-related factors may predict clinical
response, placebo data in Val30Met-FAP
patients suggest that lack of TTR tetramer
stabilization predicts clinical nonresponse.
In patients with early-stage Val30Met
amyloidosis who were treated with tafamidis, the
rate of neurologic deterioration was slowed,
quality of life was maintained, and nutritional
status was improved, compared with
placebo-treated patients [7, 108]; and TTR
stabilization was associated with slower disease
progression [8]. There was also some indication
that 12 months of open-label tafamidis might
improve some signs and symptoms of TTR-FAP
associated with non-Val30Met mutations in older
patients with more advanced disease [106].
Considering the mechanism of action and the
available results on TTR stabilization, the tafamidis
effect on disease progression is expected to extend
to TTR amyloid polyneuropathy due to
non-Val30Met mutations [106].
Long-term study demonstrated that the
clinical benefits experienced by Val30Met-FAP
patients receiving tafamidis were sustained for
the duration of the study (30 months for Study
Fx-006) [8]. Furthermore, there was an
advantage of initiating treatment earlier, or at
an earlier stage of disease, although those
starting treatment later still experienced
patterns of slowed disease progression [8],
suggesting that earlier initiation of tafamidis
therapy may result in improved clinical
outcomes. These results underscore the need
to identify subjects early and treat
Val30Met-FAP soon after the diagnosis is
made. Moreover, the summary of product
characteristics in Europe states: ‘‘Treatment
should be initiated by and remain under the
supervision of a physician knowledgeable in the
management of patients with transthyretin
amyloid polyneuropathy’’ [100].
Noticeably, across the different groups of
tafamidis-treated patients with TTR
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amyloidosis, including those with
cardiomyopathy and a small number of
patients with renal impairment, the AEs (e.g.,
UTI, respiratory infections, diarrhea, headache,
pain, and vomiting) were generally mild to
moderate in severity, with no major safety
concerns identified [7, 8, 106, 107]. Overall,
tafamidis 20 mg once daily is safe and well
tolerated.
In cardiomyopathy patients receiving
open-label tafamidis, measures of disease
progression did not deteriorate markedly
during 12 months [107] warranting further
evaluation of tafamidis in TTR amyloid
cardiomyopathy. In addition, it has been
reported that increasing the dose of tafamidis
appears to be safe [109, 110]. Currently, a
multicenter, double-blind, placebo-controlled,
randomized, Phase 3 study is being conducted
(ClinicalTrials.gov identifier, NCT01994889) to
investigate the efficacy, safety, and tolerability
of tafamidis 20 or 80 mg once daily for patients
with TTR cardiomyopathy.
While tafamidis treatment may present
benefits to patients with polyneuropathy or
cardiomyopathy, it is unlikely that CNS
manifestations of TTR amyloidosis, such as
leptomeningeal or ocular amyloidosis, would
be effectively treated with oral tafamidis
therapy, as the drug does not penetrate
extensively into the brain or eye in rats.
Rather, tafamidis accumulates preferentially in
the bloodstream and in the liver, which is the
primary source of mutant TTR.
Tafamidis is the only currently approved
pharmacotherapy for the treatment of
early-stage TTR-FAP, with ongoing clinical
investigation for TTR-FAC. The favorable
tolerability profile and suitability for long-term
use, further underscore its benefits in patients
with TTR amyloidosis. Diagnosing patients as
early as possible for the initiation of tafamidis
therapy before substantial accumulation of
amyloid in the nerves and organs is of
paramount importance.
Following regulatory approvals in the
European Union and several countries in Latin
America and the Asia-Pacific, tafamidis has
emerged as a new standard of care for patients
with TTR-FAP. Prior to tafamidis, the only
disease-modifying treatment available for TTR
amyloidosis was liver transplantation
[111–117]. However, liver transplantation is an
invasive procedure requiring lifelong
immunosuppressive therapy and has limited
applicability to a carefully selected cohort of
primarily Val30Met patients (non-elderly) with
early-stage disease, and good nutritional status
[111, 117–119].
SUMMARY
Tafamidis is a well-tolerated and efficacious
pharmacotherapy for the treatment of
early-stage TTR-FAP. It effectively stabilizes
TTR across a number of amyloidogenic TTR
genotypes, including WT TTR, and slows disease
progression. In patients with early-stage
Val30Met amyloid polyneuropathy, tafamidis
delayed neurological deterioration, preserved
nutritional status and quality of life. A Phase
3, randomized, placebo-controlled trial
(ClinicalTrials.gov identifier, NCT01994889) is
currently underway to investigate the efficacy,
safety, and tolerability of tafamidis in patients
with TTR amyloid cardiomyopathy. The
long-term efficacy and safety of tafamidis for
periods up to 5–8 years appears favorable, based
on extension studies from the tafamidis clinical
trial program and real-world experience in
hundreds of patients to date.
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• Transthyretin (TTR), a 55 kDa tetramer also known as prealbumin, is a transporter of the retinol-
binding protein–vitamin A complex and thyroxine that circulates in the blood; TTR can undergo rate-
limiting dissociation and monomer misfolding, leading to aggregation, including the formation of 
amyloid fibrils.  
• Mutations in the TTR gene generally destabilize the tetramer and accelerate tetramer dissociation, 
promoting amyloidogenesis.  
• TTR-related amyloidosis is a rare, fatal, protein-misfolding disorder characterized by the formation 
and tissue deposition of TTR aggregates, including amyloid fibrils; TTR amyloidosis is associated with 
a broad spectrum of clinical symptoms, encompassing progressive neuropathy and cardiomyopathy.  
• Tafamidis meglumine, the first pharmacotherapy approved to slow the progression of peripheral 
neurologic impairment in TTR familial amyloid polyneuropathy, is a rationally-designed, non-NSAID 
benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes 
the tetramer, slowing tetramer dissociation and subsequent monomer formation, misfolding, and 
amyloidogenesis. 
• Tafamidis is generally well-tolerated for the treatment of early-stage TTR amyloidosis, and it 
effectively stabilizes TTR across a number of amyloidogenic TTR genotypes, including wild-type TTR, 
and may thereby slow disease progression.  
• In patients with early-stage Val30Met amyloid polyneuropathy, treatment with tafamidis results in 
reduced neurological deterioration, preserved nutritional status, and quality of life.  
 
This summary slide represents the opinions of the authors. Editorial support for the development of this manuscript was provided by Malcolm Darkes 
and Dave Cornick of Engage Scientific Solutions and was funded by Pfizer. The article processing charges for this publication were funded by Pfizer. 
For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2016. Creative 
Commons Attribution Noncommercial License (CC BY-NC). 
SUPPLEMENTARY MATERIAL 
 
The immunoturbidimetric assay quantitatively assesses whether tafamidis stabilizes the 
transthyretin (TTR) tetramer fold against urea-denaturation (Fig. S1) [1]. Urea, a chaotropic 
agent, is routinely used when assessing protein structure and folding. It interferes with the non-
covalent forces that mediate and stabilize a proteins’ three-dimensional structure (i.e., hydrogen 
bonds and hydrophobic interactions), reducing the energy barrier for protein unfolding. In urea, 
TTR tetramers are very stable and relatively resistant to denaturation whereas TTR monomers 
rapidly and irreversibly unfold, which prevents monomers from reassembling into TTR 
tetramers. Thus, tetramer dissociation becomes the sole determinant of TTR tetramer 
concentration, and decreases in tetramer concentration over time provide a direct measure of 
tetrameric dissociation. The immunoturbidity assay measures TTR tetramer in plasma. In this 
method, urea is added and after 48 hours to allow tetramer dissociation, glutaraldehyde is added 
and a TTR antibody is used to quantify the TTR protein. The glutaraldehyde, a cross-linking 
agent, heavily modifies the unfolded monomers such that they are no longer recognized by the 
TTR antibody. Therefore, TTR immunoturbidity specifically measures the remaining 
concentration of TTR tetramers. Taken together, the percentage decrease in TTR 
immunoturbidity after 48 hours of incubation in the presence of urea (the Fraction of Initial, 
FOI), provides a measure of urea-induced TTR tetramer dissociation. FOI is a quickly-measured, 
reliable output amenable to automation. 
 
To evaluate the effect of tafamidis in the clinical setting, tetramer dissociation is measured in 
plasma samples taken before the first dose of tafamidis (FOI baseline) and after dosing (FOI 
dosed) and ‘percent TTR stabilization’ is calculated as: 
 
100

baselineFOI
baselineFOIdosedFOI  
 
In experiments where tafamidis is added ex vivo, tafamidis (‘FOI dosed’) or vehicle (‘FOI 
baseline’) is added 15 minutes prior to the urea incubation. A value of 0% TTR stabilization 
indicates that tafamidis had no impact on dissociation, whereas 100% indicates a 2-fold increase 
and 200% a 3-fold increase in the amount of TTR tetramer remaining after 48 hours of 
incubation in urea. 
 
The immunoturbidimetric assay determines whether a human plasma sample is considered TTR 
“stabilized” or “non-stabilized”. Data from placebo-treated healthy volunteers participating in a 
Phase 1 study evaluating single and multiple doses of tafamidis were analyzed to assess random 
variation in FOI and demonstrated that values of percentage TTR stabilization above 32% are 
unlikely to occur in patients who do not receive TTR stabilizing therapy. Hence, a cut-off value 
of 32% was chosen above which tafamidis is considered to have stabilized the TTR tetramer 
fold.  
  
Fig. S1 Overview of the transthyretin (TTR) stabilization immunoturbidity (IT) assay. In 
the presence of urea, TTR monomer, in equilibrium with TTR tetramer, quickly denatures to 
unfolded monomer, which is irreversible in high urea concentrations, preventing the monomers 
from reassembling into TTR tetramers whereby tetramer dissociation becomes the sole 
determinant of TTR tetramer concentration. After incubation in urea, samples are cross-linked, 
quenched, and TTR levels measured using the IT assay. 
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ABSTRACT
Hereditary transthyretin (TTR) amyloidosis associated with the TTRV30M (p.TTRV50M) mutation presents
predominantly as an axonal polyneuropathy, with variable involvement of other organs. Serious central
nervous system (CNS) and eye manifestations, including stroke, dementia, vitreous opacities and
glaucoma, have been reported in untreated V30M TTR amyloidosis patients, and in these patients after
treatment with liver transplantation (LT). Distinct therapies for V30M TTR amyloidosis developed during
the last decade exhibit promising results in slowing the peripheral and autonomic nervous system
pathology. However, the effect of these therapies on the CNS and eye manifestations of V30M TTR
amyloidosis is not known. Herein, we show that in a small cohort of patients taking tafamidis orally
(20mg tafamidis meglumine daily) we could detect this small molecule in the cerebrospinal fluid
(CSF) and the vitreous body. In the CSF, the ratio of TTR tetramer to tafamidis was 2:1, leading to a
moderate kinetic stabilization of TTR in the CSF of these patients. Our data suggest that tafamidis can
cross the CSF–blood and eye–blood barriers. Future studies comparing CNS and eye manifestations
in patients treated with LT, kinetic stabilizers or TTR lowering drugs are essential to understand the
clinical effect of our observations.
Abbreviations: ATTR: transthyretin amyloid; CNS: central nervous system; CPE: ciliary pigment epithe-
lial; CSF: cerebrospinal fluid; DMSO: dimethyl sulfoxide; FT2: dual-FLAG-tagged; HPLC: high-performance
liquid chromatography; LP: lumbar puncture; LT: liver transplantation; PNS: peripheral nervous system;
RPE: retinal pigment epithelial; TTR: transthyretin; UPLC: ultra-performance liquid chromatography; VB:
vitreous body; WT: wild-type
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Introduction
Hereditary transthyretin (TTR) amyloidosis associated with the
V30M mutation [or ATTRV30M amyloidosis (p.TTRV50M)]
presents most frequently as a progressive length-dependent
axonal sensory, motor and autonomic neuropathy, with mod-
erate to severe gastrointestinal symptoms, and with variable
involvement of other organs, including the heart, kidneys, eyes
and the central nervous system (CNS) [1]. If untreated,
ATTRV30M amyloidosis leads to death 10–15 years after diag-
nosis [2]. Genetic and pharmacological evidence suggest that
TTR aggregation into amyloid fibrils and non-native TTR
oligomers is associated with the clinical manifestations of
ATTRV30M amyloidosis [3].
A variety of treatments for ATTRV30M amyloidosis with
different mechanisms of action have emerged, including liver
transplantation (LT) [4], pharmacological kinetic stabilization
of the TTR tetramer [5,6] and anti-sense oligonucleotides/
siRNA [7,8]. These strategies significantly slow, and in some
cases, halt the progression of neuropathy in patients with
hereditary TTR amyloidosis.
LT was the first treatment developed for ATTRV30M
amyloidosis [4]. It replaces a liver producing mutant and
wild-type (WT) TTR with a liver producing only WT-TTR
and efficiently leads to amelioration of the TTR-aggregation-
associated degeneration of the peripheral nervous system
(PNS). Treatment of these patients with LT has revealed facets
of ATTRV30M amyloidosis that were not known to be associ-
ated with this common mutation, likely, because untreated
patients did not live long enough to manifest degeneration
in organs with significantly lower TTR concentrations. Over
the last decade, several groups have reported severe CNS
involvement in ATTRV30M amyloidosis patients treated by
LT [9,10] or in untreated older patients exhibiting slow per-
ipheral disease progression [11]. These data suggest that tran-
sitory focal neurological episodes, stroke, cognitive dysfunction
and dementia appear to be linked to TTR-amyloid deposition
in the brain, especially in the leptomeningeal vessels, and that
CONTACT Jeffery W. Kelly jkelly@scripps.edu Departments of Chemistry and Molecular Medicine, The Scripps Research Institute, 10550 N. Torrey Pines Rd,
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clinical manifestations associated with CNS deposition of TTR
commences 10–15 years after peripheral and/or autonomic
neuropathy [9–11]. Likewise, eye involvement becomes more
severe as the disease progresses, especially in untreated
patients surviving for more than 10 years [12] or in patients
treated by LT [13]. Late onset patients (i.e. disease onset later
than 50 years old) with absent or mild peripheral neuropathy
can also present with severe eye manifestations [14].
Abnormal conjunctiva vessels, dry eye, amyloid deposition on
the anterior surface of the lens and on the pupil border, scal-
loped pupil, retinal amyloid microangiopathy, glaucoma and
vitreous opacities are some of the ocular manifestations
observed in these patients [14].
TTR in the CNS is biosynthesized mainly by the choroid
plexus epithelial cells, which secrete TTR into the cerebro-
spinal fluid (CSF) [15,16]. Ocular TTR is produced by retinal
pigment epithelial (RPE) cells and ciliary pigment epithelial
(CPE) cells, which secrete TTR into the posterior and anterior
chambers of the eye, respectively. TTR present in the vitreous
body (VB; a gel-like substance that fills the space between the
lens and the retina) is thought to originate from the
RPE cells; however, the contribution of CPE cells to vitreous
TTR and ocular TTR amyloidosis is not well understood
[17,18]. The concentration of TTR in the CSF [19] and VB
[20] (300 nM) is about ten-fold lower than in blood
(3–6lM), where it is derived mostly from hepatocyte secre-
tion [21]. Although the concentration of mutant TTR in
blood is reduced to less than 1% after LT [22], LT patients
continue to produce mutant TTR in the choroid plexus and
the eye, which together with the lower TTR concentration in
these organs, might explain the delayed appearance of CNS
and eye manifestations in these patients. Analogous amelior-
ation of peripheral post-mitotic tissue degeneration, but not
CNS or eye pathology, is expected in hereditary TTR amyl-
oidosis patients treated with anti-sense oligonucleotides and
siRNA because these drugs target exclusively TTR
liver production.
Tafamidis (VyndaqelVR ) is an orally bioavailable TTR
kinetic stabilizer that is widely used for the treatment of
peripheral and autonomic neuropathies associated with her-
editary TTR amyloidosis. This small molecule binds to the
TTR tetramer and slows tetramer dissociation into folded
monomers, consequently slowing monomer misfolding and
aggregation [23]. Since its approval in 2012, the Unidade
Corino de Andrade, the ATTR Amyloidosis Reference
Center in Porto, has approximately 300 ATTR amyloidosis
patients taking tafamidis (20mg tafamidis meglumine daily;
12.2mg of the active agent tafamidis in each 20mg capsule).
Considering the appearance of CNS and eye manifestations
in LT-treated polyneuropathy patients, we decided to inves-
tigate whether tafamidis exposure in the CSF and VB may
be sufficient to kinetically stabilize TTR there and slow
disease progression. Herein, we report the tafamidis CSF
and VB concentrations achieved upon oral 20mg tafamidis
meglumine daily dosing. Native CSF TTR concentration and
kinetic stability were also measured. Our results suggest that
tafamidis crosses the blood–CSF barrier, reaching an average
concentration of 125.3 nM (n=5), and its effect as a kinetic
stabilizer is evident in the CSF of hereditary amyloidosis
patients. Additionally, tafamidis was also detected (average
concentration: 54.2 nM) in 10 vitreous samples extracted
from tafamidis-treated patients in whom vitrectomy was
performed because of vitreous amyloidosis.
Materials and methods
Patient selection and sample collection
All patients/controls included in this study are routinely fol-
lowed in the Unidade Corino de Andrade, in the Neurology
Department or in the Ophthalmology Department of the
Hospital de Santo Antonio, Porto, Portugal. Lumbar punctu-
res (LP) were performed on five ATTRV30M amyloidosis
patients taking tafamidis (“Tafamidis Group”, 20mg tafami-
dis meglumine daily) and four ATTRV30M amyloidosis
patients, two of whom were treated by LT, who were never
exposed to tafamidis (“No Tafamidis Group”). Three
additional non-ATTR patients were also included as CSF
controls (Table 1). Routine LP and blood collections were
Table 1. Demographic, clinical and laboratorial characteristics of the CSF study patients/samples.
Hereditary ATTRV30M –
“Tafamidis Group” (n¼ 5)
Hereditary ATTRV30M –
“No Tafamidis Group” (n¼ 4) Non-ATTR controls (n¼ 3)
Patient age (mean± SD, max., min.) 35.4 ± 4.1 years (max. 41.7, min. 29.2) 45.2 ± 4.8 years (max. 48.8, min. 37.0) 28.6 ± 4.1 years (max. 34.2, min. 24.4)
Gender Female: n¼ 4, Male: n¼ 1 Female: n¼ 4 Female: n¼ 3
Age of disease onset (mean± SD,
max., min.)
28.0 ± 4.4 years (max. 36.3, min. 25.1) 32.8 ± 2.0 years (max. 35.0, min. 30.2) NA
Disease duration (mean± SD,
max., min.)
7.4 ± 2.4 years (max. 10.3, min. 4.0) 11.2 ± 5.7a years (max. 17.6, min. 3.7) NA
ATTRV30M-specific treatment
description
Tafamidis 20mg per day orally Liver transplant: n¼ 2
No treatment: n¼ 2
NA
Treatment duration (mean ± SD,
max., min.)
5.7 ± 2.4 years (max. 9.2, min. 2.6) 11.8 ± 1.5b years (max. 13.4,
min. 10.3)
NA
CNS manifestations Migraine/headache: n¼ 4
Transitory neurological episodes, with
confirmed TTR-amyloid
angiopathy: n¼ 1
Migraine/headache: n¼ 2
Subjective cognitive complaints:
n¼ 1
Subjective worsening of motor
deficits associated with subacute
myelopathy: n¼ 1
Multiple sclerosis/CNS inflammatory
disease: n¼ 3
CSF total protein (mean ± SD,
max., min.)
0.44 ± 0.17 g/L (max. 0.74, min. 0.27) 0.48 ± 0.20 g/L (max. 0.73, min. 0.25) 0.25 ± 0.02 g/L (max. 0.23, min. 0.28)
CSF erythrocytes 0 cells/lL: n¼ 4, 212 cells/lL: n¼ 1 0–2 cells/lL: n¼ 4 0–5 cells/lL: n¼ 2, 58 cells/lL: n¼ 1
aOne patient (D006; still considered asymptomatic regarding ATTR amyloidosis) not included in this average.
bTwo patients (D010, D006; untreated) not included in this average.
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performed in all patients as part of the clinical diagnosis
work-up of CNS manifestations. Two extra tubes (one CSF
and one blood) were collected with informed consent of the
patient for this study. Plasma was prepared as previously
described [24]. CSF and plasma samples were randomly
labelled at the Unidade Corino de Andrade. Labels con-
tained only patient ID (D001–D012), with no information
regarding age, gender, disease status or type of treatment.
Control CSF was purchased (commercial CSF) from
Innovative Research Inc. (5 1mL, pooled normal, from
five healthy donors, labelled as C1–C5). No information was
available regarding demographic characteristics of these con-
trol samples (not included in Table 1).
Vitrectomy with storage of the VB collected during surgery
was performed using a routine surgical procedure in eight
ATTRV30M amyloidosis patients taking tafamidis (“Tafamidis
Group”) and 19 ATTRV30M amyloidosis patients who
were never exposed to tafamidis (“No Tafamidis Group”; see
Table 2). VB was collected into a sterile 1mL tube without
dilution, which was analysed in this study. BSSVR Irrigating
Solution was used to remove the remaining VB into tube 2,
which was not analysed in this study. Two VB samples from
non-ATTRV30M amyloidosis patients were also collected and
used uniquely to produce ex vivo added tafamidis standard
curves (demographic data on these two samples are not
included in Table 2). VB samples were randomly labelled and
no information regarding age, gender or type of treatment
was sent with these samples to The Scripps Research Institute.
Control VB samples were identified. Upon arrival at The
Scripps Research Institute, samples were thawed at 25 C,
aliquoted and re-frozen at 80 C. Each aliquot was thawed
immediately before performing the corresponding assay.
High-performance liquid chromatography analysis of
tafamidis concentration
Tafamidis levels were quantified in all CSF and VB samples
employing the high-performance liquid chromatography
(HPLC) method previously described [24,25], with the fol-
lowing minor modifications. For each experiment, a stand-
ard curve was generated by adding tafamidis (using a 50
stock solution in dimethyl sulfoxide (DMSO)) to a healthy
donor CSF sample (commercial CSF) or to non-ATTR VB
sample. The final tafamidis concentrations employed for the
standard curve equal 0, 25, 50, 100, 400 nM. Protein extrac-
tion was performed as previously described for standard
curve samples and patient samples (CSF and VB) although
the amount of protein precipitate was very small when com-
pared to plasma samples [24,25]. After protein extraction,
standard curve CSF/VB- and patient CSF/VB-supernatants
(10 lL) were sequentially injected into a Thermo-Scientific
BetaBasic-18 (50 4.6mm) column using an Agilent 1260
Infinity HPLC with fluorescence detection (excitation at
310 nm, emission at 370 nm). Under these conditions, the
detection limit for tafamidis is 6.3 nM. Each sample was
analysed at least in duplicate. Tafamidis levels were also
quantified in blood plasma after CSF and VB analysis (only
plasma corresponding to patients taking tafamidis was
analysed) as above and following the plasma protocol as
previously described [24,25]. To provide additional evidence
that tafamidis was being detected in the CSF and plasma by
HPLC, we collected the putative tafamidis peak and analysed
the lyophilized fraction dissolved in methanol by negative
ion mode mass spectrometry. The expected [M-H]-masses
are 305.9803, 307.9803 and 309.9803 in an 1.0:0.65:0.11
ratio. There are three mass spectrometry peaks for tafamidis
because of the 35Cl and 37Cl stable isotopes (tafamidis has
two chlorine atoms). An Agilent 6230 TOF liquid chroma-
tography/mass spectrometry instrument was used for this
analysis. 5 lL of the lyophilized 1mL fraction dissolved in
methanol was injected directly into the mass spectrometer
using Agilent 1200 series auto-sampler without a column.
Recombinant protein expression and purification
Recombinant wild-type TTR (WT-TTR) and dual-FLAG-
tagged WT-TTR (FT2-WT-TTR) were expressed in and
purified from Escherichia coli as described previously [26].
After purification, aliquots of 200 lL of 50 lM TTR in
50mM phosphate buffer pH 7.6 (standard phosphate buffer)
were flash frozen and stored at 80 C until use. The molar
absorptivity (e) of WT-TTR (73,800M1 cm1) and FT2-
WT-TTR (85,720M1 cm1) tetramers in standard phos-
phate buffer was used to prepare TTR solutions of known
concentration.
Measurement of native TTR in CSF
Native TTR levels in CSF were quantified using a Waters
Acquity H-Class Bio-UPLC (ultra-performance liquid chro-
matography) instrument employing a Waters Protein-Pak Hi
Table 2. Demographic and clinical characteristics of the patients submitted to vitrectomy.
Hereditary ATTRV30M – “Tafamidis Group”
(n¼ 8 patients; n¼ 10 vitreousa)
Hereditary ATTRV30M – “No Tafamidis Group”
(n¼ 19 patients; n¼ 23 vitreousb)
Patient age (at vitrectomy; mean ± SD, max., min.) 62.0 ± 8.7 years (max. 72.1, min. 47.2) 52.4 ± 9.1 years (max. 72.4, min. 39.4)
Gender Female: n¼ 7, Male: n¼ 1 Female: n¼ 9, Male: n¼ 10
Age of disease onset (mean ± SD, max., min.) 53.6 ± 10.8 years (max. 64.9, min. 35.1) 37.2 ± 14.1 years (max. 69.0, min. 21.4)
Disease duration (mean ± SD, max., min.) 8.5 ± 2.9 years (max. 14.5, min. 4.5) 17.4 ± 5.3 years (max. 26.2, min. 8.5)
ATTRV30M-specific treatment description Tafamidis 20mg per day orally Liver transplant: n¼ 16
No treatment: n¼ 3c
Treatment duration (at vitrectomy; mean ± SD,
max., min.)
4.5 ± 2.3 years (max. 8.0, min. 1.7) 14.7 ± 5.2 years (max. 21.9, min. 4.3)
aTwo patients (a woman and a man) underwent bilateral vitrectomy at different time points; bfour patients (three men and one woman) underwent bilateral
vitrectomy at different time points. For age, disease duration and treatment duration, each vitrectomy was considered separately (i.e. six patients were consid-
ered at two different time points). All remaining patients were considered at only one time point. cThree patients with no treatment because of the absence of
peripheral nervous disease manifestations.
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Res Q ion exchange column (strong anion exchanger, 5lm
particle size, 4.6 100mm column). A standard curve was
prepared using recombinant WT-TTR at concentrations of
125, 250, 500 and 1000 nM in standard phosphate buffer.
The freshly prepared standard curve samples and patient
samples (9 lL) were incubated with 1 lL of the fluorogenic
small molecule A2 (500 lM) [27] for 3 h at room tempera-
ture. After incubation, the samples were injected into the
ion exchange column and separated using a linear 24%–29%
buffer B gradient over 10min (flow 0.5mL/min, buffer A:
25mM Tris pH 8; buffer B: same as buffer A, but with 1M
NaCl added). The TTR–(A2)2 fluorescent conjugate peak
(excitation 328 nm, emission 430 nm; elution time¼ 6min)
was integrated and the concentration of TTR in patient sam-
ples was quantified using the standard curve.
CSF-TTR subunit exchange assay to assess kinetic stability
Subunit exchange rates were determined as described previ-
ously [24] with the following minor modifications. FT2-WT-
TTR (2 lL of a 7 lM solution) was added to CSF (68 lL)
to afford a final FT2-WT-TTR concentration of 200 nM.
The samples were incubated at 25 C for 24 h to allow
subunit exchange to occur. At 24 h, the reaction was stopped
by the addition of the fluorogenic small molecule A2 at a
final concentration of 500lM. The samples were incubated
with A2 for at least 3 h to allow complete covalent labelling
of TTR, before being injected into the ion exchange
column and separated using the same gradient as described
previously [25]. For the ex vivo incubation with tafamidis
experiment, the small molecule was incubated at defined
concentrations (1000, 500, 250, 125, 63 and 31 nM, from a
50 tafamidis stock solution in DMSO) with one commer-
cial CSF sample (C5). After a 1-h incubation period, the
subunit exchange was measured as described above. The
rate of exchange for all subunit exchange experiments was
calculated using peak 1, as previously described [24].
Statistical analysis
The unpaired (two sample) Student’s t-test was used to com-
pare age, disease duration and disease onset. For Figure
3(A), comparison between the three groups was performed
using one-way analysis of variance (ANOVA) followed by
post hoc analysis with Tukey correction for multiple pairwise
comparisons. All p values are indicated in the figure. Error
bars represent mean and standard deviation.
Ethical statement
All patients signed an informed consent and the study was
approved by the Institutional Review Boards at the Hospital
de Santo Antonio, Porto, Portugal and The Scripps Research
Institute, La Jolla, CA, USA.
Results
Patient characteristics
Demographic and clinical characteristics of the patients from
whom the CSF samples were taken from are summarized in
Table 1. ATTRV30M amyloidosis patients included in the
“Tafamidis Group” (n¼ 5) were significantly younger than
the ATTRV30M amyloidosis patients comprising the “No
Tafamidis Group” (n¼ 4; p¼ .04). This is expected consider-
ing the short clinical experience period with tafamidis when
compared to LT. In the “No Tafamidis Group”, there are two
patients who had been treated by LT 12 and 18 years prior to
this study (47 and 48 years old, respectively).
Regarding the clinical manifestations, four patients in the
“Tafamidis Group” manifested with migraine or headache,
without associated focal neurological symptoms. The remaining
tafamidis-treated patient (D008) presented with focal transitory
neurological episodes and had a leptomeningeal and brain
biopsy confirming TTR-amyloid angiopathy. The CNS mani-
festations in this patient presented 2 years into her treatment
with tafamidis. In the “No Tafamidis Group”, CNS manifesta-
tions included migraine, cognitive complaints and worsening
of deficits in a patient that previously had an inflammatory
myelopathy considered unrelated to ATTRV30M amyloidosis.
Two CSFs showed cytological evidence of mild blood contam-
ination (i.e. presence of more than 10 erythrocytes/lL): one
from a tafamidis-treated patient (D004) and one from a non-
ATTR control (D009).
Demographic characteristics of patients who were sub-
jected to vitrectomy for amyloid vitreous opacities are shown
in Table 2. Eight tafamidis-treated patients and 19 patients
who were not exposed to tafamidis (i.e. 16 patients treated
with LT and 3 patients who had no PNS manifestations, and
therefore were not treated with ATTR-specific therapies) were
included in this study. Two patients in the “Tafamidis Group”
and four patients in the “No Tafamidis Group” underwent
vitrectomy in both eyes, at different stages of disease progres-
sion. These samples were analysed independently. Patients in
the “Tafamidis Group” were significantly older than patients
in the “No Tafamidis Group” (mean age of 62.0 ± 8.7 years vs.
52.4 ± 9.1 years, p¼ .0097, respectively) and the “Tafamidis
Group” had significantly lower PNS disease duration (mean
of 8.5 ± 2.9 years vs. 17.4 ± 5.3 years, p< .0001). Older patients
are not considered as candidates for LT and are therefore
more likely to be on tafamidis. Moreover, eye manifestations
become more prevalent with longer disease duration, both in
untreated patients or in patients treated with LT [14], explain-
ing why disease duration is lower in tafamidis-treated patients
than in LT-treated patients. This age and disease duration dis-
crepancy precluded any direct clinical comparisons between
the two groups. An appropriate ophthalmological age-
matched comparison between LT- and tafamidis-treated
patients is currently being pursued.
Tafamidis concentration in CSF and VB
Tafamidis concentrations in the CSF (n¼ 12) and VB
(n¼ 23) samples were measured by HPLC analysis
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employing fluorescence detection, utilizing a standard curve
(Figure 1(A)). We quantified tafamidis in 5 CSF samples
and 10 VB samples, that is, in all the samples from tafami-
dis-treated patients (Figure 1(B)). No tafamidis was detect-
able in samples from patients not treated with tafamidis. In
the CSF, the average tafamidis concentration was
125.3 ± 15.2 nM, whereas in the VB, the average tafamidis
concentration was approximately two-fold less
(54.2 ± 6.6 nM) (Figure 1(B)). After determining the tafami-
dis concentration in the CSF, and subsequently unblinding
the treatment modality for each sample, we measured the
plasma tafamidis concentration exclusively in the corre-
sponding five patients who were taking tafamidis. The
plasma concentration of tafamidis in this group was on
average 8.6 lM (ranging from 3.8 to 12.2lM), revealing that
only 1.5% of tafamidis in the plasma crosses the
blood–CSF barrier on average (Figure 1(C)). To provide
additional evidence that tafamidis was being detected by
HPLC fluorescence detection, we collected the putative tafa-
midis peak in the plasma (1mL volume at 13min) and ana-
lysed the lyophilized fraction that was re-dissolved in
methanol by negative ion mode mass spectrometry. We
observed the [M-H] peaks at 305.9723, 307.9708 and the
309.9746 ions in the expected1.0:0.65:0.11 ratio (Figure
1(A)) owing to the 35Cl and 37Cl stable isotopes comprising
tafamidis, which has two chlorine atoms. Next, we per-
formed a strictly analogous experiment using CSF.
Unfortunately, we were unable to identify tafamidis, as we
were below the detection limit both for healthy control CSF
to which 100 nM of tafamidis was added (Supplementary
Figure S1(A)) and for CSF from patient D001 (99.4 nM CSF
tafamidis concentration) (Supplementary Figure S1(B)).
Nonetheless, because the retention time of tafamidis in
DMSO added to control CSF and in CSF from patients tak-
ing 20mg of tafamidis meglumine orally is exactly the same
when detected by fluorescence, we are very confident that
we are quantifying tafamidis in the CSF.
We assessed the contamination of CSF by blood, which
could lead to false-positive detection of tafamidis in the
CSF. According to routine cytological examination, one CSF
had evidence of mild blood contamination (patient D004:
212 erythrocytes/lL); however, in our analysis, this patient
showed only 1.2% the concentration of tafamidis in the CSF
relative to the blood (similar or lower than the other
four samples), suggesting that blood contamination in this
sample is negligible. Notably, the other four CSF samples
Figure 1. Tafamidis is detectable and quantifiable in the cerebrospinal fluid (CSF) of 5/5 patients and the vitreous body (VB) of 10/10 patients taking tafamidis
orally. (A) Method to detect tafamidis and determine its concentration in CSF, VB or plasma. A healthy control sample with increasing ex vivo added concentrations
of tafamidis is used to produce a standard curve. An example of a plasma-derived standard curve is shown ([tafamidis]¼ 0, 1, 3, 6, 12 lM). Patient samples (CSF, VB
or plasma) are analysed using the same HPLC method, and the tafamidis concentration is determined using the standard curve generated for each run. The putative
tafamidis peak was collected from one healthy plasma sample with ex vivo added tafamidis (20 lM) and one patient plasma sample and submitted to ESI-TOF MS.
The corresponding MS spectra confirm the presence of tafamidis in both samples. (B) Concentration of tafamidis in the CSF ranges from 182.1 to 99.4 nM
(mean± SD: 125.3 ± 34.0 nM); in the VB, it ranges from 94.8 to 27.1 nM (mean ± SD: 54.2 ± 20.8 nM). (C) Tafamidis levels in concomitant plasma and CSF samples
from patients taking tafamidis orally. CSF is represented on the left axis and plasma is represented on the right axis. Concentrations are reported in micromolar
(lM) for both CSF and plasma, to facilitate comparison. For the same reason, values on the left axis are 100-fold lower than values on the right axis. Below each
patient ID is shown the percentage of tafamidis in CSF (relative to blood plasma tafamidis).
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that had measurable levels of tafamidis had no detectable
erythrocytes.
Native TTR concentration
Next, we sought to quantify the TTR concentration present
in the CSF, using a previously published method [24] that
utilizes the specific reactivity of a fluorogenic small molecule
(A2) with TTR in complex biological fluids [27]. The TTR-
(A2)2 covalent conjugate afforded is separated from other
CSF components by ion-exchange chromatography and
quantified using fluorescence detection employing a standard
curve. Native TTR concentrations were measured in CSF
from nine Portuguese ATTRV30M amyloidosis patients, two
Portuguese CSF non-ATTR controls and five CSF samples
from healthy controls (commercial CSF). One Portuguese
non-ATTR control was used in HPLC assay development and
no remaining sample was available for this experiment.
Native TTR tetramer concentrations were similar between the
“Tafamidis Group”, “No Tafamidis Group” and “Non-ATTR
controls” (averages are 265.8, 273.8 and 271.5 nM, respect-
ively) (Figure 2(A)). These values are in accordance with
previously published TTR CSF concentrations, as quantified
using antibody-based assays [19]. When comparing native
TTR tetramer concentration to the tafamidis concentration in
each CSF sample, stoichiometries ranging from 3:1 to 1:1
([TTR tetramer]:[tafamidis]) were observed (Figure 2(B)).
Kinetic stability of TTR in CSF
The subunit exchange method to quantify TTR kinetic stabil-
ity in human plasma was adapted for use in CSF [24]. The
concentration of added tetrameric FT2-WT-TTR was lowered
to a final concentration of 200 nM, consistent with the
270 nM average native tetrameric TTR concentration in the
CSF of the human subjects analysed above. The measured
rate of subunit exchange between the patient TTR and the
FT2-WT-TTR, kex, is an underestimate of the kinetic stability
of the native tetramer in CSF since the 200 nM FT2-WT-TTR
is added, which substantially reduces the tafamidis stoichiom-
etry. Interestingly, the TTR in the CSF of patients taking tafa-
midis is significantly more kinetically stable (average
kex¼ 0.002h1) than the tetramer in non-ATTR controls
(average kex¼ 0.006 h1; p¼ .03). While there is a tendency
for higher TTR kinetic stabilization in the “Tafamidis
Group”, it is not statistically significant when compared to
ATTRV30M amyloidosis patients in the “No Tafamidis
Group” (Figure 3(A); average kex¼ 0.004h1; p¼ .52). The
“No Tafamidis Group” is made up of two LT-treated
ATTRV30M amyloidosis patients and two ATTRV30M amyl-
oidosis patients who remain untreated.
To assess the effect of tafamidis in kinetically stabilizing
endogenous CSF TTR, we added increasing concentrations
of tafamidis (31 nM, 63 nM, 125 nM, 250 nM, 500 nM,
1000 nM; Figure 3(B), blue dots and error bars) to normal
control CSF (C5, [TTR tetramer]¼ 219 nM). Decreasing the
[endogenous TTR tetramer]/[tafamidis] ratio by increasing
the amount of ex vivo added tafamidis leads to an increase
in CSF endogenous TTR stability, showing that tafamidis is
kinetically stabilizing TTR present in the CSF. Likewise, cor-
relation of increased CSF TTR kinetic stability with a
decreasing [endogenous TTR tetramer]/[tafamidis] ratio is
seen in patient samples (Figure 3(B), red squares and error
bars). Patients with a [TTR tetramer]/[tafamidis] ratio closer
to 1:1 have a more stable CSF-TTR (kex¼ 0.001 h1 and
kex¼ 0.002 h1) than patients where the [endogenous TTR
tetramer]/[tafamidis] ratio is >2 (kex¼ 0.003 h1 or above).
Unfortunately, it was not possible to measure the native
TTR concentration or the kinetic stability in the VB using
our method. The gel-like viscosity of the VB, unlike the
CSF, leads to poor chromatographic separation, and
Figure 2. (A) Native TTR concentration in the CSF is not significantly different between the three groups. Average [native TTR concentration] are 265.8 nM (“Taf
Group”), 273.8 nM (“no Taf Group”) and 271.5 nM (non-ATTR controls). In the “No Taf Group”, D007 and D012 are LT-treated patients, whereas D006 and D010 are
untreated patients. Non-ATTR Controls include five commercial CSFs (C1–C5). Taf: Tafamidis. (B) Comparison of [tafamidis concentration] (using data shown in
Figure 1(A)) and [TTR tetramer concentration] (using data shown in Figure 2(A)) in CSF shows that the [TTR tetramer concentration] to [tafamidis concentration]
ratio ranges from 3.2:1 to 1.3:1.
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consequently unreliable TTR tetramer and subunit exchange
quantification.
Discussion
Up to one-third of ATTR amyloidosis patients with more
than 10 years of disease duration exhibit CNS and eye
involvement [9,14]. There is no reason to believe that the
mechanism of ocular and CNS amyloid pathology is funda-
mentally different than that of the systemic manifestations
of the TTR amyloidoses. That TTR is secreted as a tetramer
from the choroid plexus into the CSF and from the RPE
into the VB suggests that tetramer dissociation is also the
initial step of the pathophysiological amyloid cascade in the
CNS and in the eye. This hypothesis could be supported by
a clinical study demonstrating that patients taking tafamidis
are protected from CNS and eye pathology, relative to
untreated patients. In our small cohort, all five patients tak-
ing tafamidis showed CNS manifestations that might be
associated with ATTRV30M amyloidosis. LP was only done
as part of the routine clinical evaluation when patients had
CNS manifestations; therefore, only patients with CNS man-
ifestations were analysed. The same is true of the vitrectomy
patients. Only patients with formal indication for vitrectomy
(i.e. eye manifestations) were submitted to the surgery, and
therefore all eight patients (10 eyes) in our “Tafamidis
Group” had vitreous opacities. Despite this selection bias, it
is worth noting that one patient presented with severe CNS
manifestations with pathological confirmation of TTR amyl-
oid angiopathy. This patient had been taking tafamidis for
2.5 years at the time of LP and exhibited a good response
regarding PNS disease progression.
We have shown that in the small ATTRV30M amyloid-
osis cohort studied, tafamidis is found in the CSF upon oral
dosing, suggesting that this small molecule has the capacity
to cross the blood–CSF barrier. This might reflect an intrin-
sic permeability of this barrier (known to be “leakier” than
the blood–brain barrier [28]) to the small molecule, or the
disruption of the blood–CSF and/or blood–brain barriers
that has been shown to exist in other neurodegenerative dis-
eases [29]. In fact, four patients had clinical manifestations
that suggest possible involvement of the CNS, and one
patient had confirmed CNS TTR amyloid angiopathy. This
might explain why we were able to detect tafamidis in the
CSF of these patients. Future studies in patients taking
tafamidis earlier in the course of disease while free of
CNS manifestations might help to determine whether tafa-
midis is able to cross a potentially intact blood–CSF/blood–
brain barrier. Additionally, recent reports suggest that TTR
might have a neuroprotective function in the CNS [30,31],
further highlighting the need to collect more patient infor-
mation regarding tafamidis CNS concentration, CSF TTR
kinetic stabilization and possible protection against transi-
tory focal neurological episodes, stroke, cognitive dysfunc-
tion and dementia [32]. In eight patients (10 eyes) who
underwent vitrectomy for vitreous opacities, we were also
able to detect tafamidis in the vitreous although at a lower
concentration than in the CSF. This difference in concentra-
tion might be associated with a lower permeability of the
blood–eye barrier. Blood contamination during LP was not
completely excluded, but the low or absent CSF erythrocyte
count (Table 1) suggests that it is unlikely that our data
are confounded by blood contamination. Similarly, VB
contamination with blood is technically improbable dur-
ing vitrectomy.
As previously reported, the measured levels of the native
TTR tetramer in the CSF (270 nM) are much lower than
in blood (4.5 lM), and consequently these patients have
Figure 3. Tafamidis shows a kinetic stabilizer effect in the CSF. (A) Kinetic stability of the TTR in the CSF of ATTRV30M amyloidosis patients and healthy controls
was measured by subunit exchange. The “Taf Group” exhibits a statistically significant higher kinetic stability when compared to non-ATTRV30M amyloidosis con-
trols (kex¼ 0.002 h1 vs. kex¼ 0.006 h1, respectively). On average, kinetic stability of patients taking tafamidis was higher (kex¼ 0.002 h1) than patients not
treated with tafamidis (kex¼ 0.004 h1); however, the difference was not statistically significant. Note that the reported rates of subunit exchange with tafamidis
are less than the actual values because of the added FT2-WT-TTR (200 nM). (B) Ex vivo incubation of tafamidis in a healthy control CSF (blue dots and error bars;
C5) showed that decreasing the ratio of endogenous TTR concentration to tafamidis concentration (by increasing the amount of ex vivo added tafamidis, i.e. 31 nM,
63 nM, 125 nM, 250 nM, 500 nM, 1000 nM) leads to an increase in CSF endogenous TTR stability. A similar correlation is seen between [endogenous TTR tetramer]:[-
tafamidis] and the rate of subunit exchange in patient samples (red squares and error bars).
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on average of 0.5 tafamidis molecules bound to each tetra-
mer in the CSF. We were able to measure kinetic stability,
and it is obvious that the TTR tetramers (presumably com-
prised of mixed V30M and WT monomers) in patients tak-
ing tafamidis are kinetically more stable than the tetramers
in healthy controls (presumably comprising only wild-type
TTR subunits). Although there is a tendency for higher sta-
bilization in the samples from patients taking tafamidis
when compared to the “No Tafamidis Group”, this differ-
ence was not statistically significant. CSF from more
untreated and treated ATTRV30M amyloidosis patients
needs to be analysed to discern whether this trend is pre-
served and significant in larger numbers of patients.
Notably, there is a correlation between the ratio of the
“TTR tetramer concentration” to the “tafamidis concen-
tration” and TTR kinetic stability, both in patient CSF and
in healthy control CSF with ex vivo added tafamidis. This
data led us to hypothesize that increasing the oral dose of
tafamidis might be sufficient to increase the stoichiometry of
tafamidis bound to TTR, leading to additional kinetic stabil-
ization and efficient protection from CNS manifestations. A
CSF tafamidis concentration of  500 nM would correspond
to a [endogenous TTR tetramer]/[tafamidis] ratio of 0.43
([TTR] tetramer¼ 219 nM), affording a stabilization of
four-fold (i.e. kex(0 nMTafamidis)¼ 0.004 h1, kex(500 nM
Tafamidis)¼ 0.001 h1; Figure 3(B)). Interestingly, one of the
patients in the “Tafamidis Group” has a severe and rather
rare clinical manifestation (CNS TTR amyloid angiopathy,
D008). Accordingly, this patient has a higher [TTR tetramer]
to [tafamidis] ratio, and the tetramer is the least stable of
the tafamidis-treated cases (kex¼ 0.003 h1). Although this is
only one case, it might suggest that in some patients the
amount of tafamidis that is reaching the CSF at a 20mg
(tafamidis meglumine) oral dosing is not enough to prevent
TTR tetramer dissociation, monomer misfolding and aggre-
gation, and consequent CNS disease manifestations. One
should consider the possibility that since all tafamidis-
treated patients included in this study had CNS or eye
manifestations, the measured tafamidis CSF and VB concen-
trations might be in the low end of the range relative to
others treated with the same 20mg tafamidis dose.
In summary, we have shown that in a small cohort of
patients taking tafamidis meglumine 20mg daily, the CSF
and the eye are exposed to substoichiometric levels of
tafamidis relative to the TTR tetramer concentration, with
moderate kinetic stabilization of the tetramer being observed
experimentally. This study highlights the urgency to compare
CNS and eye manifestations in patients treated with varying
doses of tafamidis versus liver transplant versus TTR mRNA
lowering drugs with predominant liver action, in whom CNS
and eye pathology is expected to progress upon treatment. It
is essential to determine whether increasing the daily tafami-
dis dosage or altering the dosing regimen would lead to an
increase in CNS and eye exposure, and consequently to better
clinical outcomes in the brain and in the eye. This hypothesis
could be tested in approximately 2000 post-transplant heredi-
tary ATTR amyloidosis patients who will likely develop
de novo CNS amyloidosis in the very near future.
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Introduction
Hereditary or familial transthyretin (TTR) amyloidoses (hATTRs) are a group of  autosomal dominant 
degenerative diseases associated with one of  the established 124 amyloidogenic mutations in the TTR 
gene (1, 2). The most common TTR mutation involves substitution for valine at position 30 by methionine 
(TTRVal30Met) (3), which is linked with familial amyloid polyneuropathy (FAP), a form of  hATTR that 
presents with a predominantly neurological phenotype characterized by a progressive sensory, motor, and 
autonomic axonal neuropathy, with variable involvement of  other organs (4, 5). If  untreated, this disease 
is physically incapacitating in ≤5 years and invariably fatal in less than 2 decades (6, 7). This motivated 
the development of  a fit-for-purpose small molecule kinetic stabilizer (tafamidis) (8) and one nonsteroidal 
antiinflammatory drug repurposed as a TTR kinetic stabilizer (diflunisal) (9), followed more recently by 
two approved oligonucleotide-based TTR mRNA–lowering drugs (10, 11). The availability of  distinct ther-
apeutic strategies for FAP raises the question of  which drug to prioritize. Outcome predictors to specific 
therapies — i.e., baseline (or before treatment) demographic and clinical characteristics, as well as plasma 
biomarkers that help to determine which patients are more likely to respond to a certain drug — are essen-
tial in the emerging era of  personalized precision medicine.
BACKGROUND. The hereditary transthyretin (TTR) amyloidoses are a group of diseases for which 
several disease-modifying treatments are now available. Long-term effectiveness of these 
therapies is not yet fully known. Moreover, the existence of alternative therapies has resulted in an 
urgent need to identify patient characteristics that predict response to each therapy.
METHODS. We carried out a retrospective cohort study of 210 patients with hereditary TTR 
amyloidosis treated with the kinetic stabilizer tafamidis (20 mg qd). These patients were followed 
for a period of 18–66 months, after which they were classified by an expert as responders, 
partial responders, or nonresponders. Correlations between baseline demographic and clinical 
characteristics, as well as plasma biomarkers and response to therapy, were investigated.
RESULTS. 34% of patients exhibited an almost complete arrest of disease progression (classified 
by an expert as responders); 36% had a partial to complete arrest in progression of some but not 
all disease components (partial responders); whereas the remaining 30% continued progressing 
despite therapy (nonresponders). We determined that disease severity, sex, and native TTR 
concentration at the outset of treatment were the most relevant predictors of response to 
tafamidis. Plasma tafamidis concentration after 12 months of therapy was also a predictor of 
response for male patients. Using these variables, we built a model to predict responsiveness to 
tafamidis.
CONCLUSION. Our study indicates long-term effectiveness for tafamidis, a kinetic stabilizer 
approved for the treatment of hereditary TTR amyloidosis. Moreover, we created a predictive 
model that can be potentially used in the clinical setting to inform patients and clinicians in their 
therapeutic decisions.
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Tafamidis kinetically stabilizes the TTR tetramer, slowing its dissociation into monomers, which after mis-
folding enables aggregation that appears to be responsible for postmitotic cell dysfunction and death (12). Several 
observational open-label studies have been published after the registration trial showing that use of tafamidis 
halts or slows the progression of FAP, whereas others suggest that tafamidis is less effective in later-stage patients 
(7, 13–17). The North of Portugal has the highest number of patients worldwide exhibiting TTRVal30Met FAP 
(18). The FAP Reference Center in Porto (Unidade Corino de Andrade [UCA]) has ~300 patients treated with 
tafamidis (20 mg qd). Moreover, since the disease was first described in 1952 in Porto, UCA has followed more 
than 800 families with this mutation, including the longitudinal follow-up of presymptomatic mutation carriers.
Herein, we report a longitudinal follow-up study of  210 FAP patients treated with tafamidis (20 mg 
qd) for a maximum period of  66 months, with 2 main aims. First, we intended to scrutinize the long-term 
effectiveness of  tafamidis in a large group of  patients. Second, we sought baseline demographic and clinical 
characteristics, as well as plasma biomarkers that can be used as tafamidis outcome predictors. These fac-
tors were used to build a predictive model that is also described here.
Results
Study population. From July 2012 to January 2016, 306 patients were considered eligible to start tafamidis 
therapy at UCA (Figure 1A). Of  those, 96 were excluded from this cohort study based on preestablished 
exclusion criteria (Supplemental Table 1; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.126526DS1). All patients had at least 18 months of  follow-up, and about half  
were followed for at least 48 months (Supplemental Figure 1).
Genetic, demographic, and clinical baseline characteristics for all patients included in this study are 
shown in Table 1. The majority of  patients were heterozygous for the common TTRVal30Met mutation. The 
median age at disease onset was 34 years, reflecting a higher proportion of  early-onset cases, as described for 
the Portuguese FAP patient population (18). Median disease duration at baseline was 2 years, also reflecting 
the situation within a clinical center that follows a large number of  asymptomatic mutation carriers.
All patients presented with a predominantly neuropathic phenotype, characterized by length-depen-
dent axonal sensory-motor and autonomic neuropathy. No asymptomatic mutation carriers were included 
in this study, as they are not eligible for therapy with tafamidis according to the current country guidelines. 
Outcome measures developed and validated for other neuropathies have been adapted and used in several 
clinical trials for FAP, including the neuropathy impairment score (NIS, an outcome measure based on 
objective evaluation of  lower- and upper-limb sensory-motor function and reflexes by a trained neurologist; 
refs. 8, 19, 20); and the Norfolk Quality of  Life Questionnaire–Diabetic Neuropathy (Norfolk QOL-DN 
[ref. 21]; a patient-reported outcome measure, sensitive to different features of  this neuropathy, including 
autonomic involvement). More severely affected patients have higher NIS and/or Norfolk QOL-DN val-
ues. Additionally, we characterized sensory and motor neurological involvement by measuring sensory 
nerve action potentials (SNAPs) and compound motor action potentials (CMAPs) on routine nerve con-
duction tests. Our resulting neurophysiological score (SNF) is defined as follows:
SNF = SNAPulnar nerve + SNAPsural nerve + CMAPulnar nerve + CMAPtibial nerve + CMAPperoneal nerve
(Equation 1)
More severely affected patients have low SNAPs and/or CMAPs, resulting in a lower SNF. As expected 
based on the short median disease duration, most patients included in this study had mild to moderate 
disease, represented by a median baseline NIS of  8 points (Table 1).
Response classification. As expected in a complex disease such as FAP, no single available outcome mea-
sure reflects disease progression fully (20). For example, symptoms such as severe diarrhea, urinary retention, 
and erectile dysfunction, resulting from autonomic nervous system involvement, are frequently seen in these 
patients (4, 22). Changes in these disease manifestations are not captured by NIS or SNF. Additionally, the 
impact of these symptoms in each patient’s quality of life can be highly variable. For this reason, we based our 
response classification on an expert opinion. At the end of the observation period, a clinical expert in TTR-
FAP on our research team individually reviewed each patient record, including neurology, cardiology and 
nephrology visits, as well as NIS, neurophysiology data, quality-of-life evaluations, and weight measurements. 
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Based on this complete evaluation, patients were classified as responders, partial responders, and nonrespond-
ers (Figure 1A). Seventy-two patients (34%) were considered to have no discernible disease progression and 
were therefore classified as responders. Change in NIS, calculated as the difference between NIS at each time 
point and NIS at baseline, showed that responders’ disease was mostly stable or improved (i.e., NIS change 
from baseline ≤0 for almost the entire study period; Figure 1B, green line). Continuous worsening of sensory, 
motor, and/or autonomic neuropathy, not different from the expected progression without therapy, was seen in 
62 patients (30%), who were classified as nonresponders. This group showed an NIS increase from baseline of  
3 points or more, after 18 months of treatment with tafamidis (Figure 1B, red line). An additional group of 76 
patients (36%) were classified as partial responders, including patients whose autonomic nervous system mani-
festations improved dramatically while their sensory and/or motor neuropathy still progressed, or patients who 
continued progressing overall, albeit more slowly than nonresponders. Accordingly, this group showed an NIS 
increase from baseline of 1 point or more, also after 18 months of treatment with tafamidis (Figure 1B, blue 
line). Overall, when the rate of NIS change was analyzed, responders remained stable (0 points/yr), while par-
tial responders increased 1.8 points/yr, and nonresponders increased 5.9 points/yr (Supplemental Figure 2). 
As explained above, the overlap of the rates of change in NIS seen among the 3 groups reflects the existence of  
other disease manifestations that are not measured by NIS, but which were considered in our expert classifica-
tion. For example, responders and partial responders can be separated from nonresponders, as the first 2 groups 
gained weight or remained stable significantly more than nonresponders for the first 4 years of follow-up (Fig-
ure 1C). The same results were observed with modified BMI (Supplemental Figure 3).
Figure 1. Patients can be classified in 3 groups according to expert opinion and selected outcome measures. (A) Study flowchart. (B) NIS change from baseline 
and (C) change in weight (in kg) from baseline according to expert opinion response classification in 3 groups. x axis in B and C represent number of follow-up 
months (m); numbers below B and C represent number of patients evaluated at each time point (NR, nonresponders; PR, partial responders; R, responders). 
Data are shown as median, with error bars representing interquartile range; P values were calculated using Kruskal-Wallis test with Dunn’s multiple-comparisons 
correction. *P < 0.05, **P < 0.01; P values are only shown when differences exist between the 3 groups using multiple-comparisons correction.
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Norfolk QOL-DN data were collected at baseline and yearly after the start of  tafamidis treatment. 
Interestingly, no differences in changes to the Norfolk QOL-DN data existed among patients who were 
classified as responders, partial responders, and nonresponders (Supplemental Figure 4).
In summary, our data suggest that in the long-term commercial setting, tafamidis fully stabilizes neu-
ropathy and weight loss in about one-third of  FAP patients. Additionally, another third exhibited slower 
overall disease progression, or continued progressing, while having clear improvements from autonomic 
neuropathy and weight loss. Finally, these data also suggest that despite therapy with tafamidis, about a 
third of  patients continue progressing as rapidly as untreated FAP patients.
Clinical and demographic baseline outcome predictors. We next sought to investigate baseline characteris-
tics that could help predict response to tafamidis. In a univariate analysis, sex was a strong predictor of  
response, with women more likely to become responders than men (Table 2).
Disease severity was the next sex-independent predictor variable. Patients with mild neurological 
impairment at baseline, as reflected by a median NIS of  6 and SNF of  70.5, were significantly more likely to 
become responders. In addition, moderate disease at baseline was significantly linked with partial response, 
while more advanced patients were less likely to respond well to tafamidis (Table 2). Baseline patient quali-
ty-of-life self-assessment measured by Norfolk QOL-DN was also able to distinguish responders from non-
responders, with patients reporting worse quality of  life more likely to become nonresponders (Table 2).
Age at baseline, age at disease onset, and disease duration were not predictors of  response to tafamidis 
(Supplemental Table 2). Routine laboratory tests — including renal, liver, and thyroid function, lipid pro-
file, complete blood count, general inflammatory markers, uric acid, and iron — did not show significant 
differences among the 3 groups at baseline (Supplemental Table 2).
Baseline plasma biomarkers predicting outcome. Plasma TTR levels were previously reported to be lower in 
patients with TTR amyloidoses (23). Moreover, low TTR levels have been associated with a decrease in survival 
in patients with WT-TTR cardiomyopathy (24). In order to determine whether there were significant differences 
among the 3 groups in tetrameric TTR levels at baseline, we measured TTR concentration (CTTR) employing a 
fluorogenic small molecule (A2) that binds and reacts with natively folded TTR, rendering the conjugate fluores-
cent, which when combined with ultra-performance liquid chromatography (UPLC) separation enables quan-
tification of native TTR tetramer (25, 26). We found that patients who become responders had higher levels of  
tetrameric TTR (3.0 μM) than partial responders (2.7 μM) and nonresponders (2.3 μM) at baseline (Table 2 and 
Figure 2A). This difference was not explained by sex differences in plasma TTR levels (Figure 2B). Likewise, 
CTTR showed weak or no correlation with disease severity, as measured by SNF (Figure 2C) and NIS (Figure 2D). 
This suggests that tetrameric TTR levels can be used as an independent predictor of response to therapy, i.e., 
patients who have higher levels of tetrameric TTR are more likely to become responders.
Troponin T, a measure of  cardiac muscle damage, was significantly lower at baseline in the responders 
compared with the other 2 groups (Table 2). This difference was independent of  sex (P = 0.136, Mann-Whit-
Table 1. Genetic, demographic, and clinical characteristics of the study population at baseline
Study population (n = 210)
Genotype Val30Met/WT: 206 (98.1%), Val30Met/Val30Met: 2 (1.0%), 
Val28Met/WT: 1 (0.5%), Val30Met/Thr119Met: 1 (0.5%)
Sex F:M (%M) 93:117 (55.7%)
Age of disease onset (yr) 34.1 (29.0–43.1; 19.6–81.0)
Age at baseline (yr) 36.5 (32.0–45.7; 22.5–84.3)
Disease duration at baseline (yr) 2.1 (1.3–3.6; 0.3–16.5)
NIS 8 (4–16; 0–116)
Norfolk QOL-DN (n = 201) 22 (10–38; 0–108)
SNF (n = 207) 57.9 (32.8–79.0; 0.1–139.7)
F, female; M, male. Median values are shown for all continuous variables; interval between the first quartile (Q1) and 
the third quartile (Q3) is shown in parentheses; minimum and maximum are also included between parenthesis in 
italic. Nine patients did not complete the Norfolk QOL-DN questionnaire at baseline and 3 patients did not perform 
baseline neurophysiological measurements. NIS, neuropathy impairment score; Norfolk QOL-DN, Norfolk Quality of Life 
Questionnaire–Diabetic Neuropathy; SNF, neurophysiological score.
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ney U test); however, there was a correlation between troponin T values and disease severity as measured 
by SNF (Spearman’s correlation coefficient = –0.59, P < 0.0001) and NIS (Spearman’s correlation coefficient 
= 0.49, P = 0.0003). Although the number of  patients for whom troponin T values were available was low 
(n = 51), this suggests that having less cardiac involvement might be also predictive of  a better response to 
tafamidis, albeit not independent from the other measures of  clinical severity.
Tafamidis and extent of  TTR stabilization in plasma correlates with clinical outcome. Next, we hypothesized 
that the tafamidis plasma concentration, which correlates with the extent of  TTR kinetic stabilization, could 
explain why some patients respond to tafamidis better than others (26). TTR tetramer dissociation into mono-
mers is the rate-limiting step of  the TTR amyloidogenesis cascade. The process of  TTR amyloidogenesis is 
thought to be the cause of  tissue degeneration and disease progression (27). Tafamidis acts by kinetically 
stabilizing the TTR tetramer, slowing down tetramer dissociation into monomers, and consequently slowing 
aggregation and disease progression (12) (Figure 3A). We developed biochemical methods to measure total 
tafamidis plasma concentration (CTaf) (26), as well as a TTR subunit exchange method to quantify the rate of  
tetramer dissociation to monomers in plasma (25). When analyzing CTaf by response classification, we found 
that nonresponders had significantly lower tafamidis levels (Figure 3B; 6.8 μM) than partial responders (8.4 
μM) and responders (8.7 μM). The same difference was seen at 24 months of  therapy, and the same tendency 
was found in the samples for which a last time point (more than 24 months) was analyzed (Supplemental 
Figure 5, A and B). These patients were all taking tafamidis meglumine 20 mg once daily (corresponding 
to 12.5 mg tafamidis). Blood samples were collected at the time of  the visit, and information regarding the 
last tafamidis dose was not collected. However, tafamidis levels at 12 months correlated well with tafamidis 
levels at 24 months within the same individual, and the overall differences between 12 and 24 months were 
not significant, suggesting that temporal variations in drug levels were minor (Supplemental Figure 6, A and 
B). This was not unexpected based on the reported long half-life of  tafamidis (~50 hours). Interestingly, when 
analyzing men and women separately, we found that the differences in CTaf between different response groups 
were driven entirely by male patients (Figure 3C, CTaf NR-women = 8.4 μM, CTaf PR-women = 9.2 μM, CTaf R-women = 8.4 
μM; and Figure 3D, CTaf NR-men = 6.3 μM, CTaf PR-men = 7.6 μM, CTaf R-men = 9.7 μM).
CTaf should correlate with the extent of  TTR tetramer kinetic stabilization (defined as the difference 
between the rate of  tetramer dissociation at 12 months or 24 months and the rate of  tetramer dissociation 
at baseline), and it did (Figure 3E and Supplemental Figure 7A), reflecting target engagement. Consis-
tent with the differences in CTaf reported above, the extent of  stabilization was also different according to 
response classification in male patients (Figure 3F).
According to these observations, CTaf, and consequently, the extent of  TTR tetramer stabilization, is a 
predictor of  response only in male patients. This suggests that additional mechanisms for nonresponse may 
play an important role in women.
Factors that influence CTaf. Interestingly, our data show that CTaf has a wide range of  concentrations, i.e., 
from ~20 μM to ~0 μM (Figure 3B). We next sought to investigate factors that could help explain this 
Table 2. Baseline characteristics by response classification group
Responders (R) Partial responders (PR) Nonresponders (NR) R vs. NR R vs. PR PR vs. NR
Demographic characteristics
Sex (%F) 68.1% 35.5% 27.4% <0.0001 <0.0001 NS
Disease severity
NIS 6 (4–10) 10 (6–5) 14 (8–31) <0.0001 0.004 0.014
SNF 70.5 (56.2–96.1) 58.0 (35.7–77.3) 30.5 (16.5–55.5) <0.0001 0.0002 0.003
Norfolk QOL-DN 16 (9–29) 20.5 (11–36) 28.5 (14–52) 0.002 NS NS
Plasma biomarkers
Troponin T (ng/mL) 0.007 (0.004–0.011) 0.013 (0.007–0.019) 0.013 (0.010–0.028) 0.015 0.033 NS
CTTR (μM) 3.0 (2.3–3.8) 2.7 (2.1–3.3) 2.3 (1.5–3.1) 0.002 NS NS
Median values are shown for all continuous variables; interval between Q1 and Q3 is shown in parentheses. P values for continuous variables were 
calculated using a Kruskal-Wallis test with Dunn’s multiple-comparisons correction; P values for sex were calculated using a χ2 test. Troponin T values were 
only available from 51 patients (21 responders, 18 partial responders, 12 nonresponders); CTTR is the concentration of TTR in plasma, also shown in Figure 
2A. NIS, neuropathy impairment score; SNF, neurophysiological score; Norfolk QOL-DN, Norfolk Quality of Life Questionnaire–Diabetic Neuropathy.
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variation in CTaf. In general, drug levels are influenced by sex, age, drug absorption and metabolism, body 
weight and size, and renal and/or hepatic impairment (28). Women had overall higher levels of  tafamidis 
in plasma at 12 months than men (8.6 μM versus 7.6 μM, Figure 4A), but this difference was not statistical-
ly significant. Moreover, at 24 months, both men and women had the same median CTaf in plasma (7.6 μM; 
Figure 4B). When adjusting for BMI, there were no significant differences in CTaf between men and women 
at 12 months (CTaf men = 0.34 μM/[kg/m
2], CTaf women = 0.35 μM/[kg/m
2]) and 24 months (CTaf men = 0.36 μM/
[kg/m2], CTaf women = 0.33 μM/[kg/m
2]).
Differences in metabolism could also explain some of  the CTaf variation. Approximately 20% of  taf-
amidis is reported to be metabolized by glucuronidation to acylglucuronide (herein referred to as tafa-
midis-gluc.). If, in fact, patients with low CTaf are faster metabolizers, one would expect to find higher 
tafamidis-gluc. levels in the plasma of  patients with low unmetabolized tafamidis. We were able to detect 
the peak corresponding to tafamidis-gluc. in plasma of  patients taking tafamidis by comparison to synthe-
sized tafamidis-gluc. (Supplemental Figure 8, A–D). By comparing the area of  the metabolite peak (elution 
volume 9 mL) with the area of  the unmetabolized drug (elution volume 13 mL), we found a strong positive 
correlation between the two, suggesting that increased glucuronidation is unlikely to explain low tafamidis 
levels (Figure 4C). In the subset of  patients analyzed, tafamidis-gluc. represented 1%–15% of  the total CTaf.
Finally, we did not find significant correlation between tafamidis plasma levels and age, weight, BMI 
and modified BMI (mBMI), estimated glomerular filtration rate (eGFR; measure of  renal function) and 
asparate aminotransferase (AST; measure of  hepatic function) at 12 or 24 months (Table 3). Only alanine 
aminotransferase (ALT; measure of  hepatic function) at 24 months had a weak correlation with tafamidis 
levels (r < −0.20, Table 3).
In summary, we were able to exclude common factors that play a role in drug pharmacokinetics as 
being responsible for the lower tafamidis concentrations seen preferentially in nonresponders; however, it 
is worth noting that our analysis did not fully exclude the hypothesis of  faster tafamidis excretion or poor 
absorption in patients with low tafamidis levels.
A predictive model of  response to tafamidis. The observations in the preceding sections show that several 
variables that can be measured before or soon after tafamidis therapy is initiated vary significantly among 
Figure 2. Concentration of tetrameric plasma 
TTR at baseline is significantly different 
between responders and nonresponders. (A) 
Concentration of tetrameric plasma TTR (CTTR) 
at baseline is significantly higher in responders 
than in nonresponders; P values were calculated 
using Kruskal-Wallis test with Dunn’s multi-
ple-comparisons correction; nNR = 55, nPR = 72, 
nR = 70. (B) No differences were seen between 
men and women in CTTR at baseline. P values 
were calculated with Mann-Whitney U test; 
nmen = 106, nwomen = 91; for A and B, horizontal 
bars represent median and error bars represent 
interquartile range. (C) Weak correlation or no 
correlation is seen between CTTR and SNF (n = 
194), and (D) CTTR and NIS at baseline (n = 197); 
for C and D, r represents Spearman’s correlation 
coefficient. Red line represents best fit; curved 
red lines represent 95% confidence intervals of 
the best fit.
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Figure 3. Concentration of tafamidis in plasma and extent of tetramer stabilization are different according to response classification. (A) Diagram 
representing the TTR amyloidogenesis cascade hypothesis and the experimental approach for this experiment. Using samples collected at baseline (bas) 
and after 12 months of therapy, the rate of dissociation of the TTR tetramer was determined at baseline and after 12 months of tafamidis therapy; the 
extent (Δln kex) of TTR tetramer stabilization was calculated as shown in the figure; additionally, total concentration of tafamidis (CTaf) in plasma was 
measured in the 12-months samples. (B) Total CTaf in plasma is significantly lower in nonresponders (n = 62) when compared with partial responders (n = 
75) and responders (n = 71). (C) Total CTaf in women is not significantly different according to response classification (NR: n = 17, PR: n = 26, R: n = 49). (D) 
CTaf in men is significantly lower in nonresponders (NR: n = 45, PR: n = 49, R: n = 22). (E) Correlation between plasma CTaf and the extent of TTR stabilization 
(n = 194), showing that a higher CTaf is positively correlated with a more stable TTR tetramer. r, Spearman’s correlation coefficient; red line represents best 
fit (R2 = 0.26); curved red lines represent 95% confidence intervals of the best fit. (F) TTR in plasma of male nonresponders (n = 40) is significantly less 
stable when compared with male partial responders (n = 44) and male responders (n = 22); for B–D and F, horizontal bars represent median and errors bar 
represent interquartile range. P values were calculated using Kruskal-Wallis test with Dunn’s multiple-comparisons correction.
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nonresponders, partial responders, and responders. Therefore, these variables could in principle be used to 
predict a patient’s responsiveness to tafamidis. To explore this possibility, we converted the categorical out-
come variable (i.e., the response classification), which has the values “nonresponder”, “partial responder”, 
and “responder”, to a numerical variable with corresponding values of  0, 0.5, and 1, respectively. We then 
fit the linear model shown below to the numericized responses for the 210 patients in our database:
SR = a0 + bNF×SNF + bM×M + bM-Taf×M×CTaf + bTTR×CTTR,   (Equation 2)
where SR is the numericized response score; a0 is the constant of  regression; SNF is the neurophysiology score 
(a sum of several SNAPs and CMAPs); M is the sex of  the patient, coded as 1 for males and 0 for females; 
and CTaf and CTTR are the micromolar plasma concentrations of  tafamidis and tetrameric TTR, respectively.
Note that the fourth term has a product of  2 variables, M and CTaf. Given the coding for M, M×CTaf = 
0 for females and M×CTaf = CTaf for males. This interaction variable therefore accounts for our observation 
that plasma CTaf differed significantly among the response classifications only for male patients.
The quantities denoted by b with subscripts are the regression coefficients for the corresponding vari-
ables. The best-fit values for the parameters are as follows: a0 = 0.195 ± 0.076, bNF = 0.0046 ± 0.0007, bM = 
−0.447 ± 0.083, bM-Taf = 0.027 ± 0.008 μM
−1, and bTTR = 0.068 ± 0.022 μM
−1. The model captures a moder-
ate amount — about 35% (R2 = 0.35) — of  the variation in the responses of  individual patients to tafamidis 
therapy. However, given the discrete nature of  the response classification variable, this is not the best way 
to judge the utility of  the model. Instead, we divided the model outputs into quintiles and calculated the 
proportions of  nonresponders, partial responders, and responders in each quintile (Figure 5A).
Figure 4. Variation in CTaf is not explained by sex or by tafamidis glucuronidation. (A) CTaf is not different between 
women and men at 12 months (P = 0.70; nmen = 116, nwomen = 92) and (B) 24 months of therapy (P = 0.77; nmen = 116, nwomen 
= 93); for A and B, horizontal bars represent median and errors bar represent interquartile range. P values were calculat-
ed using a Mann-Whitney U test. (C) Left panel: Chromatogram representing fluorescence detection of tafamidis-gluc. 
and unmetabolized tafamidis in the plasma of a patient taking oral tafamidis (for details, see Supplemental Methods 
and Supplemental Figure 8). Right panel: Correlation between the AUC for the tafamidis peak and the metabolite peak 
(tafamidis-gluc.). r, Spearman’s correlation coefficient; red line represents best fit (R2 = 0.44); curved red lines repre-
sent 95% confidence intervals of the best fit.
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The proportions of  each response category in a given quintile can then be taken as estimates of  the 
probabilities that a new patient who also falls into that quintile (based on their calculated SR, obtained from 
evaluating Equation 2 with that patient’s sex, SNF, CTaf, and CTTR values) will have a given response to tafa-
midis. For example, a hypothetical male patient (M = 1) with SNF = 32.9, CTaf = 14.9 μM, and CTTR = 3.6 μM 
has a calculated response score value of  SR = 0.195 + (0.0046 × 32.9) + (−0.447 × 1) + 0.027 × 1 × 14.9 + 
0.071 ± 0.068 × 3.6 = 0.55. An SR of  0.55 would place this hypothetical patient in the third quintile (Figure 
5A), where their probability of  being a nonresponder, partial responder, or responder is 19% ± 6%, 43% ± 
8%, or 38% ± 7%, respectively (uncertainties represent the standard errors for proportions).
The robustness of this model is difficult to assess using traditional methodology employed to evaluate bina-
ry classifier systems (for example, receiver operating characteristic [ROC] curves) because it has 3, rather than 2, 
classifications. Therefore, to give a sense of the ability of our model to discriminate between the response catego-
ries, we show 2 ROC curves for our model (Figure 5B): one showing discrimination between the combined non-
responder and partial responder categories versus the responder category (NR+PR vs. R; purple curve) and the 
other discrimination between the nonresponder category versus the combined partial responder and responder 
categories (NR vs. PR+R; cyan curve). The former curve emphasizes identification of responders, whereas the 
latter emphasizes identification of nonresponders. The AUCs of the 2 ROC curves were 0.82 and 0.81, respec-
tively, indicating that our model is effective at discriminating both responders and nonresponders.
The relative importance of  the variables in our model can be assessed by leaving each one out of  the 
model in turn and assessing the performance of  the abbreviated models. This exercise revealed that SNF was 
the most important variable in our model, since leaving it out diminished the AUCs of  the ROC curves to 
0.75 for the NR+PR vs. R curve and 0.72 for the NR vs. PR+R curve. The importance of  the other vari-
ables decreased in the following order: sex (M) > M×CTaf > CTTR. The best fit parameters and AUCs for the 
abbreviated models are presented in Supplemental Table 3.
NIS was left out of  our model because SNF and NIS provide somewhat redundant information about 
the extent of  disease progression in terms of  nerve function, but SNF better discriminated responders, partial 
responders, and nonresponders (Table 2). In fact, SNF decreased exponentially as NIS increased, so that SNF 
decreased precipitously over a narrow range of  small NIS values (Supplemental Figure 9). Thus, SNF seems to 
be more sensitive than NIS to early disease progression in FAP. However, NIS is more widely available and 
a fully validated clinical score. For this reason, we built an alternative model (Model-NIS), in which SNF was 
replaced by NIS (Supplemental Figure 10). Finally, since the biochemical methods to measure CTaf and CTTR 
might not be available in all clinical centers following these patients, we built a simplified version of  our model 
(Model-S), in which plasma measurements of  tafamidis and TTR concentrations were left out (Supplemental 
Figure 11). In both cases (Model-NIS and Model-S), discrimination between the 3 response groups was still 
possible (Supplemental Figures 10 and 11), although not as clear as with the original model (Figure 5A).
The usefulness of  our model for estimating an individual patient’s chances of  being a nonresponder, 
partial responder, or responder to tafamidis therapy (20 mg qd) can only truly be tested by prospectively 
applying it to a cohort of  patients as they begin treatment and then comparing the proportions of  each 
response category in each quintile to the expected proportions from our model. However, in the interim, 
Table 3. Relation between plasma CTaf and patient characteristics that could influence tafamidis pharmacokinetics
CTaf (at 12 mo) CTaf (at 24 mo)
r P value r P value
Age –0.0485 0.4868 –0.0721 0.2993
Weight –0.0129 0.8528 –0.0878 0.2127
BMI –0.0013 0.9846 –0.0818 0.2460
mBMI 0.1067 0.1260 0.0208 0.7687
eGFR –0.0482 0.4903 –0.0065 0.9261
AST –0.0403 0.5634 –0.0606 0.3847
ALT –0.1029 0.1390 –0.1690 0.0147
BMI is shown in kg/m2; mBMI (modified BMI) in kg/m2 × g/L of serum albumin; and eGFR in mL/min/1.73 m2. AST, aspartate transaminase; ALT, alanine 
transaminase; eGFR, estimated glomerular filtration rate. Only ALT at 24 months is not independent from CTaf (P < 0.05 highlighted in bold); however, the 
Spearman’s correlation coefficient (r) for ALT suggests negligible correlation.
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we were able to test the validity of  our approach by randomly dividing the patient data set into “training” 
and “test” sets. The training set was used for fitting the model, setting the boundaries for the quintiles, and 
calculating the expected proportions of  each response category in each quintile. The fitted model was used 
to calculate response values for the test set, which were then sorted into the quintiles defined by the training 
group, and the proportion of  each response category in the quintiles from the test set was compared with 
the expected proportions from the training set. We repeated this procedure 100 times and found that the 
proportions of  the responder categories in the quintiles from the training set predicted the proportions in 
the test set with a root mean square deviation of  ±14%. This error was consistent with the standard errors 
shown in Figure 5 for the proportions in the quintiles calculated from the full data set — which are typically 
on the order of  7%–8% — given that the training and test sets were each half  the size of  the full data set. 
These results suggest that our model can indeed be useful for predicting the likelihood that a given patient 
will respond to tafamidis therapy.
Discussion
Herein, we have shown that over a maximum follow-up period of  66 months, at least one-third of  
patients taking tafamidis respond to the drug with almost complete cessation of  disease progression. Our 
criteria to define responders (resulting in a median NIS score change from baseline ≤0 for 54 months) 
are more stringent than the criteria used in previous studies (change in NIS in the lower limbs [NIS-LL] 
<2 points in 18 months) (8, 13). We identified an additional one-third of  patients with partial remission 
of  important disease manifestations while continuing progressing from other disease aspects (defined 
as partial responders). The lack of  an untreated control group was a limitation of  our study that could 
Figure 5. Predictive model 
of response to tafamidis. 
(A) The response score (SR) 
interval of each quintile is 
shown in the x axis, and the 
probability for each response 
classification within each 
quintile is shown in the y 
axis. Error bars represent 
95% confidence limits. (B) 
Receiver operating character-
istic (ROC) curves for the pre-
dictive model. Purple curve: 
Discrimination between the 
combined nonresponder and 
partial responder categories 
versus the responder catego-
ry (NR+PR vs. R). True posi-
tives in this case are patients 
who are nonresponders or 
partial responders with SR 
below a given cutoff; false 
positives are responders with 
SR below a given cutoff (SR 
cutoffs are shown as purple 
numbers). Cyan curve: Dis-
crimination between the non-
responder category vs. the 
combined partial responder 
and responder categories (NR 
vs. PR+R). True positives in 
this case are patients who are 
nonresponders with SR below 
a given cutoff; false positives 
are partial responders or 
responders with SR below a 
given cutoff (SR cutoffs are 
shown as cyan numbers).
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not be avoided, given that tafamidis is the standard of  care for patients in Portugal. However, one can 
compare our results with previously reported natural history studies or placebo-controlled clinical trials 
for FAP. It is clear that patients in the responder and partial responder groups progressed slower (median 
NIS progression rate: 0 points/yr for responders and 1.8 points/yr for partial responders) than what was 
described in the pivotal tafamidis study (8, 13) for the placebo-treated cohort (NIS-LL progression rate 
of  approximately 5 points in 12 months), which includes a patient population comparable to ours. Addi-
tionally, a combined analysis of  252 matched untreated FAP patients had an NIS-LL progression rate 
of  2.8 points/yr (17). A multinational natural history study including more advanced patients (median 
baseline NIS of  32) estimated a rate of  NIS progression of  14.3 points/yr (29). These data confirm that 
untreated patients progress at a rate of  more than 2 points per year in their NIS-LL. The fact that NIS-LL 
is a subpart of  NIS will lead to an identical or higher progression rate when considering the total score as 
we do in the current study. Additionally, we report a third of  patients using our more stringent analysis as 
nonresponders with a median NIS progression rate of  5.9 points/yr, which is within the range reported 
for the rate of  progression of  untreated FAP patients in the above-mentioned placebo-controlled studies 
or observational and natural history studies (8, 13). Moreover, our data support the tafamidis registration 
trial (8), in which 60% of  the efficacy-evaluable population was considered to be “NIS-LL responders.” 
The response classification by one single expert is a weakness in our study; however, the clinical scores 
and the opinions of  the neurologists observing each patient were taken into consideration by the expert. 
A consensus of  multiple experts on response classification should be the aim of  future studies. It is 
important to note that progression of  Norfolk QOL-DN scores was not a useful measure of  tafamidis 
response in this group of  patients. Patients who were unequivocally progressing from their motor and 
sensory neuropathy showed minimal changes in this patient-reported outcome measure, possibly reflect-
ing patients’ expectations of  a treatment effect and the open-label nature of  this study.
One limitation of  our 3-group approach is that, while clinically rigorous and supported by different 
scores, it might have led us to lose power in our prediction model. Despite this limitation, we believe that 
this classification-by-response model can be used to rigorously compare mechanistically distinct therapies 
in the commercial setting, where observation times are longer and more meaningful. Additionally, the 
3-group approach can be used to evaluate patients with other FAP genotypes treated with tafamidis at the 
same or higher doses. Ideally, data from multiple clinical centers should be combined in order to acquire 
information on larger patient data sets.
An important aim of this study was to identify baseline demographic and clinical characteristics and 
identify plasma biomarkers that can be used as tafamidis outcome (or response-to-therapy) predictors. Our 
data show that female sex is a clear predictor of  a positive response to tafamidis. These data raise the possi-
bility that sex differences influence underlying disease mechanisms, a hypothesis that is also supported by the 
peripheral blood cell transcriptional profiling differences between men and women reported previously (30). 
Future studies of  disease-specific and response-to-therapy biomarkers should take sex in consideration. Our 
data also confirm that early-stage patients are more likely to respond positively to tafamidis. This raises the 
hypothesis that TTR dissociation, misfolding, and aggregation initiate a downstream cascade of  abnormal 
events that can auto-perpetuate itself  even when the proteinopathy trigger to pathology is removed by tafa-
midis treatment. A better understanding of  early and late disease events, as well as the role of  neuroinflam-
mation, is essential, as it may lead to complementary treatment approaches. Additionally, we have identified 
tafamidis concentration (and consequently TTR kinetic stabilization) as a predictor of  response in a subset of  
patients, predominantly men. This finding raises the possibility that some FAP patients might benefit from a 
higher dose of  tafamidis, and this should be further investigated.
These data also highlight the need for early diagnostic biomarkers in FAP to allow early initiation of  
therapy. Using a method that detects only natively folded tetrameric TTR, we found that patients who 
had higher levels of  native TTR at baseline were more likely to become responders than nonresponders. 
Future studies should further investigate the differences between our A2-UPLC tetrameric TTR quan-
tification method and the routinely used immunoturbidimetric methods to define TTR levels as a prog-
nostic indicator of  response to kinetic stabilizers. The reasons why FAP patients have low levels of  TTR 
are not understood. Interestingly, reduced CSF levels of  Aβ42 were established as diagnostic biomarkers 
after longitudinal studies following genetic Alzheimer’s disease cases (31). Analogously, longitudinal 
follow-up of  presymptomatic FAP mutation carriers should help define the role of  native TTR levels in 
detecting early symptomatic disease stages.
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Using data from this retrospective patient study, we were able to build a predictive model of  response 
to tafamidis (20 mg qd), which can potentially be used in the clinical setting to help clinicians and patients 
predict response, and eventually to prioritize therapy. To build the model, we used plasma tafamidis con-
centration at 12 months (CTaf); however, based on the reported pharmacokinetic characteristics of  tafa-
midis and also on our comparisons between 12 and 24 months, we consider that concentration after 1 
month of  therapy should be used in future studies to further validate this model. Moreover, additional 
response-to-therapy biomarkers that might strengthen this model are currently under investigation using 
unbiased plasma proteomic approaches. It is important to keep in mind that our model was built using 
patients with a predominantly neuropathic phenotype, and most of  our patients were heterozygous for the 
common Val30Met mutation (98.1%). Future studies with other mutations and mixed cardiac/neuropathy 
phenotypes should indicate whether a similar model can be applied more broadly.
Finally, our work comprises detailed clinical and biochemical human data supporting the amyloid 
hypothesis applied to the TTR amyloidoses. The amyloid hypothesis posits that the misfolding and aggre-
gation of  a given protein into a spectrum of  non-native structures, including cross-β-sheet amyloid fibrils, 
is linked to tissue degeneration (32). Overall, disease progression is slowed when the dissociation rate of  
plasma TTR tetramers is reduced by correspondingly higher plasma concentration of  the kinetic stabilizer 
tafamidis. This provides a direct link between neuropathy progression and the inhibition of  TTR aggrega-
tion via TTR native tetramer stabilization.
Methods
Study design
This was a nonrandomized, longitudinal observational study of  all patients eligible to start therapy with 
tafamidis in a single clinical center (Unidade Corino de Andrade), with at least 24 months follow-up from 
baseline (or a minimum of  18 months for patients who did not respond during that period of  time), up to 
66 months. Patients were considered eligible to start therapy with tafamidis when they met the following 
criteria: (i) confirmed TTR genetic mutation, (ii) tissue biopsy with confirmed Congo red–positive amyloid 
deposition, and (iii) symptoms or signs confirming involvement of  the peripheral nervous system (sensory, 
autonomic, and/or motor). For this study, the following exclusion criteria were considered: (i) patients 
included in the clinical trial Fx005 (ClinicalTrials.gov, NCT00409175) or Fx006 (NCT00791492), (ii) inclu-
sion in the open-label add-on trial with the siRNA drug patisiran (NCT01961921), (iii) comorbidities with 
peripheral and/or central nervous system clinical manifestations, (iv) therapy suspension before 2 years for 
reasons other than nonresponse, (v) absent clinical follow-up after 12 months of  therapy, (vi) no baseline or 
subsequent plasma samples collected, and (vii) refusal to participate in the study.
Study population
All patients eligible for this study with baseline assessment between July 2012 and January 2016 were 
included. Patients were assessed at treatment start (baseline visit) and subsequently every 6 months up to 
5.5 years. Patients were observed by one of  6 trained neurologists working or previously working at the 
FAP clinic. When considered necessary, they were also observed by a cardiologist, ophthalmologist, and/
or nephrologist. A standardized protocol included the outcome measures detailed below: NIS, Norfolk 
QOL-DN, weight, routine neurophysiologic tests including sensory and motor nerve amplitude measure-
ments, and routine blood tests. Information regarding TTR mutation was available for all patients. Disease 
duration was based on judgment by the treating neurologist regarding the information provided by each 
patient for the onset of  symptoms and signs associated with TTR-FAP.
Outcome measures
NIS, Norfolk QOL-DN, weight, BMI, and mBMI. Patients had their NIS score determined at baseline and 
every 6 months. For most patients, the neurologist scoring was the same at baseline and follow-up, reducing 
the chance for interobserver variability. Concomitantly, patients had height measurement at baseline or at 
an asymptomatic stage and weight measurements at all visits of  the study. Serum albumin was determined 
as part of  the routine blood testing at the hospital clinical laboratory.
SNF. Routine nerve conduction studies were performed concurrently with each neurology observation. 
The SNAPs of  ulnar and sural nerves were measured (peak to peak). Average SNAP was used when bilat-
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eral measurements were available for the same nerve. Most patients had bilateral sural nerve and unilateral 
ulnar nerve SNAP measurements. CMAPs of  the tibial, peroneal, and ulnar nerves were also determined, 
in most cases unilaterally. In patients for whom bilateral measurements were available, average CMAPs 
were calculated. The neurophysiology score corresponds to: sural SNAP + ulnar SNAP + tibial CMAP + 
peroneal CMAP + ulnar CMAP. No adjustments for age, sex, or height were made. In cases where sensory 
or motor potentials were not present in a specific nerve, repeated measurements were not attempted in the 
same nerve in the subsequent visit, and the corresponding SNAP or CMAP was considered 0.
Routine blood tests
Routine blood tests were performed on all patients at the hospital clinical laboratory, including renal func-
tion (creatinine, blood urea nitrogen [BUN], and uric acid), liver function (total bilirubin, aspartate and ala-
nine transaminases, alkaline phosphatase, gamma-glutamyl transaminase, serum albumin), cardiac markers 
(troponin T [Roche Elecsys high-sensitivity], NT-Pro-BNP [Roche Elecsys]), total cholesterol, triglycerides, 
serum albumin, total protein, free thyroxine, thyroid-stimulating hormone, complete blood count, sedimen-
tation rate, and C-reactive protein. Urine samples were assessed for albuminuria and proteinuria. eGFR was 
calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (33).
Responder classification
In January 2018, i.e., 66 months after the study began, an expert in TTR-FAP (TC) classified all patients as 
responders, partial responders, and nonresponders. Patient clinical records were scrutinized individually. 
Additionally, NIS, Norfolk QOL-DN, weight, and neurophysiology score were also considered. Respond-
ers were patients who showed no progression of  sensory, autonomic, and/or motor neuropathic symptoms 
and signs. The usual criterion of  progression of  less than 2 points in the NIS score was not applied (29). 
Patients were classified as nonresponders when they showed a continuous and rapid worsening of  senso-
ry, motor, and/or autonomic neuropathy not different from the expected progression without therapy. A 
group of  partial responders included patients who showed slower than expected progression of  sensory 
and/or motor neuropathy with stability of  autonomic nervous system manifestations, or patients who con-
tinued progressing from sensory and/or motor neuropathy while showing a manifest improvement of  the 
autonomic neuropathy and weight gain. Autonomic nervous system manifestations can be devastating in 
these diseases; therefore, we decided that improvement of  objective symptoms such as diarrhea, orthostatic 
hypotension and erectile dysfunction, even in the presence of  continuous progression of  sensory neuropa-
thy, should be considered at least as a partial response. None of  the biochemical measurements regarding 
TTR concentration, tafamidis concentration, or TTR stabilization played any role in the classification of  
patients as responders, partial responders, or nonresponders.
Plasma samples
Blood was collected in tubes with EDTA, followed by centrifugation at 1500 g for 20 minutes. The resulting 
supernatant (plasma) was carefully removed and centrifuged for an additional 20 minutes to remove any 
remaining cells. Plasma was transferred to 1.5 mL cryovials with a cap and stored at −75°C until it was 
shipped. After shipment in dry ice, frozen patient plasma samples were kept at −80°C. All plasma samples 
were thawed at ambient temperature before being aliquoted and used for the different assays. No more than 
2 cycles of  freeze-thaw were applied. Most patients had blood collection at baseline and every 6 months. 
For most assays, only baseline and annual samples were analyzed (12, 24, 36, 48, and 60 months). In the 
cases where a 12-month sample was not available, a 6-months or 18-month sample was used; similarly, 
when a 24-month sample was not available, an 18-month sample was used. Blood from healthy volunteers 
was obtained from the Scripps Research Institute Normal Blood Donor Services Center.
Recombinant protein expression and purification
Recombinant WT TTR (WT-TTR) and dual-FLAG-tagged WT-TTR (FT2-WT-TTR) were expressed and 
purified from Escherichia coli as described previously. The molar absorptivity (ε) of  WT-TTR (73,800 M−1 
cm−1) and FT2-WT-TTR (85,720 M
−1 cm−1) tetramers in standard phosphate buffer was used to prepare 
TTR solutions of  known concentration. After purification, aliquots were stored at –80°C in 50 mM phos-
phate buffer pH 7.6 (standard phosphate buffer).
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Measurement of tetrameric TTR in plasma
Tetrameric TTR levels in plasma were quantified using a Waters ACQUITY H-Class Bio-UPLC instrument 
employing a Waters Protein-Pak Hi Res Q ion exchange column (strong anion exchanger, 5-μm particle 
size, 4.6 × 100 mm column). A standard curve was prepared using recombinant WT-TTR at concentrations 
of  10 μM, 5 μM, and 2.5 μM in 50 mM phosphate buffer, pH 7.6. Subjects’ samples and 2 healthy control 
samples were thawed and filtered using a 0.45-μm syringe filter. Subjects’ plasma samples, healthy control 
plasma, and standard curve samples were aliquoted (9 μL) in duplicate into a 96-well plate with 1 μL of  the 
fluorescent small molecule A2 (500 μM) in each well (34). The same 2 healthy controls from the Normal 
Blood Donor Services Center were used in duplicate in each plate to determine intra-assay variability. After 
incubation, the samples were injected into the ion exchange column and separated using a linear 24%–29% 
buffer B gradient over 10 minutes (flow 0.5 mL/min, buffer A: 25 mM Tris pH 8; buffer B: same as buffer 
A, but with 1 M NaCl added). The TTR-(A2)2 fluorescent conjugate peak (excitation 328 nm, emission 
430 nm; elution time, 6 minutes) was integrated, and the concentration of  TTR in patient samples was 
quantified using the standard curve. Intraplate variability was ≤15%, and interplate variability was ≤10%.
Subunit exchange assay to assess kinetic stability
Subunit exchange rates were determined as described previously (25) with the following minor modifica-
tions. FT2-WT-TTR (2 μL of  a 40-μM solution) was added to plasma (40 μL) to afford a final FT2-WT-TTR 
concentration of  2 μM. The samples were incubated at 25°C for 48 hours to allow subunit exchange to 
occur. At 48 hours, the reaction was stopped by the addition of  the fluorogenic small molecule A2 at a final 
concentration of  500 μM. The samples were incubated with A2 for at least 3 hours to allow complete cova-
lent labeling of  TTR, before being injected into the ion exchange column and separated using a linear 24%–
39% buffer B gradient over 29 minutes using the same buffers as described above. The rate of  exchange for 
all subunit exchange experiments was calculated using peak 1, as previously described. All patient samples 
were analyzed in duplicate (technical replicates), and most samples corresponding to the same patient were 
run in the same plate. Coefficient of  variability within the samples was ≤15%. The same 2 healthy control 
plasmas were used in duplicate in all subunit exchange plates. The inter-plate variability was ≤17%.
HPLC analysis of tafamidis concentration
Tafamidis levels were quantified in the plasma samples employing the HPLC method previously described 
(26), with the following minor modifications. Four sets of  standard curves were generated simultaneously by 
adding tafamidis (using a 50× stock solution in DMSO) to a healthy donor plasma and incubating overnight 
at 37°C. The final CTaf employed for the standard curve equaled 0, 1, 3, 6, or 12 μM. Protein extraction was 
performed by mixing 40 μL of each standard curve/healthy plasma sample with 200 μL acetonitrile contain-
ing 1% (w/v) trichloroacetic acid. Samples were shaken at 1500 rpm for 30 minutes at 25°C and then centri-
fuged for 10 minutes at maximal speed in a tabletop microcentrifuge. The supernatant was separated into 4 
tubes (50 μL each), and each tube was kept at –80°C before use. One experiment was done to confirm that 
frozen standard curve tubes and freshly prepared standard curve samples gave exactly the same results. Each 
day, 10–15 aliquots from patients taking tafamidis were thawed. 20 μL plasma was mixed with 100 μL aceto-
nitrile containing 1% (w/v) trichloroacetic acid. Shaking and centrifugation were done as with the standard 
curve samples. After protein extraction, standard curve and patient sample supernatants (10 μL) were injected 
into a Thermo Fisher Scientific BetaBasic 18 (50 × 4.6 mm) column using an Agilent 1260 Infinity HPLC 
with fluorescence detection (excitation at 310 nm, emission at 370 nm). A gradient from 90% A (water 95%, 
4.9% acetonitrile, 0.1% trifluoroacetic acid)/10% B (acetonitrile 95%, 4.9% water, 0.1% trifluoroacetic acid) 
to 0% A/100% B was run for 20 minutes at 1 mL/min. A peak at ~13 mL was seen both in plasma samples 
with tafamidis added ex vivo and in patient plasma samples. Pure tafamidis in DMSO also produces a peak 
at the same retention time, and we have previously shown by mass spectrometry that this peak corresponds 
to tafamidis in patient samples. Under the conditions used, the detection limit for tafamidis was 6.3 nM. All 
samples (including patient and standard curves) were prepared and injected in duplicate. The coefficient of  
variability was ≤10%. To confirm that no tafamidis was lost in the protein precipitate using our acetonitrile 
method, we performed one experiment in which tafamidis was added ex vivo to healthy control plasma (5, 
10, 15 μM), protein was extracted as detailed above, and concentration was measured using the same HPLC 
method and standard curve of  pure tafamidis in DMSO. Calculated concentrations were 5.34 ± 0.05 μM, 
11.15 ± 0.07 μM, and 15.21 ± 0.07 μM, showing that our method measures total CTaf in plasma.
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Tafamidis-gluc. was synthesized as described in Supplemental Figure 8 and Supplemental Methods. 
Fluorescence absorption and emission scans were taken to confirm that tafamidis-gluc. has the same fluo-
rescence properties as unmodified tafamidis (i.e., maximum excitation 310 nm and maximum emission 370 
nm). Tafamidis-gluc. was then injected in the HPLC using the same method as above, producing a unique 
peak at ~9 mL. We noticed that in our analysis of  patient samples, the same peak at 9 mL was seen, and 
that this peak was not present when tafamidis was added ex vivo to healthy plasma. We performed the 
same experiment as above to confirm that all tafamidis-gluc. was extracted using our acetonitrile method. 
We then retrospectively analyzed 146 chromatograms and compared the AUC of  the tafamidis peak (13 
mL) to the tafamidis-gluc. peak (9 mL). While doing these experiments, we noticed that synthesized taf-
amidis-gluc. was hydrolyzed in healthy plasma when incubated overnight at 37°C. Therefore, we cannot 
exclude that some endogenous tafamidis-gluc. was being hydrolyzed to tafamidis, leading to an overestima-
tion of  plasma tafamidis levels.
Prediction model
The linear model represented by Equation 2 was fit to the numericized Response values using linear regres-
sion as implemented in Mathematica 11.3 (Wolfram) or Excel (Microsoft). In the few cases where data were 
missing (3 of  210 SNF scores; 9 of  210 TTR concentrations; and 2 of  210 tafamidis concentrations), we used 
mean imputation to replace them; that is, the missing values were replaced with the average value for patients 
of  the same sex and response category. The patients were then divided into quintiles based on their calculated 
response values and the proportions of  each response category in each quintile were calculated. The standard 
errors of  the proportions were calculated as usual for probabilities, i.e., standard error = (Pi × (1 − Pi)/n)
1/2, 
where Pi is the probability of  event i and n is the number of  patients in the sample (for our quintiles, n = 210/5 
= 42) (35). Note that this standard error only considers the probabilities of  the proportions individually. The 
confidence intervals of  the proportions considered jointly are larger by about 60% (35). The alternative mod-
els, Model-NIS and Model-S, were created in an exactly analogous way.
The validation of  the model by comparing the results from a training subset of  the patient database 
with a test subset was also performed using Mathematica 11.3 to randomly split the patients into groups of  
equal size, fit the data to the training set as described above, split the patients into quintiles, and calculate 
the proportions of  nonresponders, partial responders, and responders in each quintile. The fitted model 
was then applied to the test data set; the patients in the test dataset were sorted into the quintiles obtained 
from the training dataset; and the proportions of  nonresponders, partial responders, and responders in each 
quintile were calculated. This process was iterated 100 times, and then the proportions of  each response 
category were compared in the training and test datasets for each iteration. Finally, the root mean square 
of  the differences was calculated.
Blinding
All plasma samples were analyzed for CTaf, tetrameric TTR concentration, and TTR kinetic stability by a 
researcher blinded to response to therapy classification. Treatment status was not blinded. All patients were clas-
sified as responders, partial responders, or nonresponders by a researcher blinded to the biochemical analysis.
Statistics
All graphs and statistics were prepared in Prism 7 (GraphPad Software). For comparisons among 3 or more 
groups, we used a Kruskal-Wallis test with Dunn’s multiple comparison correction. For comparisons between 
only 2 groups, we used a 2-tailed Mann-Whitney U test. Correlations were assessed by calculating the Spear-
man’s correlation coefficient. All P values are indicated in the legends and figures. Scatter plots include a 
horizontal bar for the median value and error bars that represent the first quartile (Q1) and the third quartile 
(Q3). For analyses in which variables were compared among response categories at baseline, missing values 
were few (in the worst case, there were 13 missing values of  210 for baseline subunit exchange rate constants) 
and occurred at random because of  technical problems (insufficient sample for the assay, high sample vis-
cosity, etc.). Moreover, these missing values were spread across the response categories (5 nonresponders, 6 
partial responders, and 2 responders). Therefore, these values were simply omitted from the analysis. For our 
longitudinal analysis of  the change in NIS and weight as a function of  time, we had many more data points 
at early than later time points. This circumstance arose simply because the patients in our population started 
tafamidis treatment on a rolling basis between July 2012 and January 2016. Data for the later time points were 
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only available for patients who began tafamidis therapy at the beginning of  our window. This observation 
suggested that the missing values were missing at random and could be omitted.
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Supplemental Figure 1. Number of patients according to number of follow-up months 
A minimum of 2 years (24 months) for all patients, or 1.5 years (18 months) for patients that 
suspended therapy at 18 months, was established as the inclusion criterion. The exact number of 
patients in each group is shown in front of the corresponding bar. 
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Supplemental Figure 2. Rate of NIS change according to response classification. Kruskal-
Wallis Test with Dunn’s correction for multiple comparison was used to calculate P values. 
Horizontal bars represent median and errors bar represent interquartile range. 
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Supplemental Figure 3. Change in mBMI from baseline according to response classification. 
mBMI is modified body mass index (calculated as BMI multiplied by serum albumin in g/L).  
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Supplemental Figure 4. Change in Norfolk QOL-DN from baseline according to response 
classification. No statistical difference was found in Norfolk QOL-DN between the three 
response groups.  
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Supplemental Figure 5 Tafamidis levels (CTaf) are different according to response 
classification. (A)  CTaf in plasma samples collected after 24 months of therapy with tafamidis is 
lower in Non-Responders (n = 61; median 5.8 µM), than in Partial-Responders (n = 76; 8.0 µM) 
and Responders (n = 72; 8.3 µM) (B) CTaf in plasma samples collected at the last visit (36, 48 or 
60 months) of therapy with tafamidis is lower in Non-Responders (n = 33; median 5.9 µM), than 
in Partial-Responders (n = 57; 7.8 µM). Although Responders have higher tafamidis levels at the 
last visit (n = 52; 7.5 µM) when compared to Non-Responders, this difference is not statistically 
significant; we believe that this lack of statistical significance is because of the low number of 
patients, especially Non-Responders, that had visits at longer time points. P values were calculated 
using Kruskal-Wallis test with Dunn’s correction for multiple comparisons. Horizontal bars 
represent median and errors bar represent interquartile range. 
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Supplemental Figure 6. Plasma tafamidis levels are overall stable within each individual 
throughout this study. (A) CTaf at 12 months correlates well with CTaf at 24 months. Each dot 
represents one patient (n = 207); the results acquired from the 12 months’ sample are shown in the 
x axis; results from the 24 months’ sample in the y-axis. r: Spearman correlation coefficient; red 
full line represents best-fit (R2 = 0.44), dotted red lines represent 95% confidence intervals of the 
best-fit. (B) No statistically significant differences in CTaf were found within the same individual 
at 12 and 24 months. P value was calculated using the Wilcoxon matched-pairs signed rank test (n 
= 207 paired samples); median CTaf at 12 months was 8.2 µM; median CTaf at 24 months was 7.6 
µM.  
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Supplemental Figure 7. Correlation between CTaf at 24 months and the extent of TTR 
stabilization at the same time point. N = 196; r: Spearman correlation coefficient; red line 
represents best-fit (R2 = 0.37), dotted red lines represent 95% confidence intervals of the best-fit. 
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Supplemental Figure 8. Method for detection of tafamidis-glucuronide. (A) Synthetic scheme 
used to prepare tafamidis-glucuronide; DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene, DMF: 
Dimethylformamide, rt: room temperature, NMM: N-Methylmorpholine, HATU: 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, 
Pd(PPh3)4: Tetrakis(triphenylphosphine)palladium(0), THF: Tetrahydrofuran. (B) 1H-NMR (top) and 13C-
NMR (bottom) spectra of Tafamidis-gluc. obtained in DMSO-d6. (C) Tafamidis-gluc. (synthesized as 
shown in panel A) was added to healthy control plasma ex vivo; after protein extraction and reverse-phase 
chromatography separation, tafamidis-gluc. was detected using the same fluorescence channel as tafamidis; 
HPLC: high performance liquid chromatography. (D) Chromatogram representing fluorescence detection 
of tafamidis-glucuronide and unmetabolized tafamidis in the plasma of a patient taking oral tafamidis; the 
two molecules elute at different volumes, allowing individual quantification.  
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Supplemental Figure 9. Exponential relationship between SNF and NIS at baseline. SNF 
decreases exponentially as NIS increases so that SNF decreases precipitously over a narrow range 
of small NIS values and vice versa. Nonlinear regression yields the following best-fit relationship: 
SNF = 98.3 (±3.8) e−0.0509 (±0.0049)×NIS (R2 = 0.57, F = 275.5, P = 8.9×10−40). The dotted red curve 
represents the best-fit nonlinear regression curve. 
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Supplemental Figure 10. Predictive model of response to tafamidis using NIS instead of SNF 
(Model-NIS). The response score (SR) interval of each quintile is shown in the x axis, and the 
probability for each response classification within each quintile is shown in the y axis. Error bars 
represent standard deviation. The equation for this model is shown below (Equation 3).  The best 
fit values for the parameters are as follows: a0 = 0.551 ± 0.075, bNIS = −0.0057 ± 0.0013, bM = 
−0.482 ± 0.085, bM-Taf = 0.026 ± 0.008 μM−1, and bTTR = 0.076 ± 0.023 μM−1. AUC for Non-
Responders+Partial-Responders vs. Responders (NR+PR vs R) ROC curve: 0.66; AUC for Non-
Responders vs. Partial-Responders+Responders (NR vs PR+R) ROC curve: 0.77. ROC curves are 
not shown. 
SR = a0 + bNIS×NIS + bM×M + bM-Taf×M ×CTaf + bTTR×CTTR                                                                                         (3) 
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Supplemental Figure 11. Simplified version of the predictive model of response to tafamidis 
using only SNF  and sex (Model-S.) 
The response score (SR) interval of each quintile is shown in the x axis, and the probability for each 
response classification within each quintile is shown in the y axis. Error bars represent standard 
deviation. The equation for this model is shown below (Equation 4).  The best fit values for the 
parameters are as follows: a0 = 0.335 ± 0.06, bNF = 0.0052 ± 0.0007, bM = −0.199 ± 0.048. AUC 
for Non-Responders+Partial-Responders vs. Responders (NR+PR vs R) ROC curve: 0.81; AUC 
for Non-Responders vs. Partial-Responders+Responders (NR vs PR+R) ROC curve: 0.77. 
SR = a0 + bNF×SNF + bM×M                                                                                                                                 (4) 
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Supplemental Table 1. Reasons for exclusion from the study population 
Exclusion Criteria Number of patients 
Patients previously included in the tafamidis clinical trials  
[Clinicaltrials.gov: Fx-005 (NCT00409175) and Fx-006 (NCT00791492)] 44 
Patients with co-morbidities that might compromise neurological evaluation 
(i.e., diseases with concomitant peripheral nervous system, central nervous 
system or psychiatric manifestations), including: 
Diabetes Mellitus (7) 
History of neoplasia with chemotherapy or radiotherapy treatment (5)  
Heavy alcohol consumption (2) 
Infection with Hepatitis Virus C (2)  
Infection with Human Immunodeficiency Virus (1) 
Hereditary spastic paraparesis (1) 
Severe anxiety syndrome (1) 
Intellectual disability (1) 
20 
 
 
No baseline or subsequent plasma samples collected 7 
Concomitant use of siRNA investigational drug Patisiran  
(patients included in the phase 2 study and the phase 2 open label extension 
study; Clinicaltrials.gov: NCT01617967 and NCT01961921)  
6 
Poor compliance (determined by the assistant neurologist based on information 
given by the patient and / or pharmacy) 5 
Interruption before completing two years of therapy for pregnancy 5 
Lost to follow-up 4 
Early stop of tafamidis (at or before completing 18 months of therapy) because 
of disease progression 3 
Death (unknown cause) 1 
Refusal to participate in study 1 
Total 96 
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Supplemental Table 2. Baseline characteristics that are not significantly different between 
response groups. Yrs: years. BMI: modified body mass index, mBMI: modified body mass index 
(calculated as BMI multiplied by serum albumin), eGFR: estimated glomerular filtration rate 
[calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation]. 
Measurements were obtained for all patients (n = 210) unless otherwise noted. 
aThe missing values for these variables are equally represented for Responders, Partial-
Responders, and Non-Responders. 
 
 Responders (R) Partial-Responders (PR) Non-Responders (NR) 
Demographic characteristics   
Age of onset (yrs) 35.7 (29.9 – 46.7) 33.3 (28.1 – 40.8) 33.1 (29.0 – 42.7) 
Age at baseline (yrs) 37.9 (33.2 – 48.8) 36.1 (30.1 – 42.7) 35.9 (31.8 – 45.0) 
Disease duration (yrs) 1.7 (1.0 – 3.4) 2.1 (1.4 – 3.6) 2.5 (1.4 – 3.6) 
Nutritional status and Renal Function   
Weight (Kg) 61 (53 – 73) 65 (57 – 74) 64 (57 – 72) 
BMI (Kg/m2) 22.7 (20.0 – 26.1) 21.8 (19.6 -25.7) 21.9 (19.2 – 25.2) 
mBMI (Kg/m2 x g/dL) 1010.8 (868.6 – 1179.5) 1019.9 (875.4 – 1149.2) 933.4 (804.4 – 1104.5) 
eGFR (mL/min/1.73 
m2) (n=208) 112.9 (100.6 – 117.9) 112.3 (100.9 – 121.2) 112.7 (101.2 – 119.4) 
Albuminuria (n=205) 
(mg urinary albumin/g 
creatinine) 
7.8 (3.5 -34.3) 7.6 (3.8 – 35.1) 8.0 (4.3 – 53.1) 
Proteinuria (g/L) 
(n=205) 0.11 (0.08 – 0.19) 0.12 (0.08 – 0.25) 0.14 (0.09 – 0.30) 
Liver function    
Total Bilirubin (mg/dL) 
(n=188)a 0.45 (0.36 – 0.61) 0.50 (0.37 – 0.72) 0.53 (0.39 – 0.68) 
AP (IU/L) (n=141)a 52 (42 – 69) 60 (53 – 70) 65 (55 – 75) 
AST (IU/L) (n=205) 19 (15 – 23) 19 (17 – 23) 20 (17 – 26) 
ALT (IU/L) (n=205) 16 (12 – 24) 18 (14 – 26) 20 (14 – 30) 
GGT (IU/L) (n=205) 16 (12 – 23) 16 (13 -24) 16 (12 – 29) 
Albumin (g/dL) 
(n=210) 4.42 (4.11 – 4.72) 4.56 (4.31 – 4.80) 4.41 (4.18 – 4.69) 
Total protein (g/dL) 
(n=210) 6.96 (6.61 – 7.20) 6.92 (6.64 – 7.27) 6.82 (6.32 – 7.15) 
Lipid profile     
Total cholesterol 
(mg/dL) (n=207) 190 (164 – 218) 180 (157 – 210) 180 (149 – 201) 
Triglycerides (mg/dL) 
(n=209) 77 (60 – 108) 73 (51 – 94) 80 (63 – 101) 
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Supplemental Table 2 (Continuation) 
 Responders (R) Partial-Responders (PR) Non-Responders (NR) 
Thyroid function    
Free thyroxine (ng/dL) 
(n=148) 
1.2 (1.1 – 1.3) 1.2 (1.1. – 1.3) 1.2 (1.1 – 1.3) 
TSH (mU/L) (n=148) 1.8 (1.3 – 2.8) 1.7 (1.3 – 2.2) 1.8 (1.2 – 2.7) 
Complete blood count 
(n=210) 
   
Leucocytes (x103/µL)  7.1 (6.3 – 8.5) 7.3 (6.0 – 8.8) 7.4 (6.1 – 8.4) 
Erythrocytes (x103/µL) 4.6(4.4 – 4.9) 4.8 (4.5 – 5.0) 4.8 (4.4 – 5.1) 
Platelets (x103/µL) 244 (211 – 292) 237 (199 – 280) 231 (199 – 264) 
Hemoglobin (g/dL) 14.0 (13.0 – 14.4) 14.4 (13.7 – 15.1) 14.4 (12.8 – 15.3) 
General inflammatory 
markers 
   
C Reactive Protein 
(mg/L) (n=78) 
1.02 (0 – 3.19) 1.01 (0 – 2.80) 0.81 (0 – 2.13) 
ESV (n=78) (mm/hour) 10 (5 – 17.5) 7 (4 – 18.5) 10 (5 – 30) 
Others    
ProBNP (pg/mL) 
(n=185) 77.9 (43.3 – 134.1) 73.4 (35.0 – 149.2) 110.2 (41.6 – 277.7) 
Uric acid (mg/dL) 
(n=209) 
4.1 (3.3 – 5.3) 4.9 (4 – 5.5) 5.4 (4.4 – 6.3) 
Iron (µg/dL) (n=144) 90 (71 – 106) 96 (65 – 117) 105 (88 – 124) 
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Supplemental Table 3. Results of regression and predictive power of truncated predictive models 
based on Equation (2). In each truncated model, a single variable has been excluded from Equation 
(2) to determine its contribution to the predictive power of Equation (2). The quantity a0 is the 
constant of regression, while bNF, bM, bM-Taf, and bTTR are the regression coefficients. R2 is the 
coefficient of determination for the best fit of Equation (2) and its truncated variants to the 
numericized response category data (SR). AUC is the area under the ROC curves (not shown) for 
Equation (2) and its truncated variants. Two types of ROC curves are considered, one that 
characterizes discrimination between the combined Non-Responder and Partial-Responder 
categories vs. the Responder category (NR+PR vs. R) and one that characterizes discrimination 
between the Non-Responder category vs. the combined Partial-Responder and Responder 
categories (NR vs. PR+R).” 
 
 Parameters AUC 
Excluded 
variable a0 bNF bM bM-Taf bTTR R
2 NR+PR vs. R 
NR vs 
PR+R 
None 0.195 
(0.076) 
0.0046 
(0.0007) 
−0.447 
(0.083) 
0.027 
(0.008) 
0.068 
(0.022) 0.35 0.82 0.81 
SNF 0.429 
(0.073) 0 
−0.543 
(0.089) 
0.031 
(0.008) 
0.092 
(0.024) 0.22 0.75 0.72 
M 0.088 
(0.078) 
0.0053 
(0.0007) 0 
−0.0085 
(0.0048) 
0.062 
(0.024) 0.26 0.78 0.75 
M ×CTaf 0.180 
(0.078) 
0.0048 
(0.0007) 
−0.213 
(0.048) 0 
0.069 
(0.023) 0.31 0.81 0.77 
CTTR 0.348 
(0.058) 
0.0050 
(0.0007) 
−0.436 
(0.084) 
0.028 
(0.008) 0 0.32 0.81 0.79 
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Synthesis of Tafamidis-glucuronide  
Synthesis of Allyl-D-Glucuronate: 388 mg of D-glucuronic acid was dissolved in 10 mL of DMF 
at 25˚C.  329 µL of DBU was added dropwise to the solution.  After stirring for 15 min, 208 µL 
of allyl bromide was added dropwise to the solution.  The reaction was stirred for 18 hr at 25˚C.  
After reaction was completed according to TLC, the solvent was removed via vacuum distillation 
at 50˚C.  The resulting residue was purified by flash chromatography, using acetone as the eluent.  
This yielded 393 mg of allyl-D-glucuronate as a white solid (Yield 84%).  
Synthesis of Tafamidis-β-Glucuronide Allyl Ester((1)): 31 mg of Tafamidis (free acid), 38 mg of 
HATU, and 22 µL of N-methylmorpholine were suspended in 1 mL of CH2Cl2.  This suspension 
was stirred at 25˚C for 1 hr.  23 mg of allyl-D-glucuronate was added to the suspension and the 
reaction was stirred for 24 hr at 25˚C.  The resulting precipitate was filtered off, and the reaction 
was purified by flash chromatography using 5% MeOH in CH2Cl2. This produced 9 mg of 
Tafamidis-β-glucuronide allyl ester as a white solid (Yield 17%). 
Synthesis of Tafamidis-β-Glucuronide: 9 mg of Tafamidis-β-glucuronide allyl ester was dissolved 
in 1 mL of THF at 25˚C. 15 µL of morpholine and 1 mg of Pd(PPh3)4 were added to the solution.  
The reaction was stirred for 2 hours at 25˚C.  The solvent was removed under reduced pressure, 
and the resulting residue was dissolved in 900 µL of MeOH and purified via reverse-phase HPLC 
using an Agilent 1260 Infinity HPLC. Removing the solvent under reduced pressure and 
temperature yielded 4 mg of Tafamidis-β-glucuronide as a white solid (Yield 47%).   
 
 
1. Perrie JA, Harding JR, Holt DW, Johnston A, Meath P, and Stachulski AV. Effective 
synthesis of 1beta-acyl glucuronides by selective acylation. Organic letters. 
2005;7(13):2591-4. 
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A bs tr ac t
Background
Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived trans-
thyretin amyloid in peripheral nerves and the heart. A therapeutic approach medi-
ated by RNA interference (RNAi) could reduce the production of transthyretin.
Methods
We identified a potent antitransthyretin small interfering RNA, which was encapsu-
lated in two distinct first- and second-generation formulations of lipid nanoparticles, 
generating ALN-TTR01 and ALN-TTR02, respectively. Each formulation was studied 
in a single-dose, placebo-controlled phase 1 trial to assess safety and effect on trans-
thyretin levels. We first evaluated ALN-TTR01 (at doses of 0.01 to 1.0 mg per kilogram 
of body weight) in 32 patients with transthyretin amyloidosis and then evaluated 
ALN-TTR02 (at doses of 0.01 to 0.5 mg per kilogram) in 17 healthy volunteers.
Results
Rapid, dose-dependent, and durable lowering of transthyretin levels was observed 
in the two trials. At a dose of 1.0 mg per kilogram, ALN-TTR01 suppressed trans-
thyretin, with a mean reduction at day 7 of 38%, as compared with placebo (P = 0.01); 
levels of mutant and nonmutant forms of transthyretin were lowered to a similar 
extent. For ALN-TTR02, the mean reductions in transthyretin levels at doses of 0.15 
to 0.3 mg per kilogram ranged from 82.3 to 86.8%, with reductions of 56.6 to 67.1% 
at 28 days (P<0.001 for all comparisons). These reductions were shown to be RNAi-
mediated. Mild-to-moderate infusion-related reactions occurred in 20.8% and 7.7% 
of participants receiving ALN-TTR01 and ALN-TTR02, respectively.
Conclusions
ALN-TTR01 and ALN-TTR02 suppressed the production of both mutant and nonmu-
tant forms of transthyretin, establishing proof of concept for RNAi therapy targeting 
messenger RNA transcribed from a disease-causing gene. (Funded by Alnylam Phar-
maceuticals; ClinicalTrials.gov numbers, NCT01148953 and NCT01559077.)
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Transthyretin amyloidosis is a life-threatening disorder caused by the deposi-tion of hepatocyte-derived transthyretin 
amyloid in various tissues and organs.1,2 Circu-
lating transthyretin is derived from the liver3 and 
can form amyloid deposits in peripheral nerves 
and in the gastrointestinal tract, heart, and kid-
neys. Transthyretin is also synthesized by the 
retina and choroid plexus,4,5 which can lead to 
vitreal and leptomeningeal deposits. More than 
100 genetic variants of the gene encoding trans-
thyretin (TTR) are associated with autosomal 
dominant forms of the disease, known as familial 
amyloidotic polyneuropathy 6-8 and familial amy-
loidotic cardiomyopathy.9-11
The most common mutation associated with 
familial amyloidotic polyneuropathy is V30M; in 
addition to polyneuropathy, cardiac involvement 
can be manifested early as conduction distur-
bances in patients with the V30M mutation and 
as cardiomyopathy in some patients with the 
V30M mutation who have advanced disease and 
in patients with familial amyloidotic polyneu-
ropathy with other mutations.12,13 The predomi-
nant mutation associated with familial amyloid-
otic cardiomyopathy is V122I; patients with this 
mutation are susceptible to isolated cardiac in-
volvement and usually do not have polyneuropa-
thy.9 Most patients are heterozygous for the TTR 
mutations, and the amyloid deposits consist of 
mutant and nonmutant transthyretin.14,15
Liver transplantation is performed in patients 
with familial amyloidotic polyneuropathy but 
has substantial limitations, including transplant 
availability and substantial morbidity and mor-
tality.16-20 Also, transplantation eliminates the 
production of mutant but not nonmutant trans-
thyretin, so further deposition of nonmutant 
transthyretin occurs after transplantation, lead-
ing to cardiomyopathy and worsening of neu-
ropathy. Furthermore, since liver transplantation 
does not affect the production of transthyretin 
in the eye and central nervous system, ocular or 
leptomeningeal disease can develop after trans-
plantation.21 Tafamidis, a small-molecule stabilizer 
of the transthyretin tetramer, was recently ap-
proved in the European Union on the basis of its 
ability to slow the progression of neuropathy in 
early-stage familial amyloidotic polyneuropathy.22
RNA interference (RNAi) is an endogenous 
cellular mechanism for controlling gene expres-
sion in which small interfering RNAs (siRNAs) 
that are bound to the RNA-induced silencing com-
plex (RISC) mediate the cleavage of target mes-
senger RNA (mRNA).23,24 The ability to turn siRNAs 
into drugs has depended on chemical processes 
that confer druglike properties and facilitate safe 
and effective delivery to target organs.25,26 Formu-
lations of lipid nanoparticles have emerged as 
agents to deliver siRNAs to hepatocytes and have 
resulted in a robust and durable reduction in ge-
netic expression (called knockdown) of a variety 
of hepatocyte targets across multiple species.27-29 
Biodistribution of these parenterally administered 
lipid nanoparticles is predominantly to the liver, 
with a small fraction distributing to other or-
gans that have a fenestrated endothelium (e.g., 
spleen).30,31 Penetration into the central nervous 
system or eye does not occur after systemic ad-
ministration of such formulations.
ALN-TTR01 and ALN-TTR02 are first- and 
second-generation formulations of lipid nanopar-
ticles as agents to deliver siRNAs. These formu-
lations have similar physicochemical properties 
but different ionizable lipid components, which 
are key determinants of potency.32 Each formu-
lation encapsulates an identical siRNA that tar-
gets a conserved sequence in the 3′ untranslated 
region of nonmutant and mutant mRNA in TTR, 
thereby affecting both forms of TTR (Fig. S1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). To deter-
mine the activity and relative potencies of these 
two formulations in lowering transthyretin lev-
els, and thereby select the best formulation to take 
forward, we performed studies in nonhuman pri-
mates and two sequential phase 1 trials.
Me thods
Study Patients
Patients who were 18 years of age or older were 
eligible for the ALN-TTR01 phase 1 trial if they 
had a biopsy-proven diagnosis of transthyretin 
amyloidosis with mild-to-moderate neuropathy, 
a Karnofsky performance-status score of at least 
60, a body-mass index (BMI; the weight in kilo-
grams divided by the square of the height in meters) 
of 18.5 to 33.0, a New York Heart Association class 
of II or less, and adequate liver, renal, and thyroid 
function. Men and women between the ages of 
18 and 45 years were eligible for the ALN-TTR02 
phase 1 trial if they were healthy (as determined 
on the basis of a medical history, physical exami-
nation, and 12-lead electrocardiography), had a 
BMI of 18.0 to 31.5, had adequate liver function 
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and blood counts, and did not have childbearing 
potential.
Study Design
The trial to test ALN-TTR01 enrolled participants 
from July 2010 through September 2011, and the 
trial to test ALN-TTR02 (which was developed af-
ter the ALN-TTR01 trial) enrolled participants from 
March through May 2012. Both phase 1 trials were 
multicenter, randomized, single-blind, placebo-
controlled, dose-ranging studies to evaluate the 
safety and efficacy of a single dose of ALN-TTR01 
or ALN-TTR02 in patients with transthyretin amy-
loidosis or in healthy adult volunteers, respectively.
Series of participants, consisting of four each, 
were randomly assigned to receive ALN-TTR01 
(at doses of 0.01 to 1.0 mg per kilogram of body 
weight) or ALN-TTR02 (at doses of 0.01 to 0.5 mg 
per kilogram) or placebo (normal saline) in a 3:1 
ratio. ALN-TTR01 and ALN-TTR02 were admin-
istered intravenously during a period of 15 min-
utes and 60 minutes, respectively. In the two trials, 
participants received similar premedication the 
evening before and the day of infusion to reduce 
the risk of infusion-related reactions.33,34 These 
medications included dexamethasone, acetamin-
ophen, diphenhydramine or cetirizine, and raniti-
dine. In the event of a mild-to-moderate infusion-
related reaction, the infusion could be temporarily 
interrupted and resumed at a slower rate.
Study Oversight
The study protocols were approved by the ethics 
committee at each site. All participants provided 
written informed consent. The studies were de-
signed jointly by the principal investigators at the 
study sites and representatives of the sponsor, 
Alnylam Pharmaceuticals. Data were collected by 
the investigators, gathered by Medpace, and ana-
lyzed by Veristat and the sponsor. All the authors 
interpreted the data and collaborated in the prep-
aration of the manuscript. All the authors made 
the decision to submit the manuscript for publi-
cation, and all vouch for the completeness and 
accuracy of this report and its fidelity to the pro-
tocol, available at NEJM.org.
Clinical Activity, Safety, and Pharmacokinetic 
Evaluations
We measured the pharmacodynamic activity of 
ALN-TTR01 and ALN-TTR02, as reflected by serum 
transthyretin levels, using a validated enzyme-
linked immunosorbent assay (ELISA) for total 
transthyretin (Charles River Laboratories). For pa-
tients with the V30M mutation in the ALN-TTR01 
study, measurement of mutant and nonmutant 
transthyretin was performed at Tandem Labora-
tories with the use of liquid chromatography–tan-
dem mass spectrometry (see the Methods section 
in the Supplementary Appendix for more details). 
Measurements of serum retinol-binding protein 
and vitamin A were performed at Biomnis. Baseline 
levels of transthyretin, retinol-binding protein, 
and vitamin A for each patient were defined as 
the mean of two to three measurements before the 
administration of ALN-TTR01 or four measure-
ments before the administration of ALN-TTR02.
Adverse events were monitored from the start 
of drug administration through day 28. Safety 
monitoring also included hematologic evalua-
tions, blood chemical analyses, and thyroid-func-
tion tests.
We evaluated the plasma pharmacokinetics of 
the TTR siRNA contained in both ALN-TTR01 and 
ALN-TTR02 by means of a validated ELISA-based 
hybridization assay. For detection and quantifi-
cation of siRNA, we used an oligonucleotide probe 
(lower limit of quantification, 0.5 ng per millili-
ter) (Charles River Laboratories) in the ALN-TTR01 
trial and the ATTO-Probe-HPLC assay (lower limit 
of quantification, 1.0 ng per milliliter) (Tandem 
Laboratories) in the ALN-TTR02 trial. We did not 
obtain data that addressed the question of wheth-
er plasma levels of TTR siRNA were proportionate 
to levels of transthyretin-lowering siRNA entering 
the hepatocyte. We used WinNonlin (Pharsight) to 
determine the pharmacokinetic estimates.
Statistical Analysis
We measured the knockdown of transthyretin, vi-
tamin A, and retinol-binding protein as compared 
with baseline levels. Geometric means and con-
fidence intervals were calculated by means of 
natural-log transformation, back-transformed for 
presentation (Fig. 1A, 2A, and 2C). Repeated-
measures analysis of variance examined log knock-
down ratios. Main effects were dose, time, and 
interaction. Covariance was unstructured, and the 
day after drug administration was a nominal vari-
able. Dose-by-time interaction was significant in 
both ALN-TTR01 (P = 0.0054) and ALN-TTR02 
(P<0.001) trials. We used t-tests to perform com-
parisons between the ALN-TTR01 and ALN-TTR02 
groups and the placebo groups (Fig. 1A and 2A). 
We used linear regression to test correlations be-
tween either nonmutant or mutant (log) concen-
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trations (Fig. 1D) and the knockdown of trans-
thyretin, vitamin A, and retinol-binding protein 
(Fig. S3 in the Supplementary Appendix). Nadir 
levels were defined as the minimum level per par-
ticipant during the 28-day period after drug ad-
ministration. We used analysis of variance or 
Tukey’s tests to analyze nadir levels and (log) 
knockdown (Fig. 2C). We used the Cochran–
Mantel–Haenszel test with continuity correction 
(adjustment for participant) to examine cleavage 
products versus transthyretin-aligned clones be-
fore and after drug administration. All statistical 
analyses were performed with the use of SAS soft-
ware, version 9.3, and R software, version 2.13.2.
R esult s
Nonhuman Primate Studies
The region of the TTR 3′ untranslated region that 
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Figure 1. Efficacy of ALN-TTR01 in Patients with Transthyretin Amyloidosis.
Panel A shows the geometric mean percent serum transthyretin (TTR) knockdown (reduction in genetic expression), as compared with 
baseline, at the indicated time points over a 28-day period in groups of patients receiving either increasing doses of placebo or ALN-TTR01, 
a formulation of lipid nanoparticles containing a small interfering RNA (siRNA) targeting mutant and nonmutant transthyretin. Negative 
values indicate increased knockdown levels. Asterisks indicate P<0.05 for the comparison between the group receiving 1.0 mg of the drug 
per kilogram and the placebo group, according to repeated-measures analysis of variance and post hoc tests. The I bars indicate 95% con-
fidence intervals. Panel B shows the percent serum transthyretin knockdown for individual patients treated at a dose of 1.0 mg per kilogram, 
according to TTR mutational status. Panel C shows the time course for suppression of transthyretin, vitamin A, and retinol-binding protein 
(RBP) in Participant 50.03, who received a dose of 1.0 mg per kilogram. Panel D shows the correlation between mutant and nonmutant 
transthyretin at all time points before and after drug administration in four patients with the V30M mutation who received a dose of 1.0 mg 
per kilogram. The coefficient of determination (R2) and P values were calculated according to simple linear regression. Shading indicates 
the 95% confidence interval.
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ALN-TTR02 is identical in cynomolgus monkeys 
and humans. In nonhuman primates that re-
ceived ALN-TTR01 in a single dose of 1.0 mg per 
kilogram, the mean percent transthyretin knock-
down at the nadir level (7 days after administra-
tion) was approximately 50%, with recovery to 
the baseline level by day 28 (Fig. S2A in the Sup-
plementary Appendix). By contrast, ALN-TTR02 
showed an improvement in potency by a factor of 
more than 10. Knockdown of approximately 75% 
was seen at day 7 at a dose of 0.1 mg per kilogram 
and 90% at day 14 at a dose of 0.3 mg per kilo-
gram, with more than 70% suppression persisting 
at day 28 in the high-dose group.
To explore whether the effect of ALN-TTR02 
was maintained with multiple doses, monkeys re-
ceived 0.3 mg per kilogram every 4 weeks for five 
doses. The kinetics of transthyretin knockdown 
and recovery were essentially identical after each 
dose, though the degree of transthyretin suppres-
sion at nadir levels increased with each consecu-
tive dose (85% and 94% suppression after doses 
1 and 5, respectively), and the extent of recovery 
before drug administration decreased (Fig. S2B in 
the Supplementary Appendix).
Study Participants
Baseline characteristics of the patients with trans-
thyretin amyloidosis and healthy volunteers in 
the two studies are shown in Table 1. All the 
patients with transthyretin amyloidosis had early-
stage familial amyloidotic polyneuropathy,35 with 
the majority enrolled in Portugal and Sweden, 
where the disease is endemic.6 The most common 
mutation in participants was V30M.6-8 Healthy 
volunteers had no known TTR mutation. None of 
the patients with the V30M mutation had received 
previous therapy with tafamidis. All participants 
in the ALN-TTR02 trial were male, since the pro-
tocol excluded women with childbearing potential 
in this early-phase study involving healthy volun-
teers. At study entry, serum transthyretin levels 
were modestly lower in patients with transthyre-
tin amyloidosis than in healthy volunteers, a find-
ing that was consistent with reports showing 
lower transthyretin levels in patients with trans-
thyretin amyloidosis than in either asymptomat-
ic disease carriers or healthy controls.36
Efficacy
ALN-TTR01
After a single dose of ALN-TTR01, no significant 
change from pretreatment baseline levels was ob-
served in serum transthyretin levels, as compared 
with the placebo group, at doses of 0.01 to 0.7 mg 
per kilogram. In contrast, significant lowering 
from baseline was seen in the group receiving 
1.0 mg per kilogram as early as day 1, with a 
mean reduction of 38% in transthyretin levels on 
day 7 (P = 0.01) (Fig. 1A). In the group receiving 
1.0 mg per kilogram, which included two series 
of four participants each, there was considerable 
variability among participants in the observed 
degree of transthyretin knockdown.
Among four participants with the V30M mu-
tation and one with the S77Y mutation, peak 
knockdown ranged from 16 to 41% and recovered 
close to predose baseline levels by day 28 (Fig. 1B). 
However, the one patient with the S77F mutation 
(Participant 50.03) had a robust response, with 
more than 50% transthyretin knockdown at day 2 
and a nadir level of 81% by day 10 (Fig. 1B and 1C). 
By day 28, there was still more than 50% knock-
down, and recovery to the baseline level did not 
occur until day 70. Since the main role of trans-
thyretin is to bind retinol-binding protein, and 
lowering is therefore expected to reduce circulat-
ing levels of retinol-binding protein and vitamin A 
(retinol),37,38 the assays of serum retinol-binding 
protein and retinol provided additional measures 
of the pharmacodynamic activity of ALN-TTR01. 
As anticipated, the lowering of transthyretin in 
Participant 50.03 resulted in similar kinetics of 
lowering and recovery for retinol-binding protein 
and vitamin A (Fig. 1C).
Among the four patients with the V30M mu-
tation in the group receiving 1.0 mg per kilo-
gram, there was a strong correlation between 
mutant and nonmutant transthyretin (Fig. 1D), 
showing that both forms of the protein were 
reduced to the same extent, with the same kinet-
ics of lowering and recovery (data not shown).
ALN-TTR02
We observed no significant changes in trans-
thyretin levels, as compared with placebo, at the 
two lowest doses of ALN-TTR02. However, sub-
stantial transthyretin knockdown was observed 
in all participants receiving doses of 0.15 to 0.5 mg 
per kilogram (Fig. 2A). Transthyretin knockdown 
was rapid, potent, and durable across all three 
dose levels, with highly significant changes, as 
compared with placebo (P<0.001), through day 28. 
In light of the robust response seen at 0.15 and 
0.3 mg per kilogram and modest incremental im-
provement in response at 0.5 mg per kilogram, 
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only one participant received the dose of 0.5 mg 
per kilogram.
There was little variability among participants 
in the kinetics of response (Fig. 2B), especially at 
doses of at least 0.3 mg per kilogram, with more 
than 50% lowering by day 3, a nadir level by ap-
proximately day 10, and continued suppression 
of more than 50% at day 28, with full recovery 
occurring by day 70. Maximum values for trans-
thyretin knockdown for participants receiving 
0.15 mg, 0.3 mg, and 0.5 mg per kilogram were 
85.7%, 87.6%, and 93.8%, respectively. The aver-
age nadirs at doses of 0.15 mg and 0.3 mg per 
kilogram were 82.3% (95% confidence interval [CI], 
67.7 to 90.3) and 86.8% (95% CI, 83.8 to 89.3), 
respectively; these nadirs showed little variability 
among participants when analyzed as either ab-
solute transthyretin levels or percent transthyre-
tin knockdown and were highly significant, as 
compared with placebo (P<0.001) (Fig. 2C). The 
degree of knockdown appeared to determine the 
duration of suppression, with mean reductions at 
day 28 of 56.6% (95% CI, 11.6 to 78.7) and 67.1% 
(95% CI, 45.5 to 80.1) for participants receiving 
0.15 mg and 0.3 mg per kilogram, respectively, 
and a 76.8% reduction at day 28 for the single 
patient receiving 0.5 mg per kilogram. The trans-
thyretin knockdown observed in humans at a dose 
of 0.3 mg per kilogram was virtually identical to 
that seen in nonhuman primates at the same dose 
level (Fig. S2C in the Supplementary Appendix). 
These reductions in transthyretin by ALN-TTR02 
correlated with changes in levels of retinol-bind-
ing protein and vitamin A (Fig. S3 in the Supple-
mentary Appendix).
To further demonstrate the specificity of the 
effect of ALN-TTR02, transthyretin was also mea-
sured in a group of healthy volunteers in a phase 1 
trial of ALN-PCS, which contains an siRNA tar-
geting PCSK929 (a target for cholesterol lowering) 
that is formulated in the same type of lipid nano-
particle used in ALN-TTR02. A single dose of 
0.4 mg of ALN-PCS per kilogram (so-called con-
trol siRNA) had no effect on transthyretin (Fig. 2A 
and 2C), which showed that the effect of ALN-
TTR02 on transthyretin was due to specific target-
ing by the siRNA and not a nonspecific effect of 
the formulation of lipid nanoparticles.
We obtained additional evidence in support of 
the specificity and mechanism of action of the 
pharmacodynamic effect of ALN-TTR02 using 
the 5′ RACE (rapid amplification of complemen-
tary DNA ends) assay28,29 on blood samples ob-
tained from participants receiving a dose of 0.3 mg 
per kilogram to detect the predicted TTR mRNA 
cleavage product in circulating extracellular RNA 
(for details, see the Methods section in the Sup-
plementary Appendix). TTR mRNA was detected 
both in predose samples and in samples obtained 
24 hours after drug administration. Consistent 
with the RNAi mechanism, the predicted mRNA 
cleavage product was absent in the predose sam-
ples and present in postdose samples in all three 
participants (Table 2).
Safety and Pharmacokinetics
The use of ALN-TTR01 and ALN-TTR02 did not 
result in any significant changes in hematologic, 
liver, or renal measurements or in thyroid func-
tion, and there were no drug-related serious ad-
verse events or any study-drug discontinuations 
because of adverse events (Tables 3 and 4, and 
Table S1 in the Supplementary Appendix). Mild-
to-moderate infusion-related reactions occurred 
in 20.8% of participants receiving ALN-TTR01 at 
Figure 2 (facing page). Efficacy of ALN-TTR02 
in Healthy Volunteers.
Panel A shows the geometric mean percent serum 
transthyretin knockdown, as compared with baseline, 
at the indicated time points over a 70-day period in 
groups of patients receiving placebo, control siRNA 
(siRNA targeting PCSK9 formulated in the same type 
of lipid nanoparticles as were used in ALN-TTR02), 
or increasing doses of ALN-TTR02. Asterisks denote 
P<0.001 for the comparison between the group receiv-
ing a dose of 0.3 mg per kilogram and the placebo 
group, according to repeated-measures analysis of 
variance and post hoc tests. The comparisons for 
groups receiving doses of 0.15 mg and 0.5 mg per 
 kilogram maintained similar significance from days 2 
through 28. The I bars indicate 95% confidence inter-
vals. Panel B shows the percent serum transthyretin 
knockdown for one participant treated with placebo 
and three participants treated with doses of 0.15 mg 
of ALN-TTR02 per kilogram (left) and for one partici-
pant treated with placebo and three participants treat-
ed with doses of 0.3 mg of ALN-TTR02 per kilogram 
and one treated with a dose of 0.5 mg per kilogram 
(right). Panel C shows mean serum transthyretin lev-
els at nadir levels (left) and the geometric mean per-
cent serum transthyretin knockdown at nadir levels 
(right) for control siRNA, placebo, or increasing doses 
of ALN-TTR02. Circles show results for individual par-
ticipants, and horizontal lines show means for each 
group. Asterisks indicate P<0.001 for pairwise com-
parisons with placebo, according to analysis of vari-
ance and post hoc tests.
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doses of at least 0.4 mg per kilogram. A moderate 
infusion-related reaction occurred in the single 
participant who received ALN-TTR02 at a dose of 
0.5 mg per kilogram (overall incidence, 7.7%). 
Mild reactions resolved spontaneously, whereas 
moderate reactions readily responded to tempo-
rary interruption of the infusion with or without 
the administration of additional glucocorticoids, 
followed by resumption of drug administration 
at a slower rate. The infusion-related reactions 
that were observed in the two trials were not as-
sociated with any inductions of proinflammatory 
cytokines. Levels of complement C3a were tran-
siently elevated in the single participant who had 
an infusion-related reaction in the ALN-TTR02 
trial. Antibodies to the pegylated lipid compo-
nent of ALN-TTR02 were not detected in any par-
ticipants.
The plasma pharmacokinetic profiles of ALN-
TTR01 and ALN-TTR02 showed that the values for 
the peak plasma concentration and for the area 
under the curve through the last day for the TTR 
siRNA increased in an approximately dose-pro-
portional manner over the range of doses that 
were tested (Fig. S4A and S4B in the Supplemen-
tary Appendix).
Discussion
Harnessing RNAi holds promise for the treat-
ment of human disease and requires safe and 
effective delivery. Results with formulations of 
lipid nanoparticles as agents to deliver siRNAs in 
animals, including nonhuman primates,28,29 have 
shown activity toward silencing of disease-modi-
fying genes expressed in the liver. Our data pro-
vide proof that siRNAs can be delivered to hu-
man liver and therein modulate gene expression 
through RNAi.
The findings for ALN-TTR01 in patients with 
transthyretin amyloidosis showed that a single 
dose could rapidly and potently suppress hepatic 
production of transthyretin and that both mutant 
and nonmutant proteins were similarly affected. 
In one patient with 81% knockdown, substantial 
Table 2. Detection of Transthyretin Messenger RNA Cleavage Product in Three 
Participants Receiving 0.3 mg of ALN-TTR02 per Kilogram.*
Participant No.
Clones Aligned 
with Transthyretin†
Transthyretin-Aligned Clones 
with Predicted Cleavage
Before 
Therapy
After 
Therapy‡
Before 
Therapy
After 
Therapy‡§
no. no. (%)
014 46 34 0  34 (100)
015 65 49 0 48 (98)
016 8 35 0 14 (40)
* The listed results were obtained with the use of the 5′ RACE (rapid amplification 
of complementary DNA ends) assay.
† A total of 96 clones were selected for sequencing.
‡ Analyses were performed 24 hours after drug administration.
§ P<0.001 by the Mantel–Haenszel chi-square test with continuity correction.
Table 1. Baseline Characteristics of the Study Participants.
Characteristic ALN-TTR01 Trial ALN-TTR02 Trial
Disease status Transthyretin amyloidosis No disease
No. of participants (drug:placebo ratio) 32 (24:8) 17 (13:4)
Median age (range) — yr 37 (21–77) 27 (21–44)
Male sex — % 56 100
Country of enrollment — no. of participants
Portugal 23 0
Sweden 5 0
France 3 0
United Kingdom 1 17
TTR genotype — no. of participants
Val30Met (V30M) 29 0
Ser77Tyr (S77Y) 2 0
Ser77Phe (S77F) 1 0
Mean serum transthyretin (range) — μg/ml 253.3 (123.8–558.9) 290.8 (195.3–370.9)
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suppression of more than 50% was still main-
tained 28 days after drug administration, which 
underscored the finding from previous studies 
in animals that the duration of target suppression 
was in part a function of the degree of initial 
knockdown.28,29
The results for ALN-TTR02 were remarkable 
for the exceptional potency, as compared with 
ALN-TTR01, a finding that was predicted in the 
studies of nonhuman primates. Within the ac-
tive dose range of 0.15 to 0.5 mg per kilogram, 
there was little variability among participants 
within each dose group in nadir levels of trans-
thyretin knockdown and in the kinetics of sup-
pression and recovery. From the standpoint of 
nadir levels of transthyretin and the degree of 
suppression at 28 days, the response appeared to 
plateau at 0.3 mg per kilogram, with incremental 
additional suppression seen in the one participant 
who was treated at a dose of 0.5 mg per kilogram. 
The safety profile associated with this degree of 
activity was encouraging.
The one clear adverse event that was associated 
with RNAi therapy and not with placebo was a 
moderate infusion-related reaction in the partici-
pant who received ALN-TTR02 at a dose of 0.5 mg 
per kilogram. This reaction was managed by slow-
ing the infusion rate. The reduced rate of moder-
ate infusion-related reactions in the ALN-TTR02 
trial, as compared with the ALN-TTR01 trial, was 
probably due to the use of lower doses of the 
drug and an extended infusion time (60 minutes 
vs. 15 minutes).39 There was a reversible decline 
in levels of retinol-binding protein and vitamin A 
associated with transthyretin knockdown, which 
was consistent with transthyretin binding of reti-
nol-binding protein.37,38 Although transthyretin 
has a minor role in binding thyroxine in humans, 
we observed no significant change in thyroid 
function in participants with up to 94% suppres-
sion of transthyretin. The safety of long-term 
suppression of transthyretin in patients with 
transthyretin amyloidosis with respect to its ef-
fect on levels of retinol-binding protein and circu-
lating vitamin A remains to be determined. How-
ever, the benign clinical phenotype and absence 
of findings of severe vitamin A deficiency in TTR-
knockout mice or in humans deficient in retinol-
binding protein who have very low circulating 
vitamin A levels40,41 suggest that there are mecha-
nisms for vitamin A transport and tissue uptake 
that are independent of retinol-binding protein.42
The ability of ALN-TTR01 and ALN-TTR02 to 
suppress hepatic transthyretin production and 
reduce circulating levels of both mutant and non-
mutant transthyretin has implications for the 
Table 3. Select Adverse Events in the ALN-TTR01 Trial.*
Adverse Event ALN-TTR01 (N = 24) Placebo (N = 8)
0.01 mg/kg
(N = 3)
0.03 mg/kg
(N = 3)
0.1 mg/kg
(N = 3)
0.2 mg/kg
(N = 3)
0.4 mg/kg
(N = 3)
0.7 mg/kg
(N = 3)
1.0 mg/kg
(N = 6) All Doses
number (percent)
Infusion reaction 0 0 0 0 1 (33.3) 1 (33.3) 3 (50.0)  5 (20.8) 0
Fatigue 1 (33.3) 1 (33.3) 0 0 0 0 0 2 (8.3) 0
* A complete list of adverse events is provided in Table S1 in the Supplementary Appendix.
Table 4. Select Adverse Events in the ALN-TTR02 Trial.*
Adverse Event ALN-TTR02 (N = 13) Placebo (N = 4)
0.01 mg/kg
(N = 3)
0.05 mg/kg
(N = 3)
0.15 mg/kg
(N = 3)
0.3 mg/kg
(N = 3)
0.5 mg/kg
(N = 1) All Doses
number (percent)
Skin erythema† 1 (33.3) 2 (66.7) 0 2 (66.7) 1 (100.0) 6 (46.2) 2 (50.0)
Infusion reaction 0 0 0 0 1 (100.0) 1 (7.7) 0
* A complete list of adverse events is provided in Table S1 in the Supplementary Appendix.
† Skin erythema consisted of transient, asymptomatic flushing of the face, trunk, or both.
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treatment of patients with transthyretin amyloi-
dosis. Liver-derived transthyretin has been shown 
to be the disease-causing protein in studies of the 
effect of eliminating mutant transthyretin with 
liver transplantation in patients with early-stage 
familial amyloidotic polyneuropathy16,17 and of 
the development of amyloidosis in recipients of 
livers from patients with familial amyloidotic poly-
neuropathy in “domino” transplantations.43 In 
addition, the beneficial effect of reducing circu-
lating amyloidogenic precursors by more than 50% 
has been shown in both secondary (AA) amyloido-
sis and amyloid light-chain (AL) amyloidosis.44,45
These findings suggest that the robust, sus-
tained reduction in transthyretin levels that we 
have observed may ameliorate the course of dis-
ease in patients with transthyretin amyloidosis. 
The ability of ALN-TTR02 to lower both mutant 
and nonmutant proteins may also provide a ma-
jor advantage over liver transplantation, which 
affects the production of only mutant protein. 
Further studies of ALN-TTR02 are needed to ex-
amine the clinical efficacy and safety of long-term 
transthyretin knockdown in patients with famil-
ial amyloidotic polyneuropathy.
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amyloidotic polyneuropathy: a phase II
multi-dose study
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and David Adams11Abstract
Background: Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations
in the transthyretin gene. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of
multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with
transthyretin-mediated familial amyloid polyneuropathy (FAP).
Methods: In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the
following doses: 0.01 (n = 4), 0.05 (n = 3), 0.15 (n = 3), or 0.3 (n = 7) mg/kg every 4 weeks (Q4W), or 0.3 mg/kg (n = 12)
every 3 weeks (Q3W).
Results: Of 29 patients in the intent-to-treat population, 26 completed the study. Administration of patisiran led
to rapid, dose-dependent, and durable knockdown of transthyretin, with the maximum effect seen with patisiran
0.3 mg/kg; levels of mutant and wild-type transthyretin were reduced to a similar extent in Val30Met patients. A
mean level of knockdown exceeding 85 % after the second dose, with maximum knockdown of 96 %, was observed
for the Q3W dose. The most common treatment-related adverse event (AE) was mild-to-moderate infusion-related
reactions in 10.3 % of patients. Four serious AEs (SAEs) were reported in 1 patient administered 0.3 mg/kg Q3W (urinary
tract infection, sepsis, nausea, vomiting), and 1 patient administered 0.3 mg/kg Q4W had 1 SAE (extravasation-related
cellulitis).
Conclusions: Patisiran was generally well tolerated and resulted in significant dose-dependent knockdown of
transthyretin protein in patients with FAP. Patisiran 0.3 mg/kg Q3W is currently in phase III development.
Trial registration number: NCT01617967.
Keywords: Patisiran, RNA interference, Transthyretin-mediated familial amyloidotic polyneuropathy, Polyneuropathy,
Hereditary disease, Genetic mutation, Phase II, Clinical trialBackground
Transthyretin (TTR) is a tetrameric protein produced
primarily in the liver. Mutations in the TTR gene
destabilize the tetramer, leading to misfolding of mono-
mers and aggregation into TTR amyloid fibrils (ATTR).
Tissue deposition results in systemic ATTR amyloidosis* Correspondence: Ole.suhr@medicin.umu.se
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(http://creativecommons.org/publicdomain/ze[1–3]. Over 100 reported TTR mutations exhibit a
spectrum of disease symptoms. The most common mu-
tations associated with familial amyloid polyneuropathy
(FAP) and ATTR-associated cardiomyopathy, respect-
ively, are Val30Met [4] and Val122Ile [5].
Treatment options for FAP focus on stabilizing or de-
creasing the amount of circulating amyloidogenic protein.
Orthotopic liver transplantation reduces mutant TTR
levels [6], with improved survival reported in patients with
early-stage FAP, although deposition of wild-type TTR
may continue [7–12]. Tafamidis and diflunisal stabilizeis distributed under the terms of the Creative Commons Attribution 4.0
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ease progression [4, 13–15]. However, symptoms continue
to worsen on treatment in many patients [4, 13–15],
highlighting the need for new, disease-modifying treat-
ment options for FAP.
RNA interference is a cellular process that controls gene
expression, in which small interfering RNAs (siRNAs) me-
diate the cleavage of specific messenger RNAs (mRNAs)
[16, 17]. Lipid nanoparticles (LNPs) deliver siRNAs to he-
patocytes, resulting in the robust and durable reduction in
expression (so-called “knockdown”) of gene targets across
multiple species [18–23]. Patisiran (ALN-TTR02) com-
prises a TTR mRNA-specific siRNA formulated in LNPs
[20]. A phase I ascending-dose study in healthy volunteers
demonstrated rapid, dose-dependent, and durable knock-
down of serum TTR with patisiran [20]. The objective of
this study was to evaluate the safety, tolerability, pharma-
cokinetics (PK), and pharmacodynamics (PD) of multiple
ascending intravenous (IV) doses of patisiran in patients
with FAP.
Methods
Patients
Eligible patients were adults (≥18 years) with biopsy-
proven ATTR amyloidosis and mild-to-moderate neur-
opathy; Karnofsky performance status ≥ 60 %; body mass
index 17–33 kg/m2; adequate liver and renal function
(aspartate transaminase [AST] and alanine transaminase
[ALT] ≤ 2.5 × the upper limit of normal [ULN], total bili-
rubin within normal limits, albumin > 3 g/dL, inter-
national normalized ratio ≤ 1.2, serum creatinine ≤ 1.5
ULN); and seronegativity for hepatitis B virus and hepa-
titis C virus. Patients were excluded if they had a liver
transplant; had surgery planned during the study; were
HIV-positive; had received an investigational drug other
than tafamidis or diflunisal within 30 days; had a New
York Heart Association heart failure classification > 2;
were pregnant or nursing; had known or suspected
systemic bacterial, viral, parasitic, or fungal infections;
had unstable angina; had uncontrolled clinically signifi-
cant cardiac arrhythmia; or had a prior severe reaction
to a liposomal product or known hypersensitivity to
oligonucleotides.
Study design
This was a multicenter, international, open-label, multiple-
dose escalation phase II study of patisiran in patients
with FAP. Cohorts of 3 patients received 2 doses of
patisiran, with each dose administered as an IV infu-
sion. Cohorts 1–3 received 2 doses of patisiran 0.01,
0.05, and 0.15 mg/kg every 4 weeks (Q4W), respect-
ively; cohorts 4 and 5 both received 2 doses of patisiran
0.3 mg/kg Q4W. All patients in cohorts 6–9 received 2
doses of patisiran 0.3 mg/kg administered every 3 weeks(Q3W). As lipid-based delivery systems have previously
been associated with adverse immune events [24, 25],
all patients received premedication prior to each pati-
siran infusion consisting of dexamethasone, paraceta-
mol (acetaminophen), an H2 blocker (e.g. ranitidine or
famotidine), and an H1 blocker (e.g. cetirizine, hy-
droxyzine, or fexofenadine) to reduce the risk of
infusion-related reactions (further details on pre-
medication regimen are provided in Additional file 1).
Patisiran was administered IV at 3.3 mL/min over
60 min, or over 70 min using a micro-dosing regimen
(1.1 mL/min for 15 min followed by 3.3 mL/min for
the remainder of the dose). Cumulative safety and tol-
erability data on all patients was reviewed by the Safety
Review Committee (SRC). This study provides Class III
evidence on the efficacy and safety of patisiran in
patients with FAP.
Standard protocol approvals, registrations, and patient
consents
The study procedures (Clinicaltrials.gov identifier:
NCT01617967) were approved by the ethics committee
on human experimentation at each site. All patients
provided written informed consent.
Outcome measures
The primary study objective was to evaluate the safety
and tolerability of multiple ascending doses of patisiran.
Secondary objectives were to characterize the plasma
and urine PK of patisiran, and to assess preliminary evi-
dence of the PD effect of patisiran on serum total TTR
protein levels.
Serum levels of total TTR protein were assessed for all
patients using an enzyme-linked immunosorbent assay
(ELISA). Additionally, wild-type and mutant TTR pro-
tein were separately and specifically measured in serum
for patients with the Val30Met mutation using a propri-
etary mass spectrometry method (Charles River Labora-
tories, Quebec, Canada). Serum samples were collected
at screening, and on Days 0, 1, 2, 7, 10, 14, 21, 22, 23
(Q3W only); 28, 29 (Q4W only); 30 (Q4W only); 31
(Q3W only); 35, 38 (Q4W only); and 42, 49, 56, 112,
and 208 of follow-up.
Plasma concentration–time profiles were created for
TTR siRNA, based on blood samples collected on Day 0
and at the following time points: pre-dose (within 1 h of
planned dosing start), at end of infusion (EOI), at 5, 10,
and 30 min, and at 1, 2, 4, 6, 24, 48, 168, 336, 504 (Day
21, Q3W regimen only), and 672 h (Day 28, Q4W regi-
men only) post-infusion. Additional samples were col-
lected on Days 84 and 180 for the Q4W regimens, and
on Days 35, 91, and 187 for the Q3W regimen. For
cohorts 3–9, blood samples on Day 0 at EOI and 2 h
post-infusion were also analyzed for both free and
Suhr et al. Orphanet Journal of Rare Diseases  (2015) 10:109 Page 3 of 9encapsulated TTR siRNA. Serum TTR siRNA was ana-
lyzed using a validated ATTO-Probe high-performance
liquid chromatography (HPLC) assay (Tandem Labora-
tories, Salt Lake City, Utah, USA). PK analyses were
conducted using non-compartmental and/or compart-
mental evaluation of TTR siRNA plasma concentration–
time data to determine PK parameter estimates using
the validated software program WinNonlin®. Urine sam-
ples were analyzed for levels of excreted TTR siRNA,
and renal clearance was measured after dosing.
Serum levels of vitamin A and retinol binding protein
(RBP) were measured by HPLC and nephelometry, re-
spectively, at the same time points specified for total
TTR (Biomins Specialized Medical Pathology, Lyon,
France).
Safety evaluations included assessment of adverse
events (AEs), electrocardiograms (ECGs), arterial oxygen
saturation using pulse oximetry, vital signs, clinical
laboratory safety tests, and physical examinations. AEs
were defined as mild (easily tolerated with no disruption
of normal daily activity), moderate (sufficient discomfort
to interfere with daily activity), or severe (those which
incapacitated and prevented usual activity). The num-
bers and percentages of patients with any treatment-
emergent AE (TEAE), with any serious TEAE, with any
TEAE leading to discontinuation of study medication, or
with any TEAE considered a dose-limiting toxicity were
summarized by dose cohort and overall. Dose-limiting
toxicities included any of the following: any life-
threatening toxicity; ALT and AST ≥ 5 × ULN or total
bilirubin > 2.0 mg/dL; an infusion reaction that required
hospitalization; and any other toxicity that in the opin-
ion of the SRC precluded administration of a second
dose.
Statistical analyses
Based on the planned dose escalation scheme, we ex-
pected to enroll 27 patients. Patient populations in-
cluded intent-to-treat (ITT, all patients who were
enrolled and received study treatment) and per-protocol
(PP, ITT patients with no major protocol violations).
Safety measures were assessed in the ITT population.
No substitutions were made to allow for missing data
points.
Means and variances for TTR knockdown from base-
line were calculated for the PP population, with baseline
defined as the average of all pre-dose values. We used
analysis of variance (ANOVA) and analysis of covariance
(ANCOVA) to analyze the PD data (natural log trans-
formed TTR relative to baseline), with Tukey’s post hoc
tests of individual pairwise comparisons (between dose
levels). Nadir TTR levels were defined as the minimum
level per patient during the 28-day period (21-day period
for Q3W group) after each dose administration (first-dose, second-dose periods: Days 1–28, 29–56, and Days
1–21, 22–42 for Q4W and Q3W groups, respectively).
Relationships between TTR and RBP or vitamin A, rela-
tive to baseline, and the relationship between wild-type
and V30M TTR levels, were explored via linear regres-
sion. We formally evaluated the dose proportionality of
the patisiran component in PK parameters using a
power model analysis. AEs were coded using the Med-
ical Dictionary for Regulatory Activities coding system,
version 15.0, and descriptive statistics provided for AEs,
laboratory data, vital signs data, and ECG interval data.
All statistical analyses were performed using SAS (ver-
sion 9.3 or higher) and/or R (version 2.6 or higher).
Results
Baseline demographics and disease characteristics
A total of 29 patients were enrolled across 7 countries:
Brazil, France, Germany, Portugal, Spain, Sweden, and
the USA. All patients were white, 69 % were male, and
the mean (standard deviation [SD]) age was 56 (15.6)
years (Table 1). The majority of patients (76 %) had the
Val30Met TTR mutation. A small proportion (14 %) of
patients had walking difficulties requiring the use of a
stick or crutch, with the remainder having unimpaired
ambulation. The majority of patients were taking a con-
current TTR tetramer stabilizer, including 48 % on tafa-
midis and 24 % using diflunisal.
Patient disposition
Of the 29 patients enrolled, all received study treatment
and were included in the ITT population, and 26 pa-
tients completed the study. Two patients discontinued
from the study after receiving only 1 dose of patisiran: 1
patient in the 0.01 mg/kg dosing group (cohort 1) dis-
continued following a protocol amendment (Additional
file 1), and 1 patient in the 0.3 mg/kg Q3W group with-
drew from the study because of an AE. Following the
protocol-related patient discontinuation in the 0.01 mg/kg
Q4W group, an additional patient was enrolled and in-
cluded in this dose cohort. In addition to the 2 patients
who discontinued after the first dose of patisiran, 1 patient
in the 0.3 mg/kg Q4W group did not complete the study
due to a protocol violation (missed follow-up assessment).
This patient was excluded from PD analyses after Day 28
owing to an AE (extravasation of the second dose of pati-
siran), and an additional patient was recruited to the
study.
Seven patients received patisiran 0.3 mg/kg Q4W
(cohorts 4 and 5) and 4 patients received patisiran
0.01 mg/kg; all other study cohorts included 3 patients
as described. Of the cohorts treated with patisiran
0.3 mg/kg, 10 patients received their infusions over
60 min, and 9 patients (all in the Q3W group) received
the 70-min micro-dosing regimen. One patient in the
Table 1 Baseline demographics and disease characteristics (intent-to-treat population)
Parameter 0.01 mg/kg 0.05 mg/kg 0.15 mg/kg 0.3 mg/kg 0.3 mg/kg All patients
Q4W Q4W Q4W Q4W Q3W (n = 29)
(n = 4) (n = 3) (n = 3) (n = 7) (n = 12)
Sex, n (%)
Male 3 (75.0) 3 (100.0) 2 (66.7) 3 (42.9) 9 (75.0) 20 (69.0)
Female 1 (25.0) 0 1 (33.3) 4 (57.1) 3 (25.0) 9 (31.0)
Age, years
Mean (SD) 65.8 (8.96) 55.7 (24.83) 41.7 (2.52) 58.7 (16.07) 53.8 (15.6) 55.6 (15.61)
Race, n (%)
White/Caucasian 4 (100.0) 3 (100.0) 3 (100.0) 7 (100.0) 12 (100.0) 29 (100.0)
Country
Portugal 0 1 (33.3) 3 (100.0) 2 (28.6) 3 (25.0) 9 (31.0)
Sweden 2 (50.0) 1 (33.3) 0 2 (28.6) 1 (8.33) 6 (20.7)
France 2 (50.0) 1 (33.3) 0 2 (28.6) 3 (25.0) 8 (27.6)
Brazil 0 0 0 0 1 (8.33) 1 (3.4)
Germany 0 0 0 0 1 (8.33) 1 (3.4)
Spain 0 0 0 0 3 (25.0) 3 (10.3)
United States 0 0 0 1 (14.3) 0 1 (3.4)
TTR genotype, n (%)
Val30Met 2 (50.0) 2 (66.7) 3 (100.0) 6 (85.7) 9 (75.0) 22 (75.9)
Othera 2 (50.0) 1 (33.3) 0 1 (14.3) 3 (25.0) 7 (24.1)
Mean (SD) serum TTR at baseline, μg/mL 272.9 (98.96) 226.5 (12.67) 276.1 (7.65) 242.6 (38.30) 235.5 (44.45) 245.64 (49.44)
FAP stageb
1 – – – – – 25 (86.2)
2 – – – – — 4 (13.8)
Prior exposure to ALN-TTR01c
Yes 2 (50.0) 0 2 (66.7) 3 (42.9) 2 (16.67) 9 (31.0)
No 2 (50.0) 3 (100.0) 1 (33.3) 4 (57.1) 10 (83.33) 20 (69.0)
Concurrent TTR stabilizer use
Diflunisal 2 (50.0) 1 (33.3) 0 3 (42.9) 1 (33.3) 7 (24.1)
Tafamidis 0 1 (33.3) 2 (66.7) 4 (57.1) 7 (66.7) 14 (48.3)
aNon-Val30Met mutations: Arg45Thr (n = 1), Phe46Leu (n = 1), Ser77Tyr (n = 2), Ser77Phe (n = 2), Tyr116Ser (n = 1)
bFAP stage: 1 = unimpaired ambulation, mostly mild neuropathy in lower limbs; 2 = assistance with ambulation required, mostly moderate neuropathy with
progression to lower limbs, upper limbs, and trunk; 3 = wheelchair-bound or bedridden, severe neuropathy of all limbs
cALN-TTR01 was the first-generation siRNA-LNP used in phase I studies in patients with ATTR
ATTR TTR amyloid fibrils, FAP familial amyloid polyneuropathy; Q3W every 3 weeks; Q4W every 4 weeks; SD standard deviation; siRNA-LNP small interfering
RNA-lipid nanoparticles; TTR transthyretin
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criteria because of liver function data, but was given a
waiver to enter the study.
Efficacy and PD
Mean (SD) baseline serum TTR protein levels were simi-
lar across the dose cohorts: 272.9 (98.86), 226.5 (12.67),
276.1 (7.65), 242.6 (38.30), and 235.5 (44.45) μg/mL for
the 0.01, 0.05, 0.15, 0.3 Q4W, and 0.3 mg/kg Q3W dos-
age groups, respectively.In comparison to the 0.01 mg/kg dose cohort, a signifi-
cant reduction in nadir TTR levels (p < 0.001 by post hoc
tests after ANCOVA) was observed after the first and sec-
ond doses of patisiran in the 0.3 mg/kg Q4W and Q3W
cohorts (Fig. 1 and Table 2). In patients given 0.3 mg/kg
Q3W, mean ± SD TTR knockdown from baseline at nadir
was 83.8 ± 5.1 % and 86.7 ± 7.0 % after the first and second
doses, respectively, with maximum knockdown of 96 %. In
patients given the same dose Q4W, mean ± SD TTR
knockdown from baseline at nadir was 82.9 ± 5.4 % and
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Fig. 1 Dose response and duration of TTR knockdown. Mean (±SEM) percentage of baseline serum concentration–time profile. Q3W: every 3 weeks;
Q4W: every 4 weeks; SEM: standard error of the mean; TTR: transthyretin. *Includes first dose data from additional patient prior to protocol
amendment. †Excludes post-Day 28 data from patient who experienced drug extravasation during second infusion. ‡One patient discontinued
before the second dose of patisiran
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with maximum knockdown of 90.8 %. Mean TTR knock-
down from baseline of ≥ 80 % was maintained between
doses in the Q3W cohort, yet TTR levels recovered to <
80 % between doses with the Q4W regimen. In
patients with the Val30Met mutation, a very similar
degree of knockdown was observed for wild-type and
mutant TTR (Fig. 2a and b). The levels of mutant and
wild-type TTR knockdown were not assessed for each
of the rarer non-Val30Met genotypes, although overall
knockdown, as measured by ELISA, was indistinguishable
between patients with Val30Met or non-Val30Met muta-
tions. The level of serum TTR knockdown was highly
correlated with the reduction in circulating level of RBP
(r2 = 0.89, p < 10−15) and vitamin A (r2 = 0.89, p < 10-15)
(Additional file 2: Figure S1).Table 2 Serum TTR knockdown by dose group
Dose group (mg/kg) Dose 1
Maximum TTR KD (%) TTR KD at Nadir (Mean
0.01 Q4W (n = 4a) 37.8 22.1 ± 12.5
0.05 Q4W (n = 3) 58.0 48.4 ± 16.2
0.15 Q4W (n = 3) 81.7 74.5 ± 6.8***
0.3 Q4W (n = 7b) 87.5 82.9 ± 5.4***
0.3 Q3W (n = 12c) 94.2 83.8 ± 5.1***
p values from ANCOVA models including baseline TTR as covariate and dose group
***p < 0.001 vs. 0.01 mg/kg group
aIncludes first-dose data from additional patient prior to protocol amendment
bExcludes post-day 28 data from patient who experienced drug extravasation durin
cOne patient discontinued the study before second dose of patisiran
ANCOVA analysis of variance; KD knockdown; Q3W every 3 weeks; Q4W every 4 weeAlthough patients taking tafamidis or diflunisal had
significantly increased baseline levels of serum TTR
compared with patients not taking stabilizer therapy
(p < 0.001 by ANOVA) (Additional file 3: Figure S2a),
patisiran administration resulted in a similar degree of
TTR knockdown in these 2 patient groups (Additional
file 3: Figure S2b).
PK
Mean concentrations of the patisiran TTR siRNA compo-
nent decreased after EOI (Additional file 4: Figure S3),
and there was no accumulation of siRNA following the
second dose on Day 21/28. Measurements of encapsulated
versus un-encapsulated concentrations of TTR siRNA
after each dose indicated stability of the circulating LNP
formulation. For both the first and second doses, theDose 2
% ± SD) Maximum TTR KD (%) TTR KD at Nadir (Mean % ± SD)
34.4 32.9 ± 2.3
58.5 46.9 ± 15.0
86.0 77.0 ± 7.8
90.8 85.7 ± 9.6***
96.0 86.7 ± 7.0***
s as factor; models significant at p < 0.001 for Dose 1, p < 0.001 for Dose 2
g second infusion
ks; SD standard deviation; TTR transthyretin
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Fig. 2 Effect of patisiran on wild-type and mutant TTR in patients with the Val30Met mutation. a All post-dose data. b Patisiran 300 mg/kg groups
(error bars represent SEM). Q3W: every 3 weeks; Q4W: every 4 weeks; SEM: standard error of the mean; TTR: transthyretin; wt: wild-type
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and area under the plasma concentration–time curve
from zero to the last measurable time point (AUC0–last)
increased in a dose-proportional manner over the dose
range tested. Cmax and AUC0–last after doses 1 and 2 were
comparable, with no accumulation. The median terminal
half-life of patisiran at Day 0 and Days 21/28 was 39–59 h
at doses > 0.01 mg/kg, and was relatively unchanged when
comparing doses 1 and 2 for each dose cohort.Safety and tolerability
The most common TEAE related to study drug was
mild-to-moderate infusion-related reaction (IRR), which
occurred in 3/29 patients overall (10.3 %), all in the
0.3 mg/kg Q4W group (Table 3); none of these TEAEs
led to discontinuation of treatment. IRR-associated
symptoms were tachycardia, decreased oxygen satur-
ation, dizziness, abdominal pain, bronchospasm, dys-
pnea, erythema, chills, pallor, pyrexia, and tachypnea.
For 1 patient with a mild reaction, the event was man-
aged by prolonging the IV infusion time. Of note, no
IRRs were reported in the patient cohort that received
0.3 mg/kg Q3W (n = 12), 9 of whom received their infu-
sion with the micro-dosing regimen administered over
70 min. Aside from IRRs, no drug-related TEAE was ob-
served in more than 1 patient per dosage group across
the study.There were no dose-limiting toxicities or deaths due
to TEAEs reported during the course of the study. The
majority of TEAEs were of mild or moderate intensity.
Four serious AEs (SAEs) were reported in 1 patient in
the 0.3 mg/kg Q3W group (urinary tract infection, sep-
sis, nausea, and vomiting), and the patient withdrew
from the study because of the nausea and vomiting. An
additional SAE (extravasation-related cellulitis) was re-
corded in 1 patient in the 0.3 mg/kg Q4W group. The
SAEs of nausea and vomiting, and cellulitis were each
recorded by the Investigator as related to the study drug.
No clinically significant changes in liver function tests,
renal function, or hematologic parameters were re-
corded. Transient increases in white blood cell count
were observed approximately 24 h after each patisiran
infusion, which were considered related to dexametha-
sone premedication. There were no substantial changes
in serum G-CSF, IFN-α, IFN-γ, IL-1b, IL-12, and TNF-α
cytokines. Values were below the lower limit of detection
for most patients at the majority of time points. Transi-
ent increases in mean levels of IL-6, IL-1RA, and IP10
were observed after patisiran infusion in the 0.3 mg/kg
Q4W group (and in the 0.3 mg/kg Q3W group for IL-6),
although levels returned to baseline within 24 h. Tran-
sient increases in mean levels of complement factor Bb
were also seen after infusion of patisiran doses 0.05–
0.3 mg/kg. None of these elevations were associated
with AEs.
Table 3 Treatment-emergent adverse events related or possibly related to patisiran (ITT [safety] population)
Preferred term, n (%) Patisiran
0.01 mg/kg 0.05 mg/kg 0.15 mg/kg 0.3 mg/kg 0.3 mg/kg
Q4W Q4W Q4W Q4W Q3W Overall
(n = 4) (n = 3) (n = 3) (n = 7) (n = 12) (n = 29)
Infusion-related reaction 0 0 0 3 (42.9) 0 3 (10.3)
Back pain 0 0 0 2 (28.6) 0 2 (6.9)
Asthenia 0 0 0 1 (14.3) 1 (8.3) 2 (6.9)
Leukocytosis 0 0 0 0 1 (8.3) 1 (3.4)
Neutrophilia 0 0 0 0 1 (8.3) 1 (3.4)
Cellulitisa 0 0 0 1 (14.3) 0 1 (3.4)
Lymphangitis 0 0 0 1 (14.3) 0 1 (3.4)
Polyuria 0 0 0 1 (14.3) 0 1 (3.4)
Nausea/vomiting 0 0 0 0 1 (8.3) 1 (3.4)
Facial erythema 0 0 0 0 1 (8.3) 1 (3.4)
Dry mouth 0 0 0 0 1 (8.3) 1 (3.4)
Pyrexia 0 0 0 0 1 (8.3) 1 (3.4)
Dysphagia 0 0 0 0 1 (8.3) 1 (3.4)
aDue to drug extravasation
ITT intent-to-treat; Q3W every 3 weeks; Q4W every 4 weeks
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These phase II data demonstrate that administration of
patisiran to patients with FAP led to robust, dose-
dependent, and statistically significant knockdown of
serum TTR protein levels. Mean sustained reduction in
TTR of >80 % was achieved with 2 consecutive doses of
patisiran 0.3 mg/kg dosed every 3–4 weeks, with a max-
imum knockdown of 96 % achieved in the Q3W group.
These knockdown rates are consistent with the rates ob-
served in the single ascending dose, placebo-controlled
phase I study of patisiran [20]. Evidence from other sys-
temic amyloidotic diseases indicates that as little as 50 %
reduction of the disease-causing protein can result in
clinical disease improvement or stabilization [26, 27],
illustrating the potential of this therapy. The degree of
TTR knockdown with patisiran was not affected by pa-
tients taking tafamidis or diflunisal, suggesting that these
TTR stabilizer drugs do not interfere with the pharma-
cologic activity of patisiran. In patients with the Val30-
Met mutation, patisiran suppressed production of both
mutated and wild-type TTR; the latter remains amyloi-
dogenic in patients with late-onset FAP after liver trans-
plantation [28, 29].
Multiple doses of patisiran were shown to be generally
safe and well tolerated in this study. The majority of AEs
were mild or moderate in severity and no dose-limiting
toxicities were observed. While IRRs were the most
common drug-related TEAE seen at 0.3 mg/kg, no IRRs
were reported in the 0.3 mg/kg group that received the
micro-dosing infusion regimen over 70 min. Premedica-
tion was used to reduce the risk of IRRs, and is thusconsidered in assessment of the tolerability of this regi-
men. Glucocorticoids such as dexamethasone can in-
crease white blood cell levels [30], as observed
transiently in this study, and TEAEs potentially related
to premedication will be monitored during longer term
patisiran administration. The generally favorable toler-
ability profile observed in this study, with most patients
receiving TTR stabilizers, is encouraging with respect to
the potential concurrent use of these agents with
patisiran.
This multi-dose study defined patisiran 0.3 mg/kg
Q3W delivered using the 70-min micro-dosing regimen
as the formulation and dosage to administer in the on-
going open-label extension (OLE) phase of patients with
FAP. Whilst both Q3W and Q4W achieved potent TTR
knockdown, the level of TTR suppression was better
maintained between doses with the Q3W schedule,
supporting its future investigation. Preliminary data
from the OLE study show sustained TTR knockdown
of ~80 % after 168 days (9 doses), with no reported
SAEs (n = 27) [31]. The OLE study preliminary safety
data are consistent with the tolerability of patisiran ob-
served in this trial, with TEAEs all mild or moderate in
severity [31].
Patient baseline demographics and disease characteris-
tics in the present study were similar to those reported for
other recent FAP studies. In particular, the mean age
(55.6 years) was comparable to that reported for a large
natural history study of patients with FAP (56.4 years;
n = 283) [32] and for a phase II/III diflunisal study
(59.7 years; n = 130) [15], but was greater than the 39.8/
Suhr et al. Orphanet Journal of Rare Diseases  (2015) 10:109 Page 8 of 938.4 years reported for the tafamidis/placebo arms in
the tafamidis phase II/III study (n = 125) [14]. Some
75.9 % of patients in the present study had the Val30Met
mutation compared with 58.5 % (161/275 evaluable pa-
tients), 54.6 %, and 100 % in the natural history, diflunisal,
and tafamidis studies, respectively [14, 15, 32].
The results of this study supported the initiation of
a phase III study of patisiran. APOLLO is a random-
ized, placebo-controlled, phase III study of patisiran
0.3 mg/kg Q3W administered using the 70-min micro-
dosing schedule in recruiting patients with Val30Met
or non-Val30Met FAP who are not taking TTR stabilizers.
The primary study endpoint is disease progression, mea-
sured as the change from baseline in mNIS + 7 score at
18 months (Clinical trial identifier NCT01960348). Sec-
ondary endpoints include measures of quality of life and
disease burden, changes from baseline in motor and auto-
nomic neuropathy measures, and safety.Conclusion
In conclusion, the results of this phase II study provide
evidence that the investigational agent patisiran was gen-
erally well tolerated and effective in reducing both
mutant and wild-type TTR levels in patients with FAP.
The 0.3 mg/kg Q3W dosing schedule is under investiga-
tion in the phase III APOLLO trial.Additional files
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 1 
SUPPLEMENTAL MATERIALS 
Protocol amendments 
Two main protocol amendments were made, and a further 2 minor amendments (1.1 and 2.1) 
were implemented in France only. The main additions in Amendment 1 were based on new non-
clinical toxicology data from the non-human primate study and favorable clinical data from the 
phase I trials ALN-TTR02 and ALN-PCS02. In summary, Amendment 1 removed the 
requirement for the SRC to review safety data on all patients within a dose level between the 
first and second doses of study drug; removed the 0.5 mg/kg dose cohort; extended the post-
dose on-site observation period from 6 h to 24 h post-infusion; added additional safety 
evaluations; and added specific instructions for dosing of patients who weighed ≥ 105 kg. 
Amendment 2 added the every 3 weeks dosing regimen, and the slower infusion rate (70-
minute micro-dosing regimen). 
  
 2 
SUPPLEMENTAL MATERIALS 
Premedication regimen 
Patients received the following premedication regimen: dexamethasone (oral: 8 mg the evening 
before dosing and 20 mg 30–60 minutes before starting the patisiran infusion; or intravenous: 
10 mg ≥ 60 minutes before the patisiran infusion), paracetamol (oral: 500 mg the evening before 
dosing and 30–60 minutes before the patisiran infusion; or 500 mg ≥60 min before the patisiran 
infusion), H2 blocker (oral: ranitidine 150 mg, famotidine 20 mg, or equivalent, the evening 
before dosing and 30–60 minutes before starting the patisiran infusion; or intravenous: ranitidine 
50 mg, famotidine 20 mg, or equivalent, ≥ 60 minutes before the patisiran infusion), H1 blocker 
(oral: cetirizine 10 mg or hydroxyzine/fexofenadine 25 mg, the evening before dosing and 30–60 
minutes before the patisiran infusion; or diphenhydramine 50 mg or equivalent, ≥60 minutes 
before the patisiran infusion). 
1 
Figure S1 Correlation of serum TTR knockdown with change from baseline in serum 
vitamin A and RBP. 
RBP: retinol binding protein; TTR: transthyretin. 
 
1 
Figure S2 TTR knockdown with patisiran in patients taking a tetramer stabilizer.  
(a) Baseline TTR levels by stabilizer use (all cohorts). (b) TTR knockdown by patisiran (0.3 
mg/kg cohorts; error bars represent SEM). 
SEM: standard error of the mean; TTR: transthyretin. 
 
1 
Figure S3 Mean (±SD) plasma concentration–time profiles of patisiran following 1 h 
intravenous infusion (semi-log scale) for: 
(a) First (Day 0) and (b) second (Day 21/28) doses.  
Q3W: every 3 weeks; Q4W: every 4 weeks; SD: standard deviation. 
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BACKGROUND
Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits 
hepatic synthesis of transthyretin.
METHODS
In this phase 3 trial, we randomly assigned patients with hereditary transthyretin 
amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran 
(0.3 mg per kilogram of body weight) or placebo once every 3 weeks. The primary 
end point was the change from baseline in the modified Neuropathy Impairment 
Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment) 
at 18 months. Other assessments included the Norfolk Quality of Life–Diabetic Neu-
ropathy (Norfolk QOL-DN) questionnaire (range, −4 to 136, with higher scores indi-
cating worse quality of life), 10-m walk test (with gait speed measured in meters per 
second), and modified body-mass index (modified BMI, defined as [weight in kilo-
grams divided by square of height in meters] × albumin level in grams per liter; lower 
values indicated worse nutritional status).
RESULTS
A total of 225 patients underwent randomization (148 to the patisiran group and 77 
to the placebo group). The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the 
patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) 
change from baseline was −6.0±1.7 versus 28.0±2.6 (difference, −34.0 points; P<0.001) 
at 18 months. The mean (±SD) baseline Norfolk QOL-DN score was 59.6±28.2 in 
the patisiran group and 55.5±24.3 in the placebo group; the least-squares mean 
(±SE) change from baseline was −6.7±1.8 versus 14.4±2.7 (difference, −21.1 points; 
P<0.001) at 18 months. Patisiran also showed an effect on gait speed and modified 
BMI. At 18 months, the least-squares mean change from baseline in gait speed was 
0.08±0.02 m per second with patisiran versus −0.24±0.04 m per second with placebo 
(difference, 0.31 m per second; P<0.001), and the least-squares mean change from 
baseline in the modified BMI was −3.7±9.6 versus −119.4±14.5 (difference, 115.7; 
P<0.001). Approximately 20% of the patients who received patisiran and 10% of 
those who received placebo had mild or moderate infusion-related reactions; the 
overall incidence and types of adverse events were similar in the two groups.
CONCLUSIONS
In this trial, patisiran improved multiple clinical manifestations of hereditary trans-
thyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials 
.gov number, NCT01960348.)
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Hereditary transthyretin amyloi-dosis is an autosomal dominant, multi-systemic, progressive, life-threatening 
disease caused by mutations in the gene encod-
ing transthyretin (TTR).1 The liver is the primary 
source of circulating tetrameric transthyretin 
protein. In hereditary transthyretin amyloidosis, 
both mutant and wild-type transthyretin deposit 
as amyloid in peripheral nerves and the heart, 
kidney, and gastrointestinal tract,1,2 resulting in 
polyneuropathy and cardiomyopathy.1,3 Neuro-
pathic changes result in profound sensorimotor 
disturbances, with deterioration in activities of 
daily living and ambulation.4 Autonomic nerve 
involvement causes hypotension, diarrhea, impo-
tence, and bladder disturbances.4 Cardiac mani-
festations include heart failure, arrhythmias, 
orthostatic hypotension, or sudden death due to 
severe conduction disorders.5 Hereditary trans-
thyretin amyloidosis is inexorably progressive, with 
survival of 2 to 15 years after the onset of neu-
ropathy6-8 but only 2 to 5 years among patients 
presenting with cardiomyopathy.9,10
Current treatment options for hereditary trans-
thyretin amyloidosis are limited and include ortho-
topic liver transplantation and transthyretin tet-
ramer stabilizers (tafamidis or diflunisal). However, 
many patients who are treated with these ap-
proaches continue to have disease progression.4,10-16
RNA interference (RNAi) is an endogenous 
mechanism for controlling gene expression. It 
results in the cleavage of target messenger RNA 
(mRNA) by small interfering RNAs bound to the 
RNA-induced silencing complex. Patisiran, a he-
patically directed investigational RNAi therapeu-
tic agent (Fig. S1 in the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org), harnesses this process to reduce the pro-
duction of mutant and wild-type transthyretin by 
targeting the 3′ untranslated region of transthyre-
tin mRNA.17 Previously, dose-dependent reduction 
of circulating transthyretin levels has been ob-
served with patisiran administration in healthy 
volunteers and in patients with hereditary trans-
thyretin amyloidosis.17,18 In addition, patisiran has 
shown the potential to halt the disease or improve 
disease control in a phase 2, open-label extension 
study involving patients with hereditary transthyre-
tin amyloidosis.19 Here we present efficacy and 
safety data from the APOLLO trial, a randomized, 
placebo-controlled, phase 3 trial involving patients 
with hereditary transthyretin amyloidosis with 
polyneuropathy.
Me thods
Trial Oversight
We carried out a multicenter, international, ran-
domized, double-blind, placebo-controlled, phase 
3 trial of patisiran in patients with hereditary 
transthyretin amyloidosis with polyneuropathy. 
The protocol, including the statistical analysis 
plan, was developed by the sponsor, Alnylam Phar-
maceuticals, and is available at NEJM.org. The trial 
was approved by central and local institutional re-
view boards or ethics committees and conducted 
according to the Good Clinical Practice guide-
lines of the International Conference on Harmoni-
sation and the World Health Organization Dec-
laration of Helsinki. All the participants provided 
written informed consent.
All the investigators gathered the data. The 
first author and sponsor-employed authors ana-
lyzed the data, and all the authors vouch for the 
accuracy and completeness of the data and analy-
ses and for the adherence of the trial to the 
protocol. The first author and sponsor-employed 
authors prepared the first draft with editorial 
assistance provided by Adelphi Communications, 
under contract with Alnylam Pharmaceuticals. 
All the authors made the decision to submit the 
manuscript for publication. All the authors, their 
institutions, and the sponsor were required to 
maintain data confidentiality during the trial.
Trial Participants
Key eligibility criteria included an age of 18 to 85 
years; a documented pathogenic variant in TTR; 
a diagnosis of hereditary transthyretin amyloidosis 
with peripheral neuropathy, with a Neuropathy 
Impairment Score (NIS) of 5 to 130 (range, 0 to 
244, with higher scores indicating more impair-
ment) and a polyneuropathy disability score of IIIb 
or lower (with higher scores indicating more-
impaired walking ability); and adequate liver and 
renal function. Patients with previous liver trans-
plantation or who were planning to undergo liver 
transplantation during the trial period, or who 
had a New York Heart Association class of III or 
IV, were excluded. Full eligibility criteria are pro-
vided in the protocol.
Trial Design and Regimens
Patients were enrolled at 44 sites across 19 coun-
tries. Patients were randomly assigned (in a 2:1 
ratio) to receive patisiran (0.3 mg per kilogram 
of body weight) or placebo intravenously over a 
n engl j med 379;1 nejm.org July 5, 2018 13
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period of approximately 80 minutes, once every 
3 weeks for 18 months.20 Randomization was 
stratified according to NIS (5 to 49 vs. 50 to 130), 
early onset of disease (age <50 years) in the pres-
ence of the V30M variant versus all other patho-
genic variants (including late-onset disease in 
the presence of the V30M variant), and previous 
use of a transthyretin stabilizer (yes vs. no). Pa-
tients received premedication to minimize the 
risk of infusion-related reactions, with details 
provided by Adams et al.20 Patients completing 
the 18-month efficacy assessments were eligible 
to participate in an open-label extension study 
(ClinicalTrials.gov number, NCT02510261).
End-Point Measures and Safety Assessments
The primary end point was the change from base-
line to 18 months in the modified Neuropathy 
Impairment Score+7 (mNIS+7),21,22 a composite 
measure of neuropathy that assesses motor, sen-
sory, and autonomic neuropathy (range, 0 to 304, 
with higher scores indicating more impairment). 
Further details on mNIS+7, including standard-
ization of assessments and investigator training, 
have been reported.20
Secondary end points, in hierarchical order for 
statistical testing, were quality of life (score on 
the Norfolk Quality of Life–Diabetic Neuropathy 
[Norfolk QOL-DN] questionnaire; range, −4 to 
136, with higher scores indicating worse quality 
of life), motor strength (NIS-weakness; range, 
0 to 192, with higher scores indicating more 
impairment), disability (score on the Rasch-built 
Overall Disability Scale [R-ODS]; range, 0 to 48, 
with lower scores indicating more disability), 
gait speed (10-m walk test, with speed measured 
in meters per second), nutritional status (modi-
fied body-mass index [BMI], defined as [weight 
in kilograms divided by square of height in me-
ters] × albumin level in grams per liter; lower val-
ues indicated worse nutritional status), and pa-
tient-reported autonomic symptoms (Composite 
Autonomic Symptom Score 31; range, 0 to 100, 
with higher scores indicating more autonomic 
symptoms), which have been described by Adams 
et al.20 All efficacy end points were assessed at 
baseline and at 9 and 18 months, except modi-
fied BMI (at baseline and at weeks 12, 27, 51, 66, 
and 78).
Exploratory end points included pharmacody-
namic biomarkers (transthyretin and vitamin A) 
and measures of cardiac structure and function 
(echocardiography and measurement of N-termi-
nal pro–brain natriuretic peptide [NT-proBNP]) 
(see the Supplementary Appendix), as well as as-
sessment of neuropathy stage with the use of the 
polyneuropathy disability score (with higher scores 
indicating more impaired walking ability). Safety 
was monitored throughout the trial as specified 
in the protocol (see the Supplementary Appendix).
Statistical Analysis
The primary population for efficacy and safety 
analyses was the modified intention-to-treat pop-
ulation (all randomly assigned patients who re-
ceived ≥1 dose of patisiran or placebo). Selected 
analyses were also performed in a predefined car-
diac subpopulation (baseline left ventricular wall 
thickness ≥13 mm in the absence of a history of 
aortic valve disease or hypertension), to enable 
specific assessment of patisiran on cardiac man-
ifestations.
Assuming a mean (±SD) increase in the mNIS+7 
of 24±16 points at 18 months in the placebo 
group, we calculated that a sample of 154 patients 
would provide 90% power for a t-test to detect an 
8.95-point (37.3%) mean difference between the 
two trial groups at a two-sided alpha level of 0.05. 
The planned sample was estimated at 200 pa-
tients to account for discontinuation.
Efficacy end points were assessed with the use 
of a mixed model for repeated measures (see the 
Supplementary Appendix). Secondary end points 
were analyzed in a prespecified hierarchical order 
to control the overall type I error (order as de-
scribed above).
R esult s
Trial Population
From December 2013 through January 2016, a 
total of 225 patients were randomly assigned in 
a 2:1 ratio to receive patisiran (148 patients) or 
placebo (77) (Fig. 1). The two groups were gen-
erally balanced with respect to baseline demo-
graphic and clinical characteristics (Table 1). 
The V30M mutation was present in 38% of the 
patients in the patisiran group and 52% of those 
in the placebo group, with the remaining pa-
tients having 1 of 38 other pathogenic variants 
(Table S1 in the Supplementary Appendix). Over-
all, 126 patients (56%) were included in the pre-
defined cardiac subpopulation, with a higher per-
centage in the patisiran group (61%, as compared 
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with 47% in the placebo group). Overall, 138 pa-
tients in the patisiran group (93%) and 55 in the 
placebo group (71%) completed the trial (Fig. 1).
Pharmacodynamics
In the patisiran group, the reduction in serum 
transthyretin levels was rapid and sustained over 
a period of 18 months (Fig. 2A). The median re-
duction in the serum transthyretin level during 
the 18 months was 81% (range, −38 to 95) and 
was similar across age, sex, or genotype.
Efficacy
Primary End Point
The change from baseline in the mNIS+7 was 
significantly lower with patisiran than with place-
bo at 18 months, indicating a benefit with respect 
to polyneuropathy. The mean (±SD) mNIS+7 at 
baseline was 80.9±41.5 in the patisiran group and 
74.6±37.0 in the placebo group. At 18 months, the 
least-squares mean (±SE) change in mNIS+7 from 
baseline was −6.0±1.7 with patisiran, as compared 
with 28.0±2.6 with placebo (least-squares mean 
difference, −34.0 points; 95% confidence interval 
[CI], −39.9 to −28.1; P<0.001) (Fig. 2B). The ef-
fect of patisiran on mNIS+7 was seen as early as 
9 months.
The response to treatment was observed 
broadly across the patisiran group, with 74% of 
the patients having a less than 10-point increase 
from baseline in the mNIS+7 at 18 months, as 
compared with 14% of the patients in the pla-
cebo group. The treatment effect was significant 
for all subgroups and components of the mNIS+7 
(Figs. S2 and S3 in the Supplementary Appendix) 
and was consistent across all trial sites. A correla-
tion was observed between the degree of the re-
duction in transthyretin levels from baseline and 
the change in the mNIS+7 at 18 months (Fig. 3).
At 18 months, 56% of the patients who re-
ceived patisiran had an improvement (decrease 
from baseline at 18 months) in the mNIS+7, as 
compared with 4% of the patients who received 
placebo (Fig. 2D). In patients who received pati-
Figure 1. Randomization and Follow-up.
Patients were assigned in a 2:1 ratio to the patisiran group or the placebo group. Shown is the modified intention-
to-treat population, which includes all the patients who underwent randomization and received at least one dose of 
patisiran or placebo. Patients who discontinued the trial regimen permanently stopped the regimen before the last 
scheduled dose (week 78 visit). Patients who discontinued the trial regimen owing to progressive disease had a 
modified Neuropathy Impairment Score+7 (range, 0 to 304, with higher scores indicating more impairment) that 
increased by at least 24 points from baseline (on the basis of an average of two measurements) and a worsening in 
the stage of familial amyloidotic polyneuropathy relative to baseline at 9 months.
225 Patients underwent randomization
77 Were assigned to receive placebo 148 Were assigned to receive patisiran
29 (38%) Discontinued
trial regimen
7 (9%) Had adverse event
4 (5%) Died
4 (5%) Had progressive
disease
2 (3%) Were withdrawn
by physician
12 (16%) Withdrew
22 (29%) Were withdrawn
from the trial
11 (7%) Discontinued
trial regimen
3 (2%) Had adverse event
5 (3%) Died
1 (<1%) Had progressive
disease
1 (<1%) Had protocol
violation
1 (<1%) Withdrew
10 (7%) Were withdrawn
from the trial
55 (71%) Completed trial 138 (93%) Completed trial
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Characteristic
Placebo 
 (N = 77)
Patisiran 
 (N = 148)
Total 
 (N = 225)
Median age (range) — yr 63 (34–80) 62 (24–83) 62 (24–83)
Male sex — no. (%) 58 (75) 109 (74) 167 (74)
Race — no. (%)†
Asian 25 (32) 27 (18) 52 (23)
Black 1 (1) 4 (3) 5 (2)
White 50 (65) 113 (76) 163 (72)
Other 0 1 (<1) 1 (<1)
>1 Race 0 2 (1) 2 (<1)
Missing data 1 (1) 1 (<1) 2 (<1)
Geographic region — no. (%)‡
North America 10 (13) 37 (25) 47 (21)
Western Europe 36 (47) 62 (42) 98 (44)
Rest of world 31 (40) 49 (33) 80 (36)
Median time since diagnosis of hereditary transthyretin  
amyloidosis (range) — yr
1.4 (0.0–16.5) 1.3 (0.0–21.0) 1.4 (0.0–21.0)
TTR genotype — no. (%)
V30M 40 (52) 56 (38) 96 (43)
With onset of disease before 50 yr of age 10 (13) 13 (9) 23 (10)
Non-V30M§ 37 (48) 92 (62) 129 (57)
Previous use of tetramer stabilizer — no. (%) 41 (53) 78 (53) 119 (53)
FAP stage — no. (%)
1: unimpaired ambulation 37 (48) 67 (45) 104 (46)
2: assistance with ambulation 39 (51) 81 (55) 120 (53)
3: wheelchair-bound or bedridden 1 (1) 0 1 (<1)
Polyneuropathy disability score — no. (%)
I: preserved walking, sensory disturbances 20 (26) 36 (24) 56 (25)
II: impaired walking without need for a stick or crutches 23 (30) 43 (29) 66 (29)
IIIA: walking with one stick or crutch 22 (29) 41 (28) 63 (28)
IIIB: walking with two sticks or crutches 11 (14) 28 (19) 39 (17)
IV: confined to wheelchair or bedridden 1 (1) 0 1 (<1)
New York Heart Association class — no. (%)
I 40 (52) 70 (47) 110 (49)
II 36 (47) 77 (52) 113 (50)
Missing data 1 (1) 1 (<1) 2 (<1)
*  Differences in baseline demographic and clinical characteristics between the patisiran and placebo groups were tested 
with the use of t-tests for continuous variables (age and log-transformed years since diagnosis of hereditary transthyre-
tin amyloidosis) and Fisher’s exact tests for categorical variables (sex, race, geographic region, V30M or non-V30M TTR 
genotype, previous use or nonuse of tetramer stabilizer, and New York Heart Association class). A significant differ-
ence between the groups (P<0.05) was found for TTR genotype only. FAP denotes familial amyloidotic polyneuropathy.
†  Race was reported by the patients.
‡  North America included Canada and the United States. Western Europe included France, Germany, Italy, the 
Netherlands, Portugal, Spain, Sweden, and the United Kingdom. The rest of world included Argentina, Brazil, Bulgaria, 
Cyprus, Japan, Mexico, South Korea, Taiwan, and Turkey.
§  The non-V30M TTR genotype represents 38 different TTR mutations, which are listed in Table S1 in the Supplementary 
Appendix.
Table 1. Baseline Demographic and Clinical Characteristics of the Patients.*
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Figure 2. Comparisons of Changes between the Patisiran Group and the Placebo Group over Time.
Panel A shows the percentage change in serum transthyretin levels from baseline over time in the patisiran group 
and the placebo group. The nadirs in transthyretin reduction at 9 and 18 months correspond to the predose and 
postdose assessments. Panel B shows the least-squares mean change in the modified Neuropathy Impairment 
Score+7 (mNIS+7). At baseline, the mean mNIS+7 was 80.9 (range, 8.0 to 165.0) in the patisiran group and 74.6 
(range, 11.0 to 153.5) in the placebo group. Panel C shows the least-squares mean change in Norfolk Quality of 
Life–Diabetic Neuropathy (QOL-DN) scores (range, −4 to 136; with higher scores indicating worse quality of life).  
At baseline, the mean Norfolk QOL-DN score was 59.6 (range, 5.0 to 119.0) in the patisiran group and 55.5 (range, 
8.0 to 111.0) in the placebo group. In Panels A through C, I bars indicate standard errors. Panel D shows the per-
centage of patients with an improvement (decrease from baseline) in the mNIS+7 or the Norfolk QOL-DN score 
from baseline after 18 months. A post hoc analysis was used to calculate the odds ratio for improvement in the 
Norfolk QOL-DN score.
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siran and did not have an improvement in the 
mNIS+7 (54 of 137 patients with available data), 
the median change from baseline in the mNIS+7 
at 18 months was lower than that observed in all 
51 patients who received placebo and had avail-
able data (9.9-point increase and 26.5-point in-
crease, respectively).
Secondary End Points
The change from baseline in the Norfolk QOL-DN 
score was significantly lower with patisiran than 
with placebo at 18 months, indicating better qual-
ity of life with patisiran. At baseline, the mean 
(±SD) Norfolk QOL-DN score was 59.6±28.2 in 
the patisiran group and 55.5±24.3 in the placebo 
group. At 18 months, the least-squares mean (±SE) 
change in the Norfolk QOL-DN score from base-
line was −6.7±1.8 with patisiran, as compared 
with 14.4±2.7 with placebo (least-squares mean 
difference, −21.1 points; 95% CI, −27.2 to −15.0; 
P<0.001) (Fig. 2C). Consistent effects in favor of 
patisiran were noted in Norfolk QOL-DN scores 
across all subgroups (Fig. S4 in the Supplemen-
tary Appendix). At 18 months, 51% of the patients 
who received patisiran had an improvement (de-
crease from baseline at 18 months) in the Norfolk 
QOL-DN score, as compared with 10% of those 
who received placebo (Fig. 2D).
Significant between-group differences in favor 
of patisiran treatment were observed for all other 
secondary end points (Table 2). Improvement rela-
tive to baseline was also seen in gait speed in the 
10-m walk test (53% of the patients who received 
patisiran vs. 13% of those who received placebo) 
and motor strength (40% vs. 1%), as determined 
by the NIS-weakness test at 18 months. For all 
secondary end points, between-group differenc-
es in favor of patisiran were evident at the first 
efficacy assessment time point (3 months for 
modified BMI and 9 months for all others).
Select Exploratory End Points
Measures of neuropathy stage also favored pati-
siran, with the polyneuropathy disability score 
stable (96 patients [65%]) or improved (12 pa-
tients [8%]) from baseline in 108 of 148 patients 
(73%); in the placebo group, stabilization occurred 
in 23 of 77 patients (30%) and none had improve-
ment at 18 months. Among patients whose poly-
neuropathy disability score worsened at 18 months, 
worsening by more than one level was observed 
in 5 of 30 patients (17%) in the patisiran group, 
as compared with 16 of 32 (50%) in the placebo 
group.
In the cardiac subpopulation, the geometric 
mean baseline level of NT-proBNP, a measure of 
cardiac stress that is an independent predictor of 
death in patients with transthyretin cardiac amy-
loidosis, was 726.9 pg per milliliter (coefficient 
of variation, 220.3%) in the patisiran group and 
711.1 pg per milliliter (coefficient of variation, 
190.8%) in the placebo group. At 18 months, the 
adjusted geometric mean ratio to baseline was 
0.89 with patisiran and 1.97 with placebo (ratio, 
0.45; P<0.001), representing a 55% difference in 
favor of patisiran. Patisiran treatment was also 
associated with better cardiac structure and func-
tion than placebo, including significant differ-
ences in mean left ventricular wall thickness 
(P = 0.02) and longitudinal strain (P = 0.02) at 18 
months (Table 2).
Safety
Overall, 97% of the patients in each trial group 
reported adverse events (Table 3), most of which 
were mild or moderate in severity. The frequency 
of severe adverse events (28% in the patisiran 
group and 36% in the placebo group) and seri-
Figure 3. Correlation of Reduction in Transthyretin Levels with Change  
in mNIS+7 from Baseline at 18 Months.
The analysis included 188 patients with nonmissing mNIS+7 assessments 
at month 18.
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End Point Placebo Patisiran
Least-Squares Mean 
Difference 
(Patisiran − Placebo) P Value
Secondary end points in the modified ITT population*
No. of patients 77 148
Neuropathy Impairment Score–weakness†
Mean (±SD) baseline score 29.0±23.0 32.7±25.2
Least-squares mean (±SE) change from baseline at 18 mo 17.9±2.0 0.1±1.3 −17.9±2.3 <0.001
Score on the Rasch-built Overall Disability Scale‡
Mean (±SD) baseline score 29.8±10.8 29.7±11.5
Least-squares mean (±SE) change from baseline at 18 mo −8.9±0.9 0.0±0.6 9.0±1.0 <0.001
10-m walk test — m/sec§
Mean (±SD) baseline value 0.79±0.32 0.80±0.40
Least-squares mean (±SE) change from baseline at 18 mo −0.24±0.04 0.08±0.02 0.31±0.04 <0.001
Modified BMI¶
Mean (±SD) baseline value 989.9±214.2 969.7±210.5
Least-squares mean (±SE) change from baseline at 18 mo −119.4±14.5 −3.7±9.6 115.7±16.9 <0.001
Composite Autonomic Symptom Score 31‖
Mean (±SD) baseline score 30.3±16.4 30.6±17.6
Least-squares mean (±SE) change from baseline at 18 mo 2.2±1.9 −5.3±1.3 −7.5±2.2 <0.001
Exploratory end points in the cardiac subpopulation**
No. of patients 36 90
Left ventricular wall thickness — mm
Mean (±SD) baseline value 16.4±2.1 16.8±2.6
Least-squares mean (±SE) change from baseline at 18 mo −0.1±0.3 −1.0±0.2 −0.9±0.4 0.02
Left ventricular longitudinal strain — %
Mean (±SD) baseline value −15.66±3.51 −15.13±3.41
Least-squares mean (±SE) change from baseline at 18 mo 1.46±0.48 0.08±0.28 −1.37±0.56 0.02
NT-proBNP††
Baseline value
Geometric mean — pg/ml 711.1 726.9
Coefficient of variation — % 190.8 220.3
Ratio to baseline at 18 mo‡‡ 1.97 0.89 0.45§§ <0.001
*  The modified intention-to-treat (ITT) population included all the patients who underwent randomization and received at least one dose of 
patisiran or placebo.
†  Scores on the weakness component of the Neuropathy Impairment Score range from 0 to 192, with higher scores indicating more impair-
ment. The number of patients who were assessed at 18 months was 51 in the placebo group and 137 in the patisiran group.
‡  Scores on the Rasch-built Overall Disability Scale range from 0 to 48, with lower scores indicating more disability. The number of patients 
who were assessed at 18 months was 54 in the placebo group and 138 in the patisiran group.
§  A lower value indicates a slower gait speed. The number of patients who were assessed at 18 months was 55 in the placebo group and 
138 in the patisiran group.
¶  The modified body-mass index (BMI) was the BMI (weight in kilograms divided by square of height in meters) × albumin level in grams 
per liter. The number of patients who were assessed at 18 months was 52 in the placebo group and 133 in the patisiran group.
‖  Values for the Composite Autonomic Symptom Score 31 range from 0 to 100, with higher scores indicating more autonomic symptoms. 
The number of patients who were assessed at 18 months was 53 in the placebo group and 136 in the patisiran group.
**  The cardiac subpopulation included patients with a baseline left ventricular wall thickness of 13 mm or more in the absence of a history of 
aortic valve disease or hypertension.
††  N-terminal pro–brain natriuretic peptide (NT-proBNP) is a measure of cardiac stress that is an independent predictor of death in patients 
with transthyretin cardiac amyloidosis.
‡‡  Shown is the adjusted geometric mean ratio to baseline at month 18.
§§  Shown is the ratio of adjusted geometric mean ratio to baseline at month 18 between the two trial groups (patisiran:placebo).
Table 2. Secondary and Exploratory End Points.
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ous adverse events (36% and 40%, respectively) 
was similar in the two groups (Table 3, and Ta-
ble S2 in the Supplementary Appendix). Adverse 
events leading to discontinuation of the trial regi-
men occurred more frequently with placebo (14%) 
than with patisiran (5%); adverse events that led 
to discontinuation of the trial regimen in two or 
more patients were cardiac failure (two patients 
[1%] in the patisiran group) and acute kidney 
injury (two patients [3%] in the placebo group). 
Death occurred in seven patients (5%) in the 
patisiran group and in six patients (8%) in the 
placebo group. The causes of death were primar-
ily cardiovascular in nature and consistent with 
those expected in patients with hereditary trans-
thyretin amyloidosis (Table S4 in the Supplemen-
tary Appendix). The incidence of cardiac adverse 
events (28% in the patisiran group and 36% in 
the placebo group), cardiac serious adverse events 
(14% and 13%, respectively), and cardiac failure 
(9% and 10%, respectively) was similar in the two 
groups. The incidence of cardiac arrhythmias 
was lower with patisiran (19%) than with pla-
cebo (29%).
Common adverse events that occurred more 
frequently with patisiran than with placebo in-
cluded peripheral edema (30% vs. 22%) and in-
fusion-related reactions (19% vs. 9%) (Table 3, 
and Table S3 in the Supplementary Appendix). 
These were all mild or moderate in severity. One 
patient withdrew owing to a moderate infusion-
related reaction of flushing. Symptoms of infu-
sion-related reactions that were reported in at 
least 3% of patients in either group were back 
pain, flushing, abdominal pain, and nausea (Ta-
ble S3 in the Supplementary Appendix); there were 
no reported severe or serious infusion-related reac-
tions, and the frequency of infusion-related reac-
tions decreased over time. No clinically relevant 
changes in laboratory values related to patisiran, 
including platelet counts and indicators of liver 
or kidney function, were observed during the 
trial. Of the 187 patients eligible to participate 
in an open-label extension study, 186 (99%) were 
enrolled.
Discussion
Current treatment options for hereditary trans-
thyretin amyloidosis are limited; however, our 
data indicate that the lowering of transthyretin 
levels may be an effective therapeutic approach. 
We found that patisiran, an RNAi therapeutic, 
significantly improved neuropathy in patients with 
hereditary transthyretin amyloidosis. The effects 
extended across the sensorimotor and autonomic 
domains and were consistent across patient sub-
groups. In addition, patisiran treatment resulted 
in significant improvements in quality of life, 
walking, nutritional status, and activities of daily 
living. The broad patient population recruited to 
the APOLLO phase 3 trial is characteristic of the 
wide disease spectrum expected in clinical prac-
tice. Our results are corroborated by a trial of 
Event
Placebo 
(N = 77)
Patisiran 
(N = 148)
no. of patients (%)
Any adverse event 75 (97) 143 (97)
Adverse events occurring in ≥10% of pa-
tients in either group
Diarrhea 29 (38) 55 (37)
Edema, peripheral 17 (22) 44 (30)
Fall 22 (29) 25 (17)
Nausea 16 (21) 22 (15)
Infusion-related reaction 7 (9) 28 (19)
Constipation 13 (17) 22 (15)
Urinary tract infection 14 (18) 19 (13)
Dizziness 11 (14) 19 (13)
Fatigue 8 (10) 18 (12)
Headache 9 (12) 16 (11)
Cough 9 (12) 15 (10)
Vomiting 8 (10) 15 (10)
Asthenia 9 (12) 14 (9)
Insomnia 7 (9) 15 (10)
Nasopharyngitis 6 (8) 15 (10)
Pain in extremity 8 (10) 10 (7)
Muscular weakness 11 (14) 5 (3)
Anemia 8 (10) 3 (2)
Syncope 8 (10) 3 (2)
Adverse event leading to discontinuation 
of the trial regimen
11 (14) 7 (5)
Adverse event leading to withdrawal from 
the trial
9 (12) 7 (5)
Death 6 (8) 7 (5)
Any serious adverse event 31 (40) 54 (36)
Any severe adverse event 28 (36) 42 (28)
Table 3. Safety and Side Effects.
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inotersen, also published in this issue of the 
Journal, which used an antisense oligonucleotide 
approach to transthyretin lowering and showed 
the slowing of neuropathy progression in patients 
with hereditary transthyretin amyloidosis.23
Hereditary transthyretin amyloidosis has a 
rapidly progressive course, highlighted by the 
worsening condition seen in patients who re-
ceived placebo during the trial, a finding consis-
tent with those of other reports.6,24,25 Across trial 
end points, patients in the placebo group had 
evidence of increasing sensorimotor and auto-
nomic impairment, leading to worsening symp-
toms and decreased functional ability. Disease 
progression was also evident from the higher rate 
of discontinuation of the trial regimen in the 
placebo group (38%, as compared with 7% in the 
patisiran group), as well as the high incidence of 
adverse events likely to be associated with wors-
ening disease (e.g., falls, urinary tract infections, 
and syncope) in the placebo group.
In contrast, disease progression was halted or 
reversed with patisiran treatment across all pri-
mary and secondary end points. In addition, the 
polyneuropathy disability score improved in 8% of 
the patients in the patisiran group at 18 months, 
whereas no patients in the placebo group had 
improvement. This included transition from as-
sisted to unassisted walking, a notable milestone 
for patients with hereditary transthyretin amy-
loidosis, which is consistent with the effect of 
patisiran on gait speed.
There was also evidence that patisiran improved 
cardiac manifestations of hereditary transthyretin 
amyloidosis, as indicated by echocardiographic 
measures of cardiac structure and function and 
a reduction in NT-proBNP levels. It is possible that 
the increased gait speed in patients who received 
patisiran may have resulted from favorable effects 
on both the neuropathic and cardiac aspects of 
the disease.
The principal safety finding was mild-to-mod-
erate infusion-related reactions, the incidence of 
which decreased over time. The number of deaths 
in the overall population, and in the cardiac sub-
group, was similar in the patisiran group and 
the placebo group. There were no safety signals 
regarding thrombocytopenia or renal dysfunction 
with patisiran, although these events have been 
observed with other oligonucleotide therapies.26 
In conclusion, the APOLLO phase 3 trial showed 
that patisiran provided benefit to patients with 
hereditary transthyretin amyloidosis by treating 
a broad range of symptoms.
Supported by Alnylam Pharmaceuticals.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank all the patients and their families who were in-
volved in the trial; the additional APOLLO trial investigators, 
who are listed in the Supplementary Appendix; W.J. Litchy (Mayo 
Clinic), Brian Bettencourt (formerly at Alnylam Pharmaceuti-
cals), and Matt White (Alnylam Pharmaceuticals) for their con-
tributions; and the staff at Adelphi Communications and Angela 
M. Partisano (Alnylam Pharmaceuticals) for editorial assistance 
with an earlier version of the manuscript.
Appendix
The authors’ full names and academic degrees are as follows: David Adams, M.D., Ph.D., Alejandra Gonzalez-Duarte, M.D., William D. 
O’Riordan, M.D., Chih-Chao Yang, M.D., Mitsuharu Ueda, M.D., Ph.D., Arnt V. Kristen, M.D., Ivailo Tournev, M.D., Hartmut H. 
Schmidt, M.D., Teresa Coelho, M.D., John L. Berk, M.D., Kon-Ping Lin, M.D., Giuseppe Vita, M.D., Shahram Attarian, M.D., Ph.D., 
Violaine Planté-Bordeneuve, M.D., Ph.D., Michelle M. Mezei, M.D.C.M., Josep M. Campistol, M.D., Juan Buades, M.D., Ph.D., Thom-
as H. Brannagan III, M.D., Byoung J. Kim, M.D., Jeeyoung Oh, M.D., Ph.D., Yesim Parman, M.D., Yoshiki Sekijima, M.D., Ph.D., 
Philip N. Hawkins, F.Med.Sci., Scott D. Solomon, M.D., Michael Polydefkis, M.D., M.H.S., Peter J. Dyck, M.D., Pritesh J. Gandhi, 
Pharm.D., Sunita Goyal, M.D., Jihong Chen, Ph.D., Andrew L. Strahs, Ph.D., Saraswathy V. Nochur, Ph.D., Marianne T. Sweetser, M.D., 
Ph.D., Pushkal P. Garg, M.D., Akshay K. Vaishnaw, M.D., Ph.D., Jared A. Gollob, M.D., and Ole B. Suhr, M.D., Ph.D.
The authors’ affiliations are as follows: Assistance Publique–Hôpitaux de Paris (APHP), National Reference Center for Familial Amy-
loidotic Polyneuropathy, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM Unité 1195, Université Paris-Sud, Le Kremlin-Bicêtre 
(D.A.), the Department of Neuromuscular Disorders and ALS, Hôpital de la Timone, Marseille (S.A.), and the Department of Neurol-
ogy, Amyloid Network, CHU Henri Mondor–APHP, Créteil (V.P.-B.) — all in France; the National Institute of Medical Sciences and 
Nutrition–Salvador Zubiran, Mexico City (A.G.-D.); the Department of Clinical Research, eStudySite, San Diego, CA (W.D.O.); the De-
partment of Neurology, National Taiwan University Hospital (C.-C.Y.), and the Department of Neurology, Taipei Veterans General 
Hospital (K.-P.L.), Taipei, Taiwan; Kumamoto University Hospital, Kumamoto (M.U.), and the Department of Medicine (Neurology and 
Rheumatology), Shinshu University School of Medicine, Matsumoto (Y.S.) — both in Japan; the Department of Cardiology, University 
of Heidelberg, Heidelberg (A.V.K.), and Medizinische Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster, 
Münster (H.H.S.) — both in Germany; University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria (I.T.); Hospital de Santo 
António, Centro Hospitalar do Porto, Porto, Portugal (T.C.); the Amyloidosis Center, Department of Medicine, Boston Medical Center 
(J.L.B.), and Harvard Medical School (S.D.S.), Boston; the Department of Clinical and Experimental Medicine, University Hospital of 
Messina, Messina, Italy (G.V.); the Departments of Neurology and Medicine, Vancouver General Hospital, Vancouver, BC, Canada 
(M.M.M.); the Department of Nephrology, Hospital Clinic, Barcelona (J.M.C.), and the Balearic Islands Health Research Institute and 
Hospital Son Llatzer, Palma de Mallorca (J.B.) — all in Spain; the Department of Neurology, Columbia University, College of Physicians 
n engl j med 379;1 nejm.org July 5, 2018 21
Patisir an for Hereditary Tr ansthyretin Amyloidosis
and Surgeons, New York (T.H.B.); Samsung Medical Center, Sungkyunkwan University School of Medicine (B.J.K.), and the the Depart-
ment of Neurology, Konkuk University Medical Center (J.O.), Seoul, South Korea; the Department of Neurology, Istanbul University, 
Istanbul, Turkey (Y.P.); the Division of Medicine, University College London, London (P.N.H.); Johns Hopkins Bayview Medical Center, 
Baltimore (M.P.); the Department of Neurology, Mayo Clinic, Rochester, MN (P.J.D.); Alnylam Pharmaceuticals, Cambridge, MA (P.J.G., 
S.G., J.C., A.L.S., S.V.N., M.T.S., P.P.G., A.K.V., J.A.G.); and the Department of Public Health and Clinical Medicine, Umeå University, 
Umeå, Sweden (O.B.S.).
References
1. Hawkins PN, Ando Y, Dispenzeri A, 
Gonzalez-Duarte A, Adams D, Suhr OB. 
Evolving landscape in the management of 
transthyretin amyloidosis. Ann Med 2015; 
47: 625-38.
2. Ruberg FL, Berk JL. Transthyretin 
(TTR) cardiac amyloidosis. Circulation 
2012; 126: 1286-300.
3. Conceição I, González-Duarte A, Obi-
ci L, et al. “Red-flag” symptom clusters in 
transthyretin familial amyloid polyneu-
ropathy. J Peripher Nerv Syst 2016; 21: 5-9.
4. Ando Y, Coelho T, Berk JL, et al. 
Guideline of transthyretin-related heredi-
tary amyloidosis for clinicians. Orphanet 
J Rare Dis 2013; 8: 31.
5. Dungu JN, Anderson LJ, Whelan CJ, 
Hawkins PN. Cardiac transthyretin amy-
loidosis. Heart 2012; 98: 1546-54.
6. Adams D, Coelho T, Obici L, et al. 
Rapid progression of familial amyloidotic 
polyneuropathy: a multinational natural 
history study. Neurology 2015; 85: 675-82.
7. Koike H, Tanaka F, Hashimoto R, et 
al. Natural history of transthyretin Val-
30Met familial amyloid polyneuropathy: 
analysis of late-onset cases from non-
endemic areas. J Neurol Neurosurg Psy-
chiatry 2012; 83: 152-8.
8. Mariani LL, Lozeron P, Théaudin M, 
et al. Genotype-phenotype correlation 
and course of transthyretin familial amy-
loid polyneuropathies in France. Ann 
Neurol 2015; 78: 901-16.
9. Ruberg FL, Maurer MS, Judge DP, et 
al. Prospective evaluation of the morbidi-
ty and mortality of wild-type and V122I 
mutant transthyretin amyloid cardiomy-
opathy: the Transthyretin Amyloidosis 
Cardiac Study (TRACS). Am Heart J 2012; 
164(2): 222-228.e1.
10. Castaño A, Drachman BM, Judge D, 
Maurer MS. Natural history and therapy 
of TTR-cardiac amyloidosis: emerging 
disease-modifying therapies from organ 
transplantation to stabilizer and silencer 
drugs. Heart Fail Rev 2015; 20: 163-78.
11. Liepnieks JJ, Zhang LQ, Benson MD. 
Progression of transthyretin amyloid neu-
ropathy after liver transplantation. Neu-
rology 2010; 75: 324-7.
12. Adams D, Buades J, Suhr O, Obici L, 
Coelho T. Preliminary assessment of neu-
ropathy progression in patients with he-
reditary ATTR amyloidosis after orthotop-
ic liver transplantation (OLT). Orphanet J 
Rare Dis 2015; 10: Suppl 1. abstract.
13. Coelho T, Maia LF, da Silva AM, et al. 
Long-term effects of tafamidis for the 
treatment of transthyretin familial amy-
loid polyneuropathy. J Neurol 2013; 260: 
2802-14.
14. Cortese A, Vita G, Luigetti M, et al. 
Monitoring effectiveness and safety of Ta-
famidis in transthyretin amyloidosis in 
Italy: a longitudinal multicenter study in a 
non-endemic area. J Neurol 2016; 263: 916-
24.
15. Planté-Bordeneuve V, Gorram F, Salhi 
H, et al. Long-term treatment of trans-
thyretin familial amyloid polyneuropathy 
with Tafamidis: a clinical and neurophys-
iological study. J Neurol 2017; 264: 268-76.
16. Lozeron P, Théaudin M, Mincheva Z, 
Ducot B, Lacroix C, Adams D. Effect on 
disability and safety of Tafamidis in late 
onset of Met30 transthyretin familial 
amyloid polyneuropathy. Eur J Neurol 
2013; 20: 1539-45.
17. Coelho T, Adams D, Silva A, et al. 
Safety and efficacy of RNAi therapy for 
transthyretin amyloidosis. N Engl J Med 
2013; 369: 819-29.
18. Suhr OB, Coelho T, Buades J, et al. Ef-
ficacy and safety of patisiran for familial 
amyloidotic polyneuropathy: a phase II 
multi-dose study. Orphanet J Rare Dis 
2015; 10: 109.
19. Partisano AM, Berk JL, Adams D, et 
al. Long-term, open-label clinical experi-
ence with patisiran, an investigational 
RNAi therapeutic for patients with he-
reditary transthyretin-mediated (hATTR) 
amyloidosis with polyneuropathy. Or-
phanet J Rare Dis 2017; 12: Suppl 1: 165. 
abstract.
20. Adams D, Suhr OB, Dyck PJ, et al. 
Trial design and rationale for APOLLO, a 
Phase 3, placebo-controlled study of pati-
siran in patients with hereditary ATTR 
amyloidosis with polyneuropathy. BMC 
Neurol 2017; 17: 181.
21. Suanprasert N, Berk JL, Benson MD, 
et al. Retrospective study of a TTR FAP 
cohort to modify NIS+7 for therapeutic 
trials. J Neurol Sci 2014; 344: 121-8.
22. Dyck PJ, Kincaid JC, Dyck PJB, et al. 
Assessing mNIS+7Ionis and international 
neurologists’ proficiency in a familial 
amyloidotic polyneuropathy trial. Muscle 
Nerve 2017; 56: 901-11.
23. Benson MD, Waddington-Cruz M, 
Berk JL, et al. Inotersen treatment for pa-
tients with hereditary transthyretin amy-
loidosis. N Engl J Med 2018; 379:22-31.
24. Coelho T, Maia LF, Martins da Silva A, 
et al. Tafamidis for transthyretin familial 
amyloid polyneuropathy: a randomized, 
controlled trial. Neurology 2012; 79: 785-
92.
25. Berk JL, Suhr OB, Obici L, et al. Re-
purposing diflunisal for familial amyloid 
polyneuropathy: a randomized clinical 
trial. JAMA 2013; 310: 2658-67.
26. Sepp-Lorenzino L, Ruddy M. Chal-
lenges and opportunities for local and 
systemic delivery of siRNA and antisense 
oligonucleotides. Clin Pharmacol Ther 
2008; 84: 628-32.
Copyright © 2018 Massachusetts Medical Society.
 
CHAPTER III | Results 
 
229 
 
 
 
2. Clinical development of new drugs 
 
2.3. Inotersen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Article 12 
Benson, M.D., Waddington-Cruz, M., Berk, J.L., Polydefkis, M., Dyck, P.J., Wang, 
A.K., Planté-Bordeneuve, V., Barroso, F.A., Merlini, G., Obici, L., Scheinberg, M., 
Brannagan, T.H. 3rd, Litchy, W.J., Whelan, C., Drachman, B.M., Adams, D., Heitner, 
S.B., Conceição, I., Schmidt, H.H., Vita, G., Campistol, J.M., Gamez, J., Gorevic, P.D., 
Gane, E., Shah, A.M., Solomon, S.D., Monia, B,. Hughes, S.G., Kwoh, T., McEvoy, 
B.W., Jung, S.W., Baker, B.F., Ackermann, E.J., Gertz, M.A., Coelho T.  
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.  
N Engl J Med. 2018. 379(1): p. 22-31. 
Copyright © 2018, Massachusetts Medical Society 
Reprinted with permission 
 
 
 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 379;1 nejm.org July 5, 201822
The authors’ full names, academic degrees, 
and affiliations are listed in the Appendix. 
Address reprint requests to Dr. Coelho at 
Hospital de Santo António–Centro Hos-
pitalar do Porto, Largo Professor Abel 
Salazar, 4099-001 Porto, Portugal, or at 
 tcoelho@ netcabo . pt.
N Engl J Med 2018;379:22-31.
DOI: 10.1056/NEJMoa1716793
Copyright © 2018 Massachusetts Medical Society.
BACKGROUND
Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants 
in the gene encoding transthyretin (TTR) that induce transthyretin misfolding and 
systemic deposition of amyloid. Progressive amyloid accumulation leads to multi-
organ dysfunction and death. Inotersen, a 2′-O-methoxyethyl–modified antisense 
oligonucleotide, inhibits hepatic production of transthyretin.
METHODS
We conducted an international, randomized, double-blind, placebo-controlled, 15-month, 
phase 3 trial of inotersen in adults with stage 1 (patient is ambulatory) or stage 2 
(patient is ambulatory with assistance) hereditary transthyretin amyloidosis with poly-
neuropathy. Patients were randomly assigned, in a 2:1 ratio, to receive weekly sub-
cutaneous injections of inotersen (300 mg) or placebo. The primary end points were 
the change in the modified Neuropathy Impairment Score+7 (mNIS+7; range, −22.3 
to 346.3, with higher scores indicating poorer function; minimal clinically meaningful 
change, 2 points) and the change in the score on the patient-reported Norfolk Quality 
of Life–Diabetic Neuropathy (QOL-DN) questionnaire (range, −4 to 136, with higher 
scores indicating poorer quality of life). A decrease in scores indicated improvement.
RESULTS
A total of 172 patients (112 in the inotersen group and 60 in the placebo group) re-
ceived at least one dose of a trial regimen, and 139 (81%) completed the intervention 
period. Both primary efficacy assessments favored inotersen: the difference in the 
least-squares mean change from baseline to week 66 between the two groups (inot-
ersen minus placebo) was −19.7 points (95% confidence interval [CI], −26.4 to −13.0; 
P<0.001) for the mNIS+7 and −11.7 points (95% CI, −18.3 to −5.1; P<0.001) for the 
Norfolk QOL-DN score. These improvements were independent of disease stage, 
mutation type, or the presence of cardiomyopathy. There were five deaths in the 
inotersen group and none in the placebo group. The most frequent serious adverse 
events in the inotersen group were glomerulonephritis (in 3 patients [3%]) and throm-
bocytopenia (in 3 patients [3%]), with one death associated with one of the cases of 
grade 4 thrombocytopenia. Thereafter, all patients received enhanced monitoring.
CONCLUSIONS
Inotersen improved the course of neurologic disease and quality of life in patients 
with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephri-
tis were managed with enhanced monitoring. (Funded by Ionis Pharmaceuticals; 
NEURO-TTR ClinicalTrials.gov number, NCT01737398.)
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A utosomal dominant mutations in the gene encoding transthyretin (TTR) cause a rare systemic disorder known as 
hereditary transthyretin amyloidosis. The single 
amino-acid changes that result from these muta-
tions destabilize the tetrameric transthyretin pro-
tein complex to cause aggregation of monomers 
into insoluble, extracellular amyloid deposits.1 Ac-
cumulation of amyloid deposits in multiple organ 
systems leads to progressive peripheral polyneu-
ropathy, cardiomyopathy, nephropathy, and gastro-
intestinal dysfunction.2-5 The average life expec-
tancy, untreated, from symptom onset is 3 to 15 
years.6 The presence of cardiomyopathy is asso-
ciated with a worse prognosis. Patients typically 
die from malnutrition and cachexia, renal failure, 
cardiac disease, and sudden death.7
The liver is the primary source of systemic 
transthyretin protein. Liver transplantation has 
historically been the standard of care for heredi-
tary transthyretin amyloidosis, but continued de-
position of wild-type transthyretin amyloid after 
transplantation can limit its effectiveness.8-11 Al-
though some treatments are currently available 
— such as tafamidis (Vyndaqel) and diflunisal, 
small molecules that stabilize the circulating tetra-
meric form of transthyretin and slow disease pro-
gression11-16 — additional treatments could be of 
value.
Inotersen (formerly IONIS-TTRRx/ISIS 420915) 
is a 2′-O-methoxyethyl–modified antisense oligo-
nucleotide inhibitor of the hepatic production of 
transthyretin protein. In healthy volunteers, inot-
ersen showed dose-dependent and sustained re-
ductions of circulating transthyretin levels.17 We 
conducted a randomized, double-blind, placebo-
controlled, phase 3 trial (NEURO-TTR) to deter-
mine the efficacy and safety of inotersen treatment 
in patients with hereditary transthyretin amyloi-
dosis with polyneuropathy in the presence or ab-
sence of cardiomyopathy.
Me thods
Patients
The trial was conducted at 24 centers in 10 coun-
tries. Adults 18 to 82 years of age who had received 
a diagnosis of stage 1 (patient is ambulatory) or 
stage 2 (patient is ambulatory with assistance) he-
reditary transthyretin amyloidosis with polyneu-
ropathy and who had a Neuropathy Impairment 
Score (NIS) of 10 to 130, a TTR mutation deter-
mined by genotyping, and documented amyloid 
deposits determined on biopsy were eligible for 
this trial. The NIS scale ranges from 0 to 244 
points, with a higher score indicating poorer func-
tion and a minimal clinically meaningful differ-
ence of 2 points.18 Key exclusion criteria were 
clinically significant abnormalities in screening 
laboratory values, a Karnofsky performance status 
score of 50 or less (on a scale of 0 to 100, with 
lower scores indicating greater disability), other 
causes of polyneuropathy besides hereditary trans-
thyretin amyloidosis, previous liver transplanta-
tion, and heart failure of New York Heart Asso-
ciation class III or higher. The use of tafamidis 
or diflunisal during the intervention period was 
not allowed.
Trial Oversight
The trial protocol, available with the full text of 
this article at NEJM.org, was approved by insti-
tutional review boards or local ethics commit-
tees. The trial was conducted in accordance with 
Good Clinical Practice guidelines of the Interna-
tional Conference on Harmonisation and the 
principles of the Declaration of Helsinki. All the 
patients provided written informed consent to 
participate in the trial. An independent data and 
safety monitoring committee reviewed unblind-
ed safety data approximately four times per year.
Data were collected by the site investigators, 
and the sponsor (Ionis Pharmaceuticals) was re-
sponsible for data analysis. All the authors had full 
access to the data. The first draft of the manu-
script was written by a contract medical writer 
and the sponsor, with input from the authors on 
subsequent drafts. All the authors approved the 
final version, made the decision to submit the 
manuscript for publication, vouch for the com-
pleteness and accuracy of the data and analyses 
presented, and affirm that the trial was conduct-
ed and reported with fidelity to the protocol and 
statistical analysis plan, available with the pro-
tocol at NEJM.org.
Trial Design
After a 6-week screening period, eligible patients 
were randomly assigned, in a 2:1 ratio, to receive 
300 mg of inotersen (equivalent to 284 mg of free 
acid) or placebo (Fig. S1 in the Supplementary Ap-
pendix, available at NEJM.org). Patients were strat-
ified according to the following factors: Val30Met 
TTR mutation (148G→A) versus non-Val30Met TTR 
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mutation, stage 1 versus stage 2 disease, and previ-
ous treatment with tafamidis or diflunisal versus 
no known previous treatment. Patients received 
three subcutaneous injections during the first 
week to achieve near steady-state drug levels, fol-
lowed by a once-weekly subcutaneous injection 
for the next 64 weeks. A total of 13 of 67 doses 
(19%) were required to be administered at pre-
specified clinical visits. All other doses could be 
administered at home by the patient, a trained 
family member, or a health professional. All the 
patients received vitamin A supplements at the 
recommended daily allowance (approximately 
3000 IU) to ensure adequate delivery of dietary 
vitamin A to tissues in the context of low trans-
thyretin levels. The trial also included a 1-week 
efficacy-assessment period and a 6-month post-
intervention evaluation period if a patient was 
not enrolled in the open-label extension study.
End Points and Assessments
The primary end points were the change from 
baseline to week 66 in the standardized modi-
fied Neuropathy Impairment Score+7 (mNIS+7) 
composite score18-22 and in the total score on the 
Norfolk Quality of Life–Diabetic Neuropathy 
(QOL-DN) questionnaire.23,24 The mNIS+7 has 
eight components, with a composite score rang-
ing from −22.3 to 346.3 (the higher the score, 
the poorer the function). A decrease in score in-
dicates an improvement, and a 2-point change 
has been defined as the minimal clinically mean-
ingful change detectable.14,18 The Norfolk QOL-DN 
is a 35-item questionnaire that comprises five 
domains, with a total score ranging from −4 to 
136 (the higher the score, the poorer the quality 
of life). Changes in the patient-reported Norfolk 
QOL-DN score have been shown to be propor-
tional to changes in the NIS.24 (See Table S1 in 
the Supplementary Appendix for complete scor-
ing scales according to component of the mNIS+7 
and domain of the Norfolk QOL-DN question-
naire.) All mNIS+7 assessors were specially trained 
and prequalified by a central reader. The NIS 
component was performed by an independent 
neurologist who was not aware of the trial-group 
assignments and not involved in the day-to-day 
conduct of the trial or care of the patient. Safety 
assessments included collection of adverse events 
that occurred from the time of the first dose to 
the end of the trial (including the postinterven-
tion follow-up period), clinical laboratory tests, 
vital signs, 12-lead electrocardiography, and elec-
troretinography (ERG) examinations to detect early 
signs of vitamin A deficiency.
Statistical Analysis
The planned sample of 135 patients was calcu-
lated under the assumptions of an effect size of 
9.6 points and a standard deviation of 14 in the 
mNIS+7, an effect size of 10.7 and a standard de-
viation of 18 in the Norfolk QOL-DN score, and 
a dropout rate of 25%. Using a 2:1 allocation ra-
tio, we estimated that the trial had a power of at 
least 90% for the mNIS+7 end point and a power 
of at least 80% for the Norfolk QOL-DN end point, 
using a two-sided test with an alpha level of 5%.
Efficacy analyses included all randomly as-
signed patients who received at least one dose of 
a trial regimen and who had at least one post-
baseline efficacy assessment for the mNIS+7 or 
the Norfolk QOL-DN score. Subgroup analyses 
were performed on the basis of the three strati-
fication factors and according to the presence or 
absence of cardiomyopathy, geographic region, 
and selected demographic characteristics for each 
of the two end points. The presence of cardio-
myopathy was defined by a diagnosis of trans-
thyretin cardiomyopathy at trial entry or by the 
following criteria: an interventricular wall thick-
ness of 13 mm or more on transthoracic echocar-
diography at baseline, as ascertained by a central 
reader, and no known history of persistent hyper-
tension (systolic blood pressure, ≥150 mm Hg) 
within 12 months before screening. Safety analy-
ses were performed on all randomly assigned 
patients who received at least one dose of a trial 
regimen.
The primary end points were analyzed with 
the use of a ranking strategy, with the mNIS+7 
tested first and the Norfolk QOL-DN score tested 
second. No adjustments were made for multiple 
testing. The data were analyzed with the use of a 
mixed-effects model with repeated measures. The 
mNIS+7 was scored at baseline (two assessments), 
week 35 (one assessment), and week 66 (two as-
sessments). The two assessments at baseline and 
week 66 were averaged at the component level. 
Week 66 was the time point for the primary 
analysis. Predefined sensitivity analyses included 
alternative methods for imputing missing data 
at the visit level. A total of 16 prespecified sub-
group analyses are reported. Data are summarized 
according to trial group with the use of descrip-
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tive summary statistics. All statistical tests were 
conducted with the use of two-sided tests with an 
alpha level of 5%. Additional details on eligibility 
criteria, trial regimens, efficacy and safety assess-
ments, and methods of statistical analysis are 
provided in the Supplementary Appendix.
R esult s
Patient Characteristics and Follow-up
The trial was conducted from March 2013 through 
November 2017. Of 278 patients who were 
screened for participation in the trial, 173 were 
randomly assigned in a 2:1 ratio to receive inot-
ersen or placebo (Fig. 1). A total of 172 patients 
(112 in the inotersen group and 60 in the pla-
cebo group) received at least one dose of a trial 
regimen. The baseline characteristics were well 
balanced overall between the two groups (Ta-
ble 1). The mean age of the trial population was 
59 years; 69% of the patients were male, and 92% 
of the patients were white. Approximately half 
carried the Val30Met mutation (from a total of 
27 mutations). A total of 67% of the patients had 
stage 1 disease, 58% had previously received ta-
famidis or diflunisal, and 63% had cardiomyopa-
thy. At the time of trial entry, cardiomyopathy was 
more prevalent in the inotersen group than in 
the placebo group, and patients in the inotersen 
group had a longer duration of disease (since diag-
nosis of cardiomyopathy) than those in the placebo 
group.
Of the 172 randomly assigned patients who 
received at least one dose of a trial regimen, 139 
(81%) completed the 15-month intervention pe-
riod (Fig. 1). A total of 25 (22%) of the patients 
who received inotersen and 8 (13%) of those who 
received placebo discontinued the trial regimen. 
Adverse events were the main reason for discon-
tinuation in the inotersen group (16 patients, 14%), 
whereas voluntary withdrawal (3 patients, 5%) 
and disease progression (3 patients, 5%) were the 
most common reasons for discontinuation in the 
placebo group. A total of 135 patients were en-
rolled in the open-label extension study.
Primary Efficacy End Points
Both primary end points, the mNIS+7 and the 
Norfolk QOL-DN score, achieved significant dif-
ferences between the inotersen group and the 
placebo group at week 66 after 15 months of inter-
vention (Fig. 2). The difference in least-squares 
mean change from baseline to week 66 between 
the two groups (inotersen minus placebo) was 
−19.7 points (95% confidence interval [CI], −26.4 
to −13.0; P<0.001) for the mNIS+7 and −11.7 
points (95% CI, −18.3 to −5.1; P<0.001) for the 
Norfolk QOL-DN score, favoring inotersen (Ta-
ble S3 in the Supplementary Appendix). Moreover, 
significant between-group differences were ob-
served in both end points at the interim week 35 
assessment. At week 35, the difference in the 
least-squares mean change from baseline for the 
mNIS+7 was −8.7 points (95% CI, −13.5 to −3.9; 
P<0.001) and for the Norfolk QOL-DN score was 
−6.1 points (95% CI, −11.8 to −0.5; P = 0.03). 
Prespecified sensitivity analyses showed a robust 
and beneficial inotersen treatment effect under 
all assumptions (Table S4 in the Supplementary 
Appendix).
On average, patients who received inotersen 
had an increase of 5.8 points (95% CI, 1.6 to 10.0) 
from baseline in the mNIS+7 (vs. 25.5 points 
[95% CI, 20.2 to 30.8] with placebo) and of 1.0 
points (95% CI, −3.2 to 5.2) in the Norfolk QOL-
DN score (vs. 12.7 points [95% CI, 7.4 to 17.9] 
with placebo) by the end of the intervention pe-
riod. Further analysis of patients who completed 
the intervention period showed that 36% of the 
patients in the inotersen group had an improve-
ment (no increase from baseline) in the mNIS+7 
and 50% had an improvement in the Norfolk 
QOL-DN score (Table S5 in the Supplementary 
Appendix).
All subgroup analyses that were performed 
according to stratification factor showed a signifi-
cant benefit of inotersen as compared with placebo 
at week 66 in the mNIS+7 (difference in least-
squares mean change from baseline: Val30Met 
mutation, −18.9 [95% CI, −28.1 to −9.6; P<0.001], 
and non-Val30Met mutation, −21.3 [95% CI, −31.1 
to −11.5; P<0.001]; stage 1 disease, −14.2 [95% CI, 
−22.5 to −5.9; P<0.001], and stage 2 disease, −29.1 
[95% CI, −40.2 to −18.0; P<0.001]; previous treat-
ment with tafamidis or diflunisal, −20.0 [95% CI, 
−29.2 to −10.8; P<0.001], and no previous treat-
ment, −20.8 [95% CI, −30.6 to −11.0; P<0.001]), 
consistent with the results of the primary analy-
sis. The benefit of inotersen over placebo for the 
subgroup analyses according to the Norfolk 
QOL-DN stratification factor was also consistent 
with the primary analysis (difference in least-
squares mean change from baseline: Val30Met 
mutation, −12.2 [95% CI, −21.6 to −3.0; P = 0.01], 
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and non-Val30Met mutation, −11.1 [95% CI, −20.9 
to −1.4; P = 0.03]; stage 1 disease, −9.9 [95% CI, 
−18.2 to −1.7; P = 0.02], and stage 2 disease, −15.0 
[95% CI, −26.2 to −3.9; P = 0.008]; previous treat-
ment with tafamidis or diflunisal, −9.0 [95% CI, 
−18.2 to 0.1; P = 0.05], and no previous treatment, 
−14.7 [95% CI, −24.5 to −4.9; P = 0.003]). (For de-
tails, see Figs. S2 and S3 in the Supplementary 
Appendix.)
Consistent benefit for both primary end 
points in favor of inotersen was also observed at 
week 66 when analyzed according to the presence 
of cardiomyopathy (difference in least-squares 
mean change from baseline: mNIS+7, −17.2 
[95% CI, −25.6 to −8.7; P<0.001]; Norfolk QOL-DN 
score, −9.0 [95% CI, −17.5 to −0.6; P = 0.04]) or 
absence of cardiomyopathy (difference in least-
squares mean change from baseline: mNIS+7, 
Figure 1. Randomization and Follow-up.
One patient in the inotersen group underwent randomization in error and did not begin the trial regimen. Adverse 
events leading to discontinuation of inotersen were thrombocytopenia (in 2 patients), abdominal distention, intesti-
nal perforation, nausea, vomiting, pyrexia, hypersensitivity, decreased platelet count, cachexia (in 2 patients), arthralgia, 
myalgia, chorea, dementia, embolic stroke, intracranial hemorrhage, myelopathy, myoclonus, acute kidney injury, 
glomerulonephritis, tubulointerstitial nephritis, pruritus, reticular erythematous mucinosis, and deep-vein thrombo-
sis; 6 of 16 patients (38%) discontinued inotersen because of multiple events. Adverse events leading to discontinu-
ation of placebo were pain, increased weight, and arthralgia. Of the 2 patients in the inotersen group who discontin-
ued the trial regimen because they were withdrawn by the sponsor, 1 patient whose data were unblinded for safety 
monitoring was allowed to enroll in the open-label extension study. NIS denotes Neuropathy Impairment Score.
173 Underwent randomization (2:1 ratio)
278 Patients were assessed for eligibility
105 Were excluded
97 Did not meet eligibility criteria
49 Had NIS that was out of range
4 Withdrew consent
4 Had other reasons
1 Was ineligible
112 Were assigned to receive
inotersen, 300 mg
60 Were assigned to receive
placebo
25 Discontinued trial regimen
16 Had adverse event
2 Had disease progression
2 Met renal stopping rule
2 Withdrew voluntarily
2 Were withdrawn
by sponsor
1 Underwent liver trans-
plantation
8 Discontinued trial regimen
3 Withdrew voluntarily
3 Had disease progression
1 Had adverse event
1 Met renal stopping rule
87 Completed the trial 52 Completed the trial
3 Had postintervention follow-up3 Had postintervention follow-up
49 Entered open-label
extension study
86 Entered open-label
extension study
1 Entered open-label
extension study
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Characteristic
Placebo 
(N = 60)
Inotersen 
(N = 112)
Total 
(N = 172)
Age — yr 59.5±14.0 59.0±12.5 59.2±13.0
Male sex — no. (%) 41 (68) 77 (69) 118 (69)
Race — no. (%)†
White 53 (88) 105 (94) 158 (92)
Black 1 (2) 3 (3) 4 (2)
Asian 3 (5) 1 (<1) 4 (2)
Other or multiple 3 (5) 3 (3) 6 (3)
Geographic region — no. (%)
Europe 23 (38) 37 (33) 60 (35)
North America 26 (43) 56 (50) 82 (48)
South America or Australasia 11 (18) 19 (17) 30 (17)
BMI‡ 24.2±4.9 24.0±4.9 24.1±4.9
Modified BMI§ 105.0±22.8 101.1±22.8 102.5±22.8
Val30Met TTR mutation — no. (%)¶‖ 33 (55) 56 (50) 89 (52)
Disease stage — no. (%)‖**
1: patient is ambulatory 42 (70) 74 (66) 116 (67)
2: patient is ambulatory with assistance 18 (30) 38 (34) 56 (33)
Previous treatment with tafamidis or diflunisal — no. (%)‖ 36 (60) 63 (56) 99 (58)
Duration of disease from diagnosis of hATTR-PN — mo†† 39.3±40.3 42.4±51.2 41.3±47.6
Stage 1 45.4±43.1 43.2±47.8 44.0±46.0
Stage 2 24.8±29.0 40.9±57.8 35.8±50.7
Duration of disease from onset of hATTR-PN symptoms 
— mo††
64.0±52.3 63.9±53.2 63.9±52.7
Stage 1 64.4±53.0 59.4±53.1 61.2±52.9
Stage 2 63.2±52.2 72.6±52.9 69.6±52.4
Presence of cardiomyopathy — no. (%)‡‡ 33 (55) 75 (67) 108 (63)
mNIS+7 composite score§§ 74.8±39.0 79.2±37.0 77.6±37.6
Norfolk QOL-DN total score¶¶ 48.7±26.7 48.2±27.5 48.4±27.2
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. The term hATTR-PN denotes 
hereditary transthyretin amyloidosis with polyneuropathy.
†  Race was reported by the patients.
‡  The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
§  The modified BMI was defined as BMI × albumin level in grams per deciliter.
¶  See Table S2 in the Supplementary Appendix for a complete listing of TTR mutations represented in the trial.
‖  Values are based on data from the electronic case-report form.
**  Baseline disease stage and polyneuropathy disability scores were compared and queried as necessary for consistency 
at the center level in the assessment of ambulatory status.
††  Only year and month were collected for diagnosis of hATTR-PN and onset of hATTR-PN symptoms. The duration 
from diagnosis of hATTR-PN and onset of hATTR-PN symptoms was calculated relative to the date of informed con-
sent.
‡‡  The presence of cardiomyopathy was defined by a diagnosis of transthyretin cardiomyopathy at trial entry or by the 
following criteria: an interventricular wall thickness of 13 mm or more on transthoracic echocardiography at baseline, 
as ascertained by a central reader, or no known history of persistent hypertension (systolic blood pressure, ≥150 mm 
Hg) within 12 months before screening.
§§  Composite scores on the modified Neuropathy Impairment Score+7 (mNIS+7) scale range from −22.3 to 346.3, with 
higher scores indicating poorer function.
¶¶  Total scores on the Norfolk Quality of Life–Diabetic Neuropathy (QOL-DN) questionnaire range from −4 to 136, with 
higher score indicating poorer quality of life.
Table 1. Baseline Demographic and Clinical Characteristics of the Patients.*
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−25.2 [95% CI, −36.1 to −14.3; P<0.001]; Norfolk 
QOL-DN score, −16.4 [95% CI, −27.3 to −5.4; 
P = 0.004]) (Figs. S4 and S5 in the Supplementary 
Appendix). Global longitudinal strain and other 
echocardiographic variables, however, did not 
differ significantly between the inotersen group 
and the placebo group after 15 months of inter-
vention (Table S6 in the Supplementary Appen-
dix). Further subgroup analyses according to geo-
graphic region, age, sex, and patient-reported race 
showed significant benefit in favor of inotersen 
in the mNIS+7 at week 66 (Figs. S6 and S7 in the 
Supplementary Appendix). The least-squares mean 
difference between the trial groups for body-mass 
index showed a trend in favor of inotersen to slow 
weight loss (Table S7 in the Supplementary Ap-
pendix).
Secondary and Tertiary Efficacy End Points
Results from analyses of the mNIS+7 test at the 
component and subcomponent level, as well as 
the Norfolk QOL-DN questionnaire according to 
domain, are shown in Figure S8 in the Supple-
mentary Appendix, along with the results from 
a second quality-of-life instrument, the 36-Item 
Short Form Health Survey (Table S8 in the Sup-
plementary Appendix).
Pharmacodynamics
In the inotersen group, reductions in circulating 
transthyretin reached steady-state levels by week 
13 and were sustained through the end of the 
intervention period (Fig. S9 in the Supplementary 
Appendix). From week 13 to week 65, decreases 
in serum transthyretin from baseline levels in the 
inotersen group reached a median nadir of 79.0% 
and mean nadir of 74.0%. There was no correla-
tion between the absolute or relative change from 
baseline in serum transthyretin levels and the 
change from baseline in the mNIS+7 score in pa-
tients who received inotersen (Pearson’s r, 0.11, 
and P = 0.33 for absolute change; Pearson’s r, 0.06, 
and P = 0.57 for relative change) (Fig. S10 in the 
Supplementary Appendix). These findings were 
consistent with a flat drug exposure–response 
relationship, which was expected at the single-
dose level.
Safety
There were five deaths during the trial, all in the 
inotersen group (Table 2). Four of the five deaths 
were consistent with progression or complication 
of the underlying disease (two deaths from ca-
chexia and one each from intestinal perforation 
and congestive heart failure) (Table S9 in the Sup-
plementary Appendix). One patient in the inotersen 
group had a fatal intracranial hemorrhage in as-
sociation with a platelet count of less than 10,000 
per cubic millimeter that occurred before the in-
troduction of frequent platelet monitoring.
Glomerulonephritis occurred in three patients 
(3%) in the inotersen group (Table 2). Each of these 
Figure 2. Change from Baseline in Primary End Points.
Brackets indicate the difference in the least-squares mean change from 
baseline between the inotersen group and the placebo group. Composite 
scores on the modified Neuropathy Impairment Score+7 (mNIS+7) scale 
range from −22.3 to 346.3 (the higher the score, the poorer the function), 
and total scores on the Norfolk Quality of Life–Diabetic Neuropathy (QOL-DN) 
questionnaire range from −4 to 136 (the higher the score, the poorer the 
quality of life). A decrease in score indicated an improvement on each 
scale. A 2-point change in the NIS+7 has been defined as the minimal clini-
cally meaningful change detectable.14,18 Changes in the patient-reported 
Norfolk QOL-DN score have been shown to be proportional to changes in 
the Neuropathy Impairment Score (range, 0 to 244, with a higher score in-
dicating poorer function).24 I bars indicate standard errors.
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three patients carried the Val30Met mutation. 
Two had shown a decline in the estimated glo-
merular filtration rate. In all three cases, the renal 
biopsy showed complex pathologic features, con-
sistent with crescentic glomerulonephritis super-
imposed on a background of amyloidosis and (in 
two cases) interstitial fibrosis. One patient was 
successfully treated with glucocorticoids and cy-
clophosphamide and regained clinically signifi-
cant renal function. Another patient did not re-
ceive immunosuppressive therapy owing to delayed 
diagnosis, and permanent hemodialysis was initi-
ated. A third patient was identified as having 
clinically significant proteinuria after the imple-
mentation of more frequent renal monitoring of 
every 2 to 3 weeks; this patient did not show a 
decline in renal function. Urinary protein excre-
tion returned to baseline levels after treatment 
with glucocorticoids.
A higher proportion of patients in the inoter-
sen group (60 of 112, 54%) had a confirmed de-
crease in the postbaseline platelet count to less 
than 140,000 per cubic millimeter than in the 
placebo group (8 of 60, 13%) (Table S10 in the 
Supplementary Appendix). Decreases in the inot-
ersen group occurred gradually over a period of 
several weeks, with an onset within the first 13 
weeks of dosing and a mean nadir between 3 to 
6 months after treatment initiation (Fig. S11 in 
the Supplementary Appendix). Thrombocytopenia 
with platelet counts of less than 25,000 per cubic 
millimeter occurred in 3 patients (3%) who re-
ceived inotersen. Platelet counts in 2 of these 
3 patients returned to baseline or near-baseline 
levels after discontinuation of the trial regimen 
and treatment with glucocorticoids. The third pa-
tient presented with an intracranial hemorrhage 
and died before treatment could be initiated. No 
cases of thrombocytopenia with platelet counts of 
less than 50,000 per cubic millimeter occurred 
after the institution of weekly platelet monitoring. 
Two patients in the inotersen group had a dose 
reduction to 150 mg weekly because of decreases 
in platelet counts. There was some evidence of an 
immune-mediated mechanism in the severe events, 
as indicated by recovery with glucocorticoid treat-
ment and the presence of antiplatelet IgG in each 
of the 3 patients. Importantly, further investiga-
tion ruled out a heparin-induced thrombocytope-
nia–type mechanism and effects on platelet pro-
duction.
Adverse events with both an incidence of at 
least 10% in either group and an incidence that 
was at least twice as high in the inotersen group 
as in the placebo group were nausea, pyrexia, 
chills, vomiting, anemia, thrombocytopenia, and 
lowered platelet counts (Table S11 in the Supple-
mentary Appendix). Some events were consistent 
with known symptoms or complications of the 
underlying disease, such as nausea, vomiting, and 
anemia. The incidence of hemorrhages was simi-
lar in the two groups.
The mean rate of injection-site reactions was 
1.1% of all injections in the inotersen group. A 
total of 68 events were reported by 36 patients. 
A total of 97% of the events were mild in severity. 
There were no severe events, and no patient dis-
continued inotersen treatment prematurely owing 
to events at the injection site. The mean percent-
age of subcutaneous injections that were admin-
istered at home was approximately 80% in both 
trial groups (Table S12 in the Supplementary 
Appendix).
Other safety variables, including vital signs, 
Event
Placebo 
(N = 60)
Inotersen 
(N = 112)
no. of patients (%)
Any adverse event 60 (100) 111 (99)
Event related to trial regimen† 23 (38) 87 (78)
Any serious adverse event 13 (22) 36 (32)
Event related to trial regimen† 1 (2) 8 (7)
Glomerulonephritis 0 3 (3)‡
Thrombocytopenia 0 2 (2)
Deep-vein thrombosis 1 (2) 1 (<1)
Intracranial hemorrhage 0 1 (<1)§
Tubulointerstitial nephritis 0 1 (<1)¶
Pulmonary embolism 0 1 (<1)
Embolic stroke 0 1 (<1)
Myelopathy 0 1 (<1)
Death 0 5 (4)
*  Shown are adverse events that occurred from the time of the first dose to the 
end of the trial, including the postintervention follow-up period.
†  Shown are patients with events that were considered by the investigator to be 
related or possibly related to the trial regimen, as well as patients with miss-
ing data on the relatedness of the event to the trial regimen.
‡  The event for one patient was originally reported as acute kidney injury but 
was subsequently diagnosed by biopsy as glomerulonephritis.
§  The patient had a fatal intracranial hemorrhage due to severe thrombocytopenia.
¶  The patient also had glomerulonephritis that was confirmed by biopsy.
Table 2. Summary of Adverse Events.*
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body-weight change, corrected QT interval (Frid-
ericia’s formula), concomitant medications, sui-
cidal ideation or behavior, and ERG results, were 
either similar in the two trial groups or were 
modified favorably during inotersen treatment. 
There were no clinical manifestations of vitamin A 
deficiency.
Discussion
In this international, randomized, placebo-con-
trolled trial, inotersen modified the course of 
neuropathy and improved quality of life in patients 
with hereditary transthyretin amyloidosis. Both 
primary end points, the mNIS+7 and the Norfolk 
QOL-DN score, showed significant benefits with 
inotersen treatment. These benefits were indepen-
dent of TTR mutation type, disease stage, and 
cardiomyopathy status at baseline. Subcutaneous 
injections of inotersen and placebo were adminis-
tered at home, outside prespecified clinical vis-
its. The clinical response to inotersen treatment 
was probably due to many factors in addition to 
the lowering of transthyretin levels, including the 
individual rate of disease progression, baseline 
amyloid burden, and the rate of amyloid clearance 
from tissue. Results from the NEURO-TTR trial 
are similar to those from a trial of patisiran, also 
published in this issue of the Journal, which used 
a lipid nanoparticle–encapsulated small interfer-
ing RNA to lower production of transthyretin.25
The principal safety concerns that were iden-
tified for inotersen treatment were thrombocy-
topenia (three patients had a platelet count of 
<25,000 per cubic millimeter), the occurrence of 
glomerulonephritis (three patients), and an im-
balance in deaths from any cause (five patients, 
as compared with none in the placebo group). 
We cannot be sure whether this imbalance was 
due to acceleration of the underlying disease in 
some cases, the play of chance, or some other 
cause. After the implementation of enhanced 
monitoring, no additional cases of severe thrombo-
cytopenia occurred, and a single case of glomeru-
lonephritis was identified early without loss of 
renal function. Integrated analysis of clinical data 
from patients treated systemically with antisense 
oligonucleotides from the same 2′-O-methoxy-
ethyl–modified chemical class suggests that these 
severe events may represent a drug–disease in-
teraction.26-28
Limitations of the current trial included the 
exclusion of patients with end-stage disease and 
insufficient power to measure the effects of inoter-
sen treatment on cardiomyopathy.29 In addition, 
patients who were assigned to receive inotersen 
had more advanced autonomic neuropathy and 
sensorimotor neuropathy than those assigned to 
receive placebo, and a greater proportion had car-
diomyopathy at trial entry.
In conclusion, weekly subcutaneous injections 
of inotersen provided benefit to patients with he-
reditary transthyretin amyloidosis with polyneu-
ropathy, as measured by both clinical assessments 
and quality-of-life instruments. Implementation of 
enhanced safety monitoring allowed early detec-
tion and management of thrombocytopenia and 
glomerulonephritis.
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Abstract
Objective
To assess the natural history and treatment effect on survival among patients with transthyretin-
associated familial amyloid polyneuropathy (TTR-FAP) stage 1 Val30Met.
Methods
Multi-institutional, hospital-based study of patients with TTR-FAP Val30Met prospectively
followed up until December 2016, grouped into untreated (n = 1,771), liver transplant (LTx)-
treated (n = 957), or tafamidis-treated (n = 432) cohorts. Standardizedmortality ratios, Kaplan-
Meier, and Cox methods were used to estimate excess mortality, survival, and adjusted hazard
ratios (HRs) for all-cause mortality.
Results
Disease-modifying treatments decreased TTR-FAP excess mortality from 10 to 4 (standardized
mortality ratio 3.92, 95% confidence interval [CI] 2.64–5.59). Median overall survival of
untreated and LTx-treated cohorts was 11.61 (95% CI 11.14–11.87) and 24.73 years (95% CI
22.90–27.09), respectively, and was not reached in the tafamidis-treated cohort (maximum
follow-up, 10 years). Both disease-modifying treatments improved survival. Among early-onset
patients (younger than 50 years of age), tafamidis reduced the mortality risk compared with
untreated patients by 91% (HR 0.09, 95% CI 0.03–0.25, p < 0.001) and with LTx-treated
patients by 63% (HR 0.37, 95% CI 0.14–1.00, p = 0.050). Previous tafamidis treatment did not
affect mortality risk after LTx (HR 0.83, 95% CI 0.25–2.78, p = 0.763). Among late-onset
patients (50 years and older), tafamidis reducedmortality risk by 82% compared with untreated
patients (HR 0.18, 95% CI 0.06–0.49, p = 0.001).
Conclusion
LTx and tafamidis convey substantial survival benefits, but TTR-FAP mortality remains higher
than in the general population. These results strongly reinforce the importance of timely
diagnosis and earlier treatment, boosting the pursuit for an increased life expectancy.
Classification of evidence
This study provides Class III evidence that for patients with stage 1 Val30Met TTR-FAP, LTx
and tafamidis increase survival.
MORE ONLINE
Class of Evidence
Criteria for rating
therapeutic and diagnostic
studies
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Transthyretin-associated familial amyloid polyneuropathy
(TTR-FAP) is an autosomal-dominant, adult-onset, progressive
neurodegenerative systemic disease, described in 1952 by Cor-
ino de Andrade.1 TTR-FAP is rare with endemic populations
predominantly in Portugal, Sweden, Japan, and Brazil.2–4 Its
symptoms stem from amyloidosis that results from misfolding
of the TTR protein tetramer.2,5–7 More than 120 TTR gene
mutations are associated with TTR-FAP, the most common of
which is Val30Met.5 If untreated, the disease progresses rapidly
to death, usually within the first decade after symptom onset.2,8,9
Orthotopic liver transplantation (LTx) was first implemented
in the 1990s as a surgical gene therapy strategy to ameliorate
or halt familial TTR amyloidosis.10,11 In the past decade, the
oral disease-modifying treatment tafamidis became avail-
able as a treatment option at 20 mg once daily, first in the
context of clinical trials (2007) and later as an approved drug
(November 2011 in the European Union) for the treatment
of adult patients with early-stage TTR-FAP to delay disease
progression.12,13 Other treatment options are being evaluated
in phase 3 trials.14,15
Although disease-modifying treatments are used worldwide to
delay or halt disease progression, challenges in clinical as-
sessment remain because of disease rareness, clinical hetero-
geneity, incomplete natural history, and uncertain treatment
effectiveness. Hence, in this study, we aimed to assess natural
history survival, evaluate the effect of LTx and tafamidis on
survival, explore prognostic factors, and compare treatment
effectiveness in patients with early-onset (younger than 50
years of age) and late-onset (50 years and older) disease.
Methods
The report of this study follows the STROBE (Strengthening
the Reporting of Observational Studies in Epidemiology)
statement.16
Study design and participants
This was a multi-institutional, hospital-based cohort study of
consecutive symptomatic adult patients (18 years and older)
with a diagnosis of TTR-Val30Met FAP given prospective
longitudinal follow-up since the first patient observation in
19391 through the end of the study on December 31, 2016, at
either of 2 Portuguese referral centers. Historically, diagnosis
of TTR-Val30Met FAP was based on the patient’s clinical
findings, family history, and pathology. Since 1985, when
genetic testing became available,17 it was possible to link all
cases to families in whom the Val30Met mutation was con-
firmed. Asymptomatic carriers were excluded.
To account for selection bias and to reduce clinical hetero-
geneity, we predefined different populations for comparative
purposes.
For the tafamidis cohort, we included all patients who started
treatment, regardless of whether they discontinued tafamidis
(intention-to-treat approach), and all those who underwent
subsequent LTx because of patient preference or disease
progression despite tafamidis treatment.
The intended overall LTx cohort for comparative analysis
consisted of patients who underwent transplantation begin-
ning in 1992, the year LTx became a routine treatment option
in Portugal. Although clear-cut absolute and relative contra-
indications for LTx are difficult to establish, the following
factors are considered at Portuguese centers for the selection
of patients: age (younger than 50 years); disease duration (<7
years); low polyneuropathy disability score (stage 1 disease);
modified body mass index ≥600 kg/m2·g/L; no severe auto-
nomic dysfunction; absence of amyloid cardiomyopathy; and
no significant renal dysfunction.18,19
Patients who underwent LTx in 2012 or later were excluded
(in Portugal, tafamidis became a first-line treatment option in
2012, and selection to treatment biases could have occurred
because of physician or patient preference), as were patients
who underwent LTx at more advanced stages of the
disease20—stages 2 and 3, for which tafamidis is not approved.
We anticipated that more than 20 years of important changes
could have occurred in the LTx setting and could have in-
creased survival because of improvements in surgical tech-
niques, surgeons’ learning curves, enhancement of adjuvant
pharmacologic treatments (e.g., protocols for lifelong
immunosuppressants), and optimization of patient selection
criteria for LTx (e.g., selection of patients with better prog-
nosis factors).21 Therefore, we tested this hypothesis by
comparing survival between patients who underwent LTx
before 2007 and during or after 2007 (the year tafamidis
became available as a treatment option in a clinical trial
context). If no significant differences were found, the overall
LTx cohort selected for primary comparative analysis
encompassed stage 1 patients who underwent LTx between
1992 and 2011 (20-year time interval) to maximize in-
formative cohort follow-up (up to 25 years). Nonetheless,
even in this scenario, we conducted an exploratory compar-
ative analysis considering only LTx patients who underwent
LTx in 2007 and later to assess the robustness of the findings.
If significant differences were detected, the primary compar-
ative analysis included only patients who underwent LTx in
more recent years.
Glossary
CI = confidence interval; HR = hazard ratio; LTx = liver transplant; mOS = median overall survival; RMST = restricted mean
survival time; SMR = standardized mortality ratio; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
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The overall untreated cohort was evaluated within 3 disease-
onset periods: 1992 onward, 1972–1991 (20-year time in-
terval as for the intended overall LTx cohort), and before
1972. We anticipated survival gains over time, even among
untreated patients, as changes occurred in global health care
services relating to TTR-FAP. However, patients with disease
onset in more recent years who have not received treatment
are more likely to have poorer prognoses (for example,
patients with late-onset disease), not fulfilling eligibility cri-
teria for available treatment. Therefore, we selected the
1972–1991 untreated cohort for subsequent analysis, pro-
spectively studied since disease onset (stage 1 patients).
Procedures
Data were extracted from clinical records regarding sex, dates
of birth, disease onset and death, and treatment-related data
(type, date of initiation, and follow-up). Disease onset was
defined as the patient’s age when TTR-FAP symptoms were
first noticed by the patient. Data discrepancies were actively
searched by means of database queries and resolved through
revision of the patient chart. With the exception of 4% of the
patients (n = 121), who were censored at the time of their last
visit, date of death was confirmed in the National Health
Service User Registry.
Statistical analysis
Pearson χ2 test was used to compare categorical variables.
Continuous variables were checked for normal distribution
and analyzed accordingly with parametric or nonparametric
tests. The overall effect of TTR-FAP treatment on mortality
was assessed through standardized mortality ratios (SMRs)
calculated for the years 1991 (before treatment availability)
and 2016 (end-of-study year), by sex and age group.22
Survival was estimated using the Kaplan-Meier method. All-
cause mortality was evaluated from disease onset (index event)
except for the analysis of prognostic factors among treated
cohorts, in whom overall survival was evaluated since treatment
initiation to account for the effect of disease duration before
treatment on survival. Patients were monitored until death or
end of study. Administrative censoring of data was performed
for patients who were alive at the end of the study (n = 1,176),
for those enrolled in ongoing clinical trials (n = 34), and for
those lost to follow-up (n = 121). For patients in the tafamidis
cohort, the primary analysis also censored patients who un-
derwent subsequent LTx (n = 44)with censoring starting at the
time of transplantation. Sensitivity analysis was also performed
that encompassed all tafamidis-treated patients and included
survival follow-up of patients enrolled in clinical trials and of
those who underwent subsequent LTx.
Adjusted hazard ratios (HRs) and 95% confidence intervals
(95%CIs) were calculated through Cox regression models, all
of which were stratified by hospital referral center. Within
each treatment cohort, exploration of prognostic factors for
survival included sex, late-onset status, stage (for LTx only),
and disease duration before treatment, all of which were
explored together in a Cox proportional hazards model ad-
justed for decade of onset as a covariate.
Comparisons of treatment effectiveness were made separately
for populations with early- and late-onset disease according to
a Kaplan-Meier method crediting time before treatment in the
LTx and tafamidis cohorts to the untreated cohort. A Cox
regression model with treatment as a time-varying covariate
was used, with adjustment for age at onset in 5-year categories
and for sex.23,24 The treatment variable used a value of zero
until treatment initiation and a value of one from treatment to
death or censoring. This allowed follow-up before LTx or
tafamidis initiation to be credited to the untreated natural
history cohort. To assess the robustness of the findings, we
have also compared survival between cohorts using the re-
stricted mean survival time (RMST) as a complementary
summary measure to HR,25 since there is evidence that
treatment-effect measures on the basis of RMST are more
conservative than HRs26 and do not rely on hazards pro-
portionality. RMST-based treatment-effect measures were
calculated taking the time horizon as the minimum of the
largest observed event time among all cohorts.
For the early-onset population, and to address whether pre-
vious treatment with tafamidis modified survival after LTx, we
conducted an exploratory analysis that compared patients
with and without previous tafamidis treatment. To ensure
similar follow-up, non–tafamidis-treated patients included
only those who underwent LTx from 2007 to 2011. A further
exploratory analysis for the early-onset population was per-
formed, comparing LTx and tafamidis-treated cohorts, and
evaluating mortality risk since treatment initiation (index
event) for a period of 10 years. For the population with late-
onset disease, LTx is not a general treatment option; there-
fore, analysis of treatment effectiveness compared only the
tafamidis and untreated cohorts.
Statistical analysis and graphs were performed using Stata
Statistical Software: Release 15.0 (StataCorp LLC, College
Station, TX). The threshold for statistical significance was set
at α = 0.05.
Standard protocol approvals, registrations,
and patient consents
The study protocol was approved by the institutional ethics
board committees (Centro Hospitalar do Porto and Centro
Hospitalar Lisboa Norte) and by the National Data Pro-
tection Committee. Informed consent was obtained from live
participants.
Primary research question
Has disease-modifying treatment (LTx and tafamidis) im-
proved survival among patients with Val30Met TTR-FAP?
This study provides Class III evidence that for patients with
stage 1 Val30Met TTR-FAP, LTx and tafamidis increase
survival. This study is rated Class III because of the potential
of important confounding differences between groups.
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Data availability
Anonymized data generated during the current study are
available on reasonable request from individuals affiliated with
research or health care institutions located in Portugal, as
approved by the National Data Protection Committee. See
data available from Dryad (table 1, doi.org/10.5061/dryad.
3583v22).
Results
Characteristics of the study cohorts
The study included 3,221 symptomatic patients. Sixty-one
patients were excluded because of missing data at disease
onset (n = 57) or date of LTx (n = 4). Our sample for analyses
thus included 3,160 patients: 1,771 in the untreated, 957 in
the LTx-treated, and 432 in the tafamidis-treated cohorts
(data available from Dryad, table 1, doi.org/10.5061/dryad.
3583v22). Median follow-up was 10.25 years in the untreated
cohort, 13.67 years in the LTx cohort, and 5.45 years in the
tafamidis-treated cohort. Overall, 1,853 patients (58%) died.
The mean (SD) age at disease onset was 36.7 (12.2) years and
1,697 patients (53.7%) were male (data available from Dryad,
table 1, doi.org/10.5061/dryad.3583v22). The cohorts did
not differ in sex distribution (p = 0.321). The proportion of
patients with late-onset disease and their median age at dis-
ease onset differed between cohorts (p < 0.0001). Both were
lower in the LTx-treated cohort than in either other cohort, as
expected given that LTx is not routinely recommended for
patients with late-onset disease. Median duration of disease
before treatment was longer among LTx-treated than
tafamidis-treated patients (p < 0.0001), also as expected given
the additional waiting time for LTx (data available from
Dryad, table 1, doi.org/10.5061/dryad.3583v22). Similar
results were found for comparisons between the selected
cohorts used for analysis of comparative treatment effective-
ness (table 1).
Effect of treatment
SMR analysis for year 1991 (before LTx became available)
indicated that untreated patients had a 10-fold (SMR 9.79,
95% CI 6.65–13.90) excess mortality rate than did the general
population. In 2016, patients with TTR-FAP faced a 4-fold
(SMR 3.92, 95% CI 2.64–5.59) excess mortality rate com-
pared with the general population, indicating a decrease of
60% after treatment (LTx or tafamidis) became available. The
excess mortality rate was highest in patients 45 to 54 years of
age than in other age groups and was higher in women than in
men (table 2).
Survival prognostic factors
Untreated cohort (natural history)
The 1972–1991 untreated cohort, which exhibited a median
overall survival (mOS) of 11.61 years (95% CI 11.14–11.87
years), showed the highest survival among all untreated
cohorts (figure 1). In this cohort, the mortality risk was higher
Table 1 Characteristics of patients with Val30Met TTR-FAP in the selected cohorts
Untreated (year of onset
1972–1991) LTx (year of LTx 1992–2011)a
Tafamidis (year of
treatment initiation
2007–2016)
Early Late Early Late Early Late
Patients, n 755 116 855 32 347 85
Male, % 53.5 47.4 52.7 46.9 51.9 48.2
Age at onset, y
Mean ± SD 32.3 ± 6.4 58.3 ± 6.4 31.6 ± 6.1 53.4 ± 4.3 33.8 ± 6.7 61.6 ± 7.8
Median (IQR) 31 (28–36) 57 (53–63) 31 (27–35) 53 (51–57) 33 (29–38) 60 (55–67)
Disease duration from onset to treatment
initiation, y
Mean ± SD — — 4.1 ± 2.7b 4.0 ± 2.9 2.4 ± 2.0 3.2 ± 2.7
Median (IQR) — — 3.5 (2.3–5.2) 3.0 (2.4–4.8) 2.0
(1.0–3.3)
2.7
(1.6–3.8)
Follow-up from onset, y
Mean ± SD 11.9 ± 4.9 9.4 ± 4.2 14.4 ± 6.2 13.1 ± 4.7 5.9 ± 3.0 6.0 ± 3.6
Median (IQR) 11.4
(8.9–14.4)
8.8
(6.4–11.8)
14.1
(10.0–18.7)
12.8
(9.3–16.3)
5.5
(4.0–7.7)
5.4
(3.8–7.7)
Abbreviations: IQR = interquartile range; LTx = liver transplant; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
a LTx-treated cohort, excluding patients in disease stages 2 and 3.
b Among early-onset patients, disease duration was 1.7 years (p < 0.0001) higher in LTx-treated than tafamidis-treated patients.
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in men than women (HR 1.20, 95% CI 1.04–1.38, p = 0.011)
and in patients with late-onset (mOS 9.21, 95%CI 8.05–10.80)
than early-onset (mOS 11.86 years, 95% CI 11.43–12.19)
disease (HR 1.98, 95% CI 1.60–2.44, p < 0.0001) (figure 2A).
Liver transplantation
In the LTx comparison cohort (stage 1 patients, 1992–2011),
mOS since disease onset was 24.73 years (95%CI 22.90–27.09);
mOS following LTx was 20.92 (95% CI 18.43–not estimable).
LTx resulted in early excess mortality following the surgical
procedure; the cumulative mortality rate in the first year
after LTx was 14% (95% CI 11%–16%). Patients who un-
derwent LTx in more advanced stages of the disease (stage 2 or
3) experienced higher mortality risk than those in stage 1 (HR
1.58, 95% CI 0.94–2.47, p = 0.091). Among patients in stage 1
treated with LTx, the mortality risk was lower in men than in
women (HR 0.70, 95% CI 0.55–0.89, p = 0.003) and in patients
with shorter disease duration before LTx. For each year LTx was
delayed, the mortality risk increased by 17% (HR 1.17, 95% CI
1.12–1.23, p < 0.0001). We found no differences between
patients with late-onset and early-onset disease (HR 1.59, 95%
CI 0.90–2.80, p = 0.112; figure 2B).
Tafamidis
The mOS for the tafamidis-treated cohort was not reached,
though the maximum follow-up was only 10 years. The ob-
served survival rate at 10 years after treatment initiation was
92.9% (95% CI 83.1%–97.2%). Mortality risk was greater
among patients with longer disease duration before tafamidis
treatment. For each year tafamidis treatment was delayed, the
risk of death increased by 39% (HR 1.39, 95% CI 1.05–1.83, p
= 0.022). No differences were found based on sex (HR 1.29,
95% CI 0.27–6.04, p = 0.749) or late-onset vs early-onset
disease (HR 3.40, 95% CI 0.80–14.51, p = 0.098; figure 2C).
Comparative treatment effectiveness
Although a lower 1-year cumulative mortality rate and
a higher 10-year survival rate were observed in patients who
underwent LTx during 2007 or later vs those who underwent
LTx before 2007 (10% vs 14% and 85% vs 74%, respectively),
no overall survival differences were found (HR 0.80, 95% CI
0.51–1.23, p = 0.309). Therefore, in accordance with the
prespecified criteria, for primary comparative analysis, we
considered the overall LTx cohort encompassing stage 1
patients who underwent LTx between 1992 and 2011. Hence,
Table 2 Standardized mortality ratio for TTR-FAP (years 1991 and 2016)
Age group, y Patients at risk, n
Observed deaths, n/expecteda deaths, n Standardized mortality ratio (95% CIb)
Males Females All Males Females All
1991
18–24 10 0/0.02 0/0 0/0.02 — — —
25–34 197 5/0.33 0/0.04 5/0.37 15.20 (4.94–35.47) — 13.51 (4.39–31.53)
35–44 308 5/0.44 5/0.23 10/0.66 11.45 (3.72–26.72) 21.95 (7.13–51.23) 15.05 (7.22–27.67)
45–54 126 3/0.2 6/0.29 9/0.49 15.25 (3.14–44.56) 20.78 (7.63–45.24) 18.54 (8.48–35.20)
55–64 55 2/0.37 1/0.22 3/0.59 5.38 (0.65–19.42) 4.60 (0.12–25.64) 5.09 (1.05–14.88)
65–74 20 2/0.22 1/0.27 3/0.49 9.04 (1.09–32.66) 3.72 (0.09–20.71) 6.12 (1.26–17.88)
≥75 5 0/0.35 1/0.2 1/0.55 — 5.12 (0.13–28.53) 1.82 (0.05–10.13)
Total 721 17/1.93 14/1.24 31/3.17 8.82 (5.14–14.13) 11.29 (6.17–18.95) 9.79 (6.65–13.90)
2016
18–24 2 0/0.00 — — — — —
25–34 115 0/0.05 1/0.01 1/0.06 — 151.19 (3.83–842.40) 18.00 (0.46–100.27)
35–44 475 2/0.42 0/0.14 2/0.56 4.76 (0.58–17.18) — 3.55 (0.43–2.83)
45–54 388 3/0.77 5/0.38 8/1.14 3.90 (0.80–11.40) 13.30 (4.32–31.03) 6.99 (3.02–13.77)
55–64 163 4/0.64 3/0.38 7/1.02 6.21 (1.69–15.90) 7.97 (1.64–23.29) 6.86 (2.76–14.13)
65–74 87 3/0.96 2/0.39 5/1.35 3.12 (0.64–9.10) 5.16 (0.63–18.65) 3.70 (1.20–8.64)
≥75 47 5/1.78 2/1.75 7/3.53 2.81 (0.91–6.57) 1.14 (0.14–4.13) 1.99 (0.80–4.09)
Total 1,277 17/4.62 13/3.04 30/7.66 3.68 (2.14–5.89) 4.28 (2.28–7.32) 3.92 (2.64–5.59)
Abbreviations: CI = confidence interval; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
a Expected deaths that would occur if patients with TTR-FAP were at the same mortality risk as the general Portuguese population (data from INE, Statistics
Portugal), according to sex and age.
b The 95% CIs for standardized mortality ratios were computed under the assumption that occurrence of the events followed a Poisson distribution.
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according to the eligibility criteria (see methods), 871, 887,
and 432 patients in the untreated, LTx-treated, and tafamidis-
treated cohorts, respectively, were included in the evaluation
of comparative treatment effectiveness (table 1).
Early-onset disease
Both treatment cohorts experienced increased survival com-
pared with the untreated 1972–1991 cohort. The 10-year
survival probabilities after TTR-FAP onset were 72% (95%CI
69%–75%), 73% (95% CI 68%–78%), and 96% (95% CI
87%–99%) in the untreated, LTx-treated, and tafamidis-
treated cohorts, respectively. The 20- and 30-year survival
probabilities after disease onset were 7% (95% CI 5%–9%)
and 2% (95% CI 1%–4%) in the untreated cohort, and 56%
(95%CI 50%–61%) and 29% (95%CI 18%–39%) in the LTx-
treated cohort, respectively.
Overall, there was a 75% (HR 0.25, 95% CI 0.22–0.29, p <
0.0001) and a 91% (HR 0.09, 95% CI 0.03–0.25, p < 0.0001)
reduction in mortality risk in the LTx-treated and tafamidis-
treated cohorts, respectively. Survival was higher in the tafamidis-
treated cohort than in the LTx-treated cohort; mortality risk was
reduced by 63% (HR 0.37, 95% CI 0.14–1.00, p = 0.050; figure
3A). The crossing of the LTx and untreated survival curves is
indicative of nonproportionality in the hazards, and therefore the
reported HR should be thought of as an average over time.
Similar results, in terms of direction of treatment effect (although
of lower magnitude) and statistical significance, were obtained
for RMST-based measurements (table 3).
Results of the exploratory analysis considering only the more
recent LTx cohort (2007–2011) were of similar magnitude,
including comparison between the tafamidis- and LTx-treated
cohorts (HR 0.36, 95% CI 0.13–1.02, p = 0.055). Similar
results were obtained when comparing the more recent LTx
cohort with tafamidis since treatment initiation (HR 0.18,
95%CI 0.08–0.40, p< 0.0001). Sensitivity analysis that included
post-LTx and post-clinical trial follow-up data for all patients
initially treated with tafamidis showed an 87% mortality risk
reduction compared with the untreated cohort (HR 0.13, 95%
CI 0.06–0.27, p < 0.0001) and a 50% mortality risk reduction
compared with the LTx cohort (HR 0.50, 95% CI 0.24–1.06,
p = 0.072). When comparing tafamidis-naive LTx patients from
2007 to 2011 (more recent and contemporaneous) with those
who underwent transplantation but previously received tafa-
midis, no difference in posttransplantation survival rate was
observed (p = 0.763, figure 4).
Late-onset disease
Given that LTx is not generally recommended for patients
with late-onset disease and that only a small set of patients (n =
32) with late-onset disease underwent LTx, no comparative
analysis was performed for this cohort (mOS since disease
onset, 17.04 years, 95% CI 13.31–19.88). Furthermore, this
LTx-treated subgroup represented a highly selected set of
patients with late-onset disease who still fulfilled eligibility
criteria for surgery. The 10-year survival probability after TTR-
FAP onset was 49% (95% CI 39%–58%) and 92% (95% CI
71%–98%) in the untreated and tafamidis-treated cohorts, re-
spectively. Overall, among patients with late-onset disease,
tafamidis treatment (n = 85) was associated with an 82% re-
duction in mortality risk compared with the untreated (n =
116) cohort (HR0.18, 95%CI 0.06–0.49, p= 0.001; figure 3B).
Discussion
This research of more than 3,200 Portuguese patients repre-
sents the largest cohort study of patients with TTR-FAP to
date. Our findings reveal that both sexes are affected and
disease onset occurs primarily in young adulthood (28–42
years of age). We found a slight but clinically relevant im-
provement in survival among the untreated cohorts of almost
1 year, probably because of easier access to better medical
care. The reduced survival rate of untreated patients in the era
of LTx probably reflects the coexistence of clinical charac-
teristics (such as later disease stage and poor nutritional sta-
tus) and social conditions (such as health illiteracy and low
awareness of disease treatment) that precluded the eligibility
and timely access to LTx.
The main clinical relevant finding of our study is that the
advent of disease-modifying treatments (in particular LTx)
changed dramatically the long-term prognosis for patients
with TTR-FAP in the past 25 years, from a progressive, dev-
astating, fatal disease to a more chronic condition with treat-
ment leading to delayed disease progression. The beneficial
effect of treatment as a whole onmortality was demonstrated by
the 60% SMR reduction from 1991 to 2016; in 2016, however,
Figure 1 Untreated cohort (natural history) Val30Met TTR-
FAP survival
Kaplan-Meier survival estimates in the Val30Met TTR-FAP untreated cohort
(natural history) according to the era of disease onset. CI = confidence in-
terval; HR = hazard ratio; TTR-FAP = transthyretin-associated familial amy-
loid polyneuropathy.
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mortality rates remain 4-fold greater than in the general pop-
ulation. In our study, the prognosis for treated patients was
poorer for those with longer disease duration before treatment,
which is consistent with the published literature on LTx21,27,28
and with the benefits of earlier tafamidis treatment on neuro-
logic progression and nutritional status.29–31 This result strongly
reinforces the need to start treatment (either LTx or tafamidis)
at an early stage of the disease.
Figure 2 Untreated, LTx-treated, and tafamidis-treated Val30Met TTR-FAP survival
Kaplan-Meier survival estimates by sex and age at disease onset (early/late onset) according to Val30Met TTR-FAP cohort: untreated (A), LTx-treated (B), and
tafamidis-treated (C) patients. CI = confidence interval; HR = hazard ratio; LTx = liver transplant; TTR-FAP = transthyretin-associated familial amyloid
polyneuropathy.
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The results from the comparative effectiveness analysis raise
several further findings for discussion. First, among patients
with early-onset disease, tafamidis treatment may result in
improved overall survival compared with LTx, attributable
perhaps in part to the absence of early operative risks. Caution
is required, however, when interpreting this finding because
median tafamidis follow-up was relatively short as compared
with LTx median follow-up, and mOS has not yet been
reached. Moreover, within the first years after the introduction
of LTx, and in contrast to tafamidis, LTx resulted in higher
mortality rates than no treatment. Although this is an expected
finding, the proportional hazard assumption of the Cox re-
gression analysis is violated, which means that, with longer
follow-up, treatment effect is likely to change. Nonetheless, the
robustness of this finding is supported by the similar results
found in the analysis that made use of different statistical
methods (RMST), as well as in the exploratory analysis that
included only the more recent LTx cohort (2007–2011). This
Figure 3 Comparative survival estimates in patients with early- and late-onset Val30Met TTR-FAP
Kaplan-Meier survival estimates since
disease onset (with 95% CI) in Val30Met
TTR-FAP selected cohorts with compar-
ative treatment effectiveness among
early-onset (A) and late-onset (B)
patients. CI = confidence interval; HR =
hazard ratio; LTx = liver transplant; TTR-
FAP = transthyretin-associated familial
amyloid polyneuropathy.
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more recent LTx cohort experienced an overall higher survival
rate than the former LTx cohort, was contemporaneous with
the tafamidis-treated cohort, and had comparable follow-up.
Second, among patients with early-onset disease and up to 10
years of follow-up, no differences in survival were found be-
tween LTx-treated patients who did and those who did not
previously receive tafamidis treatment, though other possible
benefits of tafamidis beyond survival—such as improvement
in nutritional and overall health status13—were not analyzed
in this study.
Third, among patients with late-onset disease, a subgroup
with poorer prognosis and shorter median survival,32,33 and
for whom LTx is not generally recommended,34 tafamidis
treatment resulted in a clinically relevant survival benefit.
From a study of the largest LTx cohort of patients with TTR-
FAP (Familial Amyloidosis Polyneuropathy World Trans-
plant Registry, encompassing 2,171 patients from 81 centers
and 21 countries), researchers retrospectively reported21 a 20-
year survival rate of 55.3%, a noteworthy improvement in
overall survival compared with reports on the natural history
of the disease. In the study, higher modified body mass index,
early onset of disease (younger than 50 years), shorter disease
duration before LTx, and TTR Val30Met rather than non–
TTR Val30Met mutations were found to be independent,
favorable, significant factors for survival. The overall highest
transplantation activity contributing to this registry originates
from Portugal, which contributed more than 45% of the data.
Our research shows that TTR-FAP overall median survival
after LTx is 21 years. Limitations of LTx include waiting times
for a compatible donor organ35 and relevant intraoperative
mortality and postoperative complications as evidenced by
the high cumulative first-year mortality rate, which is similar
to what others have found.21 One interesting finding from our
study was the higher mortality risk among LTx-treated
women in comparison to men. Although the overall LTx lit-
erature is supportive of this finding,36,37 the reasons in
Val30Met TTR-FAP remain unclear. The difference in mor-
tality risk occurs early after LTx. Therefore, this difference is
probably attributable to imbalanced unobserved baseline
prognostic factors (including systematic epidemiologic bias
Table 3 Post hoc RMST estimates (with 95% CI) among TTR-FAP Val30Met early- and late-onset patients (20 years since
disease onset)
Early-onset cohorts Late-onset cohorts
Untreated LTx Tafamidis Untreated Tafamidis
Patients, n 755 855 347 116 85
RMST, y (95% CI) 12.57 (12.29–12.85) 15.08 (14.40–15.77) 18.36 (15.95–20.77) 10.35 (9.54–11.16) 14.35 (11.48–17.22)
LED, y (95% CI)
LTx vs untreated 2.51 (1.77–3.25) —
Tafamidis vs untreated 5.79 (3.36–8.21) 4.00 (1.02–6.98)
LTx vs tafamidis −3.28 (−5.78 to −0.77) —
LER, ratio (95% CI)
LTx vs untreated 1.20 (1.14–1.26) —
Tafamidis vs untreated 1.46 (1.28–1.67) 1.39 (1.12–1.72)
LTx vs tafamidis 0.82 (0.72–0.94) —
Abbreviations: CI = confidence interval; LED = life expectancy difference; LER = life expectancy ratio; LTx = liver transplant; RMST = restricted mean survival
time; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
Figure 4 LTx (with and without previous tafamidis) Val30-
Met TTR-FAP survival since LTx
Kaplan-Meier survival estimates since LTx according to previous tafamidis
treatment in Val30Met TTR-FAP LTx patients with early-onset stage 1 dis-
ease. CI = confidence interval; HR = hazard ratio; LTx = liver transplant; TTR-
FAP = transthyretin-associated familial amyloid polyneuropathy.
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against women and a poorer metabolic status) and/or higher
rate of early LTx fatal complications.
Previous studies evaluating the survival of patients with TTR-
FAP enrolled either a small number of patients27,28 or lacked
comparison groups.21 Furthermore, some assumptions and
conclusions from previous studies may be questionable, such
as reporting a 100% survival rate at 10 years among LTx-
treated patients by excluding deaths considered not related to
amyloidosis.27
An important limitation of our study is its observational de-
sign. We have attempted to deal with selection bias objectively
by using explicit criteria to define clinically comparable
cohorts and by adjusting for sex, age at onset, and disease
duration before treatment when modeling. However, because
of the unavailability of data, we were unable to include other
possible determinants of outcomes, such as nutritional status21
and other clinical characteristics.38 In addition, using historical
data for comparison has the disadvantage that cohorts may
differ in unmeasured prognostic factors for survival. In our
study, all patients had Val30Met mutation conferring genetic
homogeneity to the population evaluated. Although this may
be considered a strength of this study, it is also a further limi-
tation, because results are not generalizable to other TTR
mutations and other disease presentations, including sporadic
cases and later-stage disease, which are more common in other
geographies with higher genetic and clinical heterogeneity.32,33
Our findings suggest that potential improvements may be
made in the prognosis of patients with TTR-FAP and strongly
reinforce the importance of timely diagnosis and early treat-
ment initiation. Treatment with LTx or tafamidis dramatically
changed the clinical course of TTR-FAP. However, these
treatments have not proven to reverse established damage. In
fact, mortality rates remain higher than in the general pop-
ulation, which should stimulate further basic and clinical re-
search, targeting the development of biomarkers of early-stage
and subclinical disease, as well as new disease-specific drugs.
We report a comprehensive treatment effectiveness study
comparing natural history, LTx, and tafamidis treatment in
patients with TTR-FAP. It is unrealistic to expect that ran-
domized controlled trials will address the questions in-
vestigated here. This evidence can be a valuable source of
effectiveness, particularly in a rare-disease setting, and may
inform regulatory agencies, health technology assessment
bodies, and clinical treatment guidelines and recom-
mendations. Therefore, we suggest setting up properly
designed prospective, clinical registries as longer follow-up
data may facilitate understanding of how clinical practice can
reconcile different treatment options, especially as new drugs
emerge from phase 3 clinical trials.39,40
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DISCUSSION 
 
This chapter is dedicated to a global and transversal discussion of the aspects from 
the different articles presented in CHAPTER III - RESULTS, following the list of Specific 
Issues enumerated in CHAPTER I – INTRODUCTION - Objectives. 
1. Objectives and extent of disease-modifying therapies 
Disease-modifying therapies for ATTR amyloidosis aim to interfere with the 
pathophysiology of the disease, at different levels of the process, in order to slow the 
course of tissue degeneration. Therefore, successful drug development relies on 
accurate knowledge about disease mechanisms.166 Favorable clinical outcomes 
demonstrate proof of concept, confirming the importance of the mechanism addressed 
by each therapy. Accordingly, exploring response to new therapies, irrespective of their 
success, is likely to contribute to increase the knowledge about the disease and its 
pathogenesis.178 
Considering the low potential for restitutio ad integrum of the peripheral nervous 
system and the heart, it is expected that, even if disease-modifying therapies stop 
completely the degeneration process, they would result in no further progression of the 
disease, without substantial recovery. Nevertheless, there are several possible 
explanations for the improvement observed in some patients, in all three registration 
clinical trials presented here (articles 4, 11 and 12).  
First and foremost, the degeneration process is a dynamic one and the affected tissues 
will be a mixture of normal, partially degraded and completely degenerated segments 
and these partial lesions may well show some, although limited, degree of 
improvement, particularly in the early stage of the disease. Moreover, we speculate 
that cardiac and digestive tract impairment may be related, at least partially, to amyloid 
infiltration and not to tissue degeneration. If this is the case, a therapy that decreases 
amyloid burden, as confirmed after liver transplant,170 might be expected to confer 
some functional improvement. And finally, an important aspect of the disease, the poor 
general state of health, (including the loss of weight unrelated to digestive problems 
161 and the common complaints of malaise and fatigue) is comprehensibly reversible 
and may show a significant improvement, as we observed with Tafamidis treatment 
(articles 4, 5, 6 and 7). 
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Patients with advanced disease are commonly avoided in clinical trials. Reasons for 
this include the difficult management of these candidates and foremost, the ceiling 
effect associated with outcome measures in this disease stage. In real-life use, the 
uppermost level of damage and consequent absence of recovery potential may lead 
to the conclusion that disease-modifying drugs have no significant clinical effect in very 
advanced patients, who would benefit more from symptomatic treatment and good 
supportive care. In fact, we will not be sure of this until disease-modifying therapies 
approved for early stage patients are scrutinized in late stage patients.  
The expectation of a lower pharmacologic benefit with advanced disease underlines 
the dramatic consequences of the common delays in ATTR polyneuropathy 
diagnosis.141,142 To have efficacious but inapplicable therapies, due to the late 
recognition of the disease, is a serious medical error that deserves all possible efforts 
to be prevented. To increase awareness about this rare disorder is very important but 
the discovery of biomarkers and easier strategies for earlier ATTR amyloidosis 
diagnosis should also reduce the time required for an accurate diagnosis. 
2. Rules and needs for the approval of new drugs for rare diseases  
In Europe and in the United States of America (USA), regulatory agency approval of 
new drugs follows demanding rules, requiring the demonstration of efficacy and safety 
based on “substantial evidence” obtained from two (“affirm and confirm”) controlled 
studies. Randomized, double-blind, placebo-controlled clinical trials are universally 
accepted as the gold standard to show that any observed differences between the 
treated and non-treated groups are due to the beneficial effect of the drug under study 
and not due to other factors, such as biased observations, placebo effect or 
spontaneous variation.179 
In the case of approval of drugs for the treatment of rare diseases (orphan drugs), 
there is some flexibility. Historic control groups are sometimes allowed or availed from 
similar studies. One single trial may be recognized as enough evidence, if results are 
robust and preferably, when different aspects of the disease have been consistently 
evaluated through multiple outcome measures.180 These rules, common to Europe and 
USA, may have different interpretations as we saw with Tafamidis conditional approval 
in Europe, where regulators recognized and valued the positive results in multiple 
secondary outcome measures. In contrast, the FDA in the USA looked at the same 
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data package and rejected Tafamidis for ATTR polyneuropathy, because of the 
absence of statistical significance in the pre-specified primary outcome measures in 
the intent-to-treat (ITT) population. The exclusive inclusion of Val30Met patients was 
another issue. They asked for a second trial, successfully completed, for approval. 
According to these rules, the design of a clinical trial to assess an orphan drug must 
be based on sound knowledge of the natural history of the disease, in its multiple and 
variable presentations, including the evaluation of disease progression, quantified with 
resort to appropriate scores or scales, previously validated to demonstrate their 
sensitivity, reliability and responsiveness.181 
Unfortunately, when basic and clinical investigators decided to move forward to 
evaluate the TTR stabilizers, Tafamidis and Diflunisal, for the treatment of FAP in 
placebo-controlled trials they soon realized how insufficient the natural history studies 
were. Besides, no specific score had been adequately and extensively validated, to 
quantify ATTR polyneuropathy progression. In consequence the outcome measures 
selected for the first studies had to be validated in parallel with the development of the 
clinical trials (articles 1, 2 and 3), with obvious risks. Several lessons from the partial 
failure of the first trial with Tafamidis (article 4) were later used to build a new and 
improved score, the mNIS+7182,183 and to change the design of gene-silencing drug 
trials (article 3), as well as the cardiomyopathy trial with Tafamidis.184 
3. Strengths and limitations of clinical trials  
Despite their crucial role, clinical trials have significant limitations: they are conducted 
over a fairly short time window, in a relatively small number of selected, compliant 
patients, without significant co-morbidities or psycho-social problems.185 That is why 
real-life assessments with commercially available drug in innumerous unselected 
patients, during a much longer follow-up period, are an important source of information 
(article 8). Some drugs that appear to have limited efficacy in placebo-controlled trials 
turn out to be very useful in the real world setting and vice versa. 
The complexity and variability of ATTR amyloidosis is challenging. The final objective 
of treating ATTR amyloidosis must include all the different aspects of the disease. 
However, drug development based on clinical trials is focused on a predominant 
aspect, v.g. polyneuropathy, which was evaluated by the primary outcome measure in 
all the ATTR polyneuropathy registration trials. The inclusion of multiple secondary 
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outcome measures and exploratory endpoints may enlarge the scope of the 
evaluation, but always in a restricted way. That is why the success of the most recent 
clinical trials represents a first step towards improving patient outcomes and quality-
of-life. The trials must be augmented by new trials or well-controlled studies directed 
toward assessing involvement of additional organs (v.g. the heart or the kidneys) with 
further clinical evaluation of approved drug’s impact on all the multiple aspects of this 
systemic disease.  
The need for longer follow-up observation periods in ATTR polyneuropathy was well 
demonstrated with the liver transplantation experience. The occurrence of CNS137,138 
and eye disease135,136 had been hypothesized from the beginning, as choroid plexus 
and retinal pigmented epithelium synthesize and secrete variant TTR into the cerebral 
spinal fluid and the eye, respectively (unaffected by liver transplantation). However, 
the severity and the extent of the involvement of the eye and the brain were 
unexpected. The rapid progression of heart disease81 and the late progression of 
neuropathy82 due to continuing deposition of wild TTR83-85 led some to hypothesize 
seeding of aggregation in the TTR amyloidoses, a controversial mechanism with a 
preliminary demonstration.86 Likewise in the future, we may be surprised with 
unexpected responses to new therapies, uncovering new pathogenic mechanisms, 
unrecognized until now, and new clinical manifestations.  
The short duration of clinical trials is also an issue with regard to detecting and 
evaluating safety problems, as some side effects require prolonged use to manifest. 
One important concern relates to the long-term use of TTR mRNA lowering strategies, 
because we really do not know if, and how much, TTR is needed for a healthy long 
life.52,73 
4. Development of outcome measures and design of clinical trials  
The World Health Organization (WHO) proposed to divide disease consequences into 
three classes, designated as impairment, disability and handicap.186 Impairment is 
related to organ dysfunction and abnormalities of body structures, such as the 
abnormal findings of a neurological exam or neurophysiological evaluations. Disability 
concerns the loss of functional skills, like walking, dressing oneself or eating. Handicap 
is associated with the social consequences of the disease, namely the incapacity to 
work and the loss of social interactions.  
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Different outcome measures are needed to evaluate these different categories.187 
When drugs are tested for the first time, it is important to have impairment evaluations 
to determine if there is a biological effect of the treatment, confirming the mechanistic 
rationale. In the particular case of trials for neuropathies, it may be argued that 
neurological evaluation is subjective, thus justifying the simultaneous use of the more 
objective neurophysiological evaluations, integrated in compound neurological scores. 
Nonetheless, functional scales or patient’s self-reported evaluations, like the quality-
of-life questionnaires, are important to perceive the real impact of the treatment on 
each patient, including the possible consequences of drug side effects. In fact, 
regulatory authorities commonly require their inclusion in study protocols.  
Finally, questionnaires directed to assess handicaps are particularly useful to evaluate 
the socio-economic consequences of a given drug or treatment.  
The scores most commonly used in the field of peripheral neuropathies, has supporters 
and critics.188 
One major issue concerns the methodology used for the score construction, commonly 
based on the classical test theory.189 This method establishes multiple items with 
ordered response options quantified with an ordinal scale (Likert-type). Such 
methodology induces users to think that one point difference, for instance, the 
difference between 0 and 1 is equivalent to the difference between 2 and 3 but, in fact, 
the real difference is unknown and may be quite variable in each interval. Moreover, 
the final sum score comprising all items, is built up and analyzed with parametric 
methods, without considering their non-linearity.190 The Rasch methodology191 could 
appropriately circumvent these problems, by modulating the answers according to their 
relevance and assessing them with the same metric.  
Other questions pertain to the artificial reinforcement of scores through repeated 
evaluation of the same impairment or function. The compound scales include items 
from the neurological and the neurophysiological exams, which are assessments of 
the same nerve impairment. Scores with these characteristics may inflate the 
difference between drug and placebo arms while, in the long term, this difference may 
prove less important to the patients188  
Finally, the introduction of a new concept, the minimal clinically important difference 
(MCID),192 defined as the smallest change in a given outcome measure that the patient 
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perceives as beneficial. MCID can be calculated with various anchor-based or 
distribution-based methods and could be particularly useful to compare different 
treatment strategies. 
5. Lessons learnt from the relative failure of Tafamidis trial  
As previously stated, the first clinical trial conducted with the disease-modifying agent 
Tafamidis faced the absence of natural history longitudinal studies and validated 
outcome measures for ATTR polyneuropathy. The more extensive clinical reports 
regard the first descriptions of neuropathy or cardiomyopathy in several clusters or 
families.3,10,16 They described homogeneous populations with the same genetic error, 
emphasized the most relevant and common clinical aspects and lack prospective data 
from longitudinal follow-up.  
One of the most relevant clinical observations is a longitudinal study of 495 Portuguese 
ATTR polyneuropathy patients followed for more than 10 years.144 Progression of 
sensory, motor and autonomic neuropathy was analyzed and divided into three stages 
defined according to the ambulatory status as stage 1 – fully ambulatory patients; stage 
2 - patients needing unilateral or bilateral support to walk; and stage 3 - patients 
wheelchair bound or bedridden. The mean duration of the different stages and the 
mean total duration of the disease was also established. Although missing any 
quantified evaluation of progression, many decisions concerning the design of 
Tafamidis trial and the validation of outcome measures were based on this study. The 
three stages ATTR polyneuropathy or FAP classification is still used by regulators to 
define any ATTR polyneuropathy drug indication. 
In order to move forward, scores developed and previously applied in clinical trials with 
diabetic neuropathy were selected.193-195 Diabetic neuropathy shares several 
similarities with FAP, particularly an important autonomic component besides the more 
common sensory and motor aspects. However, its progression is considerably milder 
and slower, and it was difficult to predict if problems could arise due to these major 
differences.196 
TTR stabilizers, Diflunisal197 and Tafamidis (article 4), were the first drugs proposed 
for phase 3 clinical trials. Diflunisal benefited from being an approved drug with a 
different indication (a NSAID), able to enter directly in a phase 3 trial and Tafamidis, 
designed specifically to stabilize TTR while lacking non-steroidal anti-inflammatory 
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activity, came slightly later after a phase 1 trial in healthy volunteers. The main purpose 
of both trials was to test the effect of these drugs on neuropathy progression, an aspect 
of the disease better studied and predominant in the largest well-known foci of the 
disease. 
A cross sectional, single center study, including FAP patients in stages 1, 2 and 3 and 
healthy volunteers (article 1 and 2) was conducted to validate the outcome measures 
used in the Tafamidis trial. The lack of a longitudinal component and observations from 
a single center, with a quite homogeneous population, are the main limitations of this 
work. Anyway the study provided evidence that NIS-LL, Norfolk, modified Body Mass 
Index (mBMI), composite scores of neurophysiological assessments, evaluating either 
small nerve fibers or large nerve fibers, are sensitive and reliable outcome measures, 
able to differentiate between healthy controls and all disease stages and weighting the 
different aspects of the disease across progression. The different measures show a 
good correlation between them. One major limitation is the early ceiling effect of the 
sensory component of NIS-LL (article 2). 
The Tafamidis trial did not achieve statistical significance in the pre-specified analysis 
of the two primary outcome measures, NIS-LL categorical analysis of change from 
baseline in the ITT population198 and Norfolk score change from baseline in the same 
population (article 4). Some may argue this is an unequivocal sign of lack of efficacy. 
However, several aspects of the design of the trial and the choice of outcome 
measures can explain the disappointing results. Noteworthy the careful analysis of 
these explanations was the basis for important changes in trial design and outcome 
measure choices for the subsequent trials (article 3).  
The choice of the outcome measures was one of the major problems. The NIS-LL had 
a very early ceiling effect on the sensory component, because it just considers the 
evaluation at the most distal part of the great toe. In fact, when we consider the motor 
component score in isolation, we find a significant difference between drug and 
placebo arms, due to multiple level evaluation. Also, if we had used a compound score, 
as all the other trials did, we would have seen positive results. Finally, the option for 
the categorical analysis of NIS-LL, particularly the pre-specified decision to consider 
patients leaving the study for liver transplant as non-responders, was completely wrong 
because patients were in the waiting list for liver transplant and this was the only 
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therapy with known results. When the dropouts of these patients are added to the 
global discontinuation group for statistical analysis, a significant difference is achieved 
between the two arms of treatment, in the ITT population, for this primary outcome 
measure. All these aspects were successfully revised for the development of the 
mNIS+7 score (article 3). 
The trial design brought about another problem: the inclusion of patients with an 
extremely early disease stage, with symptoms but no changes in the neurological 
exam, with a NIS-LL score of 0. Inclusion of these patients explains why so many 
patients in the placebo arm were responders (article 4). The progression of the disease 
is not linear and, in the first years of symptoms, it may be extremely slow. Again, this 
issue was addressed in the next trials, including criteria that established a minimal 
value for the NIS score and/or a slight abnormal value in the sural nerve conduction 
studies (articles 11 and 12).  
6. Tools to evaluate new drugs in clinical practice   
In the last decade appropriate outcome measures such as the mNIS+7 score (article 
3) and the Norfolk questionnaire (article 1) were developed and/or validated to be 
successfully applied in randomized clinical trials for patients with ATTR 
polyneuropathy. mNIS+7 score was successfully developed to maximize the power to 
discriminate the outcomes of the two branches of treatment, in the gene-silencing 
trials. 
Nowadays, with multiple drugs available and patients scattered around in many 
centers with less experience in the follow-up and management of these patients, we 
may question if mNIS+7 is the best tool to evaluate the efficacy of each drug in a given 
patient and, moreover, to compare treatments. 
Several practical questions limit the use of mNIS+7 in a routine practice environment. 
Use of this scale is time consuming, requires special equipment not commonly 
available, even in tertiary care centers, and needs final revision in a central laboratory, 
which is associated with delays and costs. Furthermore, differences between the 
results of the available treatments may be small and certainly more difficult to compare 
than the outcomes of treatment versus placebo groups in the clinical trials. To help 
differentiate treatments it is possible that we need a new score, simple and accessible, 
based on a clinical exam and standardized questionnaires; including sensory, motor 
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and autonomic aspects of neuropathy. This work requires the contribution of modern 
clinimetrics,188 refusing ordinal scales and compound scores and calculating the MCID 
as discussed above. It should be multicentered and cover genetic and phenotype 
heterogeneity. Subsequently, a similar proposal should be presented to medical 
specialties other than Neurology, to cover different organ involvement, such as the 
heart, the kidneys and the eyes.  
7. Present landscape of ATTR polyneuropathy treatment 
7.1. The drugs approved in Europe 
At this moment, European clinicians have three drugs approved for the treatment of 
ATTR amyloidosis presenting as a primary polyneuropathy, the TTR stabilizer 
Tafamidis (Vyndaqel ™),175 and two gene-silencing or TTR mRNA lowering therapies, 
Patisiran (Onpattro ™)176 and Inotersen (Tegsedi ™).177 
All three drugs received precise and limited indications: they were approved for the 
treatment of neuropathy related to hereditary ATTR amyloidosis, with any mutation, in 
stage 1 (patients fully ambulatory) in the case of Tafamidis, or stage 1 and 2 (patients 
needing uni or bilateral support to walk), in the case of Patisiran and Inotersen. A 
recommendation common to all the three drugs advises, “therapy should be initiated 
under the supervision of a physician knowledgeable in the management of 
amyloidosis”. 
7.1.1. Tafamidis 
Tafamidis was approved for oral daily use of a 20 mg capsule, to stop or decrease 
neuropathy progression in stage 1 symptomatic patients (fully ambulatory) with 
hereditary ATTR amyloidosis with any mutation.175 
Besides the pivotal double-blind clinical trial (article 4), one smaller open-label study 
included 21 patients with 8 different mutations and followed them for more than one 
year.199 Results are difficult to interpret because there was no control arm: TTR 
stabilization was demonstrated across all mutations but all patients showed some 
degree of progression, unclassifiable due to the lack of a randomized control group 
with similar characteristics (article 6). A second open-label study200 included 
cardiomyopathy patients, in the USA, with similar conclusions (article 6). 
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Three centers, in France201,202 and Italy203 presented their experience using Tafamidis 
in unselected patients, the vast majority in stage 2 or 3. In general, results were 
disappointing, showing a significant progression of the disease. No major safety issues 
were detected. 
Along with the real-life experience after Tafamidis approval in Europe, in 2012, a 
clinical trial with Tafamidis in two different doses, 20 and 80mg, was implemented 
across the world, for patients with TTR related cardiomyopathy, either hereditary or 
wild-type, with 30 months duration. The primary outcome measures, a hierarchical 
combination of all-cause mortality and frequency of cardiovascular related 
hospitalizations, reached statistical significance in the whole group of treated patients, 
irrespective of drug dose, compared with the placebo group. Some results point to a 
more robust result with the higher dose. No safety issues were detected with either 
dose.204 
The evaluation of several years of Tafamidis use in clinical practice, in Portuguese 
stage 1 patients with the Val30Met mutation, showed results similar to the results of 
the clinical trial (article 8). The results were used to build a model to predict the 
response, a tool that will be useful in the future to manage the multiple possibilities for 
ATTR polyneuropathy treatment. Patients with more advanced disease, irrespective of 
the age of onset, male gender and patients with a lower concentration of Tafamidis in 
blood after one year of treatment show a poorer response. 
These results, taken together with the French201,202 and Italian203 reports and the 
results from the clinical trial with cardiomyopathy patients,204 point out to one important 
issue. It may be that patients with more advanced disease are poor responders 
because of a yet unknown disease mechanism developing with nerve lesion 
progression, independent from the cascade of amyloid formation and deposition. 
However, another possibility demands testing – poor responders also have a lower 
concentration of Tafamidis in blood and we hypothesize that increasing the dose from 
20 up to 80mg could be enough to circumvent the poor response.  
We could argue that the highest dose should be uniformly prescribed because the 
recent trial with 80 mg did not raise any safety concerns. Moreover, this dose affords 
complete biochemical stabilization of plasma TTR.205 The counter argument is that 
there are many ATTR polyneuropathy patients, particularly women, with a complete 
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and prolonged response at the 20 mg Tafamidis dose. Collectively this data makes a 
compelling case to conduct a clinical trial with 20 versus 80 mg of Tafamidis to 
understand if the lower concentration of Tafamidis in the blood is the cause of the non-
response.  
7.1.2. Patisiran 
Patisiran was approved for the treatment of hATTR polyneuropathy in adult patients 
with stage 1 or stage 2 polyneuropathy. The recommended dose is 300 micrograms 
per kg body weight administered via intravenous (i.v.) infusion once every 3 weeks. 
The maximum recommended dose is 30 mg, for patients weighing ≥ 100Kg. All patients 
should receive premedication at least 60 minutes prior to the start of infusion, including 
i.v. dexamethasone (10 mg, or equivalent), oral paracetamol (500 mg), i.v. 
diphenhydramine (50 mg, or equivalent) and ranitidine (50 mg, or equivalent). Daily 
supplementation of vitamin A (≈ 2500 IU) is recommended.176 
The clinical development of Patisiran was based on several controlled clinical trials 
with patients, from phase 1 to phase 3, and one open-label study allowing concomitant 
use of TTR stabilizers (articles 9, 10 and 11). All studies showed a similar, marked and 
sustained knockdown of wild and variant TTR when the dose of 300 micrograms per 
kg was used.  
The phase 3 registration trial (article 11) and the open-label study (article 10) showed 
very robust evidence of efficacy and no major adverse events classified as drug related 
or leading to study discontinuation. Infusion related reaction were mild and easy to 
control with a decrease in the infusion rate.  
FDA identified a safety concern related to the more frequent occurrence of cardiac 
deaths in the Patisiran group while recognizing that numbers were too small and 
difficult to interpret and that this group included patients with gene mutations 
associated with a higher mortality.206 In parallel, the agency considered that the data 
collected during the study concerning cardiac related endpoints did not show enough 
evidence of efficacy to justify an approval with that indication.  
This safety signal encompasses the problems detected during the Endeavour trial with 
a subcutaneous formulation of the same oligonucleotide present in Patisiran, in 
patients with cardiomyopathy related to ATTR amyloidosis. The excessive number of 
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deaths in the treatment arm (16/1 with a randomization ratio 2/1) led to the early 
termination of this trial. No explanation for these findings was presented. The 
enlargement of Patisiran prescription will certain contribute to clarify this safety issue. 
But meanwhile careful evaluation of cardiac involvement must be pursued in all 
patients receiving Patisiran.  
7.1.3. Inotersen 
Inotersen is indicated for the treatment of stage 1 or stage 2 polyneuropathy in adult 
patients with hATTR amyloidosis. The recommended dose is 284 mg by subcutaneous 
injection, once every week. Daily supplementation of vitamin A (≈ 2500 IU) is 
recommended. Regular monitorization of platelets and renal function is needed to 
prevent serious adverse events such as severe thrombocytopenia and 
glomerulonephritis. Dose adjustment can be done in case of reduction in platelet count 
but permanent discontinuation may be indicated in the case of severe events.177 
Clinical development of Inotersen included a phase 1-2 trial in healthy volunteers,207 
the phase 3 registration trial and an open-label study with a small group of 
cardiomyopathy patients.208 
The clinical trial efficacy data (article 12) shows a significant difference between the 
two treatment arms, in primary outcome measures, mNIS+7 and Norfolk-QOL and 
identified safety problems related to the occurrence of episodes of severe 
thrombocytopenia and glomerulonephritis. The results of the open-label study were not 
adequate to evaluate Inotersen impact on the progression of the disease due to the 
absence of a control group but didn’t raise any further safety issues. 
There are some safety issues related to both drugs, Inotersen and Patisiran, due to 
their common mode of action.  
The first question concerns the decrease of vitamin A in the plasma related to the 
knockdown of TTR, the main transporter of the complex between RBP and vitamin A. 
Patients receive daily maximal doses of oral vitamin A and, until now, the experimental 
use of Inotersen and Patisiran (that goes up to several years) caused no clinical signs 
of vitamin A deficiency. Nonetheless, particular attention to the eyes and skin must 
follow because this could be a long-term side effect.  
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A major issue on the long-term use of gene-silencing drugs is related to the possible 
protective role of TTR in the peripheral nervous system57 and cardiovascular system.73 
When we face such a disabling disease, we must concentrate on the need to find an 
efficacious drug to stop the progression of the disease. However, if we are successful 
in this task, patient expectations will increase and we may well find in the future that 
the loss of a protective role of native folded tetrameric TTR causes problems and 
fragilities. This is a speculative hypothesis because we do not know if the residual 
percentage of TTR that remains in circulation would be enough to fulfil this putative 
protective function. 
7.2. Liver transplant indications 
The approval of these three drugs changes considerably the landscape of ATTR 
amyloidosis treatment, while offering an alternative to liver transplantation, the 
disease-modifying treatment available since 1990. Liver transplant has a major impact 
in slowing disease progression relative to the natural history of this disease, with 
marked increase of survival (article 12). This is particularly true for a specific group of 
patients with the TTRVal30Met mutation exhibiting early onset disease, short duration 
of symptoms,172 no cardiomyopathy174 and good nutritional status.173 Liver 
transplantation remains a limited option, due to organ shortage, and contraindications 
related to co-morbidities. Furthermore, it is an aggressive procedure, with early 
mortality associated with surgical complications and significant morbidity, in relation to 
lifelong immunosuppression.  
Liver transplantation, with all its limitations, has no reason to remain a first line 
treatment of patients with stage 1 or early stage 2 ATTR amyloidosis polyneuropathy. 
However, for patients with end-stage renal failure or severe cardiac failure, kidney and 
cardiac transplant, respectively, it remains an important option particularly for younger 
patients. In this case, it is controversial if these patients should have a double 
transplant including the liver and the organ in failure or if, on the contrary, they should 
receive the organ in failure and a gene-silencing drug to prevent further 
progression/recurrence of the disease. For a while, double transplantation, either liver 
and kidney or liver and heart, should remain as the best option, considering the present 
need for more information on liver toxicity risks and drug interaction in the field of gene-
silencing therapies. 
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Unfortunately, we must also recognize that limited access to these expensive drugs 
may justify the maintenance of liver transplant as a therapeutic alternative in many 
regions of the world. 
7.3. A drug treatment algorithm 
The choice between the three drugs must be based, in first place, in the efficacy and 
safety profile of each drug. Practical consideration on the possibilities of compliance 
with each administration route and the risks of Inotersen treatment in patients with 
evidence of mild renal disease or under anticoagulation therapy might also influence 
the final decision. 
It is controversial if treatment-naïve patients, in stage 1, should receive one of the 
gene-silencing drugs as a first line treatment, instead of Tafamidis, considering the 
more robust demonstration of efficacy of those drugs. Based on the predictive model 
of response to Tafamidis, according to the Portuguese experience (article 8), Tafamidis 
should be the first choice for female patients with the Val30Met mutation and a low NIS 
score, considering the simplicity of oral intake and the safety profile. For male patients, 
particularly if they have a high NIS score, gene-silencing drugs are the best option from 
the beginning. And finally, for stage 2 patients the choice is between Patisiran or 
Inotersen, according to patients and doctors’ evaluation of risks and logistic 
considerations.  
7.4. Drug treatment for patients with predominant heart or renal disease   
The only controlled clinical trial that showed unequivocal positive results in 
cardiomyopathy patients was the Tafamidis trial.204 The approval of a higher dose in 
Europe and the first approval in the USA are both pending but there are strong 
arguments to favor the use of Tafamidis in patients with a predominant cardiac 
phenotype. For those numerous patients with a mixed phenotype the decision between 
Tafamids and a gene-silencing agent is more difficult and must rely on clinician 
judgment. Anyway, careful assessment of heart condition must be performed regularly 
in all patients, irrespective of the predominant phenotype.  
Patients with severe or end-stage renal failure are frequently excluded from clinical 
trials, because experimental drugs’ pharmacokinetics is commonly not fully understood 
in these conditions. The lack of information about the behavior of a disease-modifying 
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drug cannot preclude patients with renal disease from being appropriately treated. 
Small clinical studies, focused on these patients, should allow clinicians to collect all 
the safety and efficacy information needed to treat patients adequately. An interesting 
finding was reported in Portugal where patients with mild or moderate renal 
involvement had a decrease/regression of proteinuria when treated with Tafamidis.209  
 7.5. The use of off-label drugs 
Several drugs are available for off-label prescription. The demonstration of efficacy is 
quite variable, from studies with transgenic mice and small non-controlled studies in 
patients to a randomized, double blind, placebo-controlled phase 3 clinical trial in 
neuropathy patients.197 
Epigallocatechin-3-gallate (EGCG) is a catechin present in green tea. In high doses, it 
is able to stabilize TTR tetramers, inhibit TTR aggregation, and disrupt amyloid fibrils. 
A study in transgenic mice demonstrated a significant reduction in TTR deposition in 
nervous tissue, after 6 weeks treatment.210 
Doxycyline, 100 mg twice daily, combined with tauro-ursodeoxycholic acid 250 mg 
three times daily or ursodeoxycholic acid 750 mg once daily, was evaluated in two 
preliminary clinical studies,211,212 in patients with neuropathy and/or cardiomyopathy, 
with contradictory results. 
Diflunisal, a NSAID available in several countries, is a particular case: it was evaluated 
in a randomized double blind placebo-controlled clinical trial,197 with neuropathy 
patients in all stages of disease and many different mutations and showed efficacy to 
decrease disease progression when placebo and treatment arms were compared; 
during the trial some expected side effects were detected, namely mild progressive 
renal function impairment, edema and gastric problems. The side effect profile, 
particularly in the long term, is the major issue. Nevertheless, the drug is commonly 
used whenever other approved alternatives are not available. 
The severity and invariably fatal outcome of ATTR amyloidosis justifies the prescription 
of medicines off-label, whenever no approved drug is available, if there is any evidence 
of a disease-modifying effect and the safety profile is acceptable. On the other hand, 
from a research perspective, clinicians must remain engaged in the development of 
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controlled studies with each drug. Diflunisal trial is an important example of such an 
effort.  
8. Questions brought by the increased survival of transplanted patients 
8.1. CNS and eye involvement as major unmet needs. 
As previously stated, the increased lifespan of transplanted patients (article 13) led to 
a major increase in CNS137,138 and eye disease135,136 (owing to the local continuing 
production and deposition of variant TTR) and prompted the need to understand if the 
drugs in use enter the eye and the CNS.  
The demonstration of the ability of Tafamidis at the dose of 20mg to penetrate into 
these compartments (article 7) may be an important first step, in spite of the low 
concentration achieved in both locations. Much more must be clarified about the 
natural history of eye and brain involvement of TTR amyloidoses and the brain and 
eye exposure of all drugs in use. Considering the putative neuroprotective role of TTR 
in the CNS and the eye,213 the preference for stabilizers could be supported to treat 
the eye and CNS manifestations of the ATTR amyloidoses. 
9. Future perspectives 
9.1.  Combination therapies 
We hypothesize that different drugs with distinct mechanisms of action will be needed 
to address the degenerative pathogenic mechanisms, the involvement of multiple 
organs, and treatment across various stages of ATTR amyloid disease progression. It 
is probable that we will need to use more than one drug to cover distinct aspects of the 
ATTR amyloidoses.  
Combination therapy could also allow the use of smaller doses, if a synergist effect 
could be realized. Though speculative, combining gene-silencing therapies and TTR 
stabilizers could permit a reduction in the percentage of TTR knockdown, because the 
remaining protein could be easily stabilized.  
9.2. New drugs in clinical development 
Monoclonal antibodies directed at misfolded TTR were shown to prevent amyloid fibril 
formation and to promote antibody-dependent phagocytic uptake of misfolded TTR.214 
PRX004 is an investigational antibody being evaluated in a phase 1, open-label, dose 
escalation study. 
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A new TTR stabilizer, AG-10, binds with high affinity and negative cooperativity to TTR, 
with a strong effect on wilt type as well as the Val122I mutation. A phase 3 study in 
cardiomyopathy patients is underway.215  
9.3 The case for peri-symptomatic/pre-clinical treatment 
The disease process comprises a pre-clinical period, when amyloid formation and 
consequent tissue lesion start but the functional reserve of the affected organs allows 
for a silent progression, without clinical manifestations, and a very early symptomatic 
(also designated as peri-symptomatic) period, during which the progression of tissue 
lesion translates into mild non-specific symptoms with a normal physical exam. Studies 
evaluating the diagnostic yield of intra-epidermal nerve fiber density assessment in 
skin punch biopsies,216 nerve MRI217 and some neurophysiological exams218-220 have 
shown abnormal results in mutation carriers with doubtful or no symptoms, shortly 
before disease diagnosis. We lack consensus on the best tools to confirm the diagnosis 
of these very early stages. Furthermore, we may hypothesize that blood biomarkers of 
the first steps of TTR misfolding could be particularly useful to confirm such a timely 
diagnosis.221 
It is reasonable to consider that mutation carriers diagnosed while asymptomatic, 
through genetic counseling, would have much better outcomes if treated in the pre-
clinical/peri-symptomatic stage, when tissues without significant potential for complete 
recovery, such as the nerves and the heart, are minimally injured. Such an approach 
requests a safe drug with a simple route of administration. Tafamidis and Diflunisal 
have been proposed and prescribed off-label, with this indication. Even from a drug 
rational point of view, it is reasonable to consider oral TTR stabilizers an adequate 
option, because they interfere with the first step of the pathogenic cascade. Controlled 
trials are needed to test this hypothesis.  
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER V | CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V | Conclusions 
 
277 
CONCLUSIONS 
 
This work presents the most relevant aspects of the clinical development of the three 
disease-modifying drugs currently approved in Europe for the treatment of neuropathy 
related to ATTR amyloidosis. The data also demonstrate that the first disease-
modifying therapy, liver transplantation, slowed the progression relative to the natural 
history of the disease among Portuguese patients, transforming a severe, rapidly 
progressive, and invariably fatal disease into a chronic condition with less disability and 
longer survival.  
These developments are “a triumph of translational medicine”220 and highlight the 
importance of a longstanding and continuing collaboration between basic scientists, 
pharmaceutical / biotechnology company researchers and clinicians. Last but not least, 
nothing would have been possible without the major contribution of the patients that 
accepted to take part in the experimental studies.  
Unfortunately, despite all these major achievements, many patients continue to face a 
devastating disease, due to late diagnosis, or type of disease presentation and/or 
progression predominantly unrelated to neuropathy or failure to access any ATTR 
disease-modifying therapy in many regions of the world. In fact, present successes 
and multiple unmet needs stand side by side. 
Outcome measures were validated to be used in the registration clinical trials, with a 
learning curve that led from the formal failure of the trial with Tafamidis to the success 
of the trials with Patisiran and Inotersen. However, the continuing evaluation of these 
drugs in a commercial and enlarged prescription setting, prompts the need for a new 
validate score, simple, reliable, responsive, without costs and easy to apply in daily 
clinical practice. 
Liver transplantation is no longer a first line therapy for ATTR amyloidosis. However, 
end-stage renal or heart failure will continue to be an indication for organ replacement, 
either as dual transplantation, including the liver, or as an isolated transplant of the 
organ with end-stage failure.  
All the three approved drugs have limitations and/or safety issues that must continue 
to be explored. The good results presented here represent a first step towards 
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improving patient outcomes and quality of life. We need new trials or well-controlled 
studies directed toward assessing involvement of additional organs (v.g. the heart or 
the kidneys) with further clinical evaluation of approved drug’s impact on all the multiple 
aspects of this systemic disease. A particularly difficult challenge come from the 
involvement of CNS and the eyes, due to the presence of blood-brain and blood-eye 
barriers that conditionate drug availability at these target organs. 
New drugs with different mechanisms of action are under laboratory and/or clinical 
investigation. Drug development is a never-ending process. Researchers, 
pharmaceutical companies, clinicians and patients must remain available for additional 
clinical studies, in order to obtain the best results from each medication and 
combinations of medications. 
A promising approach to the treatment of this condition would be a combination of early 
biomarkers development, allowing for expedite and non-invasive preclinical or peri-
symptomatic early diagnosis, along with the demonstration of the efficacy of certain 
drugs, v.g. TTR stabilizers, to completely prevent the overt expression of the disease, 
for the longest possible time.  
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